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ABSTRACT  
 
Introduction - Currently there is limited evidence supporting podiatric treatment of 
children with JIA. The foot orthoses (FOs) prescribed to JIA children so far appeared to 
be very expensive and required long time to manufacture before the fitting. This 
randomised controlled trial (RCT) aimed to determine whether pre-formed FOs that can 
be prescribed at chair side, impacted on pain, quality of life (primary outcomes) and/or 
gait-parameters (secondary outcomes) in children affected by JIA.  
 
Methods - The study took place at the Gait Analysis laboratory at Queen Margaret 
University – Edinburgh and at the TORT Centre, Ninewells Hospital-Dundee. Children 
with JIA were diagnosed according to the ILAR criteria. Intervention was blinded to 
the patients. The trial group received Slimflex-plus FOs, with the addition of chair side 
corrections and the control FOs supplied were made with leather board (1mm thick) 
only. Both FOs had the same black EVA top cover. Primary outcomes were 
investigated using validated questionnaires (VAS, CHAQ and PedsQL). Tekscan™ 
equipment (F-Scan™ and HR Walkway®) measured secondary outcomes in-shoe 
pressure and force data with and without FOs intervention. Multiple foot strikes and 
repetitive gait patterns were compared pre and post-treatment. Primary and secondary 
outcome measures were recorded at baseline, 3
rd
 and 6
th
 month’s period.  
  
Results - Sixty children were recruited; 48.3% (n=29) control and 51.7% (n=31) active 
treatment group. Within the control group 20.7% (n=6) of patients were male. Within 
the active treatment group, 29% (n=9) subjects were male.  Age ranged between 5 to 18 
years, median age for the control group was 11 (range=12.90) and for the trial group 
were 11.50 (range=12.11). In order to attribute any effect solely on the FOs 
intervention, details of changes of medication and/or new joint injections were recorded 
during the trial. In the control group 65.5% (n=19) were considered to be prescribed 
with stable medications. Similarly, amongst children receiving active treatment 74.2% 
(n=23) were deemed to be taking stable medications. Overall, 99.4% (n=179/180) 
appointments were completed, only one subject did not attend the 6 month session. 
Significant improvement was identified in the primary outcomes favouring active 
treatment with regards to pain and quality of life measures: VAS (p<0.05); CHAQ 
(p<0.05); PedsQL paediatric-generic (p<0.05) Peds paediatric rheumatology (p<0.05); 
PedsQL parent-generic (p<0.05); PedsQL parent-rheumatology (p<0.05). In all these 
quality of life tools where p<0.05, clinical significance was also obtained. Significant 
differences were also identified between the groups for gait time, stance time, total 
plantar surface, heel contact, midfoot, 5
th
 metatarsal head and distal phalanx. 
 
Discussion - The results strongly suggest that FOs are effective in improving pain, 
quality of life and most gait parameters in JIA children. FOs can be customised at 
chair-side so JIA children can receive immediate podiatric benefit from the same day of 
the biomechanical assessment. Compliancy rate proved to be extremely high 
confirming that the podiatric treatment is well accepted by JIA children. 
 
Conclusion - Primary and secondary outcome’s results, strongly support the use of FOs 
in the treatment of JIA children, which highlights the important role of the podiatrists 
within the multidisciplinary team in paediatric rheumatology.  
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Chapter 1: Introduction  
 
In this thesis the clinical management of children who present with Juvenile Idiopathic 
Arthritis (JIA) in the lower limbs were researched. At present, there are no guidelines 
available for practitioners to effectively treat children diagnosed with JIA with the use 
of FOs. This randomised controlled trial (RCT), carried out with patients recruited in 
Scotland, (Edinburgh Royal Hospital for Sick Children, and Ninewells Hospital - 
Dundee) were investigated the effectiveness of foot orthoses (FOs) in reducing pain 
and improving the quality of life for JIA children. FOs have been widely used by 
podiatrists to treat different pathologies in adults and children. The use of pre-formed 
semi-rigid FOs may represent a cost effective option, available for practitioners within 
the NHS and private practice. In addition, off-the-shelf devices can easily be 
customised by the podiatrist with the appropriate use of corrections and special 
materials, to improve the patient’s foot functional need. These types of FOs are 
becoming more and more popular compared to the Plaster of Paris (POP) custom-made 
FOs, because there is no need of special laboratories and machines to complete the 
manufacturing process. All the equipment required for manufacturing a custom-made 
FOs are often not available due to financial restrictions, limited space and/or health and 
safety issues. The time required to manufacture a custom-made FOs is significantly 
longer compared to the off the shelf device. Recent studies in adults and children which 
investigated the differences between off-the-shelf and custom-made FOs, have shown a 
similar efficacy in improving pain levels and biomechanical pathologies. The limited 
research available at present in JIA podiatric management reported that the custom-
made FOs used for the trials was very expensive and that it took almost two months 
before the fitting appointment was made. In contrast, pre-formed semi-rigid FOs have 
the significant advantage that they can be supplied to the children on the same day as 
the initial biomechanical assessment. It can be argued, that if fitting appointments are 
postponed for long periods of time, it could have a negative effect on the condition of 
joints and may increase the pain suffered by JIA children. As a result, the 
multidisciplinary team follows an early treatment approach in an attempt to minimise 
long term deformities. Therefore, the prescription of off-the-shelf FOs would be in line 
with the mentioned approach to current treatment.  
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 Juvenile Idiopathic Arthritis 1.1.
JIA is the most common chronic rheumatic disease in childhood and adolescence and 
may cause short-term and long-term disability (Ravelli and Martini 2007). According 
to a Cochrane review, JIA can be diagnosed in children up to the age of 18 years 
(Takken et al. 2008). In the UK specifically, the prevalence is approximately 0.65 per 
1000 children (Manners and Bower 2002) with a more general worldwide incidence of 
between 0.07 and 4.01 per 1000 every year (Hendry et al. 2008; Karmazyn et al. 2007). 
Previous research which investigated controlled quantitative gait analysis in JIA 
recorded significant differences compared to healthy children in recorded kinematics 
and temporal data (Brostrom et al. 2007). Evidence from two-cross sectional studies 
highlights that children with arthritis are physically less active compared to healthy 
children (Takken et al. 2008).  
 
The provision of health care to JIA has been reported to be particularly challenging 
(Hazel et al. 2010; McDonagh 2007). Significant advances have been made lately with 
regards to new treatments, medications and research. A multidisciplinary approach to 
treat young arthritic patients has been reported to be necessary by Hazel et al. (2010). 
As in most clinical cases, successful outcomes with symptomatic children often depend 
on the single practitioner’s ability to communicate effectively with the child and the 
parent. However, different therapists involved with the care of arthritic children should 
all be part of a united team, working together and communicating constructively to 
reach the best care for the patient (Hazel et al. 2010).  Initially the main aim for the 
multidisciplinary team should be to relieve pain and discomfort, to reduce joint 
inflammation, to promote function and prevent deformities. With regards to long term 
care the focus should then concentrate on encouraging normal growth and 
development, while reducing possible side effects related to the disease and its 
treatment (Szer et al 2006).  
 
Short and long term interventions are extremely important aspects, FOs may help in the 
reduction of pain, promote better joint alignment and function that could diminish the 
risk in developing deformities; additionally, through better bone and joint alignment 
FOs effect may contribute to normal growth and development.  
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Multidisciplinary team work may encourage JIA children to cope independently 
thorough the difficult transition into adult life and enable them to achieve their true 
potential in life (McDonagh 2007). It can be argued that in most of these publications, 
podiatrists are not considered to be part of multidisciplinary paediatric team. None of 
the authors referenced above considered or questioned what might be the benefits that 
podiatrists could bring into the multidisciplinary team. Sadly, this may be related to the 
lack of recognised evidence to support podiatric intervention available at present. This 
multicentre RCT will provide new research on the possible benefit and the potential 
role of podiatrists within the paediatric rheumatology teams.  
 
   Lower Limb Problems in JIA 1.2.
The joints in the lower limbs are the most commonly affected in JIA children (Szer et 
al 2006). It is extremely important for practitioners to thoroughly examine these joint 
conditions, as symptomatic joints may result in antalgic gait (Hendry et al. 2008). It 
often happens that painful joints may generate compensation in children’s walking 
during the normal gait cycle. This could have an impact on normal ambulation and 
possibly change the time mechanics of initial contact phase, mid-stance and/or 
propulsion phase. As the child may experience pain from a young age, abnormal 
walking habits may be adopted unconsciously to prevent pain (Thomson and Volpe 
2001). A descriptive study of foot problems with 144 JIA children reported that ankle 
joint limitation was frequently diagnosed, although unrelated to the specific JIA 
subgroup (Spraul and Koenning 1994). Podiatrists could intervene at the early stage of 
the pathology with corrective FOs and specific exercises to prevent and improve 
abnormal biomechanics. However, podopaediatric care is currently limited within NHS 
paediatric hospitals. 
 
If the hip becomes affected, it may results in a position of flexion and excessive 
internal rotation (Bresnahan 2002). This may be exacerbated if the child has not been 
mobile during the active phase of the disease; therefore, fixed flexion deformities may 
become noticeable during walking. During biomechanical assessments, practitioners 
are also likely to find weaknesses at the hip muscles as a result of reduction of activity 
level (Thomson and Volpe 2001). The lack of extension movement directly affects the 
child’s normal stride. The presence of active disease in the lower limbs results in 
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overall joint limitation, an increase of double support time to minimise active joint 
demand, and reduced walking speed and step length (Hartmann et al. 2010; Hendry et 
al. 2008). The recent clinical study carried out by Hartmann et al. 2010 also reported 
that the JIA children tend to present with a ‘crouch-like gait’ with distinctive hyper-
flexion in the hip and at the knee joint. In addition, significant reduction in ankle 
plantar flexion was found in the 36 subjects recruited in this study. The study 
concluded that physiotherapy and sports therapy intervention may be recommended, 
and that further studies are necessary to advance JIA clinical management. Even in the 
recent publications by Hartmann et al. 2010, the input that a podiatrist could bring to 
the care of JIA children is not even considered or mentioned as an alternative option. 
This fact confirms that podiatrists need to prove the importance of their clinical skills 
and use current research to develop and justify their role within the paediatric 
rheumatology team. 
 
If the knees are involved with active disease, flexion abnormalities may be diagnosed. 
Nowadays if a joint is inflamed and painful, the child is encouraged to remain as active 
as possible to prevent muscle strength reduction and prolonged antalgic gait (Thomson 
and Volpe 2001). In addition, in JIA children apropulsive gait is often seen, usually 
related to metatarsalgia (inflammation of metatarsal heads), which can possibly have a 
negative impact on the amount of dorsiflexion at the ankle joint and reduce calf muscle 
power and flexibility (Thomson and Volpe 2001). Podiatrists are able to diagnose and 
effectively treat metatarsalgia by using deflecting-cushioning materials and other 
orthotic devices (Durham 2007). It can be argued that according to Durham (2007) 
patients diagnosed with metatarsalgia should be referred directly to podiatrists as soon 
as the symptoms appear, rather than waiting for a prolonged period of time which may 
lead to an increase in pain and further complications. 
 
Leg length discrepancy may occur as a result of growth or enthesitis issues and it is not 
uncommon in JIA children (Simon et al. 1981).  In this quite dated study, it has been 
reported that particularly JIA oligoarthritis patients are more likely to develop lower 
limb asymmetry. In the early stages of the disease, the affected leg is usually longer. As 
a natural compensation to prevent scoliosis and tilted hip, the child tends to flex the 
knee and force it into a valgus position. Usually the subtalar joint (STJ) excessively 
pronates on the longer leg in attempt to compensate the limb asymmetry. Without 
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treatment, these positions may become fixed (Simon, Whiffen and Shapiro 1981). 
Practitioners should always check the presence of asymmetry in length of limbs, as it 
can result in flexion deformity and pain in the foot, ankle, knee and/or hip level (Szer et 
al 2006). 
 
JIA patients may have a lower aerobic capacity. This appears to be directly related to 
foot impairments, including joint pain, stiffness and deformities that can alter walking 
patterns; therefore, sharply reducing physical activities compared to healthy children 
(Broström et al. 2002).  This study may favour and justify the intervention by the 
podiatrist to improve gait related issues, although it does not explain specifically what 
type of devices can be effective to improve biomechanical pathologies. In a more 
recent publication by Hendry et al. 2008, it appears that foot problems are common in 
JIA, with a prevalence of over 90%. DMARD
1
 and biological therapies are often 
prescribed to control active joint disease and pain. In addition, JIA children with gait 
abnormalities and active foot disease were referred directly for podopaediatrics care 
(Hendry et al. 2008). It can be argued that encouraging results for the role of podiatrists 
within JIA children were outlined in this small survey; on the other hand, only 10% of 
the audited patients received podiatry foot care intervention in the previous 12 months.  
 
Finally, the authors also reported that multidisciplinary intervention should be required 
in the paediatric rheumatology team and that more research is needed to prove the 
valuable input for podiatric intervention (Hendry et al. 2008). This thesis will 
investigate the use of FOs with its effects on symptoms and gait in JIA children with 
problems in the lower limbs.   
 
  Foot Orthoses in JIA 1.3.
Foot orthoses (FOs) have been used for many years by podiatrists to improve gait 
abnormalities and prevent deformities (Evans 2003; Landorf and Keenan 2000; Selby-
Silverstein et al. 2001). In children, FOs have been found to improve parameters of 
gait; however, little research has been carried out on subjects with JIA (Sullivan 1999). 
                                                 
DMARD: Disease-modifying anti-rheumatic drug. 
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Currently there are no guidelines available for podiatrists to treat JIA children with the 
use of FOs. At present, only one article was found which investigated foot orthotic 
management in JIA (Powell et al 2005). The authors investigated the efficacy of 
custom orthotics in improving pain and functional status in children with JIA. 
However, the custom made orthoses tested in this small study are very expensive and 
require specialised laboratory equipment and materials to dispense. 
 
In the survey published by Hendry et al. 2008, seven of the ten children audited were 
diagnosed with polyarticular JIA. After biomechanical assessment, STJ pain, pes-
planovalgus and digital pathologies were diagnosed. Participants were provided with 
footwear advice, orthotic therapy, silicone digital-splints, and strengthening exercises. 
The podiatry care was aimed at correcting biomechanical problems and improving pain 
by using customised FOs, splints and exercises. Final results showed that the overall 
clinical management of JIA appeared to be ‘good’, however, foot related problems and 
abnormal gait patterns unfortunately still persisted in some participants (Hendry et al. 
2008). This negative feedback on the podiatric intervention may be attributed to the 
different casting techniques and orthotic manufacturers. In addition, each child had to 
wait between one and two months for their fitting, which may have had a negative 
effect on their gait and prolonged symptoms. Current podiatry practice aims to 
intervene as early as possible to reduce the risk of damages and developing deformities; 
hence, delay in supply of FOs does not comply with the methods reported in the survey 
published by Hendry et al. (2008). The results in this survey also showed that review 
appointments were carried out between one and six months from the fitting 
appointment. It can be argued that the review gap may be too long because the 
podiatrist should usually follow the progress of the patient more regularly. Finally the 
author reported that more extensive research is required to justify the role of FOs in the 
field of paediatric rheumatology (Hendry et al. 2008). 
 
Higher cost custom-made FOs requires longer time for the manufacturing process 
compared to off-the-shelf devices. Time and costs are extremely important issues that 
have been taken into consideration in this RCT. These much cheaper pre-formed semi-
rigid FOs will be prescribed to the recruited JIA children on the day of the initial visit. 
During the initial consultation, chair side modifications will also be applied to the trial 
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patients in order to customise the devices to the individual biomechanical needs. This 
thesis will explore the feasibility of FOs intervention in JIA. 
 
 Research Problem and Hypotheses 1.4.
1.4.1. Research Problem 
Modern modular foot-orthoses systems allow an integration of the cost and efficiency 
benefits afforded by the use of pre-formed semi-rigid FOs components, while 
simultaneously allowing a high degree of individualisation of prescription. Such 
systems, while popular, still remain unproven. Recent studies in paediatric 
rheumatology have made a contribution in developing guidelines with regards to 
pharmacological intervention in arthritic children. In addition, specific drug therapy 
protocols have been published to effectively help general practitioners, physiotherapists 
and ophthalmologists to successfully treat children with JIA patients (BSPAR 2006; 
Hull 2001; NICE guidelines 2002). A Cochrane systematic review on treatment of pes 
planus, highlighted that children with JIA were excluded as a group from most of the 
studies (Ashford et al. 2005). 
 
At present little evidence exists for the podiatric management of children affected by 
this disabling pathology, especially for orthotic management. This thesis will provide 
evidence to support the use of readily available off-the-shelf FOs in treating JIA 
children.  
1.4.2. Research Question 
 
How effective is the podiatric intervention using pre-formed semi-rigid FOs in 
improving pain level and quality of life in JIA children?  
1.4.3. Research Aim 
 
The aim of this study is to investigate the effectiveness of commonly prescribed pre-
formed semi-rigid FOs in children diagnosed with JIA. 
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1.4.4. Research Objectives 
 
1. To evaluate the current literature with regards to the effectiveness of pre-formed 
semi-rigid FOs in JIA children. 
2. To carry out a survey to investigate if podiatrists are likely to treat JIA children in 
Scotland and to determine what devices are most likely to be prescribed. 
3. To determine the effects of pre-formed semi-rigid FOs on pain in paediatric 
rheumatology globally. 
4. To study the effects of pre-formed semi-rigid FOs on quality of life in paediatric 
rheumatology using the PedsQL™ Paediatric (inventory) - version 4.0 for children 
and parents. 
5.  To study the effects of pre-formed semi-rigid FOs on quality of life in paediatric 
rheumatology using the PedsQL™ Rheumatology Module – version 3.0 for 
children and parents. 
6. To investigate the effects of pre-formed semi-rigid FOs using the child health 
assessment questionnaire (CHAQ). 
7. To analyse the quantitative kinematic and kinetic parameters when barefoot, with 
shoes, and with shoes with orthoses. 
1.4.5. Hypotheses 
1. FOs reduces global pain using VAS on children diagnosed with JIA.  
2. FOs improves quality of life in paediatric rheumatology using the PedsQL™ 
Paediatric (inventory) - version 4.0 for children and parents. 
3. FOs improves quality of life in paediatric rheumatology using the PedsQL™ 
Rheumatology Module – version 3.0 for children and parents. 
4. FOs improves quality of life in using the child health assessment questionnaire 
(CHAQ).  
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 Outline of the Thesis 1.5.
1.5.1. Chapter 2: Critical Appraisal 
This chapter will provide up-to-date evidence on epidemiology, aetiology, 
pathology and clinical features in the lower limbs (hip, knee, foot) in JIA children. 
In addition, the current treatment of JIA will be presented, as well as details of 
normal and pathological gait in JIA will be explained. Furthermore, comparison 
between custom made and off-the-shelf devices used will be provided. Finally, a 
comprehensive literature review on the questionnaires used to investigate pain and 
quality of life will be available for the reader.  
1.5.2. Chapter 3: Methods – Instrumentation & Pre-Tests 
This section will present the methods used to record plantar foot pressure 
measurements during gait analysis with JIA children. Also in this chapter 
calibration details and repeatability and reproducibility studies will be provided on 
the HR WalkwayTM and the F-Scan
® 
systems.  
1.5.3. Chapter 4: Methods – Randomised Controlled 
Study 
This chapter will provide information about the research procedures such as 
recruitment, inclusion exclusion criteria, justifications of methods and the type of 
podiatric interventions provided for the RCT study. Finally, data collection and 
statistical method adopted will be presented.  
1.5.4. Chapter 5: Results 
In this chapter, results will be presented for both control and trial groups. Data 
analysis on patient’s demographics, pharmaceutical intervention and joint 
symptoms will be reported. Then statistical analysis will be carried out in order to 
explore data obtained from the VAS, CHAQ and PedsQL questionnaires. Finally, 
secondary outcomes parameters results will be presented.  
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1.5.5. Chapter 6: Discussion 
This chapter will discuss the findings related to primary and secondary outcomes in 
relation to published work and practice. Also the strengths and the limitations of the 
study will be discussed.    
1.5.6. Chapter 7: Conclusions 
This last chapter will summarise the main findings emerging from this thesis and 
highlight the role for podiatrists with regards to FOs management in JIA and the 
potential role in the paediatric rheumatology team.  
 
 Definition and Abbreviation 1.6.
 
1.6.1. Definition 
 
Occasionally different researchers may not have uniform terminology; therefore, it may 
arise in controversial interpretation of literature and/or results in this thesis. To avoid 
any misinterpretation of the content of this extensive study, please find below a list of 
terms used with their related meanings: 
 
 Rearfoot:   
In this thesis, rearfoot refers to the posterior part of the foot. In some publications 
authors describe it as the ‘hind foot’.  
1.6.2. Abbreviation 
(-PP): Peak Pressure Values 
(-PTI): Pressure Time Integral  
CHAQ: Child Health Assessment Questionnaire 
FOs: Foot Orthoses 
ILAR: International League of Associations for Rheumatology 
JIA: Juvenile Idiopathic Arthritis 
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JRA: Juvenile Rheumatoid Arthritis (term no longer in use, still present in some 
American publications) 
PedsQL: Paediatric quality of life tool, divided into Generic & Rheumatology Module 
PRINTO: Paediatric Rheumatology International Trials Organisation 
RA: Rheumatoid Arthritis 
VAS: Visual Analogue Scale 
‘*’   means p-value < 0.05  
‘**’  means p-value < 0.01  
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Chapter 2: Critical Appraisal 
 Epidemiology 2.1.
In children JIA is diagnosed up to 18 years of age (Takken et al. 2008). Studies 
conducted in developed countries have reported a prevalence for JIA of between 0.16 
and 1.13 individuals  per 1000 and it appears to be more common in girls with a female 
to male ratio of 3 to 2 (Yang 2008). Other researchers report that prevalence varies 
between 16 and 150 per 100 000 (Szer et al 2006). An epidemiological study on JIA 
carried out in the Nordic countries reported an incidence on 15/100,000 children/year 
(Berntson et al. 2003).  Specifically in the UK the prevalence is approximately 0.65 per 
1000 children (Manners and Bower 2002) with a more general worldwide incidence of 
between 0.07 and 4.01 per 1000 every year (Hendry et al. 2008; Karmazyn et al. 2007). 
It can be argued that the prevalence of this disease is underestimated (Ravelli and 
Martini 2007). According to NICE guidelines (2002) JIA is a relatively rare disease, 
with an estimated incidence in the UK of 0.1 per 1000 children, equivalent to 1000 new 
cases per year. The prevalence is in the order of 1 per 1000 children, so about 10,000 
children in the UK are currently affected (NICE 2002). Finally, it appears that different 
authors seems to report quite different prevalence and incidence data.  
 
In 2003 a longitudinal, prospective, population based study with JIA patients involved 
twenty doctors in Iceland, Norway, Sweden, Denmark, and Finland. Data collection 
included the incidence of cases reported over a period of 1.5 years, beginning July 1, 
1997.  This study showed that in the whole group of 315 patients, the incidence rate 
was 15 per 100,000 children / year (Berntson et al. 2003). On the other hand, a more 
dated community-based survey carried out in Australia outlines the prevalence of 400 
per 100 000 of school children (Manners and Diepeveen 1996). The authors also claim 
that worldwide the number of undiagnosed children with JIA may be much higher than 
the cases actually diagnosed so far (Manners and Bower 2002; Manners and Diepeveen 
1996).  
 
Finally, the progression of knowledge in paediatric rheumatology and the development 
of new technologies should help in reducing the number of misdiagnosed children, 
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which will allow earlier intervention and hopefully this will lead to better JIA 
outcomes.  
 
 Aetiology of JIA 2.2.
The causes of juvenile idiopathic arthritis are still not clearly understood but appear to 
be related to both genetic and environmental factors (Cassidy and Petty 2005). The 
term idiopathic stands for unknown cause. In this disease, the immune system 
mistakenly targets the synovium, the tissue that lines the inside of the joint. In 
autoimmune diseases, the immune system fails to distinguish between self-antigens and 
foreign antigens. As a result, an immune system response is generated against some 
self-antigens, resulting in tissue damage. The synovium often reacts by producing 
excess fluid (synovial fluid), which may lead to swelling, pain and stiffness. This 
autoimmune disease can be difficult to control because the inflammation process can 
often spread to the surrounding tissues, eventually damaging cartilage and bone. Many 
immunological abnormalities, such as the inflammatory synovitis in JIA, are similar to 
that seen in adult rheumatoid arthritis (Szer et al 2006).  The synovium may present 
with hyperplasia of the lining layer and an infiltration of the sub-lining layer with 
mononuclear cells, including T cells, B cells, macrophages, dendritic cells, and plasma 
cells (Gregorio et al. 2007; Wedderburn et al. 2000). The inflammatory process leads to 
pannus formation
2
, with cartilage and bone erosions mediated by degenerative 
enzymes, such as metalloproteinase (Hashkes and Laxer 2005). Even though the true 
cause of this autoimmune disease have not been yet fully clarified, the next section will 
explain in more detail the pathology and the different clinical features that practitioners 
are likely to encounter during a biomechanical assessment. 
 
 
                                                 
2
 Pannus: fluid and immune system cells that accumulate in the synovium. It usually appears as thickened synovial 
tissue. It produces harmful enzymes that destroy nearby cartilage, aggravating the area and attracting more 
inflammatory white cells; thereby perpetuating the degeneration process within the joint. 
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 Pathology of JIA 2.3.
 
JIA is the most common chronic rheumatic disease in childhood and adolescence and it 
may cause short-term and long-term disability (Ravelli and Martini 2007). JIA children 
can develop symptoms in many areas of the body, especially extremities (hands and 
feet) but inflammation can often occur also in the eyes (uveitis) which may lead to 
visual impairments (BSPAR 2006). 
 
Juvenile idiopathic arthritis is a term that describes different clinical subgroups. Each 
subgroup presents with unique clinical signs, symptoms and in some cases unique 
genetic background (Ravelli and Martini 2007). In order to successfully treat children 
affected by JIA, multidisciplinary effort is often required. As previously mentioned, the 
International League of Associations for Rheumatology (ILAR) recently proposed a 
new classification system in an attempt to reduce the international differences in 
defining and diagnosing JIA. This relatively new classification system includes seven 
JIA subtypes: 
 
1. Systemic Arthritis   
 
Arthritis with, or anticipated by, daily fever for at least 2 weeks’ duration; that must 
be recorded for at least 3 days, and must coincide with one or more of the 
following:  
 
- Evanescent, non-fixed, erythematosus rash. 
- Generalised enlargement of lymph node. 
- Splenomegaly and/or Hepatomegaly  
- Serositis.  
Exclusion: a,b,c,d (see below)  
 
This subgroup is usually equally found in boys and girls, and it does not appear to 
have a preferential age at onset. In order to diagnose this subtype of JIA, children 
present with quotidian fever for at least 2 weeks. In addition, one or more of the 
following conditions must be encountered: typical evanescent, non-fixed 
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erythematosus rash, hepatomegaly or splenomegaly, generalised lymphoadenopathy 
or serositis. Abdominal discomfort and myalgias can be frequent during high peak 
fever. Systemic arthritis  is usually found to be symmetrical and polyarticular 
(Ravelli and Martini 2007). Laboratory tests highlight the presence of leucocytosis, 
a very high erythrocyte sedimentation rate (ESR), C-reactive protein concentration 
and thrombocytosis. Anaemia is often diagnosed along with systemic arthritis 
which is usually different and more severe than adult rheumatoid arthritis (RA). 
These subgroups are rarely diagnosed in adults and are usually are defined as Still’s 
disease. Approximately 5-8% of patients within this subgroup develop a life-
threatening complication known as macrophage activation syndrome (Ravelli et al. 
2005). This syndrome can be recognised by a sudden onset of fever, pancytopenia, 
hepatosplenomegaly, liver complication and coagulopathy with haemorrhagic signs. 
Laboratory investigation shows raised triglyceride concentration, low sodium 
concentration and high concentration of ferratin (Ravelli 2002). Early recognition 
and intervention of macrophage activation syndrome could improve outcomes. 
 
2. Oligoarthritis 
 
Arthritis is diagnosed in 1-4 joints during the first 6 months of the disease. This 
group is subdivided in  
- Persistent Oligoarthritis: upset no more than four joints throughout the 
course of the disease. 
- Extended Oligoarthritis: upset a total of more than four joints after the first 
6 months of disease 
Exclusion: a,b,c,d,e (see below) 
 
This subgroup is characterised by arthritic changes that affect four or less joints 
during the initial six months of the disease. This form of arthritis features 
asymmetric and early onset (usually before six years old) arthritis. Oligoarthritis 
mainly affects the knees and ankle joints. Symptoms include pain, stiffness and/or 
swelling in the joints (Brescia 2008). This disease appears to occur more often in 
females, with a high frequency of positive ANAs (Antinuclear Antibodies). 
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Children that present with oligoarthritis are likely to encounter iridocyclitis
3
 and 
this can affect up 30% of patients. The onset of iridocyclitis (also called uveitis or 
iritis) may be totally asymptomatic and one or both eyes can be affected. Most 
patients are diagnosed with iridocyclitis during the first 5-7 years after onset. 
Children should be screened periodically by ophthalmologists (Brescia 2008; 
Ravelli and Martini 2007). These groups are rarely present in adults; however, 
iridocyclitis is commonly encountered with some HLA alleles. In addition ANAs is 
found in up to 70-80% of children (Ravelli and Martini 2007). According to the 
ILAR classification, the oligoarthritis group is subdivided into: 
 
a) Persistent Oligoarthritis: if no additional joints are affected over a period of 
time, it is called persistent Oligoarthritis. This condition is a milder version of 
the disease. 
 
b) Extended Oligoarthritis: if more than four joints are involved after the first 6 
months of disease. This subgroup represents the same disease, however, the 
outcome can be more severe. High sedimentation rate results would indicate the 
presence of this subtype, which would usually involve the upper limb joint also 
(Curtis and Rea 2007; Hull 2001; Thomson et al. 2002). 
 
3. Rheumatoid – Factor-Positive Polyarthritis:  
 
- Arthritis affecting five or more joints during the first 6 months of disease; 
tests for RF is positive.  
Exclusion: a,b,c,e (see below) 
 
According to the ILAR classification, this subtype of JIA affects five or more joints 
during the first six months of the disease and IgM RF
4
 is found in a blood test on at 
least two occasions, more than three months apart.  Young girls are more 
commonly diagnosed with this phenotype than young boys and usually children 
present with symmetric Polyarthritis. Symptoms include swelling or pain of small 
                                                 
3
 Iridocyclitis: a chronic, non-granulomatous, anterior uveitis that involve the iris and the ciliar part of 
the eyes. It has the potential to cause severe visual impairment and be present with or without active joint 
symptoms.   
4
  IgM RF Immunoglobulin M Rheumatoid Factor  
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joints such as hands and feet. Occasionally ankles, knees, hips and neck are 
reported to be painful as well (Brescia 2008; Miller 2008; Ravelli and Martini 
2007). Children may present with high fevers, skin rashes, and internal organ 
impairment such as of the heart, spleen or liver. This subtype appears to count for 
20% of all JIA children (Miller 2008). Rheumatoid nodules frequently appear 
within the first year of the disease in anatomical areas, such as elbows and forearms 
(Ravelli and Martini 2007).  
 
4. Rheumatoid-Factor-Negative Polyarthritis:  
 
- Arthritis affecting five or more joints during the first 6 months of disease; 
tests for RF is negative. 
Exclusion: a,b,c,d,e (see below) 
 
This subgroup is diagnosed when arthritic changes occur in five or more joints 
during the first six months of the disease in the absence of IgM RF. This subtype is 
less defined compared to the previous subtype, however, it is the most 
heterogeneous subtype (Szer et al 2006). According to Ravelli and Martini (2007), 
three different subtypes can be distinguished: the first one appears to be very 
similar to the early onset of oligoarticular JIA, with the exception that the number 
of joints affected over the past first six months. The second phenotype is a form that 
closely resembles the adult onset RF negative RA with the difference that it features 
symmetric synovitis of large and small joints in school age children. ANAs results 
are negative and increased values of ESR
5
 are often found. The third subgroup is 
known as dry synovitis, which does not appear to have swelling of joints; however, 
children are likely to present with flexion contraction and slightly raised ESR 
values. Outcomes are generally negative with poor response to treatments and the 
deterioration of joints. 
 
 
 
 
                                                 
5
 ESR: Erythrocyte Sedimentation Rate. It is the rate at which red blood cells precipitate in a period of 1 
hour.  
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5. Enthesitis Related Arthritis: 
 
- Arthritis and Enthesitis or 
- Arthritis and Enthesitis with at least 2 of the following: 
o Sacroiliac joint tenderness and/or inflammatory lumbo-sacral pain. 
o Presence of HLA B27 
o Onset of arthritis in a male after the age of 6 years. 
o Ankylosing Spondylitis, Enthesitis Related Arthritis, and Sacro-iliitis 
with inflammatory bowel disease, Reiter’s syndrome or acute anterior 
uveitis in a first-degree relative.  
Exclusion: a,d,e (see below) 
 
This subgroup is predominantly diagnosed in males after the age of six years who 
present with enthesitis and arthritis signs. Evidence shows that children with 
enthesitis-related arthritis are prone to have HLA-B27
6
 positive (Szer et al 2006). 
Children usually report symptoms at the calcaneal insertion of the Achilles tendon, 
plantar fascia and tarsal area. With the progression of the disease, sacroiliac and 
spinal joint may become symptomatic as well, resulting in signs similar of 
ankylosing spondylitis. It is generally accepted that this subgroup mainly affects the 
lower limbs and that pain is often remitting and mild. Approximately 50% of 
children have four or fewer joints affected during the entire course of the disease. 
ILAR classification for enthesitis-related arthritis has recently been criticised 
because reactive arthritis and psoriatic arthritis are not seen as part of juvenile 
spondylo-arthritides, and arthritis of inflammatory bowel disease is confined to 
being only a descriptor of the disease (Burgos-Vargas et al. 2002; Burgos-Vargas 
2002). 
 
6. Psoriatic Arthritis:  
- Arthritis and Psoriasis or 
- Arthritis and at least 2 of the following  
                                                 
6
 HLA-B27 is a blood test to look for specific protein found on the surface of white blood cells. The 
protein is called human leukocyte antigen B27 (HLA-B27). HLAs are proteins that help the body’s 
immune system tell the difference between its own cells and foreign, harmful substances (Medline Plus 
2007). 
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o Dactylitis  
o Nail Pitting or Onycholysis 
o Psoriasis in a first degree relative 
 
Exclusion: b,c,d,e (see below) 
 
According to ILAR classification, in order to diagnose this JIA subgroup the 
simultaneous presence of arthritis and psoriatic rash need to be present. If only the 
psoriatic rash is not present, two of the following conditions need to be diagnosed: 
nail pitting, dactylitis
7
 and family history of psoriasis in a first-degree relative 
(Ravelli and Martini 2007; Thomson et al. 2002). Few controversial opinions have 
been expressed regarding this specific subgroup, clinical and laboratory evidence 
questioned the appropriateness of its inclusion in this classification (Martini 2003; 
Petty 1994). Most children present also with: early onset of the disease, asymmetric 
oligoarthritis, iridocyclitis and ANAs positive. This features are very similar to the 
oligoarthritis subgroup, however, the main difference is that children with psoriatic 
arthritis have a greater chance of developing dactylitis and arthritic changes in 
small and large joints compared to oligoarthritis patients. Finally the prognosis of 
psoriatic arthritis, as defined according to ILAR classification, is not yet being 
established (Ravelli and Martini 2007). 
 
 
7. Undifferentiated Arthritis:   
 
- Arthritis that does not fulfil inclusion criteria for any category, or that is 
excluded by fulfilling criteria for more than one category.  
 
According to ILAR criteria, it does not represent a separate subgroup. It has been 
introduced to include all children who do not satisfy the previous inclusion criteria 
for any subgroups or who can be identified in more than one subgroup. The 
evidence based reports shows that in some cases, children with definite diagnosis 
could wrongly be included in this subgroup (Burgos-Vargas 2002; Tsitsami et al. 
                                                 
7
 Dactylitis: swelling of one or more fingers that extend beyond the joint margins. 
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2003). Following the suggestion of revision of exclusion criteria, few changes were 
made and incorporated into the second revision of the ILAR criteria (Burgos-
Vargas 2002; Petty 1994; Petty 2001; Tsitsami et al. 2003).  
 
Exclusion Criteria for the Classification of JIA 
 
a. Psoriasis in the patient or a first-degree relative 
b. Arthritis in an HLA B27 positive male with arthritis onset after 6 years of age 
c. Ankylosing spondylitis, enthesitis-related arthritis, sacro-iliitis with 
inflammatory bowel disease, Reiter’s syndrome, acute anterior uveitis in a first-
degree relative.  
d. Presence of IgM rheumatoid factor on at least two occasions more than 3 
months apart. 
e. Presence of Systemic Arthritis.  
 
The rational for classifying JIA children in different groups is to distinguish patients 
with certain physical manifestations from those without, which lead to better final 
diagnosis. The main reason why ILAR classification system has been adopted is to 
make a clinical distinction between different characteristics of every group with 
common arthritis diagnosis (Petty et al. 2004). The seven distinct groups are united 
under the umbrella term JIA in which the manifestation of arthritis begins before the 
age of 16 years. In order to thoroughly diagnose JIA, clinical features (number of joint 
affected, psoriasis, enthesis and family history of psoriasis or B27- related disease) and 
laboratory tests (rheumatoid factors, HLA B27)  are used as diagnostic evidence. In 
addition, having a well-recognised classification, which is widely used also 
internationally, helps paediatric-rheumatology researchers to improve and facilitate the 
understanding of JIA (Petty et al. 2004).  
 
With regards to prognosis and outcome, recent studies highlight inconsistent and 
conflicting results which are mainly linked to the subgroup of JIA. Research carried out 
over the past 10 years shows that only 40-60% of children had inactive disease or 
clinical remission at follow-up (Oen 2002; Ravelli 2004). A study conducted on 437  
JIA children over a period of four years, reported that only 6% of patients had clinical 
remission of symptoms for at least 5 years (Wallace et al. 2005). It has been reported 
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that greater severity, extension of arthritis onset and symmetrical disease are common 
outcomes in JIA children (Ravelli and Martini 2003) although the long term prognosis 
of JIA still remains uncertain (Wallace et al. 2004). 
 
 Clinical features in the lower limb in JIA 2.4.
2.4.1. The Hip in JIA 
During a biomechanical examination the podiatrist may be likely to encounter flexion 
deformities of the hip which may have a direct effect in increasing lumbar lordosis as a 
compensation effect for the hip extension is commonly associated with JIA. Increased 
lumbar lordosis may become very noticeable with typical protrusion of the buttocks, 
which could be recognised by the practitioner as the initial signs of unrecognised 
arthritis at the hip (Szer et al 2006).  
 
The British Journal of Radiology reported a publication that highlights the role of MRI 
scans in the evaluation of hip joint disease in JIA children (Argyropoulou et al. 2002). 
The results collected from 28 pathological children, reported that MRI scans are able to 
reveal early joint involvement and evaluate in detail the extent of the active joint 
disease. The hip is not a superficial joint, the clinical
 
evaluation for active inflammation 
may be challenging and imaging
 
can be effective in the evaluation of hip joint 
involvement in
 
JIA. MRI has been used to evaluate the whole articulation surface and 
provide accurate details of
 
the synovium, cartilages and bones. This study, suggested 
that MRI of the hip is a valuable method of assessment of patients with JIA 
(Argyropoulou et al. 2002). A more recent study published by Nistala et al. (2007) 
compared the diagnostic performance of clinical assessments against MRI in arthritic 
hip in 34 JIA children. The results highlight the role of MRI when there is clinical 
uncertainty between active and damaged hips. However the authors concluded that 
clinical and laboratory findings are inadequate diagnostic tools for the assessment of 
hip arthritis when compared with MRI as the gold standard (Nistala et al. 2007). It can 
be argued that, even if MRI scan seemed to be effective in diagnosing possible arthritis 
at the hip in JIA, some hospitals may find this option not always cost effective. On the 
other hand, if MRI scan may be taken at an early stage of the disease, it can be seen as 
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a valid investigative tool to encourage early diagnosis of the disease and immediate 
pharmaceutical and physical intervention.  
 
Finally in order to provide accurate clinical features during the hip examination, 
strength tests of the hip adductor, abductor, flexors and extensor should be performed at 
the same time (Szer et al 2006). The clinician should refer back to the muscle strength 
grading chart and record the finding in the clinical records. The patient must be 
positioned against gravity at all time prior to carry out the tests
8
 (Brown et al. 2007).    
2.4.2. The Knee in JIA 
The knee appears to be one of the most commonly affected joints in JIA and extension 
and flexion limitations are often observed (Cakmak and Bolukbas 2005). Children who 
suffer from arthritis in the knee often exhibit a unilateral involvement which may lead 
to atrophy of the quadriceps muscle of the symptomatic leg. Muscle weakness and 
reduction in strength have been reported to have a negative impact on the level of 
physical activity in children with JIA (Lelieveld et al. 2008). Podiatrists are able to 
recognise the typical signs of antalgic gaits, therefore, prompt biomechanical and 
physical therapy intervention may be proven valuable to help JIA children to reduce 
knee pain.  
 
The knee in JIA may appear to have either localized or generalised swelling. In the first 
instance, fluid may be accumulated inside one or more bursae of the knee (pre-patellar, 
suprapatellar, infrapatellar, pes anserine, or gastrocnemious-semimembranous – ‘Baker 
cyst’). In the second instance the fluid may be found within the joint itself or extended 
into the surrounding soft tissues as well. The suprapatellar bursa tends to be linked with 
the articular synovial space and it seems to be the most common bursa that becomes 
swollen and painful in arthritic children. Similarly the Baker Cyst directly 
                                                 
8
 Muscle strength grading chart (Brown, Hislop, and Montgomery 2007):  
 
Muscle Gradations  Description 
5 or normal  Complete range of motion against gravity with full resistance 
4 or good  Complete range of motion against gravity but not full resistance 
3 or fair  Full range of motion against gravity but no resistance  
2 or poor  No joint motion against gravity but complete motion when gravity eliminated  
1 or trace Evidence of some muscle contractility but no motion at all 
0 or zero No evidence of contractility  
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communicates with the joint creating a synovial pouch behind the knee (Szer et al 
2006).  
 
Patients with patellofemoral pain syndrome may present with anterior knee pain that 
typically occurs with activity and often worsens when they are descending steps or 
hills. It can also be triggered by prolonged sitting and knee hypermobility (Cutbill et al. 
1997; Fulkerson 2002; Junh 1999). Clinically, an uneven sensation during extension 
and flexion may be noticeable. Pain is often reproduced by palpating the medial under-
surface portion of the patella while contracting the quadriceps muscle (Szer et al 2006). 
In addition, the clinician often performs the test commonly called ‘patella apprehension 
test’. According to Ahmad et al (2009), the moving patellar apprehension test is an 
accurate physical examination technique which if performed and interpreted correctly, 
is highly sensitive and specific for patellar instability (Ahmad et al. 2009). It can be 
argued that if carried out in children with JIA this test may be too invasive.  
 
Research on JIA children proved that full extension and 110° flexion are required to sit 
down and stand up from a chair. If these angles and the strength of the quadriceps are 
maintained, the child will have a better chance of preserving a correct function of the 
knees (Cakmak and Bolukbas 2005).  
 
2.4.3. The Foot in JIA 
 
Foot and ankle problems are often diagnosed but relatively neglected manifestation of 
JIA (Foster et al. 2007; Hendry et al. 2009; Rothschild 1999).  
 
In a retrospective study of 100 children diagnosed with oligoarthritis, overgrowth of the 
involved extremity occurred in children who developed the disease before the age of 9 
with most having overgrowth before the age of 5 which never exceeded 3 cm. The JIA 
children who developed the disease after the age of 9, however, had rapid premature 
epiphyseal plate closure resulting in shortening of the limb affected by arthritis (Simon, 
Whiffen and Shapiro 1981). JIA is a diagnosis of exclusion (Haber et al. 2010). 
Additional causes of ankle and foot pain that must be considered are: trauma, infection, 
toxic synovitis, malignant or benign bone lesion, overgrowth and other systemic 
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rheumatologic diseases. Clinical observation of the associated warmth and redness of a 
joint is also important (Ilowite et al. 1992). Pain and stiffness is usually worse in the 
mornings and then it tends to improve with movement and activity, and worsens with 
inactivity. 
  
In normal conditions, JIA children usually exhibit 20° of dorsiflexion, 50° of plantar 
flexion (Szer et al 2006).  Some small outpunching of synovium may be appreciated 
around the ankle along with tenosynovitis
9
. Tenosynovitis most often occurs on the 
extensor sheaths over the dorsum of foot and the peroneus longus and brevis tendons 
around the lateral malleoli (Haber et al. 2010). Clinically, posterior tibial tendonitis is 
often present and maybe tender on palpation. According to a research carried out by 
Rothschild (1999) on JIA children, inflammation can occur in the forefoot, rearfoot, 
and ankle. Results showed that inflammation at the ankle was found in 51% to 59%, 
subtalar joint (STJ) in 1% to 13% and finally metatarso-phalangeal joint 49% to 68% 
respectively (Rothschild 1999).  
 
Another clinical feature used to confirm the diagnoses is joint fluid content. Joint 
aspiration and synovial fluid examination are useful to rule out other causes of arthritis. 
The white blood cell (WBC) count can be beneficial in helping to distinguish JIA from 
an infected joint. Usually, a WBC count greater than 40,000 (cell/mm
3
) is associated 
with infectious arthritis. Patients with JIA may have a much higher WBC (Haber et al. 
2010). A recent comparative study on synovial fluid component identified specific 
proteins which could act as criteria to prevent disease extension and may help to 
identify children who are at higher risk for recurrent inflammation and progression of 
JIA disease (Gibson et al. 2009). 
 
Rearfoot and Midfoot Pathology in JIA 
 
Biomechanical pathologies of the foot have been diagnosed directly associated with 
synovitis of the ankle and rearfoot  joints, which has been found in up to 40% of JIA 
                                                 
9
 Tenosynovitis: inflammation of the lining of the sheath that surrounds a tendon. The cause of the inflammation 
may be unknown, or it may result from: infection, injury, overuse, strain 
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children across all different 7 JIA subtypes and particularly in 81% of children with 
systemic onset JIA (Ferrari 1998; Hendry et al. 2008).   
 
Ferrari et al. (2008) reported that varus or valgus rearfoot position is likely to be 
diagnosed in JIA children; in addition, external factors such as ground reaction forces, 
knee and hip positions may have a direct effect on the rearfoot. The valgus foot 
position may be expected to be seen more frequently since the paediatric foot is 
typically pronated (Ferrari 1998). 
 
On examination swelling at the rearfoot joint may be present. Palpation of the 
calcaneum may be symptomatic at the insertion point of the Achilles tendon and origin 
at the plantar fascia (Cassidy and Petty 2001; Szer et al 2006). Significant excessive 
pronation of the foot is a frequent finding in JIA patients which mostly occurs when 
synovitis stretches the capsule and ligaments of the STJ and talo-navicular joints and 
increases calcaneal pressure (Haber et al. 2010). In contrast, a small study conducted by 
Fairburn et al. (2002) subdivided the 15 JIA children that took part in the study in an 
attempt to identify clinical pattern during gait analysis. Significant stiffness of the STJ 
was diagnosed in two children. It must be noticed that this study concluded that despite 
the initial clinical observations it was not always possible to predict the resultant gait 
pattern particularly because of the small sample size (Fairburn et al. 2002). In addition, 
varus deformity can also occur because of synovitis, usually as a compensatory 
mechanism during ambulation to prevent excessive pressure on the metatarso-
phalangeal and STJ (Haber et al. 2010).  
 
According to Szer et. al (2006), in ‘normal’ circumstances JIA children usually appear 
to have 5° STJ eversion and 5° of STJ inversion at close kinetic chain. Generally at 
open kinetic chain 2/3 of supination and 1/3 of pronation. However, few studies are yet 
available on the degree of STJ ROM that should be expected in JIA children. Hendry et 
al. (2008) reported that 7 of the 10 pilot participants referred were diagnosed with 
polyarticular JIA and presented a pes-planovalgus foot posture and/or lesser toe 
deformities, with limited ROM and symptomatic STJ.  
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Forefoot Pathology in JIA 
 
On some occasions, children seen at both hospitals in Edinburgh and Dundee, reported 
discomfort at the metatarsal heads particularly after activity. The arthritic forefoot, 
which consists of the inter-phalangeal and metatarso-phalangeal joints, creates 
deforming biomechanical forces that can act on the rearfoot, ankle and ultimately the 
rest of the body. Clinically the inter-phalangeal or metatarso-phalangeal joint may  
induce clawing of the toes. In addition to clawing, the inter-phalangeal joints may 
become dislocated (Melvin and Atwood 1989). Pain and swelling may lead to muscle 
contractions and eventual phalangeal joint flexion deformities may occur, which could 
present with the typical hallux valgus or hallux rigidus shape (Haber et al. 2010; 
Melvin and Atwood 1989).  
 
Szer et al. (2006) report that, clinically the ROM of forefoot abduction and adduction 
should be respectively 10° and 20°. Conversely, from the images on the Szer et al 
(2006) textbook, inversion and eversion of forefoot are illustrated instead, which may 
be misleading for the reader. A possible printing mistake may have occurred. On the 
other hand, plantar-flexion and dorsiflexion measurements, respectively 45° and 70°-
90°, seemed be correctly shown from the Szer et al. (2006) textbook. 
 
During data collection few JIA participants were diagnosed with forefoot varus (FV). 
This pathology is defined as a static, osseous deformity of the forefoot, where the plane 
of the metatarsal heads is supinated in relation to the rearfoot, when the STJ is kept into 
neutral position (Valmassi 1996). The FV is thought to induce increased pronation of 
the STJ and mid-tarsal joints during midstance phase, in order to allow the medial 
metatarsals to gain ground contact. This may cause excessive internal rotation of most 
of the structures of the foot towards its medial side, increasing the tibio-calcaneal angle 
and pronation. Instead of being a rigid lever during propulsion phase, the forefoot may 
become a mobile structure generating larger compressive and shear forces transmitted 
to the surrounding soft tissues (Alonso-Vazquez et al. 2009). All these changes may 
lead to negative effects on the rest of the foot and to the more proximal joints of the 
lower limb, which will all have to account for these FV modifications. Patient 
diagnosed with FV are more likely to complain lower limb pain, swelling, tiredness as 
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well as problems of balance and coordination impartment (Alonso-Vazquez et al. 2009; 
Valmassi 1996). 
 
MRI is very useful clinical diagnostic tool particularly used to identify the extension of 
the synovitis at the talo-navicular joint (Cassidy and Petty 2005). More evidence is 
required to fully establish clear clinical features of forefoot in JIA which may help 
clinicians with the clinical management. 
 
 
 Current Treatment JIA 2.5.
 
JIA multidisciplinary management is a vast expanding area of paediatric care in need of 
research. The goal of JIA treatment is to achieve remission of disease; a combination of 
pharmacological interventions, physical and occupational therapy, and psychosocial 
support is required (Wallace 2006). This thesis will help to support the role of podiatric 
intervention and to encourage other professions to turn to podiatry for cost effective 
and non-invasive treatment for JIA. The unclear aetiology for rheumatic disease and the 
paucity of randomised controlled trials leaves practitioners with little evidence upon 
which to base clinical management (Wallace et al. 2005).  However, even if drugs that 
are able to cure the disease are not available yet, over the past few decades prognosis 
has improved significantly. New therapies are now available to effectively intervene 
from lesser to more severe forms of JIA (Magni-Manzoni et al. 2003). The main focus 
should be to reach complete control of the disease, to maintain the physical and 
psychological integrity of the child and to prevent any long-term damage into 
adulthood (Ravelli and Martini 2007). As a result more paediatric rheumatologists are 
now shifting the method of tackling the disease, from ‘chasing failure approach’ 
(gradually adding medications according to the symptoms) to a more aggressive 
medical-pharmaceutical intervention.  
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2.5.1. Pharmaceutical intervention  
 
Many children that took part to this RCT study were under some sort of pharmaceutical 
intervention, which was regularly monitored by the rheumatology nurses and 
consultants. All recruited JIA children had to meet inclusion and exclusion criteria 
which also related to drugs administration guidelines (please see section 4.2.3 – 4.2.4. 
for more details). Throughout the clinical trial, pharmaceutical intervention was 
recorded and cross-checked with parents and clinical records. Any changes in the drug 
dosage were recorded and monitored over the six months period in order to avoid any 
misleading interpretation of results. In order to fully understand the methodology 
adopted to carry out this research project, it is important to provide the reader with 
more details on what is the current approach adopted by paediatric rheumatology 
consultants to prescribe drugs and to achieve remission of the disease and symptoms. 
The following section will discuss in details the pharmaceutical intervention starting 
from less to more powerful drugs. 
Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
Most children newly diagnosed with JIA start with administration of non-steroidal anti-
inflammatory drugs (NSAIDs). Just a few NSAIDs are licensed for use in children. The 
most commonly used include Naproxen, Ibuprofen, Meloxicam and Indometacin. 
NSAIDs block the COX
10
 enzymes and reduce prostaglandins production
11
 throughout 
the body. As a consequence, on-going inflammation, pain, and fever are reduced. In 
certain conditions like arthritis, two weeks are required before the full benefit of this 
drug takes effect. NSAIDs tend to be well tolerated and side-effects are less common 
than in adults with RA (Ravelli and Martini 2007). Less commonly used, Meloxicam
12
, 
an inhibitor of both COX1 and COX2, has proven to be effective and safe (Ruperto et 
al. 2005). The short and long-term safety and efficacy of meloxicam oral suspension 
has proven to be comparable with the safety and efficacy of naproxen in the treatment 
                                                 
10
 Cyclooxygenase (COX) is an enzyme is responsible for formation of important biological mediators 
called prostanoids. Pharmacological inhibition of COX can provide relief from the symptoms of 
inflammation and pain. 
11
 Prostaglandins are a family of chemicals that are produced by the cells of the body and have several 
important functions. They promote inflammation, pain, and fever support the blood clotting function of 
platelets; and protect the lining of the stomach from the damaging effects of acid. 
12
 Meloxicam is a non-steroidal anti-inflammatory drug with analgesic and fever reducer effects. 
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of oligoarthritis and polyarthritis JIA. The once-daily administration of Meloxicam oral 
suspension might represent an improvement in the treatment of JIA (Ruperto et al. 
2005).   
 
Disease-Modifying Antirheumatic Drugs   
 
 
JIA treatment includes medications that reduce the progression of joint damage. These 
types of drugs are called disease-modifying antirheumatic drugs (DMARDs), and they 
are an important part of an overall treatment plan.  Disease-modifying drugs act on the 
immune system to slow the progression of arthritis. A patient starting a course of 
DMARDs may take up to 6 months for the drugs to evoke a full response; these drugs 
are viewed as slow-acting (Pisetsky 1995).   
 
It is not exactly understood how DMARDs work. DMARDs appear to decrease some 
inflammation though they are not categorized as anti-inflammatory drugs. They are 
unlike NSAIDs since they do not decrease prostaglandin production, do not directly 
relieve pain, nor reduce fever. In effect, DMARDs slow the disease process by 
modifying the immune system in some way. Studies have shown DMARDs to be very 
effective drugs, with rarely observed serious side effects. Frequent laboratory 
monitoring helps control the risk of side effects. Once thought to be a short-term 
treatment, DMARDs are now regarded as a long-term solution to controlling symptoms 
(Pisetsky 1995). 
 
Methotrexate 
 
Methotrexate belongs to the DMARDs group of drugs. Methotrexate is an 
antimetabolite, cytotoxic and immunosuppressant administered in the treatment of JIA, 
rheumatoid arthritis, juvenile dermatomyositis, vasculitis, uveitis and some cases of 
systemic lupus erythematosus, localised scleroderma and sarcoidosis (BSPAR 2007). 
The BSPAR
13
 reports that Methotrexate is not licensed for use in childhood; however, 
it is extensively used in medical practice following positive clinical trials results. The 
published guideline confirms Methotrexate as the first line disease modifying anti-
                                                 
13
 BSPAR: British Society for Paediatric and Adolescent Rheumatology 
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rheumatic drug for JIA. Methotrexate may take up to 6-12 weeks to become effective 
after commencing treatment or a dose increase (BSPAR 2007). The efficacy of 10 
mg/m
2
 per week of this drug was first established in a well-known controlled trial in 
1992 carried out with 127 children (mean age, 10.1 years) who presented JIA for a 
mean duration of 5.1 years. The favourable findings from this quite dated RCT study, 
were very encouraging news at the time for clinicians who faced difficulties in 
managing a child's disease that had previously failed to respond adequately to non-
steroidal drugs (Giannini et al. 1992).  
 
Methotrexate is not a cure for JIA but has been proven to help to control the condition 
by reducing the symptoms and the need for other medicines (BSPAR 2010). When 
prescribed at higher dosages, methotrexate is a cytotoxic drug, which indicates that it 
can be destructive to cells and can be used for some forms of cancer. Methotrexate is 
usually administered once per week either by tablet, medicine or injection. Injections 
are recommended if a higher dose is required or if tablets induce sickness. It is 
important that pregnancy be avoided, because methotrexate may cause damage to the 
unborn child (BSPAR 2010). The Royal College of Nursing published extended 
guidelines for Paediatric Rheumatology Specialist Nurses, with the intention to provide 
clinical guidance to JIA children and their parents (RCN 2004). 
 
The Paediatric Rheumatology International Trials Organization (PRINTO) conducted 
an extensive randomised trial involving 20 countries with the aim to evaluate the 
efficacy and safety of Methotrexate at an intermediate dosage (15 mg/m2/week) versus 
a higher dosage (30 mg/m
2
/ week) in patients with polyarticular-course JIA whose 
condition failed to improve while receiving a standard dosage of methotrexate. This 
multicentre centre trial on 595 patients (followed up for 6 months) concluded that that 
the level of efficacy of methotrexate in JIA is achieved with parenteral administration
14
 
of 15 mg/m2 per week and that a further increase in dosage is not directly linked with 
any additional therapeutic benefit (BSPAR 2007; Ruperto et al. 2004). According to 
NICE guideline (2002) the DMARD of choice is methotrexate, administered orally or 
parenterally. The overall response rate to oral methotrexate in polyarticular-course JIA 
                                                 
14
 Parenteral: indicate medication that are administered by injecting a drug directly into a vein 
(intravenous), muscle (intramuscular), artery (intra-arterial), abdominal cavity (intra-peritoneal), heart 
(intra-cardiac) or into the fatty tissue beneath the skin (subcutaneous). 
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is estimated to be 85% in the short term. The evidence base for the effectiveness of 
alternative drug therapies is poor and no particular therapy stands out as the first choice 
once methotrexate has failed (NICE 2002). 
 
Biologics 
 
Hashkes and Laxer (2006) strongly state that even if many advances in the treatment of 
JIA, there is still a lack of evidence for treatment of several disease subtypes. The 
authors claimed that clinical management plan needs to be specifically adapted, based 
on the different JIA groups (Hashkes and Laxer 2005). The biologic therapies 
(etanercept, infliximab, adalimumab, anakinra, abatacept and rituximab) represent one 
of the latest pharmaceutical options available to treat more difficult cases of JIA. These 
types of drugs have been proven to be effective in treating inflammatory arthritis 
(Wallace 2006). The role of biologic therapies in patients with inflammatory joint 
disease is an evolving area which has significant clinical implications for clinicians. 
The term ‘biologic’ indicates a type of treatments created in live cell (biologically 
active systems). In biologics for inflammatory arthritis, the antibodies or proteins were 
initially designed to target or disable specific pro-inflammatory cytokines. The first 
biologic therapies to be developed targeted the pro-inflammatory cytokines tumour 
necrosis factor alpha (anti-TNFα15) and interleukin 116 (IL-1receptor agonist). Their use 
in children however, may generate special problems in JIA children, including the 
increased risk of infections (especially varicella), how or when to carry out standard 
immunizations and developmental issues at the central nervous system. The cases of 
reactivated tuberculosis have been particularly difficult; so all children should have a 
documented negative TB skin test before starting any biologic therapy.  Wallace et al. 
(2006) reported that flare of disease occurred in most patients (treated for less than 1 
year) within 1 month of discontinuing etanercept (longer for infliximab). It can be 
                                                 
15
 TNF: (tumour necrosis factor) is one of many natural inflammatory mediators that can cause disease 
when it is not regulated.  Anti-TNFα therapy for arthritis may generate suppression of inflammatory 
disease processes and improve clinical results.  The aim in anti-TNFα therapy in arthritis patients is to 
control excess TNF, while limiting associated risks. 
16
 Interleukin-1: (IL-1) refers to a group of three polypeptides (interleukin-1 alpha (IL-1α), interleukin-1 
beta (IL-1ß) and interleukin-1 receptor antagonist (IL-1Ra)) that play a central role in the regulation of 
immune and inflammatory responses. Both IL-1α and IL-1β are produced by macrophages, monocytes, 
fibroblasts and dendritic cells. They form an important part of the inflammatory response of the body 
against infection. 
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argued that there is inconsistent evidence of patients with JIA successfully stopping 
etanercept without flare of disease (Wallace 2006).  
 
According to the guidelines published by the Royal College of Nursing Rheumatology 
(2009), to date, almost 1.5 million patients have been treated worldwide with anti-
tumour necrosis factor alpha (known as anti-TNFα, anti-TNFs or TNF inhibitors). The 
resultant large volume of research into anti-TNFα therapies initially showed evidence 
of the safety and efficacy of these therapies for treating RA, but more recently further 
research also supports its uses for other conditions, such as psoriatic arthritis (PsA) and 
ankylosing spondylitis (AS) and other long term conditions (RCN 2009). Finally the 
introduction of biological medications has provided a very important new therapeutic 
option for the treatment of patients with juvenile idiopathic arthritis, who are resistant 
to conventional antirheumatic agents (Ravelli and Martini 2007). 
 
The National Institute for Clinical Excellence (NICE) has published in 2002 extended 
guideline on the use of etanercept for the treatment of JIA. Etanercept is a recombinant 
human TNF receptor fusion protein that acts competitively to inhibit the binding of 
TNF to its cell-surface receptor (NICE 2002). Etanercept is licensed for the treatment 
of active polyarticular-course JIA in children aged from 4 to 17 years old who have 
responded unsuccessfully, or who are reported to be intolerant to methotrexate. 
Etanercept is supplied as a twice-weekly subcutaneous injection and may be 
administered for an indefinite period of time. However, once a child with JIA has had 2 
disease-free years, it is common clinical practice for drug treatment to be stopped, even 
if evidence shows that 30% of children would be expected to manifest symptoms again 
(NICE 2002).   
 
In the document published by NICE (2002) it appears that only a consultant who 
regularly treats children and young people with JIA and who manages specialised 
paediatric rheumatology clinics should prescribe etanercept. In addition, the clinic 
should have specially trained nurses who regularly teach children and parents how to 
administer etanercept. Both paediatric rheumatology departments involved in the 
multicentre trial, where the recruitment of JIA children took place, met the standard set 
out by NICE (2002). The paediatric rheumatologist consultants and specialist 
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rheumatology nurses worked closely with children and parents to monitor the 
pharmaceutical progress of many more aspects directly related to JIA care. 
 
2.5.2. Physiotherapy and Occupation Therapy 
 
Physiotherapy (PT) and occupational therapy (OT) provide valuable support and 
complement pharmaceutical intervention for treating JIA. Both at the Royal Edinburgh 
for Sick Children and Ninewells Hospital, PTs and OTs are actively working alongside 
the consultants and the specialised rheumatology nurses. Treatment of JIA includes 
education, medical treatment, physical therapy, and occupational therapy (Cakmak and 
Bolukbas 2005). A multidisciplinary approach is necessary for the successful treatment 
of JIA. The authors do not mention a possible involvement of podiatrists in the care of 
JIA. However, they support the participation of paediatric rheumatologists, physiatrists, 
therapists, psychologists, and dieticians (Cakmak and Bolukbas 2005). It can be argued 
that suppressing the inflammation is often insufficient to return the child to normal 
functioning (Malleson 1997). JIA children may develop painful deformities at the 
joints, not due to damaged joints, but due to inadequate treatment given to the soft 
tissue contractures that may appear as a consequence of having a painful, swollen joint. 
Therefore, in the treatment of JIA it is important to involve PTs and OTs occupational 
therapists in order to commence the appropriate rehabilitation programme in time 
(Malleson 1997).  
 
PTs and OTs clinical intervention should occur at early stages of the disease, soon after 
a diagnosis of JIA has been made and pharmacological intervention has started. 
Treatment should include: assessment and management of pain and functional 
restriction, reduction of disability using age-appropriate techniques to maintain optimal 
function, evaluation and teaching of coping skills to improve self-efficacy, education 
programme to improve compliance and finally providing regular support and referral to 
the required member of the rheumatology team (Kutcha and Davidson 2006; Szer et al 
2006). 
 
In some instances, parents may be inclined to excessively protect their children and 
limit their activities level, which can affect the proper development of the child's 
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personality and prevent them from gaining adequate self-confidence and self-esteem. 
When appropriate, psychological support can be provided (Ravelli and Martini 2007). 
Children may have problems with teasing at school, bullying, or feeling isolated during 
sports activities. The therapist’s role should include monitoring and assessing the need 
for any equipment required to enhance physical independency.   
 
The precise roles of PTs and OTs may vary between countries and hospitals. However, 
in the early stages of the disease, pain is usually the first manifestation that alerts the 
family to look for medical support. PTs and OTs should encourage the family to 
supervise the child’s functional limitation, both at school and at home, and directly 
engage in the treatment management by monitoring whether the child complies with 
the prescribed exercises. Evidence shows that when the family and the child are given 
the appropriate assistance and support, the level of anxiety decreases. "Adherence" is 
now the preferred term in the literature, replacing the term "compliance". The term 
adherence better reflects a more active role for patients in consenting to and following 
prescribed treatments (Rapoff 2006). The review published by Rapoff and Lindsley 
(2007) highlighted the difficulties that PTs and OTs usually have to face when coping 
with JIA treatment. An adherence questionnaire was distributed to 37 parents of 
children with JIA. The children involved were given medications and range-of-motion 
exercises, splints, or both. Negative reactions to medications were reported by 43% of 
parents. On the other hand, parents noted more problems (60%) with prescribed 
exercises. Children appeared to be complaining, refusing to do the exercises and crying. 
This review may help to better understand the difficult challenges that PTs and OTs 
have to face on a daily basis in encouraging self-management JIA (Rapoff and Lindsley 
2007).   
 
In conclusion PTs and OTs face a difficult task in treating JIA children. Prolonged 
physical and psychological support is required and often adherence in treatment can be 
difficult. Although podiatry does not yet appear to be a valuable part of the 
multidisciplinary team, certainly PTs and OTs already have an established clinical role 
in paediatric rheumatology. 
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 Normal Gait Cycle 2.6.
It is extremely important for podopaediatrics to be aware of what is a ‘normal gait’, to 
be able to diagnose possible pathologies in children’s ambulation. The development of 
an adult-like gait is a constant maturation closely linked with the nervous system, 
muscle and bone growth. In addition, Volpe (2001) emphasised the idea that the child 
is not a ‘mini adult’. Many parents are often concerned about their children’s walking 
style from noticeable wide base of gait, significant bowed leg, and out-toeing. Most of 
the developmental milestones in growth should occur by 4-5 years of age (Sutherland 
1997; Thomson and Volpe 2001). As a result, the minimum age inclusion criteria, for 
the recruitment of JIA children in this RCT, were set to start from 5 years old.  
 
Not many clinical trials have been conducted yet to develop models for normal 
paediatric gait compared to adults, however, Smith et al. (2008) lately carried out a 
comparison study using three-dimensional foot and ankle motion analysis with 10 
children vs. 40 adults. The authors stated that the rearfoot is referenced to the tibia and 
exhibit three main rockers in the sagittal plane: initially the ankle rocker occurs at heel 
contact during the first 5% of the gait cycle. The second rocker corresponds to a 
prolonged dorsiflexion of the rearfoot relative to the tibia. The remaining 15% of stance 
phase represents the forefoot rocker in which the rearfoot is no longer weight bearing  
due to gastroc-soleus muscle contraction activity. During the swing phase, ground 
clearance is obtained thanks to dorsiflexion of the foot and prepares for heel strike. In 
addition to this quite generalised summary of sagittal motion of a child gait, Smith et al. 
(2008) reported that STJ eversion during loading is on average of 4° and that STJ 
inversion instead occurs in late stance and continues through push-off. With regards to 
the sagittal motion of the forefoot, three dimensional data showed that it remains 
surprisingly stationary with respect to the rearfoot. Conversely, the forefoot appeared to 
pronates and abduct mostly at early and midswing phase. Even if there were limited 
number of subjects who took part in this comparative study, the technology used 
allowed data analysis of the hallux. In the sagittal plane, the hallux dorsiflexed on 
average of 35° during propulsion phase, which can be justified by the smaller strides 
that children have compared to an adult gait (Smith et al. 2008).  On the other hand, it 
can be argued that many children tend to walk on forefoot, especially early walkers, 
which may exacerbate hallux dorsiflexion ROM (Thomson and Volpe 2001).  
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After 4 years-of-age the changes in velocity, cadence and step length in normal 
children are generally attributed to limb length growth (Sutherland 1997). Walking 
velocity is indicated by stride frequency and stride length. In normal children’s gait, the 
right and left step lengths are approximately equal amongst each other. Force plate 
recording in children between 2 and 7 years-of-age highlighted an increase of vertical 
force curve during the mid-stance phase. Particularly in subjects of 4 years and older, 
similar gait patterns to adults were recorded, such as the moments of forces 
17
 and 
power curves of hip, knee and ankle movement. However, there are significant 
differences in magnitude between children and adult, suggesting that the youngest 
children use their hip flexor and extensor muscles more than their ankle plantar flexors 
for power generation (Sutherland 1997). 
 
As normal children develop, cadence appeared to decrease while walking velocity and 
step length increases. Important contributor factors in the development of a more adult 
gait is the increase of limb length and higher limb stability, proven by increased 
duration of single-limb stance (Sutherland et al. 1980). It can be argued that this well-
known publication, still often referenced in many paediatric textbooks, may be one of 
the first publications that enhanced the knowledge of paediatric gait analysis. However, 
the clinical relevance of this publication may be debatable as there are no specifications 
on the criteria used to differentiate children who were considered to be normal rather 
than abnormal. If more than one clinician was involved in the recruitment process, 
details on what was used to distinguish ‘normal’ from ‘abnormal’ children gait during 
biomechanical examination should have been reported. This important detail may have 
significantly skewed the results published. In addition, the authors failed to mention if 
the patients had lower limb injuries or operation prior to the study; or indeed if there 
were specific inclusion or exclusion criteria at all. No details are reported on the level 
of children symptoms present prior the recordings. Furthermore, even if the 186 
subjects appeared to be completely asymptomatic, it does not necessarily indicate that 
the children did not present with biomechanical abnormalities which could have 
influenced the results. The reader is not informed if the recordings were carried out 
more than once with the same children at a given interval of time, as this useful data 
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 Moment: it indicate a tendency to produce motion 
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could have proven reliability and repeatability level of the equipment used and the chief 
investigator/s skills.   
 
An important component of paediatric gait analysis is the availability of age-matched 
normative databases (Chester et al. 2007). Difficulties in comparing children’s gait 
analysis data with what is normal may be attributable to disparities in marker sets, data 
processing techniques, and consistency of clinicians. Other differences arise from 
advances in computer technology, which have significantly improved motion analysis 
systems and data processing capability over the last 10 years. To prove this statement, a 
recent study conducted by Chester, Tingley and Biden (2007) compared a modern gait 
database to the historical San Diego database, using statistical classifiers developed by 
Tingley et al. (2002). In this recent research, gait analysis was performed on 60 
children aged between 1–13 years (Sutherland et al. 1988; Tingley et al. 2002). A six-
camera Vicon 512 motion analysis system and two force plates were chosen to record 
temporal-spatial, kinematic, and kinetic parameters during ambulation. Results 
indicated significant differences in sagittal angle data between the two databases and 
the reasons for these disparities were particularly attributed to technological advances 
and data processing techniques (data smoothing, sampling, and joint angle 
approximations).   
 
Not many publications are available at present that fully describe what to expect in a 
normal child’s gait. However, it can be noticed that at 7 years old children’s cadence 
appears to be higher compared to adult gait, as well as walking velocity and pelvic 
rotation and hip joint rotation. Cadence results show an average of 140 steps per minute 
by the age of 7 years old, with mean velocity of 1.14 m/s. Typically adults instead 
appear to walk 1.46 m/s in males and 1.30 m/s for female (Sutherland et al. 1980; 
Volpe 2001). Generally children exhibit greater hip abductor during the swing phase, 
the step length increase as the limb is lengthening, which matches with the decrease in 
cadence noticeable with normal growth pattern. Tibialis anterior activity recorded with 
electromyography (EMG) showed that normal children have a prolonged stance phase 
compared to adults. In addition, paediatric gait could exhibit recurrent foot drop during 
swing phase and almost absence of heel strike, more common in very early walkers 
(Sutherland 1997; Volpe 2001).  
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In conclusion, all the studies discussed above are encouraging evidence that there is a 
need for clinicians to distinguish what is normal from abnormal. Being fully aware of 
what to expect during normal paediatric gait analysis at different ages, may be the key 
to base a more successful clinical management. It is more difficult to observe children’s 
gait and make a concrete observation when compared to adults; however, many steps 
forward have been made in technology, from three dimensional systems to digital 
plantar pressure software, which significantly aid clinicians in establishing the 
appropriate treatment for children. It can be argued that the results obtained from quite 
dated publications may be difficult to relate completely to studies carried out using 
modern technology.  
 
  Pathological Gait in JIA 2.7.
Children diagnosed with JIA may suffer from lower limb pain that may lead to posture 
and movement modifications and may cause muscular imbalance with a reduced range 
of motion in the affected joints. JIA impairs joint function and may result in significant 
physical handicap (Hafner et al. 1998). Previous research investigating controlled 
quantitative gait analysis in JIA highlighted significant alterations compared to healthy 
children in recorded kinematics and temporal data (Brostrom et al. 2007). Evidence 
from two cross-sectional studies highlights that children with arthritis are physically 
less active compared to healthy children (Takken et al. 2008). A recent study indicated 
that foot problems are common in JIA, with a prevalence of over 90%. It appears that, 
even if DMARDs, biological therapy and podiatry foot care are often used as a 
treatment, foot related issues and disability still persist in some JIA patients (Hendry et 
al. 2008). Foot impairments, including joint pain, stiffness and deformity can alter 
walking patterns, therefore sharply reducing physical activities when compared to 
healthy children. As a result children with JIA may have a lower aerobic capacity 
(Broström et al. 2002). Joint pain and inflammation trigger a vicious cycle that often 
ends in joint damage and fixed deformities (Hartmann et al. 2010). Physical activity 
(PA) is increasingly considered an important part of treatment for JIA patients in order 
to maintain joint function, to encourage normal growth and development, and to 
prevent a number of chronic diseases (Cassidy and Petty 2005; Hartmann et al. 2010; 
Rey-Lopez et al. 2008).  
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Hartmann et al. (2010) conducted a very informative comparative study with 36 JIA 
patients (with symmetrical polyarticular joint involvement of the lower extremities) and 
20 healthy controls children which showed statistically significant differences. This 
study, published by the International Journal of Paediatrics, focused on the differences 
in kinematic, kinetic, and spatio-temporal parameters with 3D gait analysis. The 
authors aimed to quantify the differences in gait and to provide data for more detailed 
sport activities recommendations. Six infrared cameras (120 Hz) (Vicon,MX3) and one 
3D ground reaction force plate (1080 Hz) allowed the recording of  high resolution data 
which highlighted reduced walking speed and step length in JIA children. Arthritic 
children also appeared to have strongly anterior tilted pelvis, reduced maximum hip 
extension, reduced knee extension during single support phase and reduced plantar 
flexion in push off. The toeing off phase of gait seemed to be slower compared to 
healthy children. Additionally, the reduced push off motion recorded at the ankle was 
confirmed by lower peaks in ankle moment and power. It is reported that the gait of 
JIA-patients can be defined as a crouch-like gait with hyper-flexion in hip and knee 
joints and reduced plantar flexion in the ankle. The authors concluded that PA, 
stretching and strengthening the flexor and extensor muscles would be recommendable; 
and that more research is necessary to optimize recommendations for sporting 
activities. It can be argued that results may have been slightly skewed by the unequal 
number of subjects present in the control group (only 20) and also that within the 
control group 17 children were female and only 3 were male. In this retrospective 
study, data collection was carried out over 3 years, as part of routine procedures to 
individualise physiotherapy intervention. The reader should have been informed if 
more than one data collector was involved during this extended recruitment time. The 
authors should have provided details on the clinicians who were involved in data 
collection and particularly more information should have been written on the technique 
adopted in placing 3D markers. The reader is uninformed if the methods carried out 
were repeatable and reproducible over time. Furthermore, no details were provided 
about whether the JIA group were taking drugs and if data recorded were repeated 
more than once per session, which could have provided more accurate results. If the 
data would have been recorded over a longer period of time (for example 2 data 
collection session over 1 week interval) results would have shown that both groups 
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exhibited the same gait pattern and consequently confirmed the conclusion made by the 
authors. 
 
Similarly, a study conducted by Brostrom et al. (2002) compared gait in JIA with a 
control group. This time the number of subjects in each group was more balanced (15 
JIA and 14 control group). In this study published in the ‘Scandinavian Journal of 
Rheumatology’ all JIA subjects presented with lower limb involvement, with disease 
onset ranging from 1 to 10 years. This group was divided into two groups based upon 
whether the arthritis was affecting one leg (no= 4) or bilateral involvement (no=11) and 
classified also as oligo and polyarticular arthritis (respectively no=7 and no=8). Light-
beams were used to record walking velocity and pain level was recorded with VAS. 
Two force plates allowed ground reaction forces to be recorded and foot-switches were 
used to obtain temporal parameters. The pilot study was conducted to prove that the 
mat did not affect the ground reaction forces recorded. Unlike the previous research 
mentioned by Hartmann et al. (2010), in this study ten walking trials were recorded 
with each subject, 5 trials with laboratory built foot-switches on both feet, and the 
remaining 5 without. Each foot switch was made of two rounded plastic coated 35mm 
diameter, which was attached with double-sided tape at the heel pad and underneath the 
3
rd
 metatarsal head. The first switch aimed to record heel strike and the latter toeing off; 
a complete walking trial was recorded if the child’s right and left foot made a clean 
contact with the force plate. The authors reported that mean velocity for the children 
with JIA was significantly reduced when compared to the healthy controls. Peak 
vertical forces appeared to be different because the control group showed more 
pronounced heel strike and push-off. The smaller unilateral disease involvement group 
presented a tendency to have shorter single leg support than the control group. Results 
showed that the children who had higher VAS score exhibited slower walking speed 
and also bilateral disease involvement (Broström et al. 2002). On the other hand, it can 
be noticed that pain scores may be debatable as the reader is not informed if the 
patients were under medication that could have influenced the pain level hence the 
walking speed. It may have been more sensible to involve JIA children with stable 
pharmaceutical administration over a prolonged period of time. As previously reported 
in this thesis, certain medication may take up to 6 months to be fully effective. 
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Alternately, if the course of medication has been changed, the authors should have 
mentioned it in the result session. It can be argued that only applying a 35 mm sensor 
underneath the 3
rd
 head to record propulsion phase may be not enough especially if the 
child present certain foot deformities as a compensation for abnormal gait. Also if the 
children presented with ankle or forefoot equinus, the time in which the forefoot would 
be in contact with the ground may occur very quickly but for a prolonged period of 
time when compared, for example, to pes planus. The list of compensation mechanisms 
that can occur in abnormal JIA gait may be quite long, therefore the single application 
of a sensor only underneath the 3
rd
 metatarsal head, may be deemed to be insufficient.  
 
As mentioned by Fairburn et al. (2002) it can be challenging to identify the range of 
gait deviations associated with JIA using only simple clinical observations. In this 
prospective study of 23 children with gait abnormalities referred for biomechanical 
assessment over a three year period, the ‘Novel Pedar’ in-shoe plantar pressure 
measurement system was utilised to record gait. During recruitment, 8 out of 23 
children were excluded due to other diseases or neurological complications; the 
remaining 15 children had JIA with predominantly symmetrical polyarticular joint 
disease. The authors created clinical groupings based on the extent of joint restriction: 
minimal (group A, no= 7), and moderate–severe (with supinatory foot deformity (group 
B, no=6), or with pronatory foot deformity (group C, no=2). Gait analysis enabled 
classification of each subject into one of four gait patterns: either near normal (pattern 
I) or one of three adaptive patterns defined by the predominant abnormality—lower 
limb pain (pattern II), lower limb deformity (pattern III), or a combination of pain and 
deformity (pattern IV). All the subjects with gait patterns I and II were found in clinical 
group A. Both subjects from clinical group C exhibited gait pattern III. All subjects 
from clinical group B and the remainder from group A exhibited a mixture of gait 
patterns III and IV. Not surprisingly, the initial clinical observations did not always 
allow correct prediction of gait patterns. Conversely, scientific gait analysis allowed a 
clear distinction to be made between primary and secondary gait deviations, and 
accurate targeting of physiotherapy and orthotic management to best suit each child. 
The authors also recognised that a larger sample size of prospective quantitative 
analysis is required to provide more significant findings (Fairburn et al. 2002). Unlike 
platform systems, the use of plantar pressure FOs allows the collection and analysis of 
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data from a number of steps, while walking in shoes with or without orthoses. Plantar 
pressure data are commonly displayed as peak pressures produced during gait. 
However, some clinicians may object that the Pedar system may be too expensive, 
especially when dealing with paediatric gait where many Pedar insoles are required for 
each shoe size. In addition, the thickness of the Pedar insole is 2.2 mm which is much 
thicker than the F-Scan system only 0.15 mm; it can be argued that additional thickness 
may be perceived as intrusive or uncomfortable inside the child’s shoe especially if 
data is recorded with an orthotic inside the shoe. 
 
In the survey conducted by Hendry et al. (2008) gait abnormalities, deformity or 
abnormal foot biomechanics, and/or active foot disease were the main reasons for 
referral of JIA to the specialist podiatrist. Footwear advice, orthotic therapy and 
silicone digital splints and intrinsic muscle-strengthening exercises were used in 7 
children assessed in this survey. The authors reported that lower limb pathology, foot 
deformity, and pain may inevitably lead to altered gait function (Hendry et al. 2008). 
Therefore, the use of orthoses was deemed to be an effective, non-invasive intervention 
that aimed to correct gait patterns. Children performed simple walking trials at a self-
selected cadence. Gait was recorded using Gait-RITE, CIR-Systems. During the data 
collection the recorded variables included walking speed (m/s), double-support time (s) 
and step length (m). Walking speed ranged from 0.84–1.38 m/s, with a median of 1.09 
m/s. The median double-support time was 0.2s, ranging from 0.1–0.3s. This survey 
concluded that primarily flexion and flexion/valgus deformity at the knee and ankle, 
can lead to pathological gait patterns. 
 
In the thesis published by Broström (2004) difficulties are reported to take several 3D 
recording trials especially because JIA children often are in poor physical condition. 
Arthitic children may also present issues during gait analysis recording as they have to 
strike specifically on the force plate with only one foot at the time. This knowledge, 
together with children shorter strides, may not truly reflect the natural walking style 
during gait analysis. The clinical implication reported is that JIA gait may present with 
loss of power in plantar flexor and dorsiflexor muscle during walking, which directly 
affect heel strike and propulsion phase. JIA disease can influence strength muscle 
function at the ankle joint by 40% - 50%  The weakened lower limb muscles can not 
only impair ambulation patterns, but also directly affect walking speed. The authur also 
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concluded that gait analysis  is a proper and clinically relevant tool to establish and 
quantify joint movement with JIA (Broström 2004). 
 
In order to gain a better understanding of pathological gait, it is important also to focus 
on the movement of the trunk and centre of mass (CoM). In order to maintain a static 
position, the CoM must remain in balance over the base of support; and the vertical 
projection onto the ground is often related to the centre of gravity (CoG). The change in 
CoM motion during gait represents the overall result of joint and segment movements 
on the forward progression, and is of importance when describing pathological gait 
(Winter 1995). A comparison study carried out by Broström (2007) investigated these 
issues further, by recording with 6-camera 3D motion analysis system between JIA and 
healthy subjects, and the direct effects of intra-articular cortico-steroid treatment were 
evaluated. Seventeen children between 5 and 16 years of age (mean 11.4, SD 2.9 years, 
14 females, and 3 males) with JIA and twenty-one healthy subjects between 5 and 14 
years of age (mean 10.4, SD 2.5 and 10 female, 11 male) were recruited. The patients 
with JIA were treated and injected with methylprednisolone acetate
18
. The treatment 
policy for the study was to inject joints that are active (with synovitis) at the time of 
evaluation. Results showed that children with JIA appeared to have more posterior tilt 
in the trunk, in contrast to the general clinical perception (Brostrom et al. 2007). Data 
analyses also showed that CoM was more posterior and off-centred (medio-laterally) 
relative to the pelvis, which could have been directly related to pain level. According to 
the authors, whether the pain at the hips can lead to a compensatory mechanism in gait, 
resulting to a reduction of hip abductor moment should still be investigated further. 
However, such a mechanism may lead to greater medio-lateral CoM motion within the 
pelvis (Brostrom et al. 2007; Gutierrez et al. 2003). Several other factors may influence 
the CoM movement, for example gender differences, particularly female have more 
frontal plane pelvic motion during gait compared to males, however, further evidence 
needs to be carried out specifically in JIA (Smith et al. 2002). Finally, Broström 
(2007)’s results could have several implications in clinical practice. By understanding 
how children with JIA compensate for pain at the hip level, ultimately it may be 
possible to plan better physical treatment to improve their gait and correlate the use of 
functional FOs to aid the improvement of biomechanics.  
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In conclusion, it is encouraging to observe that level of research interest in gait in JIA. 
More research still has to be conducted to define the pathological JIA gait clearly, with 
the aim of facilitating clinicians to intervene effectively and promptly in improving gait 
patterns. 
 
 Foot Orthoses in JIA 2.8.
As previously mentioned, foot orthoses (FOs) have been used for many years with the 
aim of improving symptoms, preventing deformity and enhancing patient’s 
performance (Landorf and Keenan 2000). In children, FOs has been found to improve 
parameters of gait and posture; however, little research has been carried out on subjects 
with JIA (Evans 2003; Landorf and Keenan 2000; Marie 2005; Powell et al 2005; 
Selby-Silverstein, Hillstrom and Palisano 2001; Sullivan 1999; Szer et al 2006). In the 
well-known publication carried out by Cakmak and Bolukbas (2005) the use of FOs has 
been reported to be an effective option during the physical rehabilitation of JIA 
(Cakmak and Bolukbas 2005). Similarly Harry et al. (2004) in the journal of ‘Foot & 
Ankle Surgery’ published an extensive clinical practice guideline for diagnosis and 
treatment of paediatric flatfoot. The use of orthosis is recommended with this common 
paediatric pathology, also as pre and post-surgical intervention; in addition, follow-up 
appointments are suggested in order to assess the prescription made over a period of 
time (Harris et al. 2004).  
 
A number of theories have been suggested to explain how FOs works. It appears that 
the STJ has a direct effect on the range and direction of motion of joints both proximal 
and distal to it. Therefore, in order to prescribe functional orthotics, it is important to 
establish the STJ neutral position. As stated by Root et al (1971) “the neutral position 
of the STJ is that position of the joint in which the foot is neither pronated nor 
supinated” (Root et al. 1971). Hence, orthotic aims to maintain ankle and foot joints 
into neutral position during close kinetic chain. Podiatrists must have a thorough 
knowledge of the biomechanics of the lower limbs and an understanding of how to 
manufacture and modify FOs (Valmassi 1996). In addition, a child’s foot is much more 
flexible compared to adults with RA; therefore, when FOs is supplied, improvement of 
joint alignment is expected to be found with subsequent higher benefit in the  long term 
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(Marie 2005). There is no clear explanation on how FOs has a direct effect on foot 
pain. There are many theories such as resisting or facilitating motion (Nigg et al. 1998; 
Novick and Kelley 1990; Stacoff et al. 2000) reduction and redistribution of plantar 
pressure (Cornwall and McPoil 1997; Novick et al. 1993; Redmond et al. 2000) altered 
muscle activity (Nawoczenski and Ludewig 1999) and enhanced proprioception 
(Nawoczenski and Janisse 2004). Many researchers have been investigating to find a 
conclusive answer to this (Landorf and Keenan 2000) however, failing so far to reach 
particular theoretical model. A systematic Cochrane review on effect of FOs, concluded 
that it is possible that FOs have different mechanisms for different types of foot pain 
(Hawke et al. 2008).   
  
In 2009, NICE published an expended review on the management of rheumatoid 
arthritis in adults, which specified that ‘FOs should be available for all people with RA 
if indicated’ (NICE 2009). No such recommendation has been mentioned in JIA 
suggesting that more research, investigating the effect of FOs in JIA, is needed. 
2.8.1. Custom Made FOs 
The ‘Cochrane Database of Systematic Reviews’ in 2009 issued an extensive 
publication with the aim of evaluating randomised controlled trials and controlled 
clinical trials on the effectiveness of custom foot orthoses for different types of foot 
pain. The authors independently selected eleven trials involving 1332 subjects: five 
trials evaluated custom-made foot orthoses to treat plantar fasciitis (691 participants); 
three for foot symptoms in rheumatoid arthritis (231 participants); and one each for foot 
pain in pes cavus (154 participants), hallux valgus (209 participants) and JIA (47 
participants) (Hawke et al. 2008). The authors reported that custom-made foot orthoses 
appeared to be significantly effective in the treatment of painful pes cavus, rearfoot 
pain in rheumatoid arthritis and foot pain in JIA and painful hallux valgus; however, 
surgery was even more effective for hallux valgus and non-customised foot orthoses 
appeared just as effective for JIA but the analysis may have lacked sufficient power to 
detect a difference in effect. It is unclear if custom-made foot orthoses were effective 
for plantar fasciitis or metatarso-phalangeal joint pain in rheumatoid arthritis. 
According to this Cochrane review, after 3 months, a custom-made foot orthoses 
improves foot pain by 11 more points on a scale of 0 to 100 (possibly as many as 19 
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points or as few as 3 points). This difference is also significant in JIA patients. Finally, 
custom-made foot orthoses were a safe intervention in all studies. It can be argued that 
different types of foot pain were analysed individually in each trial; therefore, a 
generalised conclusion regarding the effectiveness of custom-made foot device for the 
treatment of foot pain should not be drawn and all results cannot be grouped into a 
single ’level of evidence’.  
 
Broström (2004), published the ‘Patient Education and Foot Disability in JIA’. The 
main focus of this work was to investigate the outcomes of an education program for 
parent and children living with JIA and the use of custom-made FOs. The effect of FOs 
was evaluated in 48 JIA children / adolescent. Two consecutive capacity tests were 
carried out by the child. Randomly in one test the child was wearing the FOs and in the 
other test without FOs. All tests were observed and scored by the same physical 
therapist who was not made aware whether the child was wearing the FOs or not 
(Marie 2005). With regard to the outcome related to the foot position with FOs, pain 
after standing, jumping and climbing the stairs was significantly lower (p<0.05), and 
balanced improved as well (p<0.05) when the child was wearing an FOs. Results 
highlighted no significant differences in the subgroup with planovalgus pathologies: in 
contrast, the cavo-varus subgroup presented with significant differences in pain level 
after standing (p<0.01), walking speed (p<0.05) and running (p<0.01) in favour of the 
FOs group. These results can be seen as an encouraging indication that at least in 
Sweden, podiatric intervention is considered as part of the treatment of JIA within the 
paediatric rheumatology team and also that custom-made FOs can be useful particularly 
in cavo-varus patients and with oligo and polyarthritis JIA (Marie 2005). The author 
acknowledges that in the study one limitation could have been the lack of a control 
group for the evaluation of the educational program. Furthermore, the high dropout rate 
amongst those recruited was not expected. Marie (2005) fails to provide the reader with 
specific details about several questions. What method was used to take the casting 
(neutral or relax calcaneal stance at open or close kinetic chain)? Who was involved in 
the manufacturing process of the FOs (was it only one technician or more?) How long 
did the child have to wait before the fitting? What cost was involved in the manufacture 
of the FOs. Was there a review appointment arranged after fitting or not? Additionally, 
when the physical therapist observed and scored the children’s activity test, with and 
without the FOs, the reader is not informed if the child wore different shoes or not. This 
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might be seen as a possible limitation, as the condition of footwear could have skewed 
the observation made by the data collector. Each child involved in the gait observation 
should have received the same shoes to limit variables in the final gait score. Finally 
the author failed to mention if the symptomatic children were under specific medication 
for JIA which, as previously mentioned, could have significantly changed the final pain 
level score, causing the reader to believe that pain reduction was solely attributed to the 
custom-made FOs intervention. 
  
2.8.2. Off the Shelf FOs 
A recent publication  revealed that the government had released figures, which stated 
that the Northwest Health service is due to record a £230m surplus in its expenditure 
(Malone 2008a). It has been indicated that a number of factors have contributed to the 
savings made in the past year. One of them appears to be the more frequent  use of 
affordable and cost-effective pre-formed orthotics, which have increased in use and 
become more commonly prescribed by podiatrists (Malone 2008a). The vast range of 
off-the-shelf devices eliminates the need for custom made orthotics. The off the shelf 
products can be customised to suit individual requirement by simply adding extrinsic 
correction. The convenience of prefabricated devices allows the NHS to manage time 
more effectively, by seeing additional patients. Finally, by eliminating orthotic 
manufacturing and laboratory cost, the NHS has been able to increase the savings and 
improve time management (Malone, 2008). These encouraging figures are expected to 
be welcomed in this difficult economic climate especially by NHS podiatry managers 
and also by many patients who are treated privately. The ideal scenario would imply 
that off-the-shelf devices have an equal if not better effect compared to the custom-
made FOs. However, it can be argued that this interesting press release may be biased 
as it is written by Malone (2008) who also works for Algeos, who supplies these FOs. 
Thus more robust research is required.  
 
Despite a lack of podiatric evidence in using pre-formed semi rigid FOs in JIA, few 
studies have been conducted in RA but still more well designed multicentre trials of 
satisfactory statistical power are needed (Korda and Bàlint 2004).  A biomechanical 
evaluation of foot pressure and loading force during gait in RA patients with and 
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without foot orthosis has been conducted by Li et al. (2000). In this study, 12 female 
RA patients with foot pain in walking, and 8 healthy women without foot pain were 
matched for age. Foot pressures and loading forces with and without orthoses were 
measured using the F-Scan system. The pressure distributions and loading forces were 
standardised by body weight and compared. The FOs were made of pre-formed 
mouldable materials, mostly polyethylene foam rubber which encourage shock 
absorption and aim to support deformities (Li et al. 2000).  Interestingly, in the 
methodology section, it is specified that one only orthotist was in charge of the fitting, 
supervising the correct use of FOs by the participants throughout the whole period of 
the study. Using the 0.15mm thick F-Scan insole, dynamic foot pressure was recorded 
with and without the off-the-shelf FOs. During recording the FOs used with RA 
patients provided significant pressure reduction (3.00 +/- 0.38 g/cm
2
) compared to the 
control group (3.29 +/- 0.29 g/cm
2
) (p<0.001). Similar redistribution of plantar 
pressures and loading forces were found between the two groups but the RA patients 
had a greater change at the stance phase of gait (p<0.0001). The authors concluded that 
the off-the-shelf mouldable FOs produce greater pressure and loading force relief and 
redistribution of pressure in RA patients compared to normal subjects (Li et al. 2000). 
It can be argued although the methodology adopted was fairly accurate; the sample size 
may be too small. The results would have possibly proved more significant if Li et al. 
(2000) recruited all RA participants instead. Then, they could have randomly 
subdivided the RA patients into two equal groups and investigated the effectiveness of 
off-the-shelf devices against a control group.  
 
In the study conducted by Dixon and McNally (2008) 22 participants were asked to run 
barefoot at 3.83 m/s (±5%) over an RS scan foot-scan (0.5 m length) pressure plate 
(500 Hz). The influence of the prescribed orthoses on lower extremity kinematics and 
pressure beneath the shoe was assessed by collection of data for 10 running trials with a 
neutral shoe and 10 trials with the addition of an orthotic device. All devices were 
constructed from moulded EVA, with a base of 60 Shore A
19
 and top layer 40 Shore A. 
Three off-the-shelf FOs’ shells were available for the participant who took part in the 
study: high, normal and low arch. The 3 types of orthotic shell were determined 
directly by the software using the arch index values developed in 1987 by Cavanagh 
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 ‘Shore A’ scale: is used for testing soft Elastomer (rubbers) and other soft polymers. 
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and Rodgers, which are considered the precursor of gait analysis (Cavanagh and 
Rodgers 1987; Dixon and McNally 2008; McCrory et al. 1997). Dynamic arch index 
values were calculated for the entire foot contact, minus toes. Less than 21% midfoot 
contact area was classified as high arch, between 21% and 28% as normal and greater 
than 28% as low arch. Modifications were added to the preformed shell as required 
according to the participant. Initial and peak angles were determined for rearfoot 
inversion–eversion, lower leg internal rotation, ankle dorsi-plantar flexion, knee flexion 
and rearfoot eversion velocity. Furthermore, the relative pressure on the lateral side to 
medial side of the shoe (pressure balance) was determined by dividing the foot into 
areas of medial and lateral heel and five metatarsals. The moulded off-the-shelf FOs 
recording showed significant reduction in peak eversion and in eversion velocity and a 
significant increase in the initial inversion angle (p<0.05). The ‘Exeter Biomechanics 
Research Team’ concluded that the devices used in this study successfully helped to 
decrease the peak eversion and the eversion velocity by encouraging the foot to operate 
in a more inverted position throughout the running recordings. Finally, this research 
confirmed that the pressure plate aids in establishing orthotic effect (Dixon and 
McNally 2008). 
 
2.8.3. Comparative Studies 
The only comparative article which investigates FOs in JIA has been compiled by 
Powell et al. (2005). The authors used a quasi-experimental method in a prospective, 
randomised, single blinded study which addressed the use of custom made orthoses in 
the management of JIA. In the study, the speed of ambulation, self-rated activity, 
functional ability level and pain, all showed significant improvements compared to off-
the-shelf cushioning inserts or supportive athletic shoes (Powell et al 2005). Forty 
children were recruited to the study which was then subdivided into three subgroups, 
receiving: a) custom-made semi-rigid foot orthotics with shock absorbing posts (n= 
15), b) off-the-shelf flat neoprene shoe inserts (n= 12), or c) supportive athletic shoes 
with a medial longitudinal arch support and shock absorbing soles (n= 13).  This study 
has been included in a Cochrane Systematic Review that focused on the potential of 
relieving foot pain within three months, by using custom made FOs (Hawke et al. 
2008). However, the study compared custom-made functional devices against non-
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functional off the shelf cushioning devices only. It would have been better to compare 
the effectiveness of expensive custom-made functional devices (costing approximately 
between £132- £232
20
) against cheaper off-the-shelf preformed functional orthotics. 
Such a study would have shown whether it is the casting methods that yield clinical 
benefit against similar but more cost effective off-the-shelf prescription. If the research 
proved that it is the functional prescription rather than the type of device that generates 
clinical benefit, then, the actual saving for the NHS would be significant. Furthermore, 
being a quasi-experimental study, it does not provide any comparison with a control 
group. A randomised control trial would have been a more robust design. 
 
Recent publications claimed that more podiatrists commonly utilise prefabricated 
orthotics when patients cannot afford custom devices (Losito 2006). However, it is seen 
as unethical when a practitioner selects a treatment based on his or her perception of a 
patient’s ability to afford the treatment. Such judgments should be evidence-based on 
the effects of types of orthotics and this highlights the need for more research into the 
effectiveness of pre-formed orthotics. 
 
Recently Redmond et al (2009) published an interesting study which compared the 
mechanical properties between customised orthotic and off-the-shelf. This cross-over 
randomised clinical trial investigated 15 patients diagnosed with flat-feet. All patients 
recruited were asymptomatic and they were between 18 and 45 years old. The study 
was carried out in Australia in 2002/2003 (at University of Western Sydney). In 
addition, one of the inclusion criteria was a relax calcaneal value higher than 5° valgus. 
Gait analysis was carried out using Pedar in-shoe plantar pressure system only on the 
right foot following the manufacturer’s instruction. Data were collected following a 
specific standardised protocol which included details such as speed, cadence, shoes, 
distance and timing. Results highlighted the forces and force time integrals in the 
midfoot and forefoot between the customised and off-the-shelf FOs (Redmond et al. 
2009). In conclusion, this cross-over randomised clinical trial showed that almost no 
changes in loading were detected between the two types of devices.  
 
                                                 
20
 Which is the equivalent of  $200–$350 as it was reported in the Powel et al. (2005) paper. 
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Redmond, Landorf and Keenan (2009) proved no statistical significant results were 
found on the customised FOs over the effect of semi-rigid prefabricated orthoses to 
justify the much higher cost involved for the devices obtained by using plaster of paris 
(POP) casting. It can be argued that the financial difference always has represented a 
big issue for the practitioner when prescribing an orthotic. This study is one of many 
studies conducted to try to prove that the “gold standard” of customised FOs no longer 
exist; and that very similar, if not better results, can be obtained with off the shelf 
semirigid orthotic. However, this study presents few issues that might have influenced 
the final results: firstly the number of patients may be too small to be draw significant 
conclusions, it may be argued that only 15 participants is not sufficient to produce a 
robust evidence based on a randomised clinical trial, even if it was a cross-over study. 
In addition, the age group may not be truly representative of the active population 
present nowadays. Secondly the author did not clearly specify what type of flatfoot the 
asymptomatic patients had. Some practitioners may argue that pes planus may present 
with true rear foot valgus or varus, fully, partially or not compensated. No indications 
on forefoot condition were reported as well. 
 
In the paper published by Redmond, Landorf and Keenan (2009) the reader is not 
informed if the subjects recruited presented with soft tissue flattening or instead it was 
due to any possible tarsal coalition. However, some practitioners may believe that one 
of the main criteria used to establish whether or not a prescription is successful, is to 
evaluate clinical improvement. Improvement of pain is generally accepted to be the 
primary outcome for any trial that compared the use of different devices. Therefore, 
even if only 15 subjects took part in the study, if all of them reported improvement of 
symptoms, that could have been significant evidence in favour of prescribing off-the-
shelf FOs compared to POP. The authors reported that all participants met the inclusion 
criteria of a relaxed calcaneal stance position of > 5° valgus. Unfortunately it is not 
specified how this procedure was carried out. Results may be affected according to the 
technique used to collect STJ ROM at close kinetic position. In addition, the reader is 
not aware if these measurements were collected by the same podiatrist or not. It can be 
argued that the more people who are involved in the collection of STJ measurement, 
the more variables and errors may be introduced into the cross-over trial. Under the 
section of orthosis type, it is specified that only one technician from the ‘The Orthotic 
Lab Pty Ltd’ was involved in the manufacturing process. The customised devices were 
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‘modified Root’ type orthosis, posted to the neutral calcaneal stance position. Materials 
used were carefully described (4mm white ‘semi-flex’ polypropylene shell, heel posts 
were made from 450kgm
3
 EVA
21
 and thin vinyl top layer was added as cover). On the 
other hand, the prefabricated devices were a commercially available brand (Cast and 
Foot Adjusted Orthoses
®
) supplied by the same laboratory (The Orthotic Laboratory 
Pty Ltd) and already had 4° varus rearfoot post. The materials used, length and heel cup 
height were the same used for the customised devices and the prefabricated orthoses 
which certainly helped data analysis comparison (Redmond, Landorf and Keenan 
2009). Interestingly, one of the authors of this research, Landor KB, is a Deputy Editor 
of Journal of Foot and Ankle Research in which the study was published. Finally, no 
disclaimer was written regarding any conflict of interest in promoting one particular 
product sold directly by the same Australian orthotic company. 
 
As previously mentioned, in this current economic situation financial cuts are made 
across all sectors, even within the health care system. It appears to be clear that there is 
a general drive from clinicians to prove whether or not the cheaper option can be 
equally if not better effective than the more expensive options for podiatric 
intervention. Another recent publication carried out by Cho et al. (2009) investigated 
the effects of shoes with FOs in patients with rheumatoid arthritis and the differences in 
terms of type of FOs and anatomical location of foot pathology. This single-blinded 
randomised controlled trial recruited participants from the outpatients of the physical 
medicine and rehabilitation clinic at a university hospital in Seoul. Forty-two patients 
with RA foot lesions (all female, with mean age 49.1 ±11.6 years old) were randomly 
divided into two different orthotic intervention groups. The anatomical locations of the 
foot lesions were recorded. The participants were provided with an extra deep forefoot-
rocketed shoe and either a custom-made semi-rigid FOs or a ready-made simple soft 
FOs. Participant was asked to wear the FOs for at least 3 hours a day over six months. 
Similar to previous mentioned studies, primary outcome measures were foot pain 
detected by using VAS scores and Foot Function Index (FFI). Secondary outcome 
measures were erythrocyte sedimentation rate and C-reactive protein levels in blood, 
amounts of medications and active joint counts (Cho et al. 2009). These were checked 
at baseline and post intervention. Unexpectedly, 8 women dropped out at follow-up 
                                                 
21
 EVA= ethyl vinyl acetate 
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after six months of treatment. At six-month follow-ups, VAS scores and total Foot 
Function Index scores had decreased significantly in both groups versus baseline but 
intergroup comparison showed no significant differences in view of the type of FOs 
and anatomical locations of foot pathology. The authors concluded that they were 
unable to highlight differences between the types of FOs in terms of their clinical 
effects in the two groups, but both groups presented signs of significant improvement.  
 
It can be argued that Cho et al (2009) should have recruited a more mixed population of 
patients, not only female. In addition, some clinicians may disagree with the review 
appointment being made 6 months after the initial fitting, which could be deemed to be 
too long a gap, especially for the RCT, as many variables could have been introduced 
within the study in between this long period of time. Fitting issues, inadequate use of 
the FOs, wearing wrong shoes or not wearing the FOs at all could have been possible 
variables that require more frequent check-up as part of clinical management, in order 
to avoid wrong interpretation of results. Not surprisingly the dropout rate was quite 
high for this RCT.  
 
The relative merit of customised versus prefabricated foot orthoses continues to be the 
subject of passionate debate between podiatrists (Menz 2009). Even if there is currently 
insufficient evidence to establish the best devices to use, more and more research 
literature suggests that prefabricated foot orthoses may produce equivalent clinical 
outcomes to customised foot orthoses for certain conditions. Prescription guidelines for 
customised FOs need to be developed, by so doing the hypothesised benefits of these 
devices would be thoroughly evaluated (Menz 2009). The clinical satisfaction to reduce 
wide range of chronic pain with FOs when all other treatments have failed, is an 
extremely positive clinical experience (Landorf and Keenan 2000). Research in 
podiatry often are criticised because the results obtained can be directly attributed to the 
different methodologies used by the authors and by the controversial quality of the 
research often available (Landorf and Keenan 2000).  Menz (2009) concluded that in 
the future, further research may indeed reveal that there are specific subgroups of 
patients and conditions that respond more favourably to particular types of customised 
orthoses compared to prefabricated orthoses or vice-versa.  
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 Pain and Quality of Life: 2.9.
As previously mentioned, the primary clinical outcome in this thesis will focus on the 
effects of pre-formed semirigid FOs on pain using the widely recognised VAS and 
other quality of life tools, particularly the CHAQ and the PedsQL
™
 (generic paediatric 
module and paediatric rheumatology module). It has been proven that parents and 
children have different perceptions of pain levels and pain coping strategies (Sawyer et 
al. 2004).  
 
2.9.1. VAS 
VAS is a psychometric response scale which can be used in questionnaires and it 
measures a characteristic or attitude that is believed to range across a continuum of 
values and cannot easily be directly measured (Grant et al. 1999). For example, with 
respect to the amount of pain that a patient feels, VAS ranges from none to the highest 
pain imaginable. From the subject’s point of view this spectrum appears continuous ± 
their individual pain; it does not have a categorization of none, mild, moderate and 
severe would instead suggest. VAS was devised to capture an idea of an underlying 
continuum sensation (Gould et al. 2001). Practically VAS is usually a horizontal line, 
100 mm in length, anchored by word descriptors at each end, as illustrated in Figure 
2.9.1.1. The parent is asked to mark on the line the point that they feel represents their 
perception of their current state. The VAS score is determined by measuring in 
millimetres from the left hand end of the line to the point that the patient marks (Gould 
et al. 2001; Grant et al. 1999). 
 
Figure 2.9.1.1: Example of VAS, 100mm long, used to record pain level. 
 
 
The VAS has been found to be a sufficiently reliable and cost-effective tool to detect 
pain (Bijur et al. 2001; Chapman and Kirby-Turner 2002; Schanberg et al. 1997). Pain 
is considered to be the most common primary outcome that measures the effectiveness 
of a specific treatment; VAS is used not only in prospective clinical studies but also in 
RCTs (Grant et al. 1999; Hendry et al. 2008; Hendry et al. 2009; Powell et al 2005). 
Furthermore a recent study conducted by  Lam et al.(2004) concluded that the VAS 
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was the best pain investigating tool to differentiate between patients and controls age 5 
years old or older (Lam et al. 2004).  
 
A recent investigation compared JIA children with the healthy population, specifically 
on the associations between physical activity and disease-related factors. This cross-
sectional study evaluated the overall well-being of participants by using a VAS. Final 
results obtained also by using VAS helped to conclude that interventions by paediatric 
rheumatologists are suggested to improve physical activity levels in patients with JIA 
(Lelieveld et al. 2008). 
2.9.2. CHAQ 
The CHAQ is a widely used tool to investigate quality of life in children. It has been 
validated for children between the ages of 1 and 19 years, contains 30 questions 
grouped into 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and 
daily activities. A scale of 0 to 3 assesses the level of difficulty in performing the tasks 
(0 = no difficulty, 1 = some difficulty, 2 = much difficulty, and 3 = unable to do). The 
highest score of a question in a domain determines the overall score for that domain. In 
order to calculate the final score, the highest scores of every domain are summarized 
and divided by eight (eight domains). Possible scores range from 0 to 3.0 (Geerdink et 
al. 2009).  
 
Also the CHAQ has been shown to be a valid and sensitive tool in the evaluation of 
functional  outcomes in children with chronic arthritis and it has been used to measure 
improvement of the pathology in many clinical trials (American College of 
Rheumatology 2009). In order to provide further data regarding quality of life in 
children with JIA, CHAQ will be used for this study. In the UK a study was carried out 
on 440 children using the British version of the CHAQ, 219 patients with JIA (17% 
systemic onset, 41% polyarticular onset, 33% extended oligoarticular subtype, and 9% 
persistent oligoarticular subtype) and 221 healthy patients. The UK-CHAQ proved to 
be able to discriminate between healthy subjects and JIA patients. In addition, in this 
well-known study conducted at the Institute of Child Health, University College in 
London the reliability and validity of the CHAQ for functional, physical and 
psychosocial assessments of children with JIA was confirmed as well (Nugent et al. 
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2001). A bigger study was carried out in 32 different countries amongst all the 
members of the Paediatric Rheumatology International Trials Organisation (PRINTO). 
This research, founded by European Union, analysed the health-related quality of life 
of 6,644 subjects. The study evaluated 3,235 children with JIA (20% systemic onset, 
33% polyarticular onset, 17% extended oligoarticular subtype, and 30% persistent 
oligoarticular subtype) against 3,409 healthy children. The results supported using 
CHAQ as a valid and reliable tool for different socio-economic and socio-demographic 
conditions of JIA children of countries that took part in the study (Ruperto et al. 2001). 
In a more dated study carried out in Italy at the Rheumatology Department Milan 
University, 96 patients with JIA were evaluated; both male and female, ranging from 3 
to 19 years (mean age 9.9). The questionnaire was completed by parents if the children 
were younger than 8 years old (23 subjects) and by the children themselves in the 
remaining subjects. Children with systemic or polyarticular onset had higher scores 
compared to those with pauciarticular onset. Significant statistical difference was found 
in the disability index value between children with different subgroups of the 
pathology. The CHAQ proved to have a positive reproducibility rate in test-retest over 
a two-week period. In addition, positive correlations were reported in between child 
and parent scores, as well as internal reliably and discriminant validity (Fantini et al. 
1995).  
 
It has been reported that in order to obtain complete systematic monitoring of disease 
activity in all JIA patients, the CHAQ should be completed by every patient at every 
outpatient paediatric rheumatology clinic visit (Sawyer et al. 2004). In order to 
encourage parents and their JIA children to complete the CHAQ at each visit, a few 
clinicians started using digital computerised version of the CHAQ within routine 
paediatric rheumatology visits (Geerdink et al. 2009). The score of the digital CHAQ is 
calculated automatically by the software, avoiding possible human errors, and it is 
available electronically to the clinicians during the patient’s consultation. In the study 
carried out by Geerdink et al. (2009) security measures were applied, data were 
protected by passwords and saved on the hard disk; finally, prints were kept in the 
patient’s paper file. This recent study on 51 JIA children, confirmed the reliability of 
the CHAQ also under the user-friendly digital option, which was completed 
systematically at the outpatient paediatric rheumatology clinic during each routine visit 
(Geerdink et al. 2009). 
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2.9.3. PedsQL 
Health-related quality of life (HRQOL) measurements have become an important 
health outcome in clinical trials, clinical practice and in improvement of clinical 
management (Fayers and Machin 2000). The PedsQL
™
 measurement model is a 
modular approach to measuring health-related quality of life (HRQOL) in healthy 
children and adolescents and those with acute and chronic health conditions. The 
PedsQL
™
 integrates both generic core scales and disease-specific modules into one 
measurement system. Evidence reports reliability and validity of PedQL
™
 4.0 Generic 
Core Scale and PedQL
™
 3.0 Rheumatology Module in paediatric Rheumatology (Varni 
et al 2004; Varni et al. 2002; Varni et al. 2003).  
 
Scores near 0 indicate poorer physical functioning and scores near 100 indicate better 
physical functioning. The parent and child must complete the questionnaires 
independently from one another. In case of some difficulties in understanding the 
question, the data collector must not interpret the sentence; instead, it is advised to 
repeat the item to them verbatim. The child and/or the parent have the option of not 
answering a question if they truly do not understand the question.  
 
In the study conducted by Varni et al. (2002) the 4 PedsQL
™
 4.0 Generic Core Scales 
(physical, emotional, social, and school functioning) and the 5 PedsQL
™
 3.0 
Rheumatology Module scales (pain and hurt, daily activities, treatment, worry, and 
communication) were administered to 231 children and 244 parents recruited from a 
paediatric Rheumatology clinic. Results showed that internal consistency reliability (α) 
for the PedsQL
™
 Generic Core total scale score (α= 0.91 for child self-report, α= 0.93 
for parent proxy report), physical health summary score (α= 0.87 for child self-report, 
α= 0.89 for parent proxy report), and psychosocial health summary score (α= 0.86 for 
child self-report, α= 0.90 for parent proxy report) were acceptable for group 
comparisons. Specifically with regards to the ‘Rheumatology Module’ scales also 
demonstrated reliability for group comparisons (α= 0.75–0.86 for child self-report, α= 
0.82–0.91 for parent proxy report). The PedsQL™ proved to be able to distinguish 
between healthy children and children with rheumatic diseases as a group. Overall, the 
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results demonstrate excellent reliability, validity and responsiveness of the PedsQL
™
 
4.0 Generic Core Scales and the PedsQL
™
 3.0 Rheumatology Module in paediatric 
Rheumatology (Varni et al. 2002). It can be argued that the same person who carried 
out the research is the actual licensor of the PedQL
™
 tool. 
 
In the study conducted from Powel et al. (2005) on the use of the custom-made FOs, 
PedsQL
™
 was used as well, however, because the intervention used in this research was 
primarily physical, as opposed to psychosocial: the child self-report and parent proxy-
report physical functioning subscales were the only subscales recorded in this study 
(Powell et al 2005).  It should be noticed that the PedsQL
™
 Physical Functioning Scale 
includes items not necessarily related to foot functioning; therefore, because of the 
nature of this scale, it may be misleading. It can be argued that in the study conducted 
by Powell et al. (2005) the authors failed to consider the overall impact that orthotics 
could potentially have on the quality of life of JIA children. Instead, they only focused 
on the results obtained by physical functioning subscale. As pain level and quality of 
life represent the primary outcome, the authors should have investigated the correlation 
between different subscales within the PedsQL. Results could have highlighted a 
repeatable trend between improvements of physical functioning level, directly linked 
with improvements of social, emotional and school functioning. Some paediatric 
clinicians may also state that by providing more quality of life data on the effect of 
prescribing FOs, the role of podiatrists may improve within the multidisciplinary team 
in paediatric rheumatology.  
 
While a PedsQL
™
 Rheumatology Module does exist (Varni et al. 2002) it was not 
considered during data collection in the trial conducted by Powel et al. (2005). Results 
obtained with the PedsQL
™
 showed that the orthotic group was the only group to show 
significant improvement in paired t tests. Interestingly in the orthotic group the 
PedsQL
™
 score showed more than twice the 5 points considered to be the clinically 
important score to indicate significant changes or differences (Powell et al 2005; Varni 
et al. 2002). Finally, the correlation between the child self-report and parent proxy-
report was positive and significant at baseline and at follow up as well (Powell et al 
2005).  
 
76 
 
Interestingly, a study was conducted by sending mail survey between February and 
March 2001. The questionnaire was sent to 20,031 families with children ages 2–16 
years throughout the state of California, amongst all new applicants to the ‘State’s 
Children’s Health Insurance Program’ (SCHIP). This information may indicate that 
many insurance companies, particularly in America, are looking for valid tools that can 
be used regularly to monitor the HRQOL. The results demonstrate the feasibility, 
reliability, and validity of the PedsQL 4.0 as a paediatric population health outcome. 
Finally the author concluded that evaluating paediatric HRQOL may be also a valid 
option to establish  the health outcomes of SCHIP (Varni et al. 2003). 
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Chapter 3: Methods – Instrumentation & Pre-Tests 
 Survey  3.1.
3.1.1. Introduction 
 
In order to decide which pre-formed semi-rigid FOs had to be used for the RCT on 
pain, quality of life and the dynamics of gait of patients diagnosed with JIA, a survey 
was carried in Scotland. 
3.1.2. Aim 
 
The aim of the survey was to investigate the type of treatment that symptomatic JIA 
children received within NHS podiatry departments in Scotland. 
 
3.1.3. Justification 
 
Currently there is limited evidence supporting podiatric treatment of children and 
particularly JIA patients. This survey was an opportunity to compare similarities and 
differences on podopaediatric clinical management within the NHS sector. Only after 
the survey was completed, it became possible to decide which was the most commonly 
prescribed FOs amongst the podopaediatric clinics in Scotland, and to choose what type 
of FOs would have been adopted for the RCT research.  
 
3.1.4. Ethics 
 
Ethical approval was obtained from the QMU Ethics Committee. All podopaediatrics 
specialists were entitled not to participate in the survey without giving any reasons. All 
podopaediatrics specialists were able to speak with an independent person, who knew 
about the project but was not directly involved in it. In order to maintain anonymity, all 
podopaediatric specialists contacted at the NHS clinics in Scotland were given a survey 
number at the beginning of the study. A sheet containing the podopaediatric assigned 
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survey number and contact details were held in a locked filing cabinet at QMU. This 
was destroyed at the end of the study. 
 
3.1.5. Results 
 
A template letter was sent out to each podopaediatric specialist’s clinic across Scotland 
by hard-copy or electronically (appendix II). The survey was designed considering the 
limited time available for a practitioner to spend on completing the survey. The 
questionnaire took no longer than five minutes to be completed. The JIA survey was 
constructed to investigate specifically which FOs were most commonly prescribed for 
the clinical management of JIA patients. Practitioners were asked: firstly, if they treated 
JIA patients within their NHS clinics; secondly, what types of FOs were normally 
prescribed (palliative custom made, functional custom made, palliative off the shelf or 
functional off the shelf FOs). Lastly, if they prescribed off the shelf FOs, which type 
and brand of FOs did they normally supply for JIA patients? Two weeks deadline were 
given to each practitioner and the majority of podopaediatrics specialists replied by 
email. In total 11 NHS podopaediatrics clinics were contacted, 8 of them replied to the 
survey. Practitioners were suitable if they positively answered to the question “have 
you treated JIA children before?” As shown in the table below, 5 out of 11 practitioners 
previously treated JIA children with FOs. The remaining 6 podiatrists were not suitable 
for the survey as they never treated JIA children. 
 
Survey Practitioner Number Did they replay? Was it suitable? 
1 No No 
2 Yes No 
3 Yes No 
4 No No 
5 No No 
6 Yes Yes 
7 Yes Yes 
8 Yes Yes 
9 Yes Yes 
10 Yes No 
11 Yes Yes 
Table 3.1.5.1: Survey results. Practioners that replied with a positive answer, were highlighted in green  
According to table 3.1.5.1 the survey practitioner number 6, appeared to use palliative 
custom made, functional custom made and functional off the shelf FOs. Survey 
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practitioner number 7 reported to prescribe palliative custom made FOs, functional 
custom made as well as functional off the shelf FOs. Survey practitioner number 8 did 
not use palliative custom made and palliative off the shelf; instead, usually prescribes 
functional custom made and functional off the shelf. On the other hand, survey 
practitioner number 9, treated JIA patients mainly using functional off the shelf devices 
only. Finally, survey practitioner number 11, appeared to use the same devices as 
survey practitioner number 8. Table 3.1.5.2 also showed that none of the 
podopaediatrics specialists used palliative off the shelf devices but instead results 
highlighted that every podopaediatric specialists prescribed functional off the shelf 
devices.  
 
According to the results obtained in table 3.1.5.2, the most commonly used pre-formed 
semi-rigid foot orthoses device appeared to be the Interpod range (three practitioners 
currently use these types of devices). The Slimflex (1
st
 Phase) and ‘Vasyli’ were 
reported to be prescribed both by two practitioners as well. 
 
Table 3.1.5.2: survey results from the suitable practitioners, on what type of devices were used to treat 
JIA children.  
 
These devices were easily available on the market, and could be bought directly online. 
At the time of the survey, these devices were available for the following foot sizes: 
 
 
 
 
Interpod Range 
 
Survey 
No. 
Palliative 
Custom made 
 
Functional 
custom made 
 
Palliative  
Off-the-shelf 
 
Functional 
Off-the-shelf 
 
Additional Notes 
6 Yes Yes No Yes 
Green Vasyli full 
length if some form 
of control, as well as 
shock absorption is 
required. 
7 Yes Yes No Yes Interpod Range 
8 No Yes No Yes 
Mostly Interpod flex, 
Slimflex Plus 
9 No No No Yes 
Formthotics, or 
Interpod 
11 No Yes No Yes 
Vasyli VOL. Algeos 
1st Phase, Slim Flex 
with adaptations. 
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Control Tech Soft - ¾ Length Available from size 2 till 12 
Control Tech Full Length -(low arch 4°, moderate arch 6°, high arch 8°): Available from size 3 till 10 
Interpod For Kids - ¾ Length - Moderate Arch (6°): Available from size  Child 9 till 2 
Interpod For Kids - Soft - Full Length - Low Arch (4°): Available from size Child 10 till 2 
 
Table 3.1.5.3 Interpod Range and available foot size details 
 
 
 
Slimflex 
 
Basic Green Slimflex Available from size 3 till 14 
Slimflex PLUS FOs Available from size 8 (Childs) till adult 12 
Slimflex Plastic FOs Available from size 3 till 12 
 
Table 3.1.5.4: Slimflex Range and available foot size details 
        
 
Vasyli 
 
Vasyli Custom Full Length (6°) 
(Low – Medium - High Density). 
Available from size Kid 12 till adult 14½ 
Vasyli Custom Regular ¾ Length (6°) 
(Low – Medium - High Density). 
Available from size Kid 12 till adult 14½ 
 
Table 3.1.5.5: Vasyli Range and available foot size details 
 
3.1.6. Discussion 
 
Each NHS podiatry clinic was managed independently, and have limited budget 
available to provide FOs to their patients. In most cases podiatrist’s clinical 
management was restricted by a specific number of FOs that could have been supplied 
each month to patients. This may be considered as unethical, as all JIA patients should 
be entitled to the same level of care, independently from monthly availability of FOs. 
This issue may be considered as a limitation in providing the appropriate level of care, 
and a restriction to cure patients symptoms based on the limited budget available. 
Realistically this is a problem that all medical sectors have to face. The limited 
resources available have always been and always will be one on the most difficult 
challenges that NHS has to face. It is well known that the main aim for NHS is to 
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provide high standard level of care at competitive and cost effective prices. For this 
reason, this JIA study required to have results from the survey, in order to establish 
what FOs were provided across different trusts in Scotland. 
 
According to the results obtained by the JIA survey, the most common form of pre-
formed semi-rigid FOs appeared to be: Interpod, Slimflex and Vasyli. However, not all 
these three pre-formed semi-rigid FOs were particularly cost effective for NHS. In 
addition, different NHS local trusts had different financial resources specifically 
dedicated for FOs prescriptions. As previously mentioned, it could be argued, that it 
may be unethical that certain JIA children may be prescribed more effective and costly 
FOs compared to other children that were born in less fortunate areas of Scotland 
where the podiatry resources were, instead, very limited. 
 
All podopaediatrics specialists seemed in favour of using functional pre-formed semi-
rigid FOs, on the other hand, none actually used palliative off the shelf FOs. These data 
indicated that all practitioners believed that the gait of JIA children should be treated; 
and consequently it could be concluded that one of the key issues to improve JIA 
symptoms was to intervene on the biomechanics of the JIA children. It could be argued 
that, if this option was the most common clinical management adopted by most 
podopaediatrics specialists in Scotland, the possible positive results of the JIA 
multicentre study may be welcomed amongst practitioners, as the possible new 
evidence to be adopted for the podiatric treatment of JIA patients. 
 
In addition, at the time of the study, it had to be taken into consideration that not all 
devices previously mentioned, could have been purchased at all foot sizes. This factor 
could be seen as a possible limitation in some of those products, as practitioners could 
experience difficulties during clinical management. In many occasions, podiatrists may 
have to decide the type of FOs based on the foot size availability and not of its efficacy. 
 
In order to standardise the type of FOs prescribed to the JIA study, the same brand of 
devices had to be prescribed to all patients that took part to the study. Finally, at the 
time of the survey, the Slimflex Plus appeared to be the most commonly prescribed 
FOs amongst clinicians in Scotland, which was available in all foot sizes (full range 
from child to adult). The Slimflex Plus could be easily adjusted and customised to meet 
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the biomechanical requirements for the patients. Podiatrists could supply the Slimflex 
Plus at chair-side to the patients, with the addition of extrinsic corrections and different 
materials.  
 
3.1.7. Conclusion 
 
This JIA survey provided useful information regarding the podiatric clinical 
management for JIA, currently in placed in different NHS trust across Scotland. The 
results obtained from this survey showed that not all podopaediatrics specialists’ clinics 
treated JIA patients; and that each clinic had different podiatric approaches. Some 
practitioners were more prone in using palliative and/or functional customised FOs; 
other podopaediatrics specialists relayed more on functional off the shelf FOs. In most 
cases the decision of devices was made on a basis of the resources available. With 
regards to pre-formed semi-rigid FOs, it appeared that the most commonly used were: 
Interpod range, Slimflex and Vasyli orthotics. However, the only FOs brand that was 
more cost effective and available in all sizes was Slimflex Plus. For these two main 
reasons, the JIA study was conducted using Slimflex Plus as a type of FOs that could 
be modified at chair-side and customised according to the different biomechanical 
requirement of the patients.  
 
 
 
 
 
 
 
 
 
 Plantar Foot Pressure Measurement 3.2.
 
Over the past two decades, measurement of pressure under the foot has generated vast 
interest amongst clinicians and researchers, particularly in the fields of diabetes, 
orthopaedics, sports science, rheumatology and podopaediatrics. During biomechanical 
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assessment of the lower limbs, podiatrists are able to diagnose pathologies related to 
abnormal loading of plantar pressure. Recordings obtained from a plantar pressure 
measurement represent valuable information for physical therapists in the analysis and 
management of adult and paediatric gait, which comprise a wide variety of foot and 
lower-extremity disorders. Orthotic devices are frequently prescribed as a conservative 
and non-invasive treatment of lower extremity injury. Gait analysis is defined as the 
systematic study of human motion using the eye and the brain of observers, aided by 
the use of technology that allows the investigation of movements, mechanics, and 
muscle activity (Whittle 2010). The increasing number of publications studying gait 
confirms the role of using a plantar foot pressure system to analyse foot parameters pre-
post treatment (Dixon and McNally 2008).  
 
One of the pioneers of gait analysis is considered to be Aristotle (384-322 a.c.) with 
‘De Motu Animalium’ (the Gait of Animals). Aristotle claimed that ‘everything that is 
in motion has been initiated by forces; as the world is not infinite, the original forces 
must have been originated by static entity’. This statement indicates the effect applied 
to an object which determines movement, is directly linked to the ground reaction 
forces applied to human motion, which is remarkable considering the historical period  
in which this philosopher developed his concepts (Bragagnolo 2000). Much later, in 
1680, Giovanni Alfonso Borelli also called his last publication ‘De Motu Animalium’ 
which became his most famous work. Unfortunately the professor in mathematics, who 
was born in Naples, passed away before his work became widely recognised (Davidson 
2003). According to the author, Mr Borelli is often referred to as the ‘father’ of 
biomechanics. In his attempt to describe the first concepts of biomechanics, Borelli 
worked to analyse in detail movements such as running and jumping, using mechanical 
principles upon muscle contraction and mathematical role movements. Finally, Borelli 
also focused on providing valuable explanations for issues such as muscle fatigue and 
organ secretion and he also tried to clarify the concept of pain (Davidson 2003). 
 
With the advance of photography, it became possible to record different sequences of 
images which displayed animal and human motion, which had been difficult to observe 
with the naked eye. The coetaneous Eadweard Muybridge (9/4/1830-8/5/1904) and 
Etienne-Jules Marey (5/4/1830-21/5/1904) are considered to be the precursors of this 
new science in the early 1900s.  In 1877 Leland Stanford hired these pioneers of 
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biomechanics to demonstrate that during the trotting gait of horses, all four limbs were 
off the ground at one point. According to Solnit (2003) an electronic shutter was 
developed to prove this theory. In 1878, Muybridge connected approximately a dozen 
cameras to record the gait of a horse sequentially. While light exposures at that time 
were often several minutes long, the 12 exposures occurred over about 30sec.  A highly 
contrasting, light background was used to enhance the images taken. The photos taken 
were numbered which allowed him to obtain time and spacing information. Stanford 
ultimately recorded the evidence which demonstrated that horse’s feet left the ground 
during a trot. Therefore with the aid of  photography a sequence of the horse ‘gallop’ 
gait was revealed for the very first time to the world. Before this discovery, the gallop 
was wrongly depicted in paintings (Solnit 2003). According to the book “River of 
Shadows” published by Solnit (2003), the motion analysis breakthroughs developed by 
the two pioneers of biomechanics were as follows: the development of an electronic 
automatically triggered shutter; advances in the development of plates to capture 
movement on an image in less time than anyone had accomplished previously; 
recording of sequential images that could be added together to represent an animated 
motion cycle (such as a gait cycle) instead of single isolated moment (Solnit 2003). 
 
In the 1980s, significant developments occurred in gait analysis to a point at which the 
data collected became a valuable tool for the development of treatment protocols in 
orthopaedic surgery (Sutherland 2002; Sutherland 2005). The force that the human 
applies to the ground is recognised to be equally matched by the reaction of the ground. 
For centuries philosophers made this type of deductions from animal or human 
movements by simply observing their paw or foot prints. The precursor of this concept 
was the English physicist Isaac Newton (1643 – 1727) who formulated that ‘‘for every 
force applied there is an equal and opposite reaction’’ (Motte 2007). Sutherland (2005) 
wrote an extensive review on the evolution of clinical gait analysis in which he 
underlined that the pressures applied by the body through the foot to the ground are 
vector forces. The world’s first three-component (pneumatic) force plate, which was 
called the ‘‘Trottoire Dynamique’’, was developed by Georges Demeny and Etienne‐
Jules Marey along with Jules Amar, who was a rehabilitation doctor working with 
amputees during and after the First World War in France (Braune 1992).  In 1938 the 
first device capable of measuring the ground reaction in three planes was developed by 
Dr. Elftman: it consisted of an upper and a lower platform suspended with calibrated 
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springs that measured the ground reaction forces and separated them into different 
components (Elftman 1938; Sutherland 2005).   
 
Plantar pressures can be measured using a variety of instruments, including: force-
sensing resistors (FSRs), hydro-cells, microcapsules, projection devices, pedoscopes, 
capacitance transducers, as well as by critical light deflection (Orlin and McPoil 2000). 
Pressure systems measure vertical force in different anatomical parts of the foot and 
they provide data regarding the effects of various podiatric interventions, including use 
of footwear, use of foot orthoses, gait training, and surgical management.  In contrast, 
although the force platform provides valuable data regarding both the vertical and shear 
components of the ground reaction force, it provides limited information on how the 
plantar surface of the foot is loaded with respect to the supporting surface during 
ambulation (Cavanagh et al. 1992; Duckworth et al. 1985). Ankle sagittal plane motion 
may be described as the ‘3 rockers’. The first rocker refers to the moment when the 
rearfoot has contact with the terrain after initial contact. The second rocker starts when 
the tibia move forward over the foot whist at midstance, Finally, the third rocker occurs 
during propulsion phase when the heel rises and the load is transferred to the forefoot 
(Perry and Burnfield 2010). It is important to be aware of the different phases that 
occur during gait in order to give meaning to the extended data that modern gait 
analysis software are able to provide at present.   
 
 
 
 
 
3.2.1. Barefoot measurements 
 
During the past two decades new technology has led to the development of new clinical 
systems applicable for the evaluation of foot pressure, step dynamics and postural 
disturbances. Lately, capturing and recording gait data has become much easier than 
ever before confirming the efficacy of treatment protocols and therapeutic regimens. 
Barefoot measurement is becoming more and more popular amongst podiatrists as it 
represents a valuable educational tool for patients with different pathologies and it can 
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be used for numerous research purposes. Regular barefoot screenings could help 
podiatrists to identify high pressure aspect of the foot that may help to prevent the 
incidence of ulcers and/or pressure sores. The data recorded allows the identification of 
precise areas of concern and the implementation of the clinical management by 
podiatrists.  
 
One of the first barefoot measurement systems was called the ‘projection device’. This 
type of device consists of a rubber mat which was filled with ink and then covered with 
paper. When plantar pressure is applied to the mat by the patient, the ink is deposited 
on the paper at the locations of highest pressure because all the layers of the mat are 
more compressed by the applied load. In 1947, Harris and Beath first reported using 
this type of device when attempting to classify the foot structure of 3619 Canadian 
soldiers (Stamm 1950). From this extensive survey, the authors concluded that even 
though it was not possible to reassess and compare the data obtained more than once, 
soldiers who presented with cavus feet with clawing toes were initially found without 
any disabling pathologies that would stop them from starting training. However, during 
intensive training, the conditions of those soldiers rapidly worsened compared to others 
without cavus foot (Stamm 1950). The mat type of projection device appeared to be 
suitable for a qualitative description of the pattern of plantar pressure, but this type of 
device cannot be used to quantify the magnitude of plantar pressures (Orlin and McPoil 
2000). 
 
Depending on the dimension of the barefoot analysis system, single or multiple foot 
strikes can be captured to observe gait abnormalities. For example, multiple foot strikes 
recorded on a HR Walkway (Tekscan) allows recording of cadence (steps per min), the 
velocity (metres per second), the gait time and the gait distance. Depending on the 
resolution of the sensels and their sizes, it is possible to display foot pressure and forces 
curve over time, extremely useful for the podiatrist to assist in the orthotic prescriptions 
and alterations. The foot recordings may be segmented in different parts (for example: 
heel, mid-foot, toes etc.) in order to allow the podiatrist to study details on foot 
functional behaviour in adult and paediatric patients. Therefore, it is possibly to 
quantify high pressure points in different anatomical areas of the plantar surface. Also a 
comparison between left and right foot is also possible which would help to investigate 
if any asymmetrical patterns are present. In clinical scenarios, using barefoot 
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measurements is intended to provide the patients with direct and tangible visual 
feedback, which may help the patient’s compliancy and may improve clinical 
outcomes.  
 
Most digital mat systems available on the market at present allow obtaining static and 
dynamic recordings instantly and are displayed frame by frame to identify pressure 
profile discrepancies. Podiatrists who are equipped with this modern technology can 
present foot images to their patients to compare pre-orthotic and post-orthotic 
intervention, sway pattern improvements, pre-surgical and postsurgical patterns and pre 
and post-manipulative adjustments. Hughes et al. (1991) reported that diabetic patients 
with neuropathy could be at risk of plantar ulceration when walking multiple barefoot 
steps on the digital platforms. In addition, patients with neurological impairment may 
have difficulty targeting the platform because of proprioception and coordination 
problems (Cavanagh and Ulbrecht 1991). 
 
One of the advantages of the barefoot analysis system is that the pressure sensors are 
always positioned parallel to the supporting surface to provide a ‘true’ vertical force 
measurements (Orlin and McPoil 2000). Digital platforms enable collection of data 
without the influence of footwear; recording can be achieved very quickly without 
wires or data-boxes attached to the subject, which may indirectly influence normal 
ambulation.  
 
On the other hand, it can be argued that some clinicians are not in favour of using 
barefoot analysis because it indirectly induces the patients to target the plate instead of 
focusing on walking naturally. Long platform is able to record high quality data which 
are significantly more expensive, and which require more space, not always available 
in private practice. Other thick platforms, unless are embedded in the floor, may appear 
slightly raised surface and might influence normal gait.  
 
The HR walkway system is a reasonably easy system to use and it does not require too 
long to become familiar with the different options available. The foot segmentation 
option can be applied to calculate toe-in or toe-out angle and to compare the line of 
progression. Calculation of values for step and gait time, distance, velocity, and 
cadence can be investigated. In addition, individual data for the left and right foot with 
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regard to the gait cycle, step-stride parameters, and symmetry scores can be obtained. 
The new updated Walkway software (version 7.0) features additional options (ie: 
Human Table Icon) that generate tables and provide clear visual display of gait 
parameters by using the.  
 
The use of the Tekscan digital mat has been reported by the Journal of the American 
Podiatric Medical Association in a publication written by Clough (2005) in which new 
methods of identification of functional hallux limitus were discussed. The Tekscan 
barefoot analysis data provides useful information for the researchers to develop 
adequate clinical management. The VAS score showed a significant improvement of 
pain level from 8/10 to 2/10. Even if this was only one clinical case, the software was 
able to aid in the podiatric prescription and quantify precisely the shifts in plantar 
pressure. 
 
A comparative technical assessment was carried out in Rome with the aim of 
investigating the appropriateness of different plantar pressure measurement devices 
(Giacomozzi 2010). After extended static pressure tests using a special customised 
pneumatic bladder, results showed the high accuracy of the Matscan from Tekscan and 
highly linear behaviour up to 800 KPa. This independent researcher also reported that 
after dedicated calibration, the resistive Matscan proved to have high correlation under 
sinusoidal loading
22
, and high precision in COP
23
 estimation (Giacomozzi 2010).  
  
Recently the ‘Journal for Foot and Ankle Research’ published a paper written by 
Zammit (2010) in which the reliability of the Tekscan Matscan-system for the 
measurement of plantar forces and pressures during barefoot level walking in healthy 
adults were investigated. This system is widely available to podiatrists and to 
researchers; however, according to the author’s knowledge, apart from the actual 
manufacturers, no independent clinical trials to date had investigated the reliability of 
the Tekscan Matscan. The author used the 2 step approach which involves striking the 
platform on the 2
nd
 step once a constant speed has been reached, and it appeared to 
reproduce plantar force and pressure data that is reflective of foot function during gait.  
                                                 
22
 Sinusoidal loading: in the form of a wave, represent one whose amplitude varies in proportion to the 
sine of some variable (such as forces or time). 
23
 COP= centre of pressure 
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Zammit (2010) particularly investigated the maximum force, peak pressure and average 
pressure variables from each recording obtained. In addition, 7 regions of the foot were 
investigated: heel, midfoot, 3
rd
-5
th
 metatarso-phalangeal joint, 2
nd
 metatarso-phalangeal 
joint, 1
st
 metatarso-phalangeal joint, hallux and the lesser toes. Results showed that the 
system displayed moderate to good reliability of mean and median calculations for all 
the 3 analysed variables (rearfoot, midfoot and forefoot) and across all 7 regions of 
plantar pressure. It can be argued that there are few limitations to be considered while 
interpreting these values which will be taken into account for the research presented in 
this thesis. Firstly, in this study the subjects recruited were mostly young (mean age 
was 28.2), therefore, conclusions cannot necessarily be generalised to other older 
clinical populations. Secondly, it can be noticed that unlike the Novel EMED
®
 system, 
which allowed uploading an automatic mask during data analysis of each recording, the 
Tekscan Matscan
®
 instead, requires a mask to be manually constructed and applied 
over each recordings. However, it must be outlined that the standardised mask can be 
modified, positioned and saved independently from different foot sizes and with 
reference to multiple anatomical landmarks analysed (for example: rearfoot, midfoot 
and forefoot). Some podiatrists may argue that that even if the mask template for each 
patient can be saved and re-uploaded for the subsequent trials, there could be some 
potential margin for error. In particular with the Zammit (2010) research, even if the 
smaller system Tekscan Matscan
® 
is portable and more convenient to move in different 
clinical environments, it only captures 1 barefoot measurement of either the left or right 
foot at the time each trial. This limitation will not apply to the HR walkway as multiple 
foot strike can be captured over the 1.97m platform and, thanks to the new version of 
the software (7.0) masking different anatomical portions of the foot, it has become 
easier and allows more precise extrapolation of data.  
 
In 2003 the journal of ‘Foot and Ankle International’ published a study in which great 
focus was given to the changes to the Achilles tendon (AT) as a result of surgical 
medialising-calcaneal-osteotomy (MCO). The researchers studied different proposed 
surgical techniques using the Tekscan HR Mat plantar changes on 14 fresh-frozen 
cadaver legs. No specifications were provided on what were the resolution and the 
dimension of the Tekscan system. With the aid of a specially designed frame, 
perpendicular axial loading (100 lbs) of each specimen was applied in neutral and at 
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15° dorsiflexion (Hadfield et al. 2003). The 3 trials were recorded, each in neutral and 
dorsiflexed positions, in order to study Achilles tendon length alteration and to monitor 
plantar foot pressure parameters. The authors reports that the findings may indicate that 
the Achilles tendon could have an effect on the inversion of the forefoot without 
undergoing a significant elongation of its fibres in any of the regions tested (Hadfield et 
al. 2003). Not many details were provided on how the pressure applied by the frame 
was constantly monitored to be at 100 lbs applied directly on the proximal area of the 
frozen cadaver’s tibia. It can be argued that at room temperature, the flesh condition 
may change rapidly making the soft tissue softer and more flexible. Therefore, unless 
each specimen recording was taken at the same room temperature, with the same 
exposure to heat, the final foot pressure recording values may be skewed. In addition, 
the reader is not informed if the tibia’s cadaver used had similar length and if there 
were any inclusion or exclusion criteria to select the specimens. However, even if the 
procedure adopted in this study may be debatable, the HR Mat enabled Hadfield (2003) 
to record valuable details for data analysis. Interestingly, during the gait analysis the 
foot was subdivided into 7 segments, coincidentally the same parameters investigated 
by Zammit (2010). In the RCT study discussed in this thesis, the same parameters will 
be analysed in order to confirm the need to analyse these anatomical areas of the foot, 
as supported by previous clinical evidence (Hadfield et al. 2003; Zammit et al. 2010).  
It is important to underline that the development of a barefoot analysis system also 
helps to develop veterinary research proposals. Research suggests that up to 30% of 
cats may suffer from osteoarthritis, with the incidence rising to 90% in cats older than 
12 years of age, and the elbow joint becoming frequently symptomatic (Hardie et al. 
2002). Lascelles (2006) investigated dog biomechanics using 7100 HR walkway 
system (precisely the same resolution of the equipment available at Queen Margaret 
University). Data recorded using the HR walkway, revealed that short-term 
postoperative morbidity may be reduced in dogs that undergo arthroscopic joint surgery 
compared to the traditional open arthrotomy technique (Lascelles et al. 2006).  
 
The HR Walkway has also been used by Lascelles (2007) to investigate kinetic 
evaluation of normal walking and jumping in cats as well. The primary outcome of this 
research was to determine whether kinetic data could be recorded from client-owned 
cats while walking and jumping. The secondary outcome was to determine whether the 
kinetic parameters of peak vertical force (PVF)  and vertical impulse (VI) were 
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significantly different across all 4 limbs (Lascelles et al. 2007).  Tekscan results 
indicated that there were no significant differences between the PVF or VI of the left 
and right limbs, but both parameters were significantly greater for the forelimbs than 
the hind limbs (p<0.01) for the walking data. The author concluded that results 
obtained proved that the system is sensitive enough to detect postoperative lameness, 
and may make it possible to assess post-operative analgesia (Lascelles et al. 2007).   
 
To date few studies have been conducted to provide comparative data from normal to 
pathological paediatric gait. An HR Mat (Tekscan) has often been used to provide a 
single capture of the foot strike during barefoot analysis (Riad et al. 2007). However, 
the evidence is scarce at present with regard to recording children’s multiple barefoot 
strike using the HR Walkway.  
 
3.2.2. In shoe measurement  
 
Similarly to barefoot measurement, in-shoe plantar pressure measurement has the 
potential to play a crucial role in the screening, treatment and orthotic management of 
patients who are at risk of, or are suffering from lower limbs pathologies (Cavanagh, 
Hewitt and Perry 1992). In the past only few gait analysis laboratories were able to 
carry out in-shoes data collection. Instead, at present this is no longer the case because 
many commercially available systems for measuring in-shoe plantar pressure (ie: Pedar 
insole system, F-Scan system, and Musgrave footprint system) are able to offer a higher 
degree of portability compared to long platforms. Therefore, podiatrists are now able to 
carry out in-shoe recording in different indoor and outdoor environments and in 
multiple clinic sites. Compared to the platform system, the use of plantar pressure 
insoles allows the collection and analysis of data from multiple steps, while walking in 
shoes with or without orthoses. Finally, plantar pressure data can be displayed as peak 
pressures produced during gait  (Fairburn et al. 2002).  
 
The use of microcapsules represented one of the first significant steps to provide a cost-
effective tool to clinicians to gain in-shoe plantar pressures data. It consisted of small 
dye-filled capsules sandwiched between 2 layers of thin foam, which were inserted in 
the patient’s shoes. As the patient walked, the capsules would break when pressure was 
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applied, causing the dye to be released into the foam layers. The release of the dye 
would stain the foam and provide an impression of the areas on the plantar surface of 
the foot with the highest pressures. However, podiatrists were unable to quantify the 
precise amount of pressure applied in a particular anatomical area. In addition, this 
system often provided a faulty reading as the microcapsules often fractured when 
inserted in the shoes (Orlin and McPoil 2000). Another system, technologically more 
advanced, consisted of the Force-Sensing Resistors (FSR). The FSR is a very thin 
layered device with metal patterns printed on 2 Mylar sheets
24
, with a conductive 
polymer layer placed between the 2 sheets (Cavanagh, Hewitt and Perry 1992). The 
conductive layer reduces resistance to the flow of electrons as the pressure between the 
Mylar layers increases. This pressure between the Mylar layers causes the resistance to 
decrease. The output of the devices using the sensor technology can be expressed either 
by force or by pressure. A company originally called ‘Tekscan’ (originally from 
Boston, USA) uses the FSR technology in a matrix array for different applications from 
dentistry to the car industry. With regard to biomechanics, this company has developed 
an in-shoe measurement insole that is commercially available under the trade name F-
Scan
™
 system (Orlin and McPoil 2000). The F-Scan
™
 in-shoe technology will be 
discussed in detail in the next section of this chapter as it has been adopted in the JIA 
study.  
 
In the research carried out by Fairburn et al. (2002), gait analysis measurements were 
performed also using the novel Pedar in-shoe system (Novel GmbH, Munich, 
Germany). The standard Novel-Pedar in-shoe pressure measurement system consists of 
an insole pair (with all optional European sizes from 24 to 45), connected to a 
lightweight belt unit worn around the waist, linked with special wires to a PC (Fairburn 
et al. 2002). The Pedar system can be connected with a synchronised digital video 
camera, allowing the simultaneous display of 2D and 3D data. In addition, step 
selection, force-time integrals and comparison for pre/post difference picture can be 
quickly obtained by the software. The Pedar system can be purchased along with an air 
pressure device called ‘Trublu®’ used to obtained accurate calibration of the insoles. 
With the aid of the Trublu
®
 calibration device, all sensors of the Pedar
®
 system are 
calibrated individually using high air pressure which occurred automatically by the 
                                                 
24
 Mylar sheet:  polyester films, exceptionally flexible, strong and durable. They have a high tensile, tear 
and impact strength. They remain tough and flexible at temperatures ranging from -70°c to 150°c. 
Widely used for different engineering purposes  
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software. It can be argued that in clinical scenario and during research trails, the 
necessity of having to link the Trublu
®
 calibration device to the software at every single 
time prior to data collection may be deemed to be time consuming. Furthermore, all the 
equipment required (Pedar
®
, Trublu
®
 and air compressor) not only may be too pricy for 
some clinicians but also it occupies lots of space, not always feasible for every private 
practice or hospital room. 
 
Finally, some podiatrists may debate that the thickness of the Pedar (1.9mm) is too 
much, especially in narrow shoes or when orthotic devices are inserted. At first, Pedar 
thickness does not seem problematic but when compared to F-Scan
™
 digital insole 
(0.15mm) it appears clear that other systems are significantly thinner. Furthermore, the 
number of total sensors present and their resolution are extremely important details that 
should to be taken into consideration when deciding what system can be used, 
especially in research. For example, in the Pedar
®
 the total numbers of sensors are 99 
compared to 960 sensing elements in the F-Scan
™
. Instead, the pressure range in the 
Pedar
®
 goes from 15 to 600 KPa, compared to the F-Scan
™ 
that goes from 125 to 862 
KPa (Tekscan 2010). 
 
The significant advantage of taking in-shoe measurements is to capture multiple 
footsteps data from both feet at the same time and record foot functional behaviours 
directly inside the shoe. Unlike to what occurs while using platform measurements, 
during in-shoe recording the patient can walk more naturally instead of targeting a plate 
on the floor, which could potentially alter normal ambulation. In contrast, the natural 
walking style of a patient may be altered by the presence of wires and data boxes 
attached to the waist. However, few systems recently developed are equipped with 
wireless connection, eliminating any possible issues related to wires connecting insole 
and data box. Dependent on the quality of the sensors of the digital insole, certain areas 
of the foot may be missed during recording under the influence of the shoe. In addition, 
the different materials used with the digital insole (for example: rigid type), could have 
a direct effect on the recordings and may alter the data, resulting in false interpretation 
of results.  
 
Some clinicians may argue that one of the disadvantages of using the in-shoes system is 
that when corrective orthotics are placed into the shoe, the depth of the shoe and 
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thickness of the digital insole may affect pressure. Some surfaces can be slippery 
therefore recording may be affected. Certain skills are required by the podiatrist when 
inserting the patient’s foot inside the shoes without creating uneven surfaces on the 
digital insole; a particularly difficult task to be carried out thoroughly when dealing 
with symptomatic children using very small shoes. Some clinicians may fail to ensure 
that the digital insole is placed correctly on top of the orthotics, with the unfortunate 
results of bending the sensors and altering the direction of forces. 
 
The F-scan in-shoe pressure measurement system provided objective quantifiable and 
reliable measures to study different types of pathologies (Ahroni, Boyko, and Forsberg 
1998b; Chen and Bates 2000; Joanne et al. 2007; Luo et al. 1998; Nicolopoulos and 
Barnett 1998; Randolph et al. 2000; Rash and Quesada 1997).  
 
F-scan system allows a high degree of portability of the system in different clinical 
settings, and it can be utilised to investigate in-shoe foot behaviours with multiple 
pathologies. The Diabetic Foot Journal published the study conducted by Joanne (2007) 
in which custom-made total contact FOs and prefabricated functional diabetic FOs 
efficacy were compared (Joanne et al. 2007). According to Cochrane systemic reviews, 
reducing plantar mechanical pressure is one of the most important clinical interventions 
required to encourage the healing process, particularly in neuropathic feet (Grimm et al. 
2004; Spencer 2008). Recent evidence also confirms that there is a direct links between 
peak plantar pressure and the development of neuropathic foot ulcers. Thus, FOs 
designed to reduce elevated plantar pressure are prescribed to prevent ulceration in 
diabetes patients (Bus et al. 2004; Spencer 2008). In the comparison clinical case study 
carried out by Joanne (2007) on diabetic patients it was possible to prove that F-scan 
in-shoe pressure measurement systems, have the great potential to instantly identify and 
optimise off-loading interventions which would reduce the patient’s risk of ulceration 
(Joanne et al. 2007). The author investigated 5 pre-selected foot outcome measures: 
peak plantar pressure, total plantar contact area, rate of forefoot load, forefoot pressure 
time integral, duration of metatarsal region load as a percentage of stances. Finally it 
was concluded that thanks to the data obtained by the Tekscan software the 
prefabricated functional FOs appeared to offer a successful alternative to the more 
costly custom-made FOs. This comparative study also highlighted the importance of 
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considering foot biomechanics to effectively prescribe load-reducing FOs in ulcer 
prevention and management (Joanne et al. 2007).  
  
In clinical practice, it is fairly common to find practitioners who have different opinion 
regarding the choices of in-shoes system that should be used with patients. For 
example, Cavanagh (1992) published a review in which the F-scan system was heavily 
criticised for not providing accurate and reliable results. This author, instead, favoured 
the use of the Pedar system as more precised equipment used for in-shoe measurements 
(Cavanagh, Hewitt and Perry 1992). Regardless of clinical preference, a few years later 
Rash (1997) carried out a comparative study between Pedar and F-scan system which 
revealed no significant difference in the ability to measure uniform absolute pressure  
(Rash and Quesada 1997). In addition, it was suggested that F-scan is more accurate 
than the Pedar over a longer period of time and by the same patient (Rash and Quesada 
1997). It has to be said that since the time that this fairly dated publication was written, 
both systems have evolved in technology and improved the resolution of their sensel. 
 
In shoe analysis systems, such as F-scan appear to have generated a lot of interest 
amongst biomechanical researchers in the late 90’s. The ‘Journal of Rehabilitation 
Research and Development’ published an interesting study conducted by Dr Luo 
(1998) in which validation of F-Scan pressure sensor system was investigated. This 
study performed a quantitative validation using a servo-hydraulic material test system
25
 
that was able to exert compression forces on the entire FOs sensor and on each single 
cell. The FOs sensor was positioned between 2 layers of plastizote (6.4mm), backed by 
2 layers of 12.7mm thick aluminium plates. Constant pressure was applied to the whole 
surface of the F-scan sensor by the MTS machine. The researcher tested the application 
of uniform pressure by moving the F-scan insole in different positions inside the 
compressor, showing no changes in the sensor output contours. Due to the heat 
generated within the electric circuit and insulation by the foam, the sensor temperature 
could have increased, leading to output voltage variations. Therefore, temperature 
changes were monitored with the aid of a digital thermometer and a thermo-sensor 
needle placed near the central region of the F-Scan insole sensor. Evaluation of the 
linearity and homogeneity of cell response was performed at five static loading levels. 
                                                 
25
 MTS 810, MTS Systems Corporation, Minneapolis, MN  
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Several tests at different temperatures were carried out in order to monitor sensor 
response in hot and cold environments. It can be argued that in the clinical scenario, 
prior to using the F-scan on a patient, the sensor would almost never be exposed to 45°. 
Therefore, although it is important to be aware that at certain temperatures the 
sensitivity of the F-scan may change, equally it should never occur that patients are 
exposed to these overwhelming temperatures during gait analysis. During this research, 
the F-scan was tested with different materials (softer and harder) to investigate how the 
sensor would react if placed over static pressure (for a period of 120 sec) and over 
dynamic pressure (1 sec). This study concluded that factors that should be considered 
while using F-scan are: contact surface, loading conditions, and temperature changes. 
Additionally, re-examination of the F-Scan sensor system is also necessary whenever it 
is upgraded. Finally the results indicated that the sensor is adequate for determination 
of pressure distribution under contact conditions with soft materials (Luo, Berglund and 
An 1998). 
 
Encouraging evidence on the reliability of the F-scan is also provided by Ahroni 
(1998). This prospective study, which was made available by the journal of ‘foot and 
ankle international’, highlights that for elderly patients with diabetes who were wearing 
their own shoes and were tested over two days with different FOs, the F-Scan insole 
system proved to be a reliable system to measure in-shoe parameters. In each of the 51 
subjects recruited from a cohort of 977 diabetic veterans with risk factors for foot 
ulceration and amputation, high pressure and peak pressure was investigated 
particularly on the forefoot and particularly underneath the metatarsal head, which 
represent the anatomical areas with a higher incidence of developing ulcers (Ahroni, 
Boyko and Forsberg 1998b). Finally, from this quite dated research, carried out in 
Seattle, Washington, not only was it possible to confirm the reliability of the F-scan 
system, but also it was proven that this in-shoe technology could significantly prevent 
the creation of ulcers underneath exposed metatarsal heads, which may lead to 
amputations.  
 
Another comparison study published by the ‘Physiotherapy Theory and Practice 
Journal’ investigated the F-Scan in-shoe system with the AMTI26 force-plate system in 
                                                 
26
 AMTI = Advanced Medical Technologies, Inc 
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measuring vertical ground reaction force during gait. According to the author, the 
AMTI served as the ‘gold standard’ for comparison with the F-Scan system (Chen and 
Bates 2000). For this study, 2 force-plates were placed on two separate aluminium 
supports, which were firmly inserted into the concrete foundation within the floor of 
the gait laboratory. The force-plates were placed to allow 2 consecutive steps during 
the data collection (Chen and Bates 2000). The F-scan and the AMTI were adopted to 
simultaneously record the self-selected walking pace of 30 healthy adults. Participant 
presented the following characteristics: 27.7 ± 2.9 years; weight 80.1 ± 14.9 kg; height 
181.3 ± 5.6 cm). As shown the age range might be deemed to be insufficient to 
represent the entire population as well as the fact that only males were recruited in this 
study. All subjects were volunteers from the university student body. The criteria 
adopted allowed the selection of participants who were free of injury and having no 
lower extremity deformities. All subjects were right leg dominant as established by 
their kicking leg preference. Furthermore, due to limited availability of shoes and F-
scan sensors, all volunteers had to have a foot size between 9 and 11 (Chen and Bates 
2000). All subjects wore standard laboratory shoes provided by the investigators to 
avoid introducing additional variables in the in-shoe recordings. In this interesting 
paper, it is specified that one biomechanical specialist was in charge of pre-screening 
each individual subject in order to exclude those with noticeable abnormalities or 
pathological gait patterns. Prior to using the F-scan system, static STJ measurements 
were obtained at close kinetic chain using a gravitational goniometer.  
 
Chen (2000) calculated the STJ values 3 times at each trial, and then averaged the 
values to monitor if the participant met the inclusion and exclusion criteria. Therefore, 
individuals with more than 5° of ankle valgus or varus were excluded from 
participation. Data analysis revealed no statistical differences between the 2 systems 
(p>0.05). Curve correlation showed higher correlations for the 21–90% interval of the 
support phase (midstance) compared to the initial (heel strike) and a brief period before 
toe-off. These results may indicate that the F-Scan insole system is a useful system to 
measure the vertical GRF during ambulation. However, according to this research 
particular attention should be given in the interpretation of pressure and force data 
particularly during the initial 21% and final 10% of the support phase of walking (Chen 
and Bates 2000). The reader should be reminded that in this comparative study, in 
which a very limited part of the population was investigated; because only males in the 
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age range of 25 to 30 years were involved in the study. Some clinicians may argue that 
having only 3 FOs sizes available may be considered as a possible limitation to 
thoroughly test the full potentials of the system. In addition, podiatrists may argue that 
right footed subjects should not necessarily have been recruited in the study; also, the 
reader is not informed about the type of shoes used for all the recording, which may 
have directly caused the F-scan system to fail to produce valid data at heel strike and 
toeing-off. Finally, the author failed to provide valuable details on the type of criteria 
used by the biomechanical specialist to include or exclude participants. For example, it 
is not mentioned in the text if the initial gait observations were made with subjects 
walking with shoes: some participants could have appeared to have a sound 
biomechanics because they could have been previously fitted with functional devices in 
their shoes. Subsequently, the F-scan recordings were taken without the orthotics; 
therefore results obtained could have been completely skewed, particularly if such a 
small population was involved.  
 
From the Archives of Physical Medicine and Rehabilitation, it is possible to evaluate 
another study conducted by Randolph (2000) in which the reliability of measurements 
of pressures applied on the foot during walking F-scan system was investigated. This 
study was conducted in the gait laboratory of the department of Physical Medicine and 
Rehabilitation of the New York Medical College, in which 10 healthy subjects were, 
studied (2 men, 8 women, age 30 to 59 years, mean age of 46 years). The insoles were 
cut to fit the entire sole of the foot and then placed in the shoes. Final results indicated 
no significant difference between the 4 F-scan insoles tested in this small study. The 
pressure data obtained by this in-shoe measurement system appeared to be sufficiently 
reliable to be used for the podiatric management.  
Not many in-shoe measurements publications have been yet carried out by authors who 
have expertise in the rheumatology field. Interestingly, Woodburn (1996) and Li (2000) 
drew two completely opposite conclusions with regard to the use of the F-scan system. 
The former claimed that the F-Scan system lacks durability and suffers from significant 
calibration errors. In addition, few limitations related to the physical characteristics and 
capabilities of the sensor of the system were disclosed. For example: the material used 
for making the FOs did not help its durability; the author frequently experienced 
creasing in the heel region which caused to permanent damage and strain to connected 
wires and ultimately led to sensor failure. The sensors were found to be flexible in two 
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directions but not simultaneously and therefore they did not adapt well to the curved 
surfaces of the FOs inserted. Woodburn (1996) challenged the ability of the upper 
pressure range of the sensor (1250 KPa) which may be inadequate for use in some 
patient groups who experience very high plantar pressures, particularly neuropathic 
diabetics with plantar ulceration. The podiatrist involved at the rheumatology 
department of the Huddersfield Royal Infirmary, concluded his publication by reporting 
that despite an initial positive impression of the system, F-Scan is not entirely suitable 
for accurate and repeatable in-shoe pressure measurements. Nevertheless, Woodburn 
still values the F-scan, reporting that useful information can be gained where the user 
understands and takes account of the limitations of the system. 
 
On the other hand, Li (2000) used the F-Scan system with RA patients who were 
wearing FOs. The Chinese researcher raised the question whether FOs would have an 
effect on the foot pressures distribution and forces during gait. Biomechanical changes 
were investigated on 12 female RA patients and compared with 8 healthy female 
participants. FO is commonly prescribed to patient affected by this disabling 
autoimmune pathology, however, at the time of the publication little was known about 
the biomechanical effects of in-shoe foot orthoses (Janisse 1998; Li et al. 2000). Gait 
Analysis was recorded using the F-Scan software (version 3.623) and analysed with 
subjects walking in-shoe with or without foot orthoses. Each recording was carried out 
wearing commercial sport socks and a constant room temperature of 20° was 
maintained. Sensors were adjusted to fit shoe size and calibration of the F-Scan was 
carried out prior to each measurement using subjects' body weights in a single-limb 
support model (standing calibration).  
 
Although this research provided positive results of the use of the F-scan system, it can 
be argued that using brand new sensors with each patient represents a very accurate 
way to record data; however, it is feasible only with such a small population of patients 
recruited. Furthermore, in real clinical scenarios, due to financial issues, it might be 
difficult to reproduce the same methodology carried out by Li (2000). The reader is not 
informed about what types of shoes were used during the data recording. On the paper 
it is illustrated a common gymnastic shoe; however, the author simply reported that 
patients walked with ‘their shoes’, which could have potentially skewed the final 
results. Finally, some podiatrists may argue that it would have been more appropriate to 
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recruit a more mixed gender population, rather than only female. However, most 
importantly, if the recordings were repeated more than once with each patient, at a 
certain interval (for example: 6 weeks or 3 months), it would have been possible also to 
verify the effectiveness in pain relief and gait improvement over a period of time. 
 
 
 
 
  Equipment 3.3.
3.3.1. Tekscan computer requirement 
 
During the entire data collection process the same equipment has been used both for the 
repeatability and reproducibility study and for the RCT in JIA children: HR Walkway 
and F-scan system. In this chapter details of the equipment will be provided. Most of 
the gait recording has been carried out at Queen Margaret University Gait Laboratory; 
however, part of this multicentre research project has also been carried out in Dundee at 
the TORT centre in Ninewells Hospital.  
 
In order to utilise the equipment, two laptops have been provided by Queen Margaret 
University in which HR Walkway (software version 7.0) and F-scan (software version: 
6.30) were installed. According to the manual provided by the manufacturer, the 
Tekscan system must meet or exceed certain requirements. The suggested minimum 
computer requirements (desktop or laptop) for all Tekscan Systems are: Intel Pentium 
600 MHz or higher processor 1 with 128 MB RAM (512 MB RAM recommended); 1 
GB hard drive and 1 CD ROM drive; Windows 2000 (SP4), XP (SP2), Vista7 
operating system (32-bit versions only).  
3.3.2. The HR WalkwayTM 
As reported by the Tekscan, the HR Walkway system provides static and dynamic gait 
data and barefoot pressure and force measurements over several steps using a low 
profile floor walkway (Figure 3.3.2.1).  
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Figure 3.3.2.1:HR Walkway 
 
 
The barefoot analysis 
system used for this 
paediatric rheumatology 
research has 4 sensels per 
cm
2
. It was possible to carry 
out the calibration process 
by application of a known 
and controlled force. 
According to Tekscan 
(2010) the sampling rate of the 
#7101QL model is 60 Hz and the pressure range goes from 1-862 kPa, which is quite 
remarkable considering that the floor mat thickness is only 5 mm (Figure 3.3.2.1, 
Figure 3.3.2.3). Multiple foot strike was made possible as the High Resolution 
Walkway is 1956 mm long and 442 mm wide platform and counts for a total number of 
Figure 3.3.2.2: patient walking on HR Walkway 
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33,408 of high resolution sensing elements. 
 
Figure 3.3.2.3: close up on patient walking on HR Walkway with the F-Scan ankle cuff on. 
 
 
 
As previously mentioned the sequence of recording was 
randomly decided with each participant Figure 3.3.2.4. 
However, each participant was asked to familiarise with the 
platform by walking on it at least twice.  
 
 
Figure 3.3.2.4: recording icon 
Figure 3.3.2.5: example of barefoot recording 
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At the countdown of 3, the patient was asked to start walking at the desired speed. At 
the same time on the 
white screen the 
recorded button was 
selected. When a gait 
‘movie’ is being 
recorded, the left side of 
the Real-time Status Bar 
displays the "Rec. 
Frame", which is the 
"frame count "of the 
recording in progress. If  
 
the practitioner prefers to initiate the recording using the keyboard, it 
is possible to start and to stop recording using the following buttons: 
F2 and F4 respectively. It is possible to select the icon forward or 
backward. In addition, CoF trajectory (Figure 3.3.2.5,Figure 3.3.2.6, 
Figure 3.3.2.7) and movie speed can be selected as well.   
 
Figure 3.3.2.6: 
human icon 
Figure 3.3.2.7: centre of trajectory option shown on HR Walkway recording 
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With Walkway software (version 7.0) it is possible to obtain an automatic calculation 
of gait parameters and presented it in tables. The so called ‘Human Table Icon’ (Figure 
3.3.2.6) also it allows for the generation of a gait table between more than one 
recording at one time (Figure 3.3.2.8). 
3.3.3. F-Scan® Mobile 
This system enables to quantify forces, and multiple pressure parameters. The F-scan 
insoles are extremely thin (0.15 mm) and the high 
resolution F-Scan sensor ensures accurate data is 
captured. The F-scan 3000E was used for this 
research project: according to the manufacturer the 
pressure ranges from 345 to 862 kPa, and each F-
scan insole comprises a total of 954 sensing 
elements (3.9 sensel in each cm
2
). Each F-scan 
insole has the specification directly imprinted on its 
surface (Figure 3.3.3.1) which is useful to keep 
Figure 3.3.2.8: example of gait table generated by the human icon 
Figure 3.3.3.1: specification of the 
F-scan insole 
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monitoring the type of F-scan used in each data recording (Figure 3.3.3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
For the RCT all recordings have been carried out using the 3000E model of F-scan.  
The software also is able to analyse specific areas of plantar foot pressure and the 
centre of force trajectory.  The F-scan 3000E is able to be trimmed to size and fitted to 
virtually all foot sizes from very small to very big feet (Figure 3.3.3.2). With respect to 
the trial, the smallest foot size cut was 9 child’s size and the oldest recruited patients 
had size 10 adult (Figure 3.3.3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3.4: display of different pairs of F-scan insole used in the study 
 
Figure 3.3.3.3: a  pair F-scan insole used in the study 
Figure 3.3.3.2: example on how the F-scan insole was 
divided into separate folders 
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Each sensor was trimmed to fit shoe size, checked to see if it was suitable for the shoes 
and subsequently divided into pairs in individual transparent envelopes each containing 
size details. In order to avoid any damage at the sensel, the manufacturer suggests 
paying particular care in cutting the insole: normal scissors were used to trim the white 
outline of the insole; the sensel had to be cut precisely in between the columns 
according to the size intended to be prepared. The sensel could be ruined too, if the 
connection points (silver dots) were cut through. Depending on the degree of damage 
of the sensel, the F-scan insole may not be able to transmit the voltage changes to the 
F-scan mobile unit (Figure 3.3.3.5 and Figure 3.3.3.6).  
 
Figure 3.3.3.5: how to trim the F-scan insole 
 
Figure 3.3.3.6: F-scan connection points and sensel elements  
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Figure 3.3.3.7: incorrect example of how to trim F-scan insole 
 
 
Figure 3.3.3.8: correct and incorrect technique of cutting the F-scan 
 
In some instances, if just one sensor was damaged, it was possible to 
notice ‘drop out traces’ appearing on the screen prior the recording, 
causing the sensor to read a lower total force (Figure 3.3.3.7, Figure 
3.3.3.8 and Figure 3.3.3.9).  
  
The F-scan system has the great advantage that it is completely 
portable; therefore, data can be recorded in different locations (Figure 
3.3.3.10), hence suitable for a multicentre trial. 
 
Figure 3.3.3.9: drop 
out traces 
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Figure 3.3.3.10: F-scan mobile unit with battery, cable, ankle cuff and strapping 
 
As shown in Figure 3.3.3.10, the F-scan consists of the F-scan mobile unit, attached to 
an adjustable belt that is clicked around the patient’s waist. Strapped on the belt, the F-
scan battery is placed inside a pocket which supplies power to the F-scan mobile 
through a small cable inserted directly into the unit. On the opposite side of the F-scan 
unit, 2 cables are connected in portal 1 and portal 2, which link the unit to the ankle 
cuff.  It is important to make sure that the cables are firmly inserted into the ankle cuff 
as any possible interference or excessive stress applied to the cable may stop the 
transmission of the signal to the F-scan unit. The F-scan insole can be used on either 
side, there is no different between left and right (Figure 3.3.3.11).  
 
There is a narrow connection within the ankle cuff, which must be used to insert the F-
scan insole. It is important to verify that every time, the F-scan insole is introduced 
completely into the narrow connection, otherwise no signal will be transmitted to the  
Figure 3.3.3.11: F-scan ankle cuff and the connecting sensors 
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software, which will automatically inform about the faulty connection. The circular 
switch must be turned by 90° in order to secure and lock the F-scan insole inside the 
ankle cuff.    
 
The shoes were chosen on the basis of finding a suitable brand which had the same 
features from child sizes to adult sizes (Figure 3.3.3.12). Furthermore, by using the 
same shoes style with every child, it would have also limited the variables during data 
recording related to the condition of the shoes.  
 
 
 
 
 
 
 
 
 
 
 
Each participant was able to wear Clark shoes and to have the F-scan insole trimmed to 
fit each shoe size. Each F-scan insole presented with an additional lamination layer 
made of vinyl which provide an additional reinforcement to the sensor. The laminated 
F-scan insole is slightly thicker (no details of thickness are provided by the 
manufacturer) but less prone to cracks along the traces, which can be particularly useful 
for high impact sports, research or extended data collection. On some occasions, 
additional tape can be applied to the sensor neck for reinforcement and to avoid 
unwanted sensor movement during recordings of running.  
 
The manufacturer suggests that, when subjects have smaller feet, the edge of the sensor 
should be trimmed to fit and sit precisely on the insole. The best way to assure the 
optimum contact is to visually observe whether or not the sensor covers and sits on the 
full area of the inner sole of the footwear, and that the weight of the foot is going 
entirely through the active region of the sensor applied on the FOs (Figure 3.3.3.13). 
Figure 3.3.3.12: Clarks shoes 
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Figure 3.3.3.13: correct (left) and incorrect (right) position of the F-scan insole 
  
 The sensel in the insoles reacts and respond to compression force, which results in 
small changes of voltage. The change in voltage of each sensel is registered and 
directly correlated to a known calibration load (force), and then converted to a force 
(having an engineering unit such as kilograms (kg). By having force measured and a 
known area, the pressure (kg/cm
2
) can be calculated automatically by the software and 
displayed on the screen. The subject’s weight is needed when performing the 
calibration. Therefore, it is always convenient to remember to weigh the subject and 
record this detail for later reference. Once the patient is wearing the F-scan belt, linked 
to the battery and with the F-scan insole inside the shoes (with the circular switch 
turned into locked position), the last stage is to insert the wire that connect the USB 
entry of the laptop with the F-scan mobile unit. Once the connection has been made, the 
F-scan mobile unit can be switched on. The laptop will recognise the F-scan mobile 
unit and only at this stage the software can be successfully launched (Figure  3.3.3.14).   
 
 
Figure  3.3.3.14: illustration on how to connect the laptop to the F-scan mobile unit 
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    The F-scan Mobile research software available 
was version 6.30. The process for entering 
patient’s details was exactly the same as for the 
HR Walkway (Figure 3.3.3.15).  
 
The recording button was pressed at the start of 
the recording and then re-pressed to indicate the 
finish of the recording. The F-scan mobile was 
then connected to the cable and the data were 
downloaded in the programme and saved for 
future analysis.   
 
The F-scan software allows multiple displays of 
all the stances recorded and the force versus time 
graph is also shown on the screen (Figure 3.3.3.16).  
 
Figure 3.3.3.16: example of multiple phase recording’s display with force vs time graph 
 
 
Figure 3.3.3.15: example of F-Scan recording 
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 Repeatability and Reproducibility Study 3.4.
3.4.1. Aim 
The aim of this study is to test the repeatability and reproducibility of the F-Scan
 
and 
the HR Walkway in the gait of healthy children. 
 
3.4.2. Objective 
 To determine the repeatability of F-Scan® and HR WalkwayTM in healthy children”. 
 To determine the reproducibility of F-Scan® and HR WalkwayTM in healthy 
children”. 
3.4.3. Calibration  
Calibration of the HR WalkwayTM  
 
Calibration procedure was carried out following the instruction provided by the 
manual. Calibration should be 
performed before each new patient 
session, and when a new sensor is used. 
Calibration should take no longer than 
2 min. The subject had to stand as still 
as possible in order to perform the 
calibration procedure. From the 
calibration tool bar it is possible to 
access to the step calibration option 
which consist in applying only 1 foot on 
the platform at the time.  
 
If successful the calibration test should last no more than 4-5 sec. If the patient fail to 
stand on one foot or struggles to stand still for 4-5 sec, then the software would 
immediately inform the user that the calibration has been ‘unsuccessful’; therefore, the 
test has to be performed again (Figure 3.4.3.1). When finished, the ‘Calibration’ can be 
saved or delete.  
Figure 3.4.3.1: Calibration procedure window 
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Calibration of the F-Scan 
 
Calibration is the method by which the raw digital output of the sensor is converted to 
actual pressure units, such as "PSI" or "kPa". Step calibration procedures merely 
require that the patient stand completely still on the sensor (one foot at a time) for a 
moment. Calibration should be performed before each new patient session, and when a 
new sensor is used. Proper calibration of the sensors is critical to obtaining accurate 
pressure readings with the system. Two options of calibration are available: 
 
Step Calibration:  to initiate the step 
calibration, the subject must stand entirely 
with one foot on the platform. After few 
seconds, the computer instructs the 
subject to shift the weight onto the other 
and stand on one foot for 5 to 10 seconds (Figure 3.4.3.2 and Figure 3.4.3.3). This 
procedure is then repeated with the other foot. Calibration is then saved for left and 
right foot (Tekscan 2008). 
  
 
Figure 3.4.3.3: step calibration procedure for left foot 
  
 
 
 
 
Figure 3.4.3.2: step calibration icon 
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Walk Calibration: At the beginning of a trial, or 
series of trials, the user enters the patient’s weight, 
and the patient walks (Figure 3.4.3.4).  
The computer analyses walking data, and  
calculates a linear relation between raw counts and engineering units. Walk calibration 
is accomplished for the left and right foot together. Walk calibration is done 
automatically after the trial of interest is recorded. In addition, the manufacturer reports 
that walk calibration will not function well for subjects who are standing still, jogging 
or running. Also, during data recording, issues may arise if high heel impact forces and 
large propulsive forces from the toe and forefoot cause the sensor to measure force 
significantly higher than the inserted body weight. For the studies reported in this 
thesis, the walk calibration method was chosen because more suitable for the type of 
recordings taken and the age population considered in the trial. (Figure 3.4.3.5).  
.  
Figure 3.4.3.5: walking calibration successfully completed 
 
 
3.4.4. Method 
 
Healthy children recruited for the study took part in non-invasive clinical assessments. 
The Ethics Committee at Queen Margaret University granted the approval for this 
Figure 3.4.3.4: walk calibration icon 
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repeatability and reproducibility study. The recording of study data took approximately 
30 min per session. Each patient received verbal and written information regarding the 
study. A total of 30 healthy patients were recruited ranging between 5 to 18 years of 
age. Those participants willing to take part in the study were asked to attend the Gait 
Laboratory at Queen Margaret University for data collection at baseline and one week 
later. Risk assessment of the gait laboratories was carried out prior data collection. All 
participants to the study were able to withdraw from the study at any time without 
giving any reasons. All subjects were given an opportunity to speak with an 
independent person, who knew about the project but was not directly involved in it. 
 
On the day of the appointment, informed consent was obtained from the parents or 
carer (appendix XVI). Height and weight were measured in order to calculate each 
participant’s BMI and health status. Each subject was given a standardised shoe wear to 
verify shoe size before the start of gait recording; the equivalent F-scan insole size was 
used without socks. All information collected during the study was strictly confidential 
and anonymous; details were safely locked in a metal filing cabinet placed within a 
restricted personal area of the university. 
 
Inclusion Criteria: 
 
 All subjects with no lower extremity joint involvement ranging from 5 to 18 years 
old. 
 Ability to walk a minimum of 15 metres without assistive devices. 
 No medication. 
 
Exclusion Criteria: 
 
 Inability to walk barefoot or shod. 
 Concomitant musculoskeletal disease, central or peripheral nerve disease and 
endocrine disorders, especially Diabetes Mellitus.   
 Previous foot surgery.  
 Currently using foot orthosis. 
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In each appointment, the sequence of data recording was completely randomised in 
order to avoid any possible influence from the data collector. Especially when dealing 
with young children, the level of attention and tiredness can vary significantly. 
Therefore, F-scan and HR Walkway recording were randomly selected following the 
order generated by the computer programme.  
 
Each visit was completed in between 30 to 45 min each, depending upon the age of the 
participant. Usually, the younger the patient the longer was the meeting: however, the 
data collection never exceeded 45min. The equipment was set up prior to the start of 
data collection. The F-Scan insoles were accurately trimmed according to the 
instruction provided by the manufacturer.  
 
Figure 3.4.4.1: gait lab map. Indicating where the HR Walkway was placed and where the F-Scan 
recordings were carried out. The overall distance for the F-Scan recording (shod and with insole) was 7 
metres. 
 
All equipment was set up as explained on 
section 3.3 and calibration was carried out 
and saved (Figure 3.4.4.2). In order to 
familiarise with the equipment, each patient 
performed 2 walks along the length of the 
lab prior to starting the recording. Every 
patient was recorded walking from one end 
Figure 3.4.4.2: HR Walkway standing calibration with 
patient while wearing the F-Scan mobile unit 
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of the lab and stopped after 7 metres. The starting and the finishing point were defined 
by a tape attached to the floor. The tape was never removed for the whole duration of 
the data collection, allowing patients to have the gait recorded for the same distance at 
each appointment. Because of dealing with quite young children, the same chair was 
used by all participants to help them maintain balance. The subject was constantly 
monitored in order to recognise any possible mistakes which might be related to 
excessive weight applied on the chair.  
 
It is important to notice that each patient was calibrated on the Walkway platform while 
simultaneously wearing the F-scan belt, the connecting wires, the battery and finally 
the ankle cuff. The rationale behind this procedure was to avoid any possible 
introduction of variables within the recordings and to account for possible gait changes 
which may be related to wearing the F-scan belt during in-shoes analysis. Therefore, 
each participant walked the 7 metres length of the gait analysis lab, while wearing the 
1.7 kgs extra weight at barefoot, in-shoe barefoot and in-shoes with insole. Each patient 
was asked to familiarise themselves with walking barefoot on the platform prior to 
starting the recording; two trials were carried out before recording. Once the patients 
felt comfortable and ready, at the count of 3 the recording started.  A total of 3 
recordings were taken and saved with their anonymous code name. 
 
The same procedure was repeated at a 1 week interval following the randomisation 
order decided by the software. Participants were advised to wear similar clothes for the 
following week’s data collection, in order to limit and control the variables that could 
affect the final results. All data were safely stored in the computer, protected by 
password, and access to the computer at the gait analysis laboratory was allowed only 
to a restricted number of researchers. Each participant’s hard copy records are safely 
kept in a locked cabinet within the Podiatry department at Queen Margaret University.  
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3.4.5. Data Analysis  
Foot Mapping 
 
Recent research into child and adult gait provided useful evidence based on the analysis 
of different parameters of plantar foot pressure (Broström et al. 2002; Dixon and 
McNally 2008; Fairburn et al. 2002; Hadfield et al. 2003; Hendry et al. 2009). 
According to Hadfield et. al (2003), the mapping of the foot for plantar pressure was 
divided into seven separate regions (1
st
, 2
nd
, 3
rd
 till 5
th
 metatarsal head, medial and 
lateral portion of the midfoot, and medial and lateral portion of the heel): toe regions 
were completely excluded from consideration as, according to the authors, these 
regions were negligible to non-existent (Hadfield et al. 2003). 
 
Thanks to the technology available using the Tekscan equipment, it was possible to 
implement plantar pressure mapping investigation using previous clinical evidence as 
guidance for data analysis. Each foot recording was mapped into 10 different plantar 
foot regions with both the F-Scan and HR Walkway (Figure 3.4.5.1, Figure 3.4.5.2.) 
Please find below all the parameters investigated:  
  
 F-Scan 
o Total contact (left and right) 
o Heel (left and right) 
o Midfoot (left and right) 
o Forefoot (left and right) 
o 5th met. head (left and right) 
o 3rd to 4th met head (left and right) 
o 2nd met head (left and right) 
o 1st met head (left and right) 
o Lesser toes (left and right) 
o 1st Distal phalanx. (left and right) 
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Figure 3.4.5.1: F-Scan plantar pressure template 
 
 
 HR Walkway 
o Total contact (left and right) 
o Heel (left and right) 
o Midfoot (left and right) 
o Forefoot (left and right) 
o 5th met. head (left and right) 
o 3rd to 4th met head (left and right) 
o 2nd met head (left and right) 
o 1st met head (left and right) 
o Lesser toes (left and right) 
o 1st Distal phalanx. (left and right) 
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Figure 3.4.5.2: HR Walkway plantar pressure mapping template 
 
Additionally, the HR Walkway software (version 7) allowed also the investigation of  
the following parameters:  
 
 Gait Time (sec) 
 Gait Velocity (cm/sec) 
 Stance Time (sec) 
 
The PP Box approach was used during data analysis and consisted in isolating the 
anatomical part of the foot involved. From each of the 10 anatomical portions of the 
plantar surface of the foot, the PP Box approach allowed the investigation of:  
 
 Peak Pressure (identifies a specific area where there is the highest amount of 
pressure) – peak pressure versus time - (PP). 
 Pressure Time Integral (relationship between the amount of pressure that is 
applied throughout a period of time) - (PTI)  
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BMI Calculation  
 
The children’s BMI score and health status were calculated according to the ‘Scottish 
Intercollegiate Guidelines Network (SIGN). This national clinical guideline (no. 115) 
provides extended details with regards to the ‘Management of Obesity’. By consulting 
the ‘Annex no.10’ it is possible to plot the ‘childhood BMI centile chart’ for boys and 
girls up to the age of 20 years old. The same SIGN guideline will be used to identify 
the obesity rate for the 60 JIA children who took part in the RCT study as well.    
Repeatability and Reproducibility Analysis  
According to Portney and Watkins (2000), the ICC
27
 is an important statistical test that 
must be used in clinical research when comparing data. Furthermore, the authors report 
that the inter-rater values are considered to be: ‘good’ when ICC is above 0.75; 
‘moderate’ when ICC value is between 0.5 and 0.75; finally ‘poor’ is considered to be 
present if ICC values are below than 0.5 (Portney and Watkins 2000). Similarly, a 
much older publication made by Fleiss (1986), which investigated the design and 
analysis of the experiments, reports that if the ICC values are above 0.75 is deemed to 
be ‘excellent’. Any ICC values obtained between 0.4 and 0.75 are considered to be 
‘fair-to-good. Finally, any ICC value below 0.4 is deemed to be ‘poor’ (Fleiss 1986). 
As reported in the results section, the association between temporal and kinematic data 
was mostly excellent with healthy children. As Portney and Watkins (2000) is the most 
recent publication and the score-classification is stricter, it was chosen for this study. 
In order to test for repeatability of the F-scan and HR walkway, comparison of the data 
within each visit was carried out. Each recording occurred consecutively, within the 
same environment, using the same shoe size, utilising the same equipment and the same 
distance was travelled by the participants (7 metres). In addition, in each visit the 
recordings were carried out within a period of maximum 5 minutes. The same 
randomised procedure took place at baseline and at one week intervals. The 
repeatability tests of all parameters investigated, were considered individually between 
the 3 recordings at baseline and between the 3 recordings taken at week 1 (Figure 
3.3.5.3, Figure 3.3.5.4).  
                                                 
27
 ICC: intraclass correlation coefficient. 
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Figure 3.4.5.3: F-scan repeatability and reproducibility procedure 
 
Figure 3.4.5.4: HR Walkway repeatability and reproducibility n procedure 
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With regards to the reproducibility of the equipment, a comparison of the recorded data 
obtained between baseline and week 1 was carried out with F-Scan and HR Walkway 
(Figure 3.3.5.3, Figure 3.3.5.4). In order to acquire the data for the reproducibility study 
between baseline and one week intervals, the average was made of the 3 recordings 
taken at baseline, and an average of the values gathered at one week later. Therefore, 
the two averaged values were compared and ICC data analysis was carried out. The 
same data analysis procedure was repeated for each of the 10 anatomical areas 
investigated of the foot. 
Finally, data analysis was carried out during the study using the SPSS Statistics 
software (version: 17.0) and Microsoft Office Excel (2007). Data analysis mostly 
involved quantitative interpretation of parameters of gait. All raw data were initially 
inserted into excel spread sheets and subsequently exported into SPSS for statistical 
analysis. 
3.4.6. Results 
 
All 30 healthy patients recruited, attended the Motion Analysis Laboratory at Queen 
Margaret University at baseline and at 1 week intervals. Overall, 53.3% (n=16) were 
female and 46.7% (n=14) were male. Mean age was 13.3 years (SD 4.5), with a age-
range of 5 to 18.6 years. According to the BMI score, the health status of each 
participant showed that 6.7% (n=2) were underweight, 73.3% (n=22) subjects were 
healthy; 13.3% (n=4) were overweight and finally 6.7% (n=2) were obese. Health 
status of the subjects remained unaltered between baseline and week 1 interval.  
F-Scan Repeatability 
 
 
During data analysis of the PP, positive results were obtained from using the F-Scan 
equipment at baseline (Table 3.4.6.1). In all 10 anatomical areas investigated it was 
possible to observe ‘good’ ICC values for left, right and both feet. Similarly, after 1 
week, the same ‘good’ ICC results were gathered in all anatomical areas with the 
exception of the right foot for the ‘lesser toes’ at week1 which scored ‘moderate’ ICC 
values. Therefore, results confirmed the high repeatability values obtained when PP 
was investigated when using the F-Scan system (Table 3.4.6.1) 
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Table 3.4.6.1: ICC repeatability results for F-scan regarding PP at baseline and at week 1. ** means 
‘poor’; * means ’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; 
Good >0.75. 
 
Repeatability of F-Scan 
 
Peak Pressure Values 
 Baseline Week 1 
Anatomical Area Left  Right  Both  Left  Right  Both  
Total  0.933 0.970 0.960 0.972 0.940 0.961 
Heel 0.833 0.976 0.952 0.946 0.920 0.936 
Midfoot 0.879 0.885 0.879 0.909 0.858 0.883 
Forefoot  0.952 0.974 0.964 0.973 0.951 0.966 
5
th
  0.953 0.872 0.924 0.896 0.945 0.917 
3
rd
-4
th
  0.947 0.952 0.949 0.941 0.945 0.943 
2
nd
  0.961 0.963 0.962 0.980 0.947 0.971 
1
st
  0.937 0.978 0.964 0.944 0.935 0.942 
Lesser Toes 0.858 0.857 0.856 0.893 0.716* 0.807 
Distal Phalanx  0.951 0.920 0.938 0.955 0.917 0.933 
 
The PTI values at baseline of the left, right and both feet showed that ‘good’ ICC 
scores were found for all anatomical areas (Table 3.4.6.2). The analysis carried out one 
week later confirmed the ‘good’ ICC score in all parameters. Finally, also when PTI 
analysis was carried out, the ICC appeared to be highly repeatable for most anatomical 
area investigated (Table 3.4.6.2) 
   
Table 3.4.6.2: ICC repeatability results for F-scan regarding PTI at baseline and at week 1. ** means 
‘poor’; * means ’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; 
Good >0.75. 
 
Repeatability of F-Scan 
 
Pressure Time Integral  
 Baseline Week 1 
Anatomical Area Left  Right  Both  Left  Right  Both  
Total  0.959 0.924 0.947 0.943 0.951 0.928 
Heel 0.856 0.786 0.827 0.933 0.830 0.893 
Midfoot 0.846 0.761 0.809 0.836 0.847 0.838 
Forefoot  0.970 0.904 0.950 0.954 0.832 0.917 
5
th
  0.885 0.915 0.897 0.884 0.899 0.889 
3
rd
-4
th
  0.926 0.936 0.930 0.914 0.914 0.914 
2
nd
  0.937 0.963 0.952 0.970 0.898 0.954 
1
st
  0.889 0.910 0.901 0.929 0.871 0.913 
Lesser Toes 0.674* 0.860 0.728* 0.763 0.675* 0.717* 
Distal Phalanx  0.938 0.767 0.900 0.889 0.825 0.857 
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F-Scan Reproducibility  
 
 
The PP reproducibility scores were investigated in all 10 anatomical areas while using 
the F-Scan system. ‘good’ ICC values were reported from the PP reproducibility for all 
anatomical areas (Table 3.3.6.3).  
 
Table 3.4.6.3: ICC reproducibility results for F-scan regarding PP at baseline and at week 1. ** means 
‘poor’; * means ’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; 
Good >0.75. 
 
Reproducibility of F-Scan  
 
Peak Pressure Values 
Anatomical Area Left  Right  Both  
Total  0.845 0.860 0.825 
Heel 0.803 0.801 0.704 
Midfoot 0.961 0.823 0.901 
Forefoot  0.896 0.872 0.894 
5
th
  0.857 0.676 0.780 
3
rd
-4
th
  0.778 0.836 0.803 
2
nd
  0.805 0.779 0.895 
1
st
  0.846 0.939 0.857 
Lesser Toes 0.917 0.787 0.816 
Distal Phalanx  0.900 0.782 0.831 
 
 
As shown below on Table 3.4.6.4, with regards to the reproducibility of the F-Scan 
(PTI values) ‘good’ ICC results were found on most of the parameters investigated. 
Instead, ‘moderate’ ICC results were discovered on the left foot at 3rd-4th, and ‘both’ for 
the 3
rd
-4
th 
and lesser toes (Table 3.4.6.4). 
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Table 3.4.6.4: ICC reproducibility results for F-scan regarding PTI at baseline and at week 1. ** means 
‘poor’; * means ’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; 
Good >0.75. 
 
Reproducibility of F-Scan  
 
Pressure Integral 
Anatomical Area Left  Right  Both  
Total  0.853 0.850 0.638 
Heel 0.839 0.714 0.746 
Midfoot 0.889 0.804 0.784 
Forefoot  0.787 0.783 0.781 
5
th
  0.832 0.710 0.773 
3
rd
-4
th
  0.653* 0.786 0.705* 
2
nd
  0.915 0.758 0.835 
1
st
  0.888 0.838 0.833 
Lesser Toes 0.787 0.777 0.733* 
Distal Phalanx  0.827 0.765 0.755 
 
 
The trend of reproducibility ICC results for PP and PTI appear to show highly 
repeatable and reproducible ICC scores. 
HR Walkway repeatability   
 
 
With regards to the repeatability values obtained with HR Walkway system, it was 
possible to investigate the ICC results between the left, right foot and both feet 
accounted together. With regards to the PP repeatability results obtained at baseline 
with the HR Walkway, ‘good’ ICC results were highlighted in most anatomical areas 
investigated for the left, right and both feet accounted together (Table 3.3.6.5). The 
only exception was noted for the heel (left, right and ‘both’ feet) which showed 
‘moderate’ ICC repeatability. Similarly, one week later, ‘moderate’ ICC scores were 
only found on the left at the midfoot, and on the right for the heel. All remaining 
anatomical areas investigated at week 1, appeared to have ‘good’ PP repeatability 
scores (Table 3.3.6.5). Overall the PP for the HR Walkway showed highly repeatability 
values. 
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Table 3.4.6.5: ICC repeatability results for HR Walkway regarding PP at baseline and at week 1. ** 
means ‘poor’; * means ’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-
0.75; Good >0.75. 
 
Repeatability of HR Walkway 
 
Peak Pressure versus Time 
 Baseline Week 1 
Anatomical Area Left  Right  Both  Left  Right  Both  
Total  0.755 0.754 0.752 0.787 0.798 0.790 
Heel 0.725* 0.673* 0.701* 0.764 0.673* 0.754 
Midfoot 0.906 0.804 0.856 0.638* 0.920 0.766 
Forefoot  0.904 0.914 0.908 0.929 0.917 0.923 
5
th
  0.893 0.937 0.917 0.917 0.925 0.921 
3
rd
-4
th
  0.887 0.920 0.902 0.891 0.900 0.893 
2
nd
  0.959 0.933 0.943 0.942 0.937 0.939 
1
st
  0.787 0.842 0.815 0.927 0.918 0.923 
Lesser Toes 0.877 0.875 0.876 0.670* 0.901 0.790 
Distal Phalanx  0.849 0.846 0.847 0.892 0.895 0.893 
 
With regards to the PTI repeatability results obtained at baseline with the HR 
Walkway, ‘good’ ICC values were observed in most of anatomical areas for the left, 
right and ‘both’ feet (Table 3.4.6.6). The only exceptions recorded was the ‘moderate’ 
ICC values at baseline identified on the left at the heel, on the right at total contact, heel 
and lesser toes; and finally on ‘both’ feet at heel and distal phalanx.  
 
As shown on Table 3.4.6.6, when repeatability analysis was carried out one week later, 
most anatomical areas presented with ‘good’ ICC results. ‘Moderate’ ICC results were 
noted only on the left foot at total contact, 5
th
 met head and lesser toes; on the right at 
total contact, and on ‘both’ feet for the lesser toes and distal phalanx. Overall, the PTI 
repeatability measurements revealed highly repeatable values both at baseline and at 
week 1 interval. 
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Table 3.4.6.6: ICC repeatability results for HR Walkway regarding PTI at baseline and at week 1. ** 
means ‘poor’; * means ’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-
0.75; Good >0.75. 
 
Repeatability of HR Walkway 
 
Pressure Time Integral  
 Baseline Week 1 
Anatomical Area Left  Right  Both  Left  Right  Both  
Total  0.817 0.710* 0.757 0.705* 0.525* 0.810 
Heel 0.573* 0.657* 0.585* 0.816 0.866 0.807 
Midfoot 0.791 0.888 0.846 0.884 0.916 0.859 
Forefoot  0.879 0.917 0.896 0.949 0.784 0.865 
5
th
  0.778 0.908 0.842 0.540* 0.936 0.892 
3
rd
-4
th
  0.877 0.888 0.881 0.900 0.905 0.884 
2
nd
  0.936 0.883 0.909 0.957 0.899 0.888 
1
st
  0.783 0.859 0.823 0.809 0.930 0.786 
Lesser Toes 0.826 0.710* 0.760 0.704* 0.881 0.695* 
Distal Phalanx  0.699 0.789 0.745* 0.860 0.853 0.732* 
 
 
Additional gait parameters were investigated with the 30 healthy children while using 
the HR Walkway system. ICC tests revealed ‘good’ values for the cadence at baseline 
and ‘moderate’ values at week 1 (Table 3.4.6.7). With regards to gait time, distance and 
velocity parameters, ICC appeared to be ‘good’ both at baseline and week 1.  
 
Table 3.4.6.7: ICC repeatability results: cadence, gait time, distance and velocity at baseline and week 1. 
** means ‘poor’; * means ‘moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-
0.75; Good >0.75. 
   
Repeatability of HR Walkway 
Parameters Baseline Week 1 
Cadence 0.815 0.727* 
Gait Time 0.975 0.900 
Distance  0.961 0.900 
Velocity 0.819 0.880 
 
 
On the other hand, ‘moderate’ ICC values were found at baseline and week 1 for left, 
right and ‘both’ feet at heel contact, foot flat, midstance and propulsion time. 
‘Moderate’ ICC was also noted on right and ‘both’ feet for the stance time parameters 
at week 1. The remaining parameters scored ‘good’ ICC values both at baseline and 
week 1 (Table 3.4.6.8).  
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Table 3.4.6.8: ICC repeatability results for peak pressure, stance time, heel contact time, foot flat time, 
midstance time and propulsion time. ** means ‘poor’; * means ‘moderate’; ‘none’ means  ‘good’. Poor 
ICC<0.5; Moderate ICC between 0.5-0.75; Good >0.75. 
 
 
Repeatability of HR Walkway 
 Baseline Week 1 
Parameters Left  Right  Both  Left  Right  Both  
Peak Pressure 0.860 0.768 0.816 0.766 0.814 0.789 
Stance Time 0.833 0.768 0.795 0.765 0.609* 0.653* 
Heel Contact Time 0.714* 0.699* 0.703* 0.648* 0.559* 0.609* 
Foot Flat Time 0.648* 0.559* 0.616* 0.524* 0.481* 0.508* 
Midstance Time 0.680* 0.541* 0.611* 0.795 0.525* 0.643* 
Propulsion Time 0.703* 0.769 0.741* 0.681* 0.574* 0.616* 
 
As shown on Table 3.4.6.7 and Table 3.4.6.8, positive results were obtained while 
using the HR Walkway. The highly repeatable measurements gathered during the 
repeatability and reproducibility study may indicate that the equipment was able to 
collect repeatable data at baseline and at week 1.  
 
HR Walkway Reproducibility  
 
The Table 3.4.6.9 showed data related to the PP reproducibility of the HR Walkway for 
left, right and ‘both’ feet. Also in this scenario, ‘poor’ ICC results were not found for 
any of the 10 anatomical areas investigated. On the other hand, most of the PP 
parameters showed ‘good’ ICC scores for left, right and ‘both’ feet. As shown on Table 
3.4.6.9 few anatomical areas appeared to have ‘moderate’ ICC results. For example: on 
the left foot at the heel, midfoot, 3
rd
-4
th
 and 1
st
 met head; for the right at the total 
contact, heel and midfoot; and finally for ‘both’ at the total contact, heel, midfoot, 3rd-
4
th
 and 1
st
 met head. Overall these reproducibility data for PP were able to confirm that 
over a period of 1 week interval the HR walkway system was able to reproduce reliable 
data.  
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Table 3.4.6.9: ICC reproducibility results for HR Walkway regarding PP. ** means ‘poor’; * means 
’moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; Good >0.75. 
 
Reproducibility of HR Walkway 
 
Peak Pressure Values  
Anatomical Area Left  Right  Both  
Total  0.754 0.697* 0.722* 
Heel 0.635* 0.701* 0.655* 
Midfoot 0.682* 0.743* 0.709* 
Forefoot  0.871 0.864 0.865 
5
th
  0.812 0.790 0.796 
3
rd
-4
th
  0.713* 0.764 0.733* 
2
nd
  0.910 0.844 0.876 
1
st
  0.681* 0.779 0.724* 
Lesser Toes 0.819 0.884 0.855 
Distal Phalanx  0.806 0.754 0.776 
 
With regards to reproducibility of PTI, left, right and ‘both’ feet were investigated 
while using the HR Walkway system. As shown on Table 3.4.6.10 ‘good’ reproducible 
ICC values were identified for most of the anatomical areas. The only few exceptions 
were shown with ‘moderate’ ICC score for the left at heel, lesser toes, distal phalanx; 
and for ‘both’ heel and distal phalanx. Overall, the PTI reproducibility ICC score 
indicated that although some parameters were moderate, most of anatomical areas 
showed a very positive ICC score between baseline and one week interval.  
 
Table 3.4.6.10: ICC reproducibility results for HR Walkway regarding PTI. ** means ‘poor’; * means 
’moderate’; ‘none’ means ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; Good >0.75. 
 
Reproducibility of HR Walkway 
 
Pressure Integral 
Anatomical Area Left  Right  Both  
Total  0.848 0.938 0.923 
Heel 0.711* 0.773 0.726* 
Midfoot 0.877 0.820 0.845 
Forefoot  0.939 0.949 0.943 
5
th
  0.840 0.895 0.867 
3
rd
-4
th
  0.840 0.774 0.809 
2
nd
  0.894 0.918 0.903 
1
st
  0.893 0.844 0.866 
Lesser Toes 0.719* 0.835 0.783 
Distal Phalanx  0.614* 0.756 0.696* 
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With the HR Walkway system it was possible to investigate the level of reproducibility 
of cadence, gait time, distance and velocity. ‘Moderate’ ICC score was found for 
cadence and velocity of the healthy children. As shown on Table 3.4.6.11 and the 
remaining gait time and distance parameters appeared to have a ‘good’ ICC score.   
Table 3.4.6.11: ICC reproducibility results for HR Walkway regarding Cadence, Gait Time, Distance, 
Velocity. ** means ‘poor’; * means ‘moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC 
between 0.5-0.75; Good >0.75. 
   
Reproducibility of HR Walkway 
Parameters ICC 
Cadence 0.700* 
Gait Time 0.914 
Distance  0.831 
Velocity 0.733* 
 
Finally, Table 3.4.6.12 highlights that there is ‘good’ ICC level for most parameters 
investigated on the left, right and ‘both’ feet. ‘Moderate’ ICC values were found at 
stance time on the right and for ‘both’ feet; at foot flat for left and ‘both’ feet and 
finally at midstance for ‘both’ feet (Table 3.4.6.12). 
 
Table 3.4.6.12: ICC reproducibility results for HR Walkway regarding Peak Pressure, Stance Time, Heel 
Contact Time, Foot Flat Time, Midstance Time and Propulsion Time. ** means ‘poor’; * means 
‘moderate’; ‘none’ means  ‘good’. Poor ICC<0.5; Moderate ICC between 0.5-0.75; Good >0.75. 
 
Reproducibility of HR Walkway 
 
Pressure Integral 
Parameters Left  Right  Both  
Peak Pressure 0.801 0.762 0.779 
Stance Time 0.752 0.709* 0.727* 
Heel Contact Time 0.789 0.818 0.799 
Foot Flat Time 0.646* 0.848 0.737* 
Midstance Time 0.782 0.848 0.570* 
Propulsion Time 0.787 0.798 0.791 
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3.4.7. Discussion  
Reproducibility and repeatability tests are frequently carried out in research. Intra-class 
correlation coefficient (ICC) appears to be the statistical test adopted to calculate the 
level of repeatability and reproducibility when quantitative measurements are carried 
out (Li Lu and Nawar 2007). The ICC also describes how strongly units in the same 
group resemble one another. Bland and Altman in 1996 published a paper on the BMJ
28
 
in which they underlined that when the number of investigated parameters are the same 
for each participant, one way analysis of variance can be used when calculating the ICC 
(Bland and Altman 1996). Therefore, ICC tests were used to investigate repeatability 
and reproducibility values within this study. Additionally, in order to interpret ICC 
results, the Portney and Watkins (2000) score-classification was used in this validity 
study, as it is one of the most recent evidence available in this field and it follows on 
the previous founding reported by Fleiss (1986). Additionally the work carried out by 
these authors has been published by the ‘Foundation of in Clinical Research’ journal, 
which is a recognised provider of updated clinical evidence. 
According to Tekscan (2010) it is important to carry out the calibration procedure prior 
to start any recording. The F-scan equipment (overall 1.7kg) was added to the subject’s 
original weight. The walking calibration was chosen because is the most clinically 
effective, as it is automatic (Tekscan 2010). Furthermore, it is faster and helpful to 
increase the number of subjects that can be seen within busy clinical environments and 
it allows more trials to be performed. Walking calibration may be beneficial for those 
subjects who cannot stand on one foot for ten seconds (Tekscan 2008). As advised by 
the manufacturer, calibration must be repeated till the software recognised the success 
of the procedure. If a child reported soreness while standing on a single leg stance, the 
‘stand calibration’ would have been very difficult to carry out successfully with every 
participant. The continued failure to obtain a suitable standing calibration, could have 
affected the over-all length of time for each visit; as a result, each data collection could 
have been significantly longer. It can be argued that some children may become 
unhappy to spend too long time for each appointment and they may have started to 
adopt an altered gait because bored, tired or possibly in pain.  
 
                                                 
28
 BMJ: British Medical Journal  
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According to the F-scan manufacturer, it would have been possible for the patient to 
wear thin socks during recordings. However, the cushioning of the thick socks may 
increase pressure in regions that would otherwise exhibited low pressure values, and 
possibly skew the final results. It can be argued that unless every recording was carried 
out using the same type of socks, then data comparison might prove to be difficult. 
During this research project, for practicality reasons, it was decided not to wear socks 
during data recording. When dealing with children, multiple socks per each size must 
be available for each recording, and constant monitoring of the wearing patterns of the 
socks must be carried out to avoid recording issues. In addition, possible health-related 
problems could arise from using the same socks more than once between patients, 
which may have led to a risk of contagious dermatological pathologies between 
patients. The insoles were whipped with a surface disinfectant between subjects as an 
infection control measure. 
 
All lamination layers were removed from the F-Scan insole. As no running or long 
distance recordings were investigated in this study, it was decided to utilise the F-scan 
sensors alone. Additionally, the vinyl layer increases the rigidity of the insole, which 
potentially could have affected the ability of the sensors to adapt to the counter of the 
shoes and potentially skew the results. Particular care was dedicated in positioning the 
sensor correctly. If the F-Scan sensors were not precisely placed underneath the 
subject’s foot, plantar pressure data might have been quite poor. Furthermore, if the 
sensor were trimmed too much, some plantar foot pressure data would have been 
excluded during recording. On the other hand, if the F-scan insoles were too big or 
large for the shoes in which they were inserted, some vertical forces may have be 
transmitted through the sidewall of the footwear.  
Few studies have been previously carried out to test the repeatability and 
reproducibility of the F-Scan system reporting positive results in using the sensors for 
research and clinical applications (Chen and Bates 2000; Luo, Berglund and An 1998; 
Randolph et al. 2000). However, none of the publications available have yet 
investigated PP and PTI in 10 anatomical parameters.  
Data obtained showed that the repeatability study presented mostly with ‘good’ ICC 
score. However, Chen and Bates (2000) reported that caution should be exercised when 
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interpreting the pressure data during the initial 21% and final 10% of the support of 
walking (Chen and Bates 2000).  
Most of the parameters investigated with the F-Scan system showed ‘good’ ICC score 
particularly for the repeatability study. On the other hand, ‘moderate’ ICC score was 
shown more frequently during the reproducibility study. These validity results may 
indicated that the F-scan system can be used with healthy children and potentially 
adopted to identify pathological gait as well.  
 
According to Tekscan (2010) calibration procedure of the HR Walkway system must 
be carry out prior to any recordings as well. The step-calibration procedure is available 
for the HR Walkway system and it was carried out according to the indication provided 
by the manufacturer. Tekscan (2010), suggested that subjects should have enough room 
to walk two full steps before reaching the platform. Furthermore, in order to accept the 
recording the subject should have enough space for two full steps after walking off the 
mat. If the subject failed to follow these indications, the recording was discharged and a 
new trial was taken. 
Compared to other barefoot analysis system, the HR Walkway not only is able to 
provide high resolution recordings, but it also allows multiple steps recordings. This 
option is particularly useful when dealing with young children because in some 
instances up to 4 or 5 steps were recorded at the same time, which helped avoiding 
targeting errors during gait. 
Data analysis reported that during the repeatability and reproducibility test no ‘poor’ 
ICC results were obtained. It can be argued that some of the ‘moderate’ ICC results 
may be obtained due to human error that may occur during the data extrapolation 
process. In addition, if the participant wore different clothes between the two data 
collections, it could have influenced some gait parameters. Young children may exhibit 
low attention span particularly if the appointments were made early in the morning or 
late in the afternoon after a long day at school. All these possible factors should be 
taken into account when interpreting the results obtained with the F-scan and HR 
Walkway.  
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The process for data analysis and for extrapolating all the parameters had to be done 
manually which resulted to be quite lengthy. An average of 2 hours for each patient 
was required for data analysis for F-Scan and HR Walkway together and additional 
time necessary for ICC statistical analysis. It can be argued that modern technology 
should be able to carry out the extrapolation process automatically, which may help in 
reducing human error, and allow practitioners to spend more time to implement 
podiatric clinical management and patient education. 
Finally, an overall positive trend can be highlighted with most results showing a ‘good’ 
ICC score in this study which indicate that the HR Walkway may be suitable for future 
clinical investigation on healthy children and potentially also for pathological gait.  
 
3.4.8. Conclusion  
The results suggested that the repeatability and reproducibility study showed ‘good’ 
ICC scores in most of the parameters investigated with the HR Walkway system. 
Similarly, with regards to the F-Scan, the repeatability study showed ‘good’ ICC scores 
in most of the parameters investigated and few ‘moderate’ ICC values were recorded 
for the reproducibility tests. Compliancy amongst the children was really positive and 
none of the participants dropped from the study. These encouraging results will be 
taken into account for the progression of the randomised controlled trial on the effect of 
FOs in children diagnosed with Juvenile Idiopathic Arthritis (JIA) using the HR 
walkway and F-Scan system. 
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Chapter 4: Methods – Randomised Controlled Study 
 Ethics 4.1.
Ethical approval was granted by QMU ethics committee, NHS Lothian and Tayside. 
Risk assessment of the gait laboratories was carried out prior to commencing the data 
collection. Research liability was covered by QMU. 
 
All participants were able to withdraw from the study at any time without giving any 
reasons. All subjects were free to speak with an independent person, who knew about 
the project but was not directly involved in the research. Anonymity was maintained 
throughout the whole duration of the research, all subjects are given a study number 
and their identity kept confidential for the whole duration of the study and even after. 
 
 Research Procedures 4.2.
4.2.1. Patient Recruitment 
Prior to the RCT study, all equipment was tested (see chapter 3.4). The recruitment 
process occurred at the Paediatric Rheumatology Department of the Royal Edinburgh 
Hospital for Sick Children, and Ninewells Hospital (Dundee). The Rheumatology 
consultants provided significant help in identifying the potential candidates to the 
research project. In order for patients to be accepted, they had to meet the study criteria. 
Firstly, the patient had to be diagnosed with JIA according to the ILAR
29
 criteria. All 
details related to the ILAR criteria and the details of each of the 7 subtypes of JIA were 
highlighted in section 2.3 of this thesis. In addition, subjects had to meet the other 
inclusion and exclusion criteria which are underlined in section 4.2.3 and 4.2.4.  
 
The initial approach to the patient and their parent / carer occurred during the routine 
appointment in the paediatric hospitals. The patients and their parents were introduced 
to the researcher by the paediatric rheumatology consultants. The recruitment process 
for this multicentre study began by providing verbal information about the study. If the 
patient and their parents / carers appeared interested, then an information sheet was 
                                                 
29
 The ILAR criteria are already been used to classified JIA within the paediatric hospitals. 
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supplied. Information sheets for children were divided according to the age range (5 
years old, 6 to 10 years old, 11 to 15 years old and 16 to 18 years old) as advised by the 
NHS ethical committee. This division was proposed to allow a better understanding of 
the details of the research for subjects of a different age. Thus the language was 
adapted and the use of pictures and/or diagrams was introduced to explain details of the 
project. All parents / carers received the same information sheet with extended details 
of the project. 
 
Following the order in which each patient was met during the recruitment day, a phone 
call was made 1 week after the initial meeting in order to give enough time for the 
participant and their parents to think about their volunteered participation in the study. 
Those patients not interested in taking part in the study were classified as ‘not suitable’. 
For those patients willing to participate in the study, an appointment was organised. If 
the patient was initially seen at the Paediatric Rheumatology Department of the Royal 
Edinburgh Hospital for Sick Children, the child was invited to attend the Gait Analysis 
laboratory at QMU. On the other hand, if the patient was met at Ninewells Hospital 
(Dundee) the appointment was made to attend the T.O.R.T. centre
30
 in Dundee. Once 
the parent or carer agreed to take part in the study, the anonymous code was given to 
the patient. Two copies of the consent form were signed, one was given to the patient to 
be kept for their own records, and the other one was inserted into the medical file of the 
participant. Only once the consent form was signed could the data collection process 
begin. 
4.2.2. Patients 
This randomised controlled study involved male and female children ranging in age 
from 5 to 18 years old. Children younger than 5 years old were not able to take part in 
the study due to possible difficulties in following the instruction necessary to obtain 
gait analysis data, to maintain attention span for the whole duration of the study and to 
fully comprehend the questionnaire supplied for the quality of life. In addition, the belt 
used for the in-shoe analysis system available for the research would have not fitted the 
waist circumference of a child younger than 5 years old. On the other hand, participants 
older than 18 years old would have been too old according to the ILAR criteria; 
                                                 
30
 Department of Orthopaedic and Trauma Surgery, Medical School, University of Dundee. 
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therefore, they could no longer be diagnosed with JIA pathology. Additionally, in 
Edinburgh, patients of more than 18 years of age are referred from the paediatric 
hospital to the adult rheumatology department at the Western General Hospital in 
Edinburgh. Similarly these changes from paediatric to adult department also occurred 
at Ninewells.  
 
The data collection took approximately one hour for the initial assessment at baseline 
and then usually 45 mins for the two follow-up appointments at 3
rd
 and 6
th
 month 
intervals. Participants will be asked to attend for data collection at baseline, 3 months 
and 6 months intervals.  
4.2.3. Inclusion Criteria 
 Diagnosed with JIA according to ILAR criteria. 
 All subjects with lower extremity joint involvement with disease onset ranging 
from 5 to 18 years old. 
 Previous failure of orthotic management, where the patient has not worn any FOs 
for a period of at least 3 months. 
 Ability to walk a minimum of 15 metres without assistive devices. 
 Six months after start of DMARD therapy. 
4.2.4. Exclusion Criteria 
 Inability to walk barefoot or shod. 
 Concomitant musculoskeletal disease, central or peripheral nerve disease and 
endocrine disorders, especially Diabetes Mellitus. 
 Previous foot surgery. 
 Currently using foot orthosis. 
 Where supply of orthotics are contraindicated: 
o Less than 12 degrees at subtalar joint 
o Fully compensated ankle equinus 
o Osseous anomaly noted in the lower limbs and/or vertebrae during the 
physical evaluation. 
o Inappropriate footwear for fitting orthoses. 
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4.2.1. Justification for Methods 
Evidence-based medicine (EBM) or evidence-based practice (EBP) aims to apply the 
highest available evidence obtained from the scientific method to clinical decision 
making (Timmermans and Mauck 2005). Researchers should be focusing on 
establishing the strength of evidence of the risks and benefits of treatments (including 
lack of treatment) and diagnostic test (Elstein 2004). The quality of research can range 
from meta-analyses and systematic reviews of double-blind, placebo-controlled clinical 
trials at the top end, descending towards ‘conventional wisdom’ at the bottom. The 
systematic review of published studies is a method used for researching different type 
of treatments mostly in the medical field. The Cochrane is one of the best-known 
organisations for systematic reviews. Once all the best evidence is assessed, treatment 
can be classified as "likely to be beneficial", "likely to be harmful", or "evidence did 
not support either benefit or harm" (Cochrane 2011). 
 
NHS and the Oxford Centre for Evidence-based Medicine uses a system with 
categories labelled A, B, C, and D which clearly suggests the levels of evidence (LOE) 
according to the study designs and critical appraisal of prevention, diagnosis, 
prognosis, therapy, and harm studies: 
 
 Level A: Consistent Randomised Controlled Clinical Trial, cohort study, 
 Level B: Consistent Retrospective Cohort, Exploratory Cohort, Ecological 
Study, Outcomes Research, case-control study; or extrapolations from level A 
studies. 
 Level C: Case-series study or extrapolations from level B studies. 
 Level D: Expert opinion without explicit critical appraisal, or based on 
physiology, bench research or first principles (CEBM 2009). 
 
It can be argued that it is widely recognised that the most powerful type of 
experimental study is the randomized controlled trial (Altman 1996; CEBM 2009; 
Chan 2003; Stolberg et al. 2004). The randomised controlled trial is one of the simplest 
but most powerful tools of research. The RCT can be described as a study in which 
people are allocated at random to receive one of several clinical interventions that may 
have an effect on their health status (Vader 1998). RCT are also often described in 
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terms of whether they evaluate the efficacy or effectiveness of an intervention. Efficacy 
refers to interventions carried out under ideal circumstances, whereas effectiveness 
investigates the effects of an intervention under similar conditions those found in daily 
practice (Stolberg, Norman and Trop 2004).  
 
According to Altman, a RCT is the best way to compare the effectiveness of different 
interventions, and to allow valid inferences of cause and effect. As in all studies, RCT 
may also be open to bias if carried out badly. Therefore, it is essential that RCT are 
reported adequately and that the readers should not have to wonder what was probably 
done during the research, because they should be told explicitly (Altman 1996).  
 
According to Chan (2003), in order to successfully complete a RCT, it is important to 
dedicate 35% of time in planning the methodology that will be used throughout the 
whole duration of the research. The author mentioned that the designing stage is the 
foundation of the project itself, and it should be focused on a few aspects, such as: 
defining the primary and the secondary outcomes; the study population; inclusion and 
exclusion criteria and the sample size. Chan (2003) reported that 50 % of time should 
be dedicated to the conduct of the study (data capture, database design and data entry) 
and finally, the remaining 15% of time should be occupied in statistical analysis (Chan 
2003).  
 
The design of an RCT is based on having a control group which receives no treatment 
and in theory should result in no improvement over the study period. In contrast, the 
trial group should exhibit the effect of the new intervention, which may be positive or 
negative. The trial group intervention is then statistically compared against no 
treatment. In addition, by introducing the randomisation, all possible systematic bias 
involuntarily introduced during the data collection stage, should be eliminated because 
it is equally accounted for in both groups. After having evaluated the different types of 
methodologies that could have been adopted for this JIA study, the RCT design was 
chosen. With this type of methodology no direct influence from the data collector and 
external variables could have skewed the final results of this study. 
 
The randomised sequence was chronologically followed for each patient recruited in 
order to avoid any mistakes or bias influence in the selection of the groups. The patient 
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and the parent / carer was not told to which group the subject belonged till the end of 
the whole data collection process for all 60 JIA children.  
 
The sequence for the randomisation in the controlled and trial group was obtained for 
each individual motion analysis centre before the recruitment of patients began, to 
avoid any possible indirect influence or bias decision by patients, doctors or researcher.  
The block randomisation was chosen as the most suitable for the type of the RCT trial 
because according to the power calculation obtained, it was possible to have an 
estimate of what was the required number of patients that needed to be recruited in 
order to produce robust evidence based from this RCT study. According to the power 
calculation (section 4.4.4) the recommended number was 60 JIA patients in total; 
however, although it was an ambitious number of patients to achieve in such short 
period of time available to complete the PhD project, it was not possible to predict how 
many patients would have agreed to take part to the RCT or how many children would 
have met all the criteria required. For this reason, the randomisation was organised in 
blocks of 10 each time, therefore, randomly 5 patients in the controlled and 5 in the 
trial group. Once 10 patients successfully agreed to take part in the study, then the new 
randomised block of 10 was utilised till all 60 patients were recruited. In contrast, if a 
non-blocked randomised list of 60 patients was decided prior to commencing the study 
and only few patients actually were recruited, it could have generated a significantly 
unequal number of patients in either the controlled or trial group.   
 
As previously mentioned, the primary outcome data have been collected by using the 
questionnaires for quality of life. In order to avoid any bias results the order that all 
questionnaires were completed, were randomly assigned to the patients and their 
parents / carer. It can be argued that the attention span might be different according to 
the age of the participants. In order to account for any influence in answering the 
questionnaires if the younger children became tired or bored while completing the 
forms, all questionnaires were randomised. Each child randomly received 2 
questionnaires divided according to the age range: the PedsQL Paediatric module 
(version 4.0) and the PedsQL Rheumatology module (version 3.0). 
 
Similarly, the parents/cares randomly received the VAS, CHAQ and PedsQL 
questionnaires. It is important to highlight that, in order to avoid introduction of 
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variables during data collection, only the parent/carer was allowed to complete the 
questionnaires.  
4.2.2. Intervention 
Either for the control group and the trial group, every patient was recommended to 
wear the FOs gradually to gently get used to the new sensation of wearing an FOs 
inside the shoes. At the end of the first data collection appointment, every child was 
given plenty of time to walk to check the comfort of the FOs with all the shoes that 
were brought on the day. Each patient was told that, after the initial stage of gently 
breaking in, the FOs had to be worn daily in all shoes for 6 months. Each child was 
given a demonstration of how to insert the FOs inside the shoes and how to remove 
them without damaging the materials. Each participant was asked to demonstrate to the 
data collector if she/he was able to insert and remove the FOs correctly. If the patient 
was really young, for example 5 years old, also the parent / carer was asked to 
demonstrate their ability to appropriately fit the FOs inside their child’s shoes. 
 
 
Control Group 
 
The control FOs, or placebo FOs was supplied to patients who were randomly included 
in the control group. The control FOs was made of leather board (1mm), grey poron 
(1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any 
sort of biomechanical support, nor had it any effect on the distribution of pressure, as it 
was completely flat. In addition, the placebo FOs did not present with any intrinsic or 
extrinsic correction underneath the STJ (Figure 4.2.2.1).   
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Figure 4.2.2.1: control FOs: frontal - plantar – medial view. No corrections were added in the control 
FOs, made with 1mm leather board, 1mm poron and black EVA (0.75mm - exactly the same top cover as 
the trial FOs.  
 
The use of black EVA as the covering material and the leather-board as a base, allowed 
for gathering of a dynamic impression over the 6 months of the trial. This aspect is 
extremely important, because it allowed the data collector to monitor if the control 
patient wore the prescribed FOs for the whole duration of the trial, as requested. Both 
materials would quickly adapt to the dynamic behaviour of the plantar aspect of the 
foot at closed kinetic chain. If the FOs was worn correctly and on a daily basis, the data 
collector would have been able to observe that the leather-board bent to the shape of the 
foot for the pressure exerted under the rearfoot and forefoot. Additionally, during gait, 
the plantar aspect of the leather board in contact with the shoes would change to a 
darker colour. The black EVA instead, was in direct contact with the child’s foot, and it 
allowed monitoring of the dynamic impression of the foot. The dynamic impression 
produced was able to provide useful information to the data collector with regards to 
the degree of usage of the placebo FOs. If worn on a daily basis the dynamic 
impression on the placebo FOs would have been very noticeable at 3
rd
 month’s interval 
and significantly more visible by the end of the study. At each individual follow-up 
appointment, the data collector monitored the condition of the placebo FOs to check if 
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the FOs had actually been worn by the patient. All patients appeared to be very 
compliant with the instruction given as noted by the dynamic impression.   
 
Trial Group 
 
 
With regards to the trial group, the children who were randomly introduced into this 
group received the pre-formed semi-rigid FOs. The ‘Slimflex’ FOs were used as an off-
the-shelf device and subsequently customised with chair side modifications (Figure 
4.2.2.2). Slimflex plus is the same shape as the original green Slimflex but instead it is 
more rigid and supportive. This is due to the royal blue ¾ length EVA material 
incorporated as an under-layer, which acts as a hard stabiliser and provides increased 
support for greater functional control. As reported by the manufacturer (Algeos) the 
Slimflex plus can also be used with wedges and components to create a chair-side 
custom functional device if required (Algeos 2011). Slimflex plus is widely available in 
UK sizes for children 8-13 and adults 1½-12.  
 
In order to reproduce the exact same aesthetical appearance as the control FOs, grey 
poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs. 
Furthermore, depending on the type of correction applied to the trial patient, the black 
EVA also allowed the correction applied on the surface of the device to be masked. 
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Figure 4.2.2.2 : trial FOs: frontal - plantar - medial view. In this particular case 5°antipronatory wedge 
were extrinsically added underneath the heel to improve STJ excessive pronation - 1mm poron and black 
EVA (0.75mm) - exactly the same top cover as the control FOs.  
 
 
The off the shelf FOs also allowed a high degree of prescription underneath the surface 
of the device. For example, it was possible to add extrinsic antipronatory wedges to 
improve the STJ alignment. In order to apply the appropriate correction to maintain the 
STJ in neutral position, 5° or 3.5° high density EVA antipronatory wedges were mostly 
used or combined together to further correct biomechanical joint alignments. 
Depending on each child’s prescription, heel raises, antipronatory wedges and 
cushioning material like poron (1mm, 3mm, and 6mm) were utilised. Corrections were 
applied at the rear-foot and/or forefoot as well. Forefoot cushioning, kinetic wedges, 
PMP (plantar metatarsal padding), metatarsal bars, or deflection of metatarsal pressure 
could have been easily and quickly obtained by simply altering the pre-formed semi-
rigid FOs. In some cases, particularly with female patients, it was noticed that restricted 
foot wear was used on a daily basis (for example: ballerina or narrow school shoes) and 
the FOs’ fitting was more challenging.  
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The off the shelf FOs, not only allowed the podiatrist to achieve a high degree of 
freedom of prescription with the trial patient, but also helped the clinician to check how 
the FOs responded in improving the JIA child biomechanics. In order to report and 
attribute the positive or negative effect of the trial FOs, it was necessary to check if the 
patient actually wore the FOs for 6 months period of time. Equally to the control FOs, 
the covering material of the FOs significantly helped in providing details with regards 
to usage of the device. By looking at the plantar surface of the FOs in contact with the 
shoes, the researcher was able to check if patients had worn the FOs by noticing the 
condition of the extrinsic correction. For example, if the trial patient wore the FOs 
daily, the edge of the antipronatory correction would start to show signs of wear and 
become more rounded. On other occasions, if a kinetic wedge was created underneath 
the 1
st
 metatarsal head, it was possible to observe the effect of the plantar-flexion of the 
1
st
 ray into the cut-out, showing the suitability of the forefoot correction prescribed by 
the podiatrist. In addition, the forefoot portion of the FOs in contact with the shoe is 
completely white. Therefore, the data collector was able to record how much the FOs 
was worn by monitoring the gradual change of colour at 3 month and 6 month interval. 
For obvious reasons, a darker colour was interpreted as a good sign of usage of the 
FOs. 
 
During both follow-up appointments, the data collector monitored if the corrections 
were still in good condition and especially if they were at the same position as initially 
prescribed. It must be underlined that the data collector precisely recorded every single 
correction added to the FOs with each trial patient. This precaution was adopted from 
the start of the data collection in case the patient or the parent/carer decided to make 
unexpected self-modifications to the devices supplied. No instances were recorded of 
self-modification of the FOs; however, it seemed an important detail to check to avoid 
alteration of results and to prevent the introduction of a new and unknown variable 
during data analysis.  
 
Finally it can be argued that the use of the trial FOs reflects current podiatric practice 
within NHS and private clinics. Many podiatrists on a daily basis utilised cost-effective 
pre-formed semi-rigid FOs with the addition of customised correction to specifically 
suit different biomechanical lower limbs pathologies (Malone 2008b). As previously 
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mentioned, this podiatric intervention has not yet been tested and proven with JIA 
children.  
 Data Collection 4.3.
4.3.1. Data Collection 
The researcher obtained details of the medication of the patient 
and past medical history from the medical records of the 
paediatric hospital, which was accessed only after the patient 
agreed to take part in the study. On the day of the visit at QMU 
or TORT centre, the data collector thoroughly recorded if the 
patients were prescribed with any new medications. Details of 
the dosage were recorded and monitored at each individual 
follow-up appointment.  
 
Subsequently, height and weight details were recorded in order 
to calculate the BMI values and the health status according to the SIGN (2010). Each 
patient was asked to remove shoes and socks and jackets. The same height scale and 
weight balance was used for the duration of the data collection, at both gait analysis 
centres (Figure 4.3.1.1 and Figure 4.3.1.2). 
 
Figure 4.3.1.2: balance used to measure weight with all patients and the plinth used for off weight baring 
biomechanical examination  
 
At this stage, the patient was asked to sit on the provided plinth and a biomechanical 
assessment of the lower limb joint was carried out. Examination of joints at open and 
close kinetic chain was carried out. After bisecting the calcaneus, a line at the back of 
the heel was drawn. STJ measurements were then taken of relax and neutral calcaneal 
Figure 4.3.1.1: height 
measurement tool used 
with every patient 
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stance positions and recorded on the study data research sheet at baseline, 3
rd
 month 
and 6
th
 month interval. The STJ measurements were taken three times each visit in both 
feet, and then averaged in order to monitor the intra-tester repeatability. Diagnosis was 
made according to the biomechanical findings, which usually did not take longer than 
30 min. The degrees of correction required to maintain the STJ into neutral was tested 
and reliability analysis was carried out. The ICC score indicated ‘excellent’ 
repeatability results for the control and the trial group.  
 
On examination the most commonly symptomatic joints in the lower limbs appeared to 
be: the hip, medial aspect of the knee, patella-tibia tendon, tibial tuberosity, tibialis-
posterior tendon, achilles tendon, ankle joint, STJ, dorsal aspect of the midtarsal joint 
(talo-navicular and calcaneo-cuboid joint) and metatarsal heads. It was not possible to 
statistically calculate the most commonly affected joints. 
 
The questionnaires used to record quality of life score (VAS, CHAQ, PedsQL) were 
randomly supplied to the patient and the parent / carer. In order to avoid any confusion, 
the patient’s code was written on the top right corner of the questionnaires with details 
regarding baseline, 3
rd
 month or 6
th
 month appointment date. The data collector 
informed them that each questionnaire had to be completed independently, and that no 
communication was allowed between the child and the parent / carer. In this way the 
scores obtained were not influenced by other people and exactly the same instructions 
were repeated at all follow up appointments. Questionnaires had to be completed 
following the order provided by the data collector. Each sheet had a brief instructions 
section that helped to show how to fill in the questionnaire. For any clarification, the 
data collector was available to help or explain what had to be done. According to the 
instruction provided by PedsQL system, if the child was 7 years old or younger, the 
data collector had to read out the questions and circle the answer provided. During the 
5 minutes normally required for completion of the questionnaire, the data collector 
observed the suitability of the shoes and checked the fitting of the FOs inside the shoes. 
Any modification or adjustment of the FOs would have been made at this stage, prior to 
the gait analysis.  
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      Figure 4.3.1.3: control and trial FOs  
 
Each subject received a pair of standardised Clark’s shoes (Figure 3.3.3.12) and the 
suitability of the FOs inside the shoe was verified before the start of gait recording. 
Once the Clark’s shoes size was chosen, the equivalent F-scan insole (already pre-cut) 
was selected. The order in which the equipment was used was rigorously followed 
according to the randomised sequence of what gait analysis system had to be used with 
each patient. For example, one of the combination or randomised sequence might have 
been: 1
st
= HR Walkway; 2
nd
= in-shoe (with device); 3
rd
= in-shoe (without device). 
With each of the gait equipment used, 3 recordings were taken and saved.  
 
The equipment was set up and calibrated as explained in section 3.3. Each recording 
was saved in the patient’s folder, using the anonymous code. The data recording was 
successfully completed usually within 20-25 min. Under normal circumstances, it 
occurred that the quickest visits were with older JIA children. In some occasions, 
especially with 5 year old children, it took slightly longer to convey the instructions and 
in some cases they were reassured by the parents/carer while walking. In addition, with 
regards to the F-scan, in every recording the data collector was responsible for 
initiating and terminating the recording by pressing the recording button of the F-scan 
mobile unit. Two rehearsal trials were undertaken prior to the recording, to allow the 
subject to familiarise themselves with walking while using the equipment; usually 2 
walks of 7 metres each appeared to be sufficient. Each recording occurred 
consecutively, within the same environment, using the same shoe size
31
, utilising the 
same equipment; the calibration made on the day was uploaded, and finally, the same 
distance was travelled by the participant (7 m). During the follow-up appointments, the 
                                                 
31
 During the trial the shoe size was monitored and only one child within the control group showed an 
increase in foot size within the 6 months. Same prescription one size longer was then supplied to the 
patient. 
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data collector always checked the condition of the devices supplied, both control inner 
sole and the trial FOs (Figure 4.3.1.3). If the data collector, by observing the signs 
gathered by the condition of the material, realised that the FOs had not been used as 
requested, the patient was no longer suitable for the study and no further data would be 
recorded using the questionnaires and the gait analysis systems (Figure 4.3.1.4). 
 
Figure 4.3.1.4: RCT methodology diagram 
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During each appointment, pharmaceutical changes were recorded and monitored over 
the 6 months period of time. Further information was gathered from patients and from 
medical records regarding possible steroid injections changes that may have occurred 
during the six months. If any modifications, of medication or steroid injection was 
noted during the study period, that patient was classified as not stable, because any 
possible interference with the treatment could have influenced the final primary 
outcome results. 
 
4.3.2. Data Process 
Pain Questionnaires: VAS 
 
 
The VAS scores completed by the parent were extrapolated by using a simple ruler. 
Data at baseline, 3
rd
 month and 6
th
 month interval were recorded into a table and kept 
inside the patient’s medical records. It can be argued that in order to provide a clinical 
significance of the data obtained, it is essential to investigate previous VAS papers 
suggesting clinically significant difference for VAS scores. According to Kelly (1998), 
in adult patients the minimum clinically significant difference in VAS pain scores was 
found to be 9 mm. Differences of less than this amount, even if statistically significant, 
are unlikely to be of clinical significance (Kelly 1998). With regard to children, a small 
study reported that the minimum clinically significant difference in VAS pain score for 
73 children aged range from 8 to 15 years,  to be 10 mm with 95% confidence interval 
7 to 12 mm (Powell et al. 2001). More specifically for paediatric rheumatology, a study 
carried out with 533 paediatric rheumatology patients in Toronto looked at establishing 
the minimal change on pain using the VAS measured at 2 consecutive visits to a clinic. 
The authors stated that for future studies, the results should aim for a minimum 
reduction in pain score of 0.82 cm on a 10-cm VAS in order to achieve clinical 
improvement in quality of life with children affected by rheumatic disease (Dhanani et 
al. 2002). In this study a difference in VAS scores of 0.82cm was taken as clinically 
significant.  
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Quality of Life Questionnaires: CHAQ 
 
 
The CHAQ scores were obtained according to the instruction provided by the juvenile 
dermatomyositis research centre. The CHAQ scoring consists in looking at the section 
ticked by the parent of the JIA participants: each of the eight sections is scored for the 
highest value ticked in its own section. ‘Zero’ was the score associated for ‘without any 
difficulties’ or ‘not applicable’. One was recorded for ‘with some difficulties’ answer. 
Two for ‘with much difficulty’ and finally, three for ‘unable to do’. Subsequently, the 
section which referred to the ‘help required’ had to be observed (ie: AIDS, DEVICEs 
etc.). If any of these were ticked, the correspondent section had to be looked at: if that 
section score was a ‘zero’ or a ‘one’, then the score had to be increased to a ‘two’. If 
that section already scored a ‘two’, then the score remained as a ‘two’. Then, if that 
section scored a ‘three’ then the score remained as a ‘three’.  Finally, all the scores had 
to be added together and divided by ‘eight’ in order to obtain the CHAQ score.  
 
Little evidence is available with regards to the minimal clinically important differences 
(MCID) with the CHAQ score. Interestingly, in 2005 the Journal of Rheumatology 
released a publication in which claimed that the MCID for improvement of the CHAQ 
was -0.188 at most, while the MCID for worsening was at most +0.125 (Brunner et al. 
2005). Similarly, Dempster et al. (2001) claimed that clinicians, as well as researchers 
should aim for a minimum improvement of 0.13 in the CHAQ score when treating 
paediatric patients with arthritis (Dempster et al. 2001). In this study a minimum 
improvement in the CHAQ score of 0.13 was taken as a clinically significant 
difference. 
 
Quality of Life Questionnaires: PedsQL  
 
 
The Peds quality of life score was equally calculated for the generic module (version 
4.0) and rheumatology module (version 3.0). According to Mapi Research Trust 
Centre, the scores are transformed on a scale from 0 to 100. Items are ‘reversely 
scored’ and ‘linearly transformed’ to a 0-100 scale as follows: 0=100, 1=75, 2=50, 
3=25, 4=0. If more than 50% of the items in the scale are missing, the scale scores 
should not be computed. The mean score can be calculated by simply summing the 
153 
 
items over the number of items answered. According to the author there is not a total 
score (Mapi 2008). All the scores gathered were transcribed from the questionnaire into 
another form in order to have a hard copy form with all the scores. Subsequently, data 
were transposed into the excel spread sheets. 
 
According to Varni et al. (2003), a 4.4 points change in the Total Scale Score for child 
self-report represents a minimal clinically meaningful difference. Similarly, a 4.5 
change in the Total Scale Score for parent is deemed to be a minimal clinically 
meaningful difference. In this study a minimum improvement in the PedsQL total score 
of 4.4 points was considered as a clinically significant difference. 
 
 Statistical Methods 4.4.
4.4.1. Data Analysis 
All data collected during the study from baseline, 3 months and 6 months will be 
carried out using Shapiro Wilks test to check for normality. Where the variable presents 
ordinal data, the appropriate non-parametric test will be used. A series of between and 
within group analyses will be carried out. Most of the data were not parametric 
therefore data tend not fit a normal distribution curve. If results were parametric, it can 
be argued that results may have been stronger as parametric methods make more 
assumptions than non-parametric methods, such as normality (Corder and Foreman 
2009). However, the not parametric data obtained in this research do not rely on 
assumptions that the data are drawn from a given probability distribution.  
4.4.2. Comparison between controlled Group and Trial 
Group 
In order to test the hypothesis the controlled group was compared with the trial group. 
Pair wise statistical analysis was carried out using an unpaired t-test or Mann Whitney 
U test, depending on the distribution of the data. 
4.4.3. Within each individual Group Analysis 
In order to investigate the relationships between the groups at baseline, 3 months and 6 
months, a repeated measures ANOVA was carried out for parametric data where 
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sphericity exist; or a Friedman test where non-parametric and/or no-sphericity exists. 
Pair wise statistical analysis was carried out using a paired t-test or Wilcoxon’s test, 
depending on the distribution of the data. 
4.4.4. Power Calculation  
For a 5% 2-sided t-test with α=0.05 and power 80% for a RCT design with baseline and 
2 post-intervention observations, and a moderate effect size, it was estimated that a 
total of 46 subjects would be required (23 controls and 23 trial) (Noordzij et. al 2010; 
Cohen 1988). The study was overpowered to an estimated 30 subjects per group to 
allow for dropouts during the 6 months data collection period.  
 
Depending of what parameters were investigated, different tests were carried out. 
Please find below details of what tests was adopted for the primary and secondary 
outcome:  
4.4.5. Primary Outcomes:  
 
VAS scores were tested for normality and appropriate parametric and non-parametric 
tests were carried out to test if normality assumptions were met or not. With regards to 
the CHAQ and the PedsQL scores, they are considered to be a non-parametric ordinal 
data. Data were compared amongst the control and the trial group. When 2 groups were 
compared (ie: baseline – 3rd month; or 3rd month – 6th month; or baseline – 6th month), 
the following test may be chosen. If paired group design, then Shapiro-Wilks test will 
be carried out, if p>0.05 data is parametric and pair t-test is run; if p<0.05 data is not-
parametric and Wilcoxon test will be chosen. If un-paired group design, then Shapiro-
Wilks test will be carried out, if p>0.05 data is parametric an un-paired t-test is used; if 
p<0.05 data is not-parametric and Mann Whitney test will be chosen. 
 
In statistical analysis p-value is commonly accepted at 0.05; this value is indicative that 
there is less than 5% chance of achieving results by chance assuming that the null 
hypothesis (Ho) is true. It appears that 5% is an arbitrary significance level that should 
not be too high to avoid many Type I errors (assuming an effect where there is not 
one), but equally not too low to exclude too many Type II errors (assuming there is not 
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an effect where there is one). Bonferroni adjustments has been previously employed in 
research to reduce Type I errors (for example: rejecting Ho when Ho is true) when 
multiple tests are conducted for pair-wise comparison. It consists of modifying the p-
value by the number of tests that has been carried out.  Bonferroni procedures appear to 
raise few issues, and there is no formal consensus for when it should be used, even 
among statisticians (Moran 2003; Nakagawa 2004; Perneger 1998). The same authors 
also state that Bonferroni adjustments do not guarantee a “prudent” interpretation of 
results because it provides a correct answer to a largely irrelevant question. Type I 
errors cannot decrease without inflating type II errors; and type II errors are no less 
false than type I errors (Moran 2003). 
 
Perneger (1998) in the BMJ raised the question that in biomedical research if 
Bonferroni adjustments will become routinely adopted, cynical researchers would ‘slice 
their results like salami’ publishing one p-value at the time to avoid criticism from 
reviewers, which will results in lower quality of evidence base and wasting time, 
energy and public money.  
 
Additionally, the extensive use of Bonferroni procedures may increase the tendency of 
researchers not to present non-significant results, because presentation of more tests 
with non-significant data may make previously ‘significant’ results ‘non-significant’ 
under Bonferroni procedures (Nakagawa 2004). Similarly, also Moran (2003) 
mentioned that the irony of the sequential Bonferroni correction (and multiple tests in 
general) is that as a researcher performs more detailed work, the chances of finding 
significant results declines dramatically. The best approach that should be adopted, 
appears to be that researchers should simply report accurately the methodology and 
effect size along with exact p-values; and discuss in details the possible interpretations 
of each result, allowing the reader to independently reach a conclusion without the 
unclear support of Bonferroni test (Nakagawa 2004; Perneger 1998).    
 
In this RCT, the conclusion made by these authors will be taken into account in 
reporting the findings and all p-values will be clearly expressed in each of the multiple 
statistical tests that will be carried out. As this study is a pragmatic study in which 
many primary and secondary variables have not yet been explored together in JIA 
children, the reader will be informed in details about the statistical test carried out. This 
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may help the reader to make a final informed decision to whether accept or reject the 
conclusion made in this multicenter study. Thus Bonferroni adjustments where not 
carried out because of the reasons expressed in this chapter. However, as many details 
as possible will be provided to allow the reader to make an inform decision to accept or 
reject the results acquired from this multicenter study.  
4.4.6. Secondary Outcomes   
With regards to the secondary outcomes, although more variables were investigated, 
the same statistical method as the primary outcome were utilised. Gait analysis data 
was compared within and between the control group and within the trial group with F-
scan (with insole and shod) and HR walkway.  
 
Parameters investigated during Gait Analysis 
 
F-Scan 
 
HR Walkway Human Icon 
Total contact (left and right) Total contact (left and right) Gait Time (sec) 
Heel (left and right) Heel (left and right) Gait Velocity (cm/sec) 
Midfoot (left and right) Midfoot (left and right) Stance Time (sec) (left and right) 
Forefoot (left and right) Forefoot (left and right)  
5
th
 met. head (left and right) 5
th
 met. head (left and right)  
3
rd
 to 4
th
 met head (left and right) 3
rd
 to 4
th
 met head (left and right)  
2
nd
 met head (left and right) 2
nd
 met head (left and right)  
1
st
 met head (left and right) 1
st
 met head (left and right)  
Lesser toes (left and right) Lesser toes (left and right)  
1
st
 Distal phalanx. (left and right) 1
st
 Distal phalanx. (left and right)  
 
Table 4.4.6.1: Parameters investigated during Gait Analysis while using the F-Scan (with insole and 
shod) and HR Walkway.  
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Chapter 5: Results 
 Patient Demographics 5.1.
With regard to patient demographics, 60 JIA patients took part in this RCT study. 
According to the descriptive results, 48.3% (n=29) of children received the control 
FOs, and the remaining 51.7% (n=31) were fitted with the trial pre-formed semi-rigid 
foot orthosis. Overall, 99.4% (n=179/180) of the planned JIA data collection visits were 
sucessfully completed. As part of this multicentre study 78.3% (n=47) patients were 
recruited from the NHS Royal Hospital for Sick Children in Edinburgh, and the 
remaining 21.7% (n=13) JIA children were seen at the NHS Ninewells Hospitals in 
Dundee. 
5.1.1. Age 
Age ranged between 5 to 18 years, mean age for the control group was 11.17(SD3.51) 
and for the trial group were 10.64 (SD3.84). With regards to the control group, the 
minimum age was 5 and max was 17.9; similarly in the trial group minimum age was 5 
and maximum was 17.11 (Table 5.1.1.1). 
 
Table 5.1.1.1: descriptive statistics for age (year) for the control and trial group 
 
 
 
 
 
5.1.2. Gender  
 
Particularly within the control group, only 20.7% (n=6) of patients were male and 
79.3% (n=23) were female. Similarly, within the trial group, 29% (n=9) subjects were 
male and the remaining 71% (n=22) were female.   
Age (year) 
 Control Trial 
Mean (SD) 11.17 (3.51) 10.64 (3.84) 
Minimum 5 5 
Maximum 17.9 17.11 
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5.1.3. Shoes size 
Descriptive statistics highlighted that the mean value for shoes size was 35.55(SD3.88) 
(UK size=3) for the control group, similarly 35.14(SD4.54) (UK size=3) (Table 
5.1.3.1). In both groups the minimum and the maximum shoe size was 28 (UK=10 
child) and 44.5 (UK=10 adult). 
 
Table 5.1.3.1: descriptive statistics at baseline for shoe size (control and trial group); European and UK 
sizes 
 
 
 
 
5.1.4. Height  
With regard to height, at baseline the control group showed a mean of 142.07cm 
(SD17.94), minimum and maximum value of 107.20cm and 175.80cm respectively. 
Similarly, the trial group presented with a mean height of 140.39cm (SD22.17), 
minimum height of 103.30cm and maximum of 178.00cm (Table 5.1.4.1). 
 
Table 5.1.4.1: descriptive statistics at baseline for height (control and trial group) 
 
 
 
 
5.1.5. Weight 
With respect to weight recorded at baseline (Table 5.1.5.1), the control group presented 
with the mean weight of 38.97kg (SD18.04); minimum weight of only 19kg and the 
maximum of 98kg. On the other hand, the trial group appeared to have a mean value of 
42.07kg (SD23.41), and similarly the minimum weight was of only 15kg and the 
maximum reaching 121kg. 
 
 
 
Shoe Size European & (UK) at baseline 
 Control Trial 
Mean (SD) 35.55(3.88) (UK=3) 35.14(4.54) (UK=3) 
Minimum 28 (UK=10 child) 28 (UK=10 child) 
Maximum 44.50 (UK=10 adult) 44.50 (UK=10 adult) 
Height (cm) at baseline 
 Control Trial 
Mean (SD) 142.07(17.94) 140.39(22.17) 
Minimum 107.20 103.30 
Maximum 175.80 178.00 
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Table 5.1.5.1: descriptive statistics at baseline for weight (control and trial group) 
 
 
 
 
5.1.6. BMI & Health Status  
 
The BMI results showed that at baseline the control group’s mean value was 18.29 (SD 
4.05), minimum value of 12.90, maximum value of 31.70. Similarly the trial group 
presented with mean values of 19.70 (SD5.91), minimum BMI value of 12.30 and 
maximum of 38.20 (Table 5.1.6.1). 
Table 5.1.6.1: descriptive statistics for BMI values at baseline (control and trial group) 
 
 
 
 
 
Healthy status results were divided in 4 categories: underweight; healthy; over weight; 
and obese. Each of these nominal data, shown in the table below (Table 5.1.6.2), is 
divided between control and trial group. According to the descriptive statistics within 
the control group 6.9% (n=2) were deemed to be underweight, 75.9% (n=22) healthy, 
13.8% (n=4) overweight and finally 3.4% (n=1) obese. Similarly, the health status for 
the trial group appeared to have 6.5% (n=2) of the children considered to be 
underweight, 74.2% (n=23) healthy, only 3.2% (n=1) overweight, but with 16.1% 
(n=5) obese. Thus for health status and BMI there was a similar distribution between 
the groups. 
Table 5.1.6.2: descriptive statistics at baseline for health status 
 
 
 
 
 
 
Weight (kg) at baseline 
 Control Trial 
Mean (SD) 38.97(18.04) 42.07(23.41) 
Minimum 19 15 
Maximum 98 121 
BMI at baseline 
 Control Trial 
Mean (SD) 18.29(4.05) 19.70(5.91) 
Minimum 12.90 12.30 
Maximum 31.70 38.20 
Health Status at baseline 
 Control Trial 
Underweight 6.9% (n=2) 6.5% (n=2) 
Healthy 75.9% (n=22) 74.2% (n=23) 
Overweight 13.8% (n=4) 3.2% (n=1) 
Obese 3.4% (n=1) 16.1% (n=5) 
Total  100% (n=29) 100% (n=31) 
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 Pharmacological Intervention 5.2.
 
In order to attribute any effect solely on the FOs intervention, details of changes of 
medication and/or new joint injections were recorded during the trial. The ‘stable’ 
patients were considered those children that did not change medication, drug’s dosage 
or did not received injections during the whole period of the study. On the other hand, 
those JIA children who changed the medications, dosage and/or received new 
injections within the 6 months were classified as ‘not stable’. According to the data 
obtained within the control group 65.5% (n=19) seemed to be stable and the remaining 
34.5% (n=10) were proven to be unstable. Similarly, within the trial group 74.2% 
(n=23) were on stable medication and 25.8% (n=8) were unstable (Table 5.1.6.1).     
  
Table 5.1.6.1: descriptive statistics on the medication status (control and trial patients) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medication Status 
 Control Trial 
Stable 65.5% (n=19) 74.2% (n=23) 
Not Stable 34.5% (n=10) 25.8% (n=8) 
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 Quality of Life Questionnaires 5.3.
5.3.1. VAS 
Control Group (VAS) 
 
According to the descriptive statistics within the control group there was only 1 missing 
recording at 6
th
 month due to patient D9 that failed to attend the last appointment. 
Hence, the same missing data will not be found in all other tools adopted to investigate 
quality of life. Median score was 6.5 at baseline, 3.6 at 3
rd
 month and 4.65 at 6
th
 month. 
It is possible to notice a stable trend by the end of 6 months (Table 5.3.1.1, Figure 
5.3.1.1).  
 
Table 5.3.1.1: descriptive statistics on VAS data at baseline, 3
rd
 month and 6
th
 month (control and trial 
patients) 
VAS 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median (IQR) 6.5(50.5) 3.6(34) 4.65(46.75) 14(31) 5(24) 4(19) 
 
 
Figure 5.3.1.1: descriptive statistics on VAS data at baseline, 3
rd
 month and 6
th
 month (control and trial 
patients) 
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Data are NOT parametric; therefore, Friedman’s test was carried out. As shown on 
Table 5.3.1.2 there is no statistical difference for the control group.  
 
Table 5.3.1.2: details of the Friedman test on VAS data at baseline, 3
rd
 month and 6
th
 month (control and 
trial patients). From this table onward all values indicating p<0.05 will be followed by * and p<0.01 by 
**. 
   
 
 
 
 
Furthermore, data were compared within two intervals each time (baseline with 3
rd
 
month; 3
rd
 month with 6
th
 month; and baseline with 6 month). As data are not 
parametric and paired, Wilcoxon’s test was carried out. Table 5.3.1.3 highlights that the 
p>0.05 for all the intervals within the control group, which indicates a non-statistical 
difference amongst all intervals. Also when only the stable group is considered 
separately the same results are obtained. This suggests that there were no statistical 
difference in pain score when any of the interval where compared for the control group. 
 
Table 5.3.1.3: details of the Wilcoxon’s test on VAS data (control and trial patients); * means p<0.05, ** 
means p<0.01. 
Wilcoxon’s Test – VAS Score  
 Control Trial  
Baseline – 3rd month  p=0.615 p=0.003** 
3
rd
 month – 6th month  p=0.286 p=0.055 
Baseline – 6th month  p=0.808 p=0.000** 
 
 
Stable  
Baseline – 3rd month  p=0.779 p=0.044* 
3
rd
 month – 6th month  p=0.443 p=0.034* 
Baseline – 6th month  p=0.875 p=0.000** 
 
 
Not Stable  
Baseline – 3rd month  p=0.813 p=0.018** 
3
rd
 month – 6th month  p=0.553 p=0.866 
Baseline – 6th month  p=0.515 p=0.090 
 
Trial Group (VAS) 
 
Median score was 14 at baseline, 5 at 3
rd
 month and 4 at 6
th
 month (Table 5.3.1.1). 
According to the descriptive statistics (median values) the 8mm difference required to 
Friedman Test – VAS score (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.708 p=0.000** 
 
Stable  p=1.000 p=0.000** 
Non Stable p=0.439 p=0.066 
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achieve clinical significance within the appointments was found by the end of the 6 
months. As shown on Table 5.3.1.2 there is statistical difference over the 6 month 
period of time. Also when only the stable group is considered separately the same 
results are obtained. However, no statistical difference was found for the non-stable 
medication group. 
 
Table 5.3.1.3 highlights that: statistical difference was found at baseline-3
rd
 month 
(p<0.05); and at baseline-6
th
month (p<0.01); but not at 3
rd
month-6
th
month.interval 
(p>0.05). Finally, when only the stable group is considered separately the same results 
are obtained with an additional significance difference also within the 3
rd
 month and 6
th
 
month interval. Therefore, it is possible to notice of improvement of pain of the 6 
months period (Figure 5.3.1.1). 
 
 
Comparison between the Control and the Trial Group 
(VAS) 
 
According to the Shapiro-Wilks Test p<0.01**, hence data are not parametric for both 
the control and the trial group at baseline- 3
rd
 month- 6
th
 month. In order to test if there 
were statistical difference between the control and trial group at baseline, Mann 
Whitney Test was carried out; the results showed that at the start of the trial p>0.05; 
therefore there was no statistical difference (Table 5.3.1.4). On the other hand, 
statistical significance was obtained between the groups at: baseline-3
rd
month, 3
rd
 
month-6
th
 month, and baseline-6
th
month. When the groups were split according the to 
medication status, statistical difference was noted at 3rdmonth-6
th
 month and baseline-
6
th
month interval.  
 
The same statistical test used to investigate primary outcomes will be carried out for all 
other parameters.  
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Table 5.3.1.4: details of the Mann Whitney Test carried out on VAS data between control and trial 
patients at baseline; and the difference of data between: the baseline-3
rd
 month (B-3
rd
), 3
rd
 month-
6
th
month (3
rd
-6
th
), and baseline-6
th
month (B-6
th
). IQR is indicative of the inter quartile range (75%-25%). 
* means p<0.05, ** means p<0.01. 
 
 
 
 
 
Figure 5.3.1.2: VAS data between control and trial patients that indicates the significant difference 
between baseline-3
rd
 month (B-3
rd
), 3
rd
 month-6
th
month (3
rd
-6
th
), and baseline-6
th
month (B-6
th
).   
 
 
 
 
 
 
VAS - Mann Whitney Test 
 
 BASELINE DIFFERENCE 
  B-3
rd
  3
rd
-6
th
  B-6
th
  
p-value 
control: Median (IQR) 
trial: Median (IQR) 
p=0.221 
6.5(50.5) 
14(31) 
p=0.030* 
0(-0.5) 
5(8) 
p=0.002** 
0(-5) 
1(6) 
p=0.029* 
0(0.25) 
8(19) 
Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.586 
4(62) 
13(21) 
p=0.145 
0(0) 
2(6) 
p=0.002** 
0(-5) 
1(10) 
p=0.025* 
0(-2) 
8(11) 
Not Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.101 
6.75(20.5) 
35.5(47.25) 
p=0.260 
1.45(1.75) 
10.5(19.25) 
p=0.197 
0(-5.75) 
1(-1.25) 
p=0.655 
2(3.5) 
14(20.75) 
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5.3.2. CHAQ  
Control Group (CHAQ) 
 
With regards to median values at baseline was 0.13, 0 at 3
rd
 month, and 0.13 at 6
th
 
month. It is possible to notice a stable trend all over the 6 months (Table 5.3.2.1, Figure 
5.3.2.1).  
 
Table 5.3.2.1: descriptive statistics on CHAQ data at baseline, 3
rd
 month and 6
th
 month (control and trial 
patients).  
CHAQ  
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median (IQR) 0.13 (1.125) 0 (0.94) 0.13 (0.5) 0.38 (0.75) 0.25 (0.875) 0.13 (0.625) 
 
 
Figure 5.3.2.1 descriptive statistics on CHAQ data at baseline, 3
rd
 month and 6
th
 month (control and trial 
patients) 
 
 
As shown in the table below, CHAQ clinical significance for the control group is 
obtained only for the baseline-3
rd
month interval. The remaining intervals did not 
achieve clinical significance (Figure 5.3.2.2). 
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Baseline - 3
rd
 month interval (control and trial group) 
 
 
 
 
3
rd
 month - 6
th
 month interval (control and trial group) 
 
 
 
Baseline – 6th month interval (control and trial group) 
 
 
 
 
 
Figure 5.3.2.2: Clinical significance calculations for the CHAQ scores. The median value for clinical 
significance improvement for the control group (blue) and the trial group (red) was calculated of at least 
30% difference. If the median value for the 3rd month or 6th month was reduced of 30%, then clinical 
significance was achieved.   
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As shown on Table 5.3.2.2 the Friedman test indicates that p<0.01; hence there is 
statistical difference for the control group. Also when only the stable group is 
considered separately the same results are obtained. Unstable group is also significant 
at p<0.05 which is acceptable for this study.  
 
Table 5.3.2.2: details of the Friedman test on CHAQ data at baseline, 3
rd
 month and 6
th
 month (control 
and trial patients). * means p<0.05, ** means p<0.01. 
 
   
 
 
 
 
 
Table 5.3.2.3 highlights that the p<0.05* of the control group at baseline-3
rd
month and 
baseline-6
th
month, but p>0.05 at 3
rd
 month-6
th
 month interval. When the stable group is 
considered separately the results slightly change and no significant changes occur at 
both 3
rd
month-6
th
month and baseline-6
th
 month. The CHAQ data suggests by the end of 
the 6 month statistical changes occurred for the control group. Finally, the CHAQ 
scores show a trend of small improvement within baseline-3
rd
 month; however, the 
scores worsen by the end of the study for the control group. 
 
Table 5.3.2.3: details of the Wilcoxon’s test on CHAQ data (control and trial patients). * means p<0.05, 
** means p<0.01.  
CHAQ - Wilcoxon’s Test   
 Control Trial  
Baseline – 3rd month  p=0.002** p=0.015* 
3
rd
 month – 6th month  p=0.718 p=0.027* 
Baseline – 6th month  p=0.004** p=0.060* 
 
 
Stable  
Baseline – 3rd month  p=0.001** p=0.009** 
3
rd
 month – 6th month  p=0.717 p=0.021* 
Baseline – 6th month  p=0.029* p=0.001** 
 
 
Not Stable  
Baseline – 3rd month  p=0.068* p=0.673** 
3
rd
 month – 6th month  p=0.180 p=0.546 
Baseline – 6th month  p=0.068 p=0.053 
Friedman Test – CHAQ score (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.000** p=0.000** 
 
Stable  p=0.006** p=0.000** 
Non Stable p=0.024* p=0.215 
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Trial Group (CHAQ) 
 
As shown on Table 5.3.2.1 median values at baseline were 0.38, at 3
rd
 month 0.25, and 
at 6
th
 month 0.13 (Table 5.3.2.1). As shown on Table 5.3.2.2 the Friedman test 
confirms that p<0.01**, hence there is a statistical difference. Also when only the 
stable group is considered separately the same results are obtained. Wilcoxon’s test 
shows that there is statistical difference (p<0.01) only during the 3
rd
 month-6
th
 month 
interval. However, when only the stable group is considered separately, an 
improvement trend is found, and statistical difference is achieved also between 
baseline-6
th
 month intervals (p<0.01**) (Table 5.3.2.3).  
 
According to the descriptive statistics (median values) the 30% difference required to 
achieve clinical significance within the appointments was found all intervals. These 
positive results provides a further confirmation on how the CHAQ system was able to 
record improvements in the quality of life for those JIA children who worn the FOs. 
 
Comparison between the Control and the Trial Group 
(CHAQ) 
 
 
As shown in Table 5.3.2.4 results highlighted that p>0.05; therefore, there was no 
statistical difference between the groups at baseline. In addition, at baseline when the 
groups were split according the medication status, equally no statistical difference was 
noted (p>0.05).  No significance was found between the control group at Baseline-
3
rd
month, 3
rd
month-6
th
month and baseline-6
th
month.On the other hand, the CHAQ 
scores indicate that statistical difference is found for the stable group between baseline 
and 6
th
 month interval; which also is reflected the positive trend shown by the clinical 
significance improvement for the trial group only.  
 
 
 
 
 
169 
 
Table 5.3.2.4: details of the Mann Whitney Test carried out on CHAQ data between control and trial 
patients. * means p<0.05, ** means p<0.01. 
 
 
 
Figure 5.3.2.3: details of the Mann Whitney Test carried out on CHAQ data between control and trial 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
CHAQ - Mann Whitney Test 
 
 BASELINE DIFFERENCE 
  B-3
rd
  3
rd
-6
th
  B-6
th
  
p-value 
control: Median (IQR) 
trial: Median (IQR) 
p=0.247 
0.125(1.31) 
0.375(0.625) 
p=0.575 
0(0.128) 
0.13(0.25) 
p=0.136 
0(0) 
0.123(0.25) 
p=0.066 
0.125(0.125) 
0.125(0.375) 
Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.586 
0.13(1) 
0.375(0.5) 
p=0.425 
0.12(0.125) 
0.125(0.375) 
p=0.103 
0(-0.138) 
0.125(0.25) 
p=0.031* 
0.125(0.125) 
0.125(0.5) 
Not Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.101 
0.313(1.53) 
0.50(1.69) 
p=0.744 
0(0.16) 
0.063(0.03) 
p=0.711 
0(0.313) 
0.63(-0.44) 
p=0.924 
0(0.564) 
0.125(0.281) 
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5.3.3. PedsQL Paediatric Generic module (version 4.0)  
Control Group (PedsQL Peadiatric Generic) 
 
The median values at baseline were 86.10, 85 at 3
rd
 month, and 87.10 at 6
th
 month. It is 
possible to notice a stable trend of the control group data throughout the 6 months 
period of time (Figure 5.3.3.1, Table 5.3.3.1). 
 
Table 5.3.3.1: : descriptive statistics on PedsQL Paediatric Generic  data at baseline, 3
rd
 month and 6
th
 
month (control and trial patients). 
 
PedsQL Paediatric Generic (version: 4) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median (IQR) 86.1(26.48) 85(26.8) 87.11(27.15) 77.2(28.77) 83.91(16.72) 85.22(13.44) 
 
 
Figure 5.3.3.1: descriptive statistics on PedsQL Paediatric Generic data at baseline, 3
rd
 month and 6
th
 
month (control and trial patients).  
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As shown on Table 5.3.3.2 the Friedman test indicates that p>0.05; hence there is no 
statistical difference within the control group. Also when the stable group is considered 
separately the same results are obtained. 
 
Table 5.3.3.2: details of the Friedman test on PedsQL Paediatric Generic data at baseline, 3
rd
 month and 
6
th
 month (control and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Table 5.3.3.3 highlights that the p>0.05 in all 3 intervals from the control group. 
Equally, when the stable and not-stable group is considered separately the results do 
not change and no statistical significance was recorded. This suggests that there were 
no statistical difference in PedsQL paediatric generic module in any of the intervals 
considered for the control group. 
 
Table 5.3.3.3: details of the Wilcoxon’s test on PedsQL Paediatric Generic data (control and trial 
patients). * means p<0.05, ** means p<0.01. 
 
 PedsQL Paediatric Generic - Wilcoxon’s Test   
 Control Trial  
Baseline – 3rd month  p=0.503 p=0.000** 
3
rd
 month – 6th month  p=0.182 p=0.015* 
Baseline – 6th month  p=0.265 p=0.000** 
 
 
Stable  
Baseline – 3rd month  p=0.433 p=0.003** 
3
rd
 month – 6th month  p=0.298 p=0.009** 
Baseline – 6th month  p=0.460 p=0.000** 
 
 
Not Stable  
Baseline – 3rd month  p=0.799 p=0.036* 
3
rd
 month – 6th month  p=0.374 p=0.779 
Baseline – 6th month  p=0.515 p=0.025* 
 
Trial Group (PedsQL Peadiatric Generic) 
 
Median values at baseline were 77.2, at 3
rd
 month 83.91, and at 6
th
 month 84.22 (Table 
5.3.3.1). According to the descriptive statistics (median values) the 5 points difference 
required to achieve clinical significance within the appointments was found.  
Friedman Test –  PedsQL Paediatric Generic (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.488 p=0.000** 
 
Stable  p=-0.486 p=0.000** 
Non Stable p=0.832 p=0.093 
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As shown on Table 5.3.3.2 the Friedman test displayed a p<0.01** hence there is 
statistical difference. Also when only the stable group is considered separately the same 
result is obtained. According to the results clinical significance is obtained within the 
baseline-3
rd
month and baseline-6
th
month.  
 
As shown on Table 5.3.3.3 Wilcoxon’s test shows that there is statistical difference 
during baseline-3
rd
 month (p<0.05*); 3
rd
 month-6
th
 month (p<0.05*); and baseline-
6
th
month (p<0.01**) interval. Furthermore, when only the stable group is considered 
separately, statistical difference is also achieved within all intervals.  
 
Finally, there is a clear trend that indicates the improvement of quality of life score for 
the trial group. 
 
Comparison between the Control and the Trial Group 
(PedsQL Peadiatric Generic) 
 
 
Results highlighted that at the start of the trial p>0.05; therefore, no statistical 
difference was found (Table 5.3.3.4, Figure 5.3.3.2). In addition, when the stable 
groups were analysed at baseline no statistical difference was noted (p>0.05). When the 
difference in score between the intervals were analysed, the trend indicated a 
significance difference between the groups particularly at baseline-3
rd
month and 
baseline-6
th
month, and clinical significance was attained for the same intervals. The 
same trend was attained for the stable trial group.  
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Table 5.3.3.4: details of the Mann Whitney Test carried out on PedsQL Paediatric Generic data. * means 
p<0.05, ** means p<0.01.Note that the negative values are indicative of an improvement and the positive 
PedsQL scores shows a reduction in the quality of life of the patient. 
 
 
 
Figure 5.3.3.2: details of the Mann Whitney Test carried out on PedsQL Paediatric Generic data between 
control and trial patients. 
  
 
 
 
 
 
 
 
 
 
PedsQL Generic Paediatric - Mann Whitney Test 
 
 BASELINE DIFFERENCE 
  B-3
rd
  3
rd
-6
th
  B-6
th
  
p-value 
control: Median (IQR) 
trial: Median (IQR) 
p=0.058 
86(26.49) 
77.19(28.77) 
p=0.001** 
-0.31(-8.75) 
-5.31(-10.78) 
p=0.549 
-1.33(-8.24) 
-1.56(-5.94) 
p=0.000** 
-0.235(-4.3) 
-8.91(-22.18) 
Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.150 
83.13(19.69) 
82.19(13.59) 
p=0.004** 
0.31(-8.59) 
-5.31(16.25) 
p=0.537 
-1.91(-8.47) 
-1.56(-7.81) 
p=0.003** 
0.24(-5.54) 
-10(-22.64) 
Not Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.274 
86.57(45.12) 
62.74(42.77) 
p=0.076 
-2.03(-12.42) 
-5.17(-12.42) 
p=0.790 
-0.625(-8.55) 
0.7(-8.5) 
p=0.083 
0.39(-4.23) 
0.53(-22.54) 
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5.3.4. PedsQL Paediatric Rheumatology module (version 
3.0)  
Control Group (PedsQL Peadiatric Rheumatology) 
 
The median values at baseline was 78.63, 78.69 at 3
rd
 month, and 83.63 at 6
th
 month. It 
is possible to notice a stable trend by the end of 6 months (Table 5.3.4.1, Figure 
5.3.4.1). 
 
Table 5.3.4.1: descriptive statistics on PedsQL Paediatric Rheumatology data at baseline, 3
rd
 month and 
6
th
 month (control and trial patients) 
PedsQL Paediatric Rheumatology module (version 3.0) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median(IQR) 78.63(18.65) 78.69(20.48) 83.63(27.14) 72.60(29.43) 81.72(20.49) 89.67(17.92) 
 
 
Figure 5.3.4.1: descriptive statistics on PedsQL Paediatric Rheumatology data at baseline, 3
rd
 month and 
6
th
 month (control and trial patients). 
 
As shown on Table 5.3.4.2 the Friedman test indicates that p>0.05; hence, there is no 
statistical difference within the control group. Also when only the stable group is 
considered separately the same results are obtained.  
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Table 5.3.4.2: details of the Friedman test on PedsQL Paediatric Rheumatology module data at baseline, 
3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Table 5.3.4.3 highlights that the p>0.05 in all 3 intervals for the control group. Equally, 
when the stable and not-stable group is considered separately the results do not change 
and no statistical significance was recorded. This suggests that there were no statistical 
difference in the PedsQL Paediatric Rheumatology module for the control group. 
 
Table 5.3.4.3: details of the Wilcoxon’s test on PedsQL Paediatric Rheumatology data  (control and trial 
patients). * means p<0.05, ** means p<0.01. 
 
PedsQL Paediatric Rheumatology module - Wilcoxon’s Test   
 Control Trial 
Baseline – 3rd month p=0.882 p=0.001** 
3
rd
 month – 6th month p=0.276 p=0.007** 
Baseline – 6th month p=0.131 p=0.000** 
 
 
Stable 
Baseline – 3rd month p=0.571 p=0.011* 
3
rd
 month – 6th month p=0.079 p=0.001** 
Baseline – 6th month p=0.098 p=0.000** 
 
 
Not Stable 
Baseline – 3rd month p=0.646 p=0.025* 
3
rd
 month – 6th month p=0.767 p=0.674 
Baseline – 6th month p=0.575 p=0.017* 
 
 
 
Trial Group (PedsQL Peadiatric Rheumatology) 
 
Median values at baseline 72.60, at 3
rd
 month 81.72 and at 6
th
 month 89.67 (Table 
5.3.4.1). According to the descriptive statistics (median values) the 5 points difference 
required to achieve clinical significance within the appointments was found. 
 
Friedman Test   
PedsQL Paediatric Rheumatology module (version 3.0) - (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.178 p=0.000** 
 
Stable  p=0.302 p=0.000** 
Non Stable p=0.232 p=0.034* 
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As shown on Table 5.3.4.2 the Friedman test displayed a p<0.01** hence there is 
statistical difference within the trial group compared to the control group. Also when 
only the stable group is considered separately the same result is obtained. As shown on 
Table 5.3.4.3 Wilcoxon’s test shows that there is statistical difference during baseline-
3
rd
 month (p<0.01**); 3
rd
 month-6
th
 month (p<0.05*); and baseline-6
th
month 
(p<0.01**) interval. Furthermore, when only the stable group is considered separately, 
statistical difference is also achieved within all intervals. Finally, a positive trend of 
improvement was found for the trial group and according to the results, clinical 
significance was obtained within the baseline-3
rd
month and baseline-6
th
month.  
 
 Comparison between the Control and the Trial Group 
(PedsQL Peadiatric Rheumatology) 
 
 
At baseline with PedsQL Paediatric Rheumatology module, and no statistical difference 
was found. As shown in Table 5.3.4.4 and Figure 5.3.4.2, results highlighted that 
p>0.05 only between 3
rd
month-6
th
month; however, p<0.001** was found at baseline- 
3
rd
month and baseline-6
th
month intervalls. In addition, when the groups were split 
according the medication status, the same results were found (p<0.001**). The trend 
indicates significant difference between the groups particularly between the baseline-3
rd
 
month and baseline-6
th
months. 
Table 5.3.4.4: details of the Mann Whitney Test carried out on PedsQL Paediatric Rheumatology data 
between control and trial patients. * means p<0.05, ** means p<0.01. 
 
 
PedsQL Paediatric Rheumatology - Mann Whitney Test 
 
 BASELINE DIFFERENCE 
  B-3
rd
  3
rd
-6
th
  B-6
th
  
p-value 
control: Median (IQR) 
trial: Median (IQR) 
p=0.101 
78.63(18.65) 
72.6(29.45) 
p=0.001** 
0(-0.5) 
5(8) 
p=0.167 
-0.18(12.77) 
-2.86(11.56) 
p=0.000** 
-1.5(7.92) 
-9.05(-24.62) 
Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.161 
77.69(17.39) 
75.37(29.45) 
p=0.002** 
-0.51(13.23) 
-9.11(10.17) 
p=0.189 
-2.5(11.77) 
-7.2(14.33) 
p=0.000** 
-2.27(9.09) 
-10.10(23.83) 
Not Stable 
control: Median (IQR) 
trial: Median (IQR) 
p=0.286 
79.6(30.29) 
62.71(47.06) 
p=0.183 
-4.64(21.11) 
-9.04(21.86) 
p=0.859 
2.41(12.81) 
1.07(10) 
p=0.091 
-0.69(10.33) 
-5.6(26.37) 
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Figure 5.3.4.2: details of the Mann Whitney Test carried out on PedsQL Paediatric Rheumatology data 
between control and trial patients 
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5.3.5. PedsQL Parent Generic module (version 4.0)  
Control Group (PedsQL Parent Generic) 
 
The median values at baseline was 75, 87.81 at 3
rd
 month, and 86.72 at 6
th
 month. It is 
possible to notice an improvement within the baseline and 3
rd
 month; however, within 
the 3
rd
 month and 6
th
 month interval for the control group, a stable trend was found 
(Table 5.3.5.1, Figure 5.3.5.1).  
 
Table 5.3.5.1: descriptive statistics on PedsQL Parent Generic data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
 
PedsQL Parent Generic module (version 4.0) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median (IQR) 75(38.05) 87.81(40.23) 86.72(33.16) 65.31(27.03) 79.85(21.88) 84.70(19.53) 
 
 
Figure 5.3.5.1: descriptive statistics on PedsQL Parent Generic data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
 
As shown on Table 5.3.5.2 the Friedman test indicate that p<0.01**; hence, there is 
statistical difference within the control groups. Instead, when only the stable group is 
considered separately the statistical significance is obtained for the stable group 
(p<0.01**) but not for the not-stable group (p>0.05). 
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Table 5.3.5.2: details of the Friedman test on PedsQL Parent Generic data at baseline, 3
rd
 month and 6
th
 
month (control and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Table 5.3.5.3 highlights that the p<0.05* at baseline-3
rd
 month and baseline-6
th
 month; 
in contrast, p>0.05 for the 3
rd
month-6
th
month interval for the control group. Equally, 
when the stable is considered separately the results did not change; therefore, the data 
are indicative that there was statistical difference in PedsQL Parent Generic module for 
the control group. On the other hand, when not stable group is analysed, a different 
trend appeared because all intervals appeared to be p>0.05, therefore, no statistical 
significance was recorded for the control group.  
 
Table 5.3.5.3: details of the Wilcoxon’s test on PedsQL Parent Generic data (control and trial patients). * 
means p<0.05, ** means p<0.01. 
 
PedsQL Parent Generic module (version 4.0) - Wilcoxon’s Test 
 Control Trial 
Baseline – 3rd month p=0.004** p=0.001** 
3
rd
 month – 6th month p=0.032* p=0.071 
Baseline – 6th month p=0.004** p=0.000** 
 
 
Stable 
Baseline – 3rd month p=0.002** p=0.004** 
3
rd
 month – 6th month p=0.733 p=0.107 
Baseline – 6th month p=0.01** p=0.000** 
 
 
Not Stable 
Baseline – 3rd month p=0.508 p=0.093 
3
rd
 month – 6th month p=0.263 p=0.400 
Baseline – 6th month p=0.859 p=0.017* 
 
 
Trial Group (PedsQL Parent Generic) 
 
Median values at baseline were 65.31, at 3
rd
 month 79.85, and at 6
th
 month 84.70 
(Table 5.3.5.1). According to the descriptive statistics (median values) the 5 points 
Friedman Test   
PedsQL Parent Generic module (version 4.0) - (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.000** p=0.000** 
 
Stable  p=0.000** p=0.000** 
Non Stable p=0.567 p=0.034* 
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difference required to achieve clinical significance within the appointments was found. 
As shown on Table 5.3.5.2 the Friedman test displayed a p<0.01** hence there is 
statistical difference within the trial group compared to the control group. Also when 
only the stable group is considered separately the same result was obtained. As shown 
on Table 5.3.5.3 Wilcoxon’s test shows that there is statistical difference during 
baseline-3
rd
month (p<0.01**); and baseline-6
th
month (p<0.01**) interval; instead 
during 3
rd
month-6
th
month interval (p>0.05) which indicates no statistical difference. 
Furthermore, when also the stable group is considered, results remained the same. 
Finally, according to the results clinical significance is obtained within the baseline-
3
rd
month and baselin-6
th
month. Therefore, a positive trend towards improvement was 
found particularly between the baseline-3
rd
month and baseline-6
th
month interval for the 
trial group. 
 
Comparison between the Control and the Trial Group 
(PedsQL Parent Generic) 
 
As shown in Table 5.3.5.4 at the start of the trial, results highlighted that p>0.05; 
therefore, there was no statistical difference. In addition, when the groups were split 
according the medication status, equally no statistical difference was noted (p>0.05) 
(Table 5.3.5.4, Figure 5.3.5.2). Overall the data show a positive trend of clinical and 
statistical significance difference between the groups particularly between the baseline-
6
th
 months. 
 
Table 5.3.5.4: details of the Mann Whitney Test carried out on PedsQL Parent Generic data between  
control and trial patients. * means p<0.05, ** means p<0.01. 
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Figure 5.3.5.2: details of the Mann Whitney Test carried out on PedsQL Parent Generic data between  
control and trial patients  
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5.3.6. PedsQL Parent Rheumatology module (version 3.0)  
Control Group (PedsQL Parent Rheumatology) 
 
The median values at baseline was 78.04, 83.60 at 3
rd
 month, and 84.47 at 6
th
 month. It 
is possible to notice a stable trend by the end of the 6 months (Table 5.3.6.1, Figure 
5.3.6.1).  
 
Table 5.3.6.1: descriptive statistics on PedsQL Parent Rheumatology data at baseline, 3
rd
 month and 6
th
 
month (control and trial patients). 
 
PedsQL Parent Rheumatology module (version 3.0) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median(IQR) 78.04(40.58) 83.60(34.03) 84.47(35.58) 62.52(33.89) 79.00(27.95) 83.70(31.5) 
 
 
Figure 5.3.6.1: descriptive statistics on PedsQL Parent Generic data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
 
As shown on Table 5.3.6.2 the Friedman test indicates that p>0.05, hence there is no 
statistical difference within the control group. Equally, when only the stable and the 
not-stable group is considered separately, statistical significance is not achieved 
(p>0.05). 
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Table 5.3.6.2: details of the Friedman test on PedsQL Parent Rheumatology data at baseline, 3
rd
 month 
and 6
th
 month (control and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Table 5.3.6.3 highlights that the p<0.05* only at baseline-3
rd
 month interval. On the 
other hand, 3
rd
month-6
th
month and baseline-6
th
 month did not prove to be statistically 
different (p>0.05). Equally, when the stable group is considered separately the results 
did not change; instead, when the stable group is analysed all intervals appeared to be 
p>0.05, therefore, no statistical significance was recorded for the control group.  
 
Table 5.3.6.3: details of the Wilcoxon’s test on PedsQL Parent Rheumatology data (control and trial 
patients). * means p<0.05, ** means p<0.01. 
 
PedsQL Parent Rheumatology module (version 3.0) - Wilcoxon’s Test   
 Control Trial  
Baseline – 3rd month  p=0.019* p=0.002** 
3
rd
 month – 6th month  p=0.738 p=0.044* 
Baseline – 6th month  p=0.064 p=0.000** 
 
 
Stable  
Baseline – 3rd month  p=0.035* p=0.04* 
3
rd
 month – 6th month  p=0.433 p=0.046* 
Baseline – 6th month  p=0.068 p=0.000** 
 
 
Not Stable  
Baseline – 3rd month  p=0.333 p=0.327 
3
rd
 month – 6th month  p=0.515 p=0.499 
Baseline – 6th month  p=0.575 p=0.069 
 
 
5.4.6.2     Trial Group (PedsQL Parent Rheumatology) 
 
Median values at baseline were 62.52, at 3
rd
 month 79.00, and at 6
th
 month 83.70 
(Table 5.3.6.1). According to the descriptive statistics (median values) the 5 points 
difference required to achieve clinical significance within the appointments were found. 
 
Friedman Test   
PedsQL Parent Rheumatology (version 3.0) - (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.081 p=0.000** 
 
Stable  p=0.133 p=0.000** 
Non Stable p=0.387 p=0.368 
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As shown on Table 5.3.6.2 the Friedman test displayed a p<0.01** hence there is 
statistical difference within the trial group. Also when only the stable group is 
considered separately the same result was obtained. As shown on Table 5.3.6.3 
Wilcoxon’s test shows that there is statistical difference during baseline-3rdmonth 
(p<0.05*), 3
rd
month-6
th
month and within baseline-6
th
month (p<0.01**) intervals. 
When the trial-stable group was considered, statistical difference was attained across 
the all intervals (baseline-3
rd
month, p<0.05*; 3
rd
month-6
th
month, p<0.05*; baseline-
6
th
month, p<0.01**). Finally, according to the results clinical significance is obtained 
within the baseline-3
rd
month and baseline-6
th
month. Therefore, the trend that emerged 
from data analysis, indicate a progressive improvement of the PedsQL Parent 
Rheumatology module over the 6 months for the trial group. 
 
5.4.6.3     Comparison between the Control and the Trial 
Group (PedsQL Parent Rheumatology) 
 
 
As shown in Table 5.3.6.4 at the start of the trial, results highlighted that p>0.05; 
therefore there was no statistical difference. In addition, at baseline when the groups 
were split according to the medication status, equally no statistical difference was noted 
(p>0.05). Statistical significance was obtained between the groups at baseline-6
th
month 
interval, also for the stable medication group. Finally, the trend also shows that clinical 
significance was found with a greater improvement in scores for the trial group at the 
baseline-6
th
month comparison. 
 
Table 5.3.6.4: details of the Mann Whitney Test carried out on PedsQL Parent Rheumatology data 
between control and trial patients. * means p<0.05, ** means p<0.01. 
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Figure 5.3.6.2: box plot of the Mann Whitney Test carried out on the difference of PedsQL Parent 
Rheumatology data between control and trial patients. 
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5.3.7. Summary of Primary Outcomes 
 In order to allow the reader to have a clear understanding of the primary outcome 
results presented in the previous chapters, a summary of the major findings obtained 
with regards to the ‘Pain’ and ‘Quality of Life Questionnaire’ are displayed in table 
5.3.6.5. 
 
Table 5.3.7.1: this concise table shows the primary outcome results comparison between the trial and the 
control group (baseline-3
rd
month; 3
rd
month-6
th
month; baseline-6
th
month). Green background indicates 
that statistical significant difference was obtained (* means p<0.05; **  means p<0.01; p<0.001 means 
p=0.000). Red background shows that statistical significant difference was not obtained (p>0.05). 
 
Primary Outcome Results 
comparison between groups (Mann Whitney U-Test) 
 Baseline -
3
rd
month 
3
rd
month –
6
th
month 
Baseline –
6
th
month 
VAS p=0.03* p=0.002** p=0.029* 
stable p=0.145 p=0.002** p=0.025* 
 
CHAQ p=0.575 p=0.136 p=0.066 
stable p=0.425 p=0.103 p=0.031* 
 
PedsQL child rheumatology p=0.001** p=0.167 p<0.001 
Stable p=0.002** p=0.189 p<0.001 
 
PedsQL child generic p=0.001** p=0.0549 p<0.001 
stable p=0.004** p=0.537 p=0.003** 
 
PedsQL parent rheumatology p=0.124 p=0.137 p=0.020* 
stable p=0.136 p=0.258 p=0.040* 
 
PedsQL parent generic p=0.473 p=0.053 p=0.047* 
stable p=0.100 p=0.145 p=0.264 
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 Gait Analysis  5.4.
 
In this chapter the following anagrams related to specific parameters will be 
used: 
 Peak Pressure (identifies a specific area where there is the highest amount of 
pressure) – peak pressure versus time = (-PP). It can also be defined as the 
average value of the maximum pressure from each step recorded over the 
analysed foot region.  
 Pressure Time Integral (relationship between the amount of pressure that is 
applied throughout a period of time) = (-PTI). It is also defined as the amount of 
load maintained through a specific area over the time taken to complete a 
particular phase of gait.  
 
5.4.1. Gait Time (sec) 
Control Group (Gait Time)  
 
According to the descriptive statistics within the control group there was only 1 missing 
recording at 6
th
 month due to patient D9 that did not complete the last data collection 
appointment. Hence, the same missing data will not be found in all other parameters 
investigated as secondary outcomes. 
 
Table 5.4.1.1: descriptive statistics on Gait Time data at baseline, 3
rd
 month and 6
th
 month (control and 
trial patients) 
 
Gait Time (sec) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median (IQR) 1.11(0.33) 1.13(0.47) 1.11(0.54) 1.17(0.32) 1.17(0.34) 1.04(0.27) 
 
Data are NOT parametric; therefore, Friedman’s test was carried out. Data were split to 
allow comparison within the control and the trial groups. These gait time data are, 
paired and 3 groups (baseline, 3
rd
 month, 6
th
 month) were tested. As shown on Table 
5.4.1.2 the Friedman test shows that p>0.05, therefore, no significance difference is 
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obtained within the control group. Also when only the stable group is considered 
separately the same results are obtained. It is possible to notice a stable trend over a 
period of 6 months. 
 
Table 5.4.1.2: details of the Friedman test on Gait time data at baseline, 3
rd
 month and 6
th
 month (control 
and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Furthermore, gait time data were compared within two intervals each time (baseline 
with 3
rd
 month; 3
rd
 month with 6
th
 month; and baseline with 6 month). As data are not 
parametric and paired, Wilcoxon’s test was carried out. Table 5.4.1.3 highlighted that 
the p>0.05 in all 3 intervals for the control group. Equally, when the stable and not-
stable group is considered separately the results did not change and no statistical 
significance was recorded.  
 
Table 5.4.1.3: details of the Wilcoxon’s test on Gait Time data (control and trial patients). * means 
p<0.05, ** means p<0.01. 
 
Gait Time (sec) - Wilcoxon’s Test   
 Control Trial  
Baseline – 3rd month  p=0.917 p=0.877 
3
rd
 month – 6th month  p=0.761 p=0.005** 
Baseline – 6th month  p=0.487 p=0.006** 
 
 
Stable  
Baseline – 3rd month  p=0.811 p=0.638 
3
rd
 month – 6th month  p=0.670 p=0.009** 
Baseline – 6th month  p=0.420 p=0.012* 
 
 
Not Stable  
Baseline – 3rd month  p=0.799 p=0.674 
3
rd
 month – 6th month  p=0.767 p=0.362 
Baseline – 6th month  p=0.878 p=0.293 
 
 
 
 
 
Friedman Test - Gait time (sec) - (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.623 p=0.019* 
 
Stable  p=0.646 p=0.025* 
Non Stable p=0.926 p=0.607 
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Trial Group (Gait time) 
 
As shown on Table 5.4.1.1 the descriptive statistics within the trial group all 
appointments were carried out over the whole duration of the trial, and no missing data 
was recorded (Table 5.4.1.1). As shown on Table 5.4.1.2 the Friedman test displayed a 
p<0.05*, hence there is statistical difference within the trial group compared to the 
control group. Also when only the stable group is considered separately the same result 
is obtained. In addition, data were compared within two time intervals (baseline with 
3
rd
 month; 3
rd
 month with 6
th
 month; and baseline with 6 month). As data are not 
parametric and paired, Wilcoxon’s test was carried out. As shown on Table 5.4.1.3 
Wilcoxon’s test shows that there is no statistical difference during baseline-3rd month 
(p>0.05); on the other hand, significant difference was detected at 3
rd
 month-6
th
 month 
(p<0.05*); and baseline-6
th
month (p<0.05*) interval. Furthermore, when only the stable 
group was considered separately, the same results were obtained. Finally, it appears 
that there is a positive trend for the gait time of the trial group only. 
 
Comparison between the Control and the Trial Group (Gait 
time) 
 
According to the Shapiro-Wilks Test p<0.05* hence data are not parametric for both 
control and trial group at baseline,3
rd
 month and 6
th
 month. Mann Whitney Test was 
carried out in order to test statistical difference between the control and trial group at 
baseline at the start of the trial. As shown in Table 5.4.1.4 results highlighted that 
p>0.05; therefore there was no statistical difference. In addition, when the groups were 
split according the statibility status, equally the same trend was found and no statistical 
difference was noted (p>0.05).  
 
The same statistical test used to investigate secondary outcomes, will be carried out for 
all other parameters.  
. 
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Table 5.4.1.4: details of the Mann Whitney Test carried out on Gait Time data between control and trial 
patients. * means p<0.05, ** means p<0.01. 
Gait Time (sec) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
p-value p=0.391 p=0.615 p=0.902 
 
Stable p=0.810 p=0.742 p=0.060 
Not stable p=0.274 p=0.203 p=0.929 
 
 
Figure 5.4.1.1: boxplot carried out on Gait Time average data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval. 
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5.4.2. Gait Velocity (cm/sec) 
Control Group (Gait Velocity) 
 
According to Table 5.4.2.1 it is possible to notice a stable trend for the velocity median 
values over the 6 months for the control group. 
 
Table 5.4.2.1: descriptive statistics on Gait Velocity data at baseline, 3
rd
 month and 6
th
 month (control 
and trial patients) 
Gait Velocity (cm/sec) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  29 29 28 31 31 31 
Missing 0 0 1 0 0 0 
Median (IQR) 114.77(22.22) 114.6(22.22) 117.87(24.4) 111.43(12.04) 108.1(24.76) 116.9(19.7) 
 
As shown on Table 5.4.2.2 the Friedman test shows that p>0.05, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained.  
 
Table 5.4.2.2: details of the Friedman test on Gait Velocity data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Table 5.4.2.3 highlighted that the p>0.05 in all 3 intervals for the control group. 
Equally, when the stable and not-stable group is considered separately the results did 
not change and no statistical significance was recorded.  
 
 
 
 
 
 
Friedman Test  Gait Velocity (cm/sec) - (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.565 p=0.62 
 
Stable  p=0.607 p=0.265 
Non Stable p=0.905 p=0.008** 
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Table 5.4.2.3: details of the Wilcoxon’s test on Gait Velocity data at baseline, 3rd month and 6th month 
(control and trial patients). * means p<0.05, ** means p<0.01. 
 
Gait Velocity (cm/sec) - Wilcoxon’s Test   
 Control Trial  
Baseline – 3rd month  p=0.510 p=0.769 
3
rd
 month – 6th month  p=0.194 p=0.006** 
Baseline – 6th month  p=0.716 p=0.004** 
 
 
Stable  
Baseline – 3rd month  p=0.748 p=0.523 
3
rd
 month – 6th month  p=0.170 p=0.136 
Baseline – 6th month  p=0.420 p=0.007** 
 
 
Not Stable  
Baseline – 3rd month  p=0.445 p=0.123 
3
rd
 month – 6th month  p=0.721 p=0.012* 
Baseline – 6th month  p=0.575 p=0.263 
 
Trial Group (Gait Velocity) 
 
Median values at baseline were 111.43, at 3
rd
 month 108.10, and at 6
th
 month 116.90 
(Table 5.4.2.1). As shown on Table 5.4.2.2 the Friedman test displayed a p>0.05 hence 
there is no statistical difference within the trial group compared to the control group. 
Also when only the stable group is considered separately the same result is obtained. 
However, within the non-stable group significance difference was found (p<0.05*). As 
shown on Table 5.4.2.3 Wilcoxon’s test shows that there is no statistical difference 
during baseline-3
rd
 month (p>0.05). In contrast a sharp increase of velocity occurred 
within the 3
rd
 month-6
th
 month (p<0.05*); and baseline-6
th
month (p<0.05*) interval. 
These values indicate an improvement of walking velocity within the JIA children that 
were wearing the FOs although the recording was carried out barefoot on the HR-
Walkway. Furthermore, when only the stable group was considered separately, results 
showed a significance difference within the baseline-6
th
month interval (p<0.05*). 
Therefore there is a positive trend indicating the faster walking speed within the trial 
JIA patients only by 6 months. 
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Comparison between the Control and the Trial Group (Gait 
Velocity) 
 
As shown in Table 5.4.2.4 at the start of the trial results highlighted that p>0.05; 
therefore, there was no statistical difference. In addition, when the groups were split 
according the medication status, the same trend were highlighted and equally no 
statistical difference was noted (p>0.05) between the groups.  
 
Table 5.4.2.4: details of the Mann Whitney Test carried out on Gait Velocity data between control and 
trial patients. * means p<0.05, ** means p<0.01.  
 
Gait Velocity (cm/sec) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
p-value p=0.129 p=0.464 p=0.832 
 
Stable p=0.456 p=0.587 p=0.511 
Not stable p=0.101 p=0.021 p=0.408 
 
 
Figure 5.4.2.1: boxplot carried out on Velocity average data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval. 
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5.4.3. Stance Time (sec) 
Control Group (Stance Time)  
 
The median values at baseline was 0.60, 0.60 at 3
rd
 month, and 0.61 at 6
th
 month, It is 
possible to notice a stable trend for the control group throughout the 6 months (Table 
5.4.3.1).  
 
Table 5.4.3.1: descriptive statistics on Stance Time data at baseline, 3
rd
 month and 6
th
 month (control and 
trial patients). 
Stance Time (sec) 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 0.6(0.08) 0.6(0.09) 0.6(0.1) 0.6(0.11) 0.6(0.01) 0.58(0.09) 
 
As shown on Table 5.4.3.2 the Friedman test shows that p>0.05, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained.  
 
Table 5.4.3.2: details of the Friedman test on Stance Time data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). * means p<0.05, ** means p<0.01. 
 
   
Table 5.4.3.3 highlighted that the p>0.05 in all 3 intervals for the control group. 
Equally, when the stable and not-stable group is considered separately the results did 
not change and no statistical significance was recorded.  
 
 
 
 
 
Friedman Test  - Stance Time (sec) - (baseline, 3rd month & 6th month) 
 Control Trial 
p-value p=0.60 p=0.049* 
 
Stable  p=0.993 p=0.041* 
Non Stable p=0.208 p=0.350 
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Table 5.4.3.3: details of the Wilcoxon’s test on Stance Time data (control and trial patients). * means 
p<0.05, ** means p<0.01. 
 
Stance Time (sec) - Wilcoxon’s Test   
 Control Trial  
Baseline – 3rd month  p=0.297 p=0.173 
3
rd
 month – 6th month  p=0.612 p=0.469 
Baseline – 6th month  p=0.132 p=0.005** 
 
 
Stable  
Baseline – 3rd month  p=0.82 p=0.078 
3
rd
 month – 6th month  p=0.922 p=0.753 
Baseline – 6th month  p=0.844 p=0.002** 
 
 
Not Stable  
Baseline – 3rd month  p=0.144 p=0.691 
3
rd
 month – 6th month  p=0.295 p=0.306 
Baseline – 6th month  p=0.033* p=0.776 
 
Trial Group (Stance Time) 
 
Median values at baseline were 0.60, at 3
rd
 month 0.60, and at 6
th
 month 0.58 (Table 
5.4.3.1). As shown on (Table 5.4.3.2) the Friedman test displayed a p<0.05* hence 
there is statistical difference within the trial group compared to the control group. Also 
when only the stable group is considered separately the same result is obtained. 
However, within the non-stable group significance difference was not found (p>0.05).   
 
As shown on (Table 5.4.3.3) Wilcoxon’s test shows that there is no statistical 
difference during baseline-3
rd
 month (p>0.05) and 3
rd
month-6
th
month (p>0.05); in 
contrast, significance difference was found within baseline-6
th
month (p<0.05*) 
interval. Furthermore, when only the stable group was considered separately, results 
confirmed the same results in favour of the trial group (p<0.05*). Finally there is a 
positive trend for the trial group, particularly highlighted for the baseline-6
th
month 
interval. 
Comparison between the Control and the Trial Group 
(Stance Time) 
 
As shown in Table 5.4.3.4 at the start of the trial, results highlighted that p>0.05; 
therefore there was no statistical difference. In addition, when the groups were split 
according the statibility status, equally no statistical difference was noted (p>0.05) 
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(Table 5.4.3.4). It is possible to notice a fairly stable trend when data are compared 
between the groups. However, particularly for the non-stable group, statistical 
significance is attained; and there is a clear tendency towards significance difference 
also for the stable group (p=0.055) by the end of 6 months. Potentially if data were 
collected again after 9 months, statistical significance might have been achieved 
between the groups. 
 
 
Table 5.4.3.4: details of the Mann Whitney Test carried out on Stance Time data between control and 
trial patients. * means p<0.05, ** means p<0.01. 
 
Stance Time (sec) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
p-value p=0.193 p=0.941 p=0.168 
 
Stable p=0.925 p=0.217 p=0.055 
Not stable p=0.025* p=0.04* p=0.048* 
 
 
Figure 5.4.3.1: boxplot carried out on Stance Time average data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval 
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5.4.4. Total Contact 
Total - Peak Pressure Values - (t-PP) 
 
Control Group (t-PP) 
 
With regards to F-scan (shod): median value at baseline was 456.83, 534.67 at 3
rd
 
month, and 561.50 at 6
th
 month (Table 5.4.4.1).  
 
Table 5.4.4.1: descriptive statistics on Total – PP (F-Scan shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
Total – Peak Pressure Values (t-PP) - F-Scan-Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 456.83(308.91) 534.67(391.17) 561.5(291.08) 498.33(390.75) 514.5(383.33) 569.67(443.66) 
 
With regards to F-scan With Insole: median value at baseline was 498, 501.33 at 3
rd
 
month, and 518.83 at 6
th
 month (Table 5.4.4.2).   
 
Table 5.4.4.2: descriptive statistics on Total – PP (F-scan with insole) data at baseline, 3rd month and 6th 
month (control and trial patients) 
 
Total – Peak Pressure Values (t-PP) - F-Scan – With Insole  
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 498(367.58) 501.33(299.91) 518.33(337) 341.33(286.59) 335.83(261.92) 339.67(273.5) 
 
 
With regards to HR Walkway: median value at baseline was 461.50, 453.67 at 3
rd
 
month, and 491 at 6
th
 month  (Table 5.4.43). Overall, it is possible to notice a stable 
trend for the control group over the 6 months period of time. 
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Table 5.4.4.3: descriptive statistics on Total – PP (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Total – Peak Pressure Values (t-PP) - HR Walkway  
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 461.5(190.84) 453.67(184.91) 491(262) 452.83(235.84) 448.83(230.5) 436.83(210.09) 
 
Friedman test shows that most p>0.05, therefore, no significance difference is obtained 
within the control group. Also when only the stable group is considered separately the 
same results are obtained. The only p<0.05* was found from the F-scan-Barefoot (also 
for the not stable group) (Table 5.4.4.4).    
 
Table 5.4.4.4: details of the Friedman test on Total – PP data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Total  - Peak Pressure Values (t-PP)-Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.033 p=0.584 
Stable p=0.411 p=0.438 
Not stable p=0.026* p=0.444 
 
F-Scan – With Insoles p=0.140 p=0.026* 
Stable p=0.378 p=0.337 
Not stable p=0.350 p=0.013* 
 
HR Walkway p=0.943 p=0.258 
Stable p=0.697 p=0.754 
Not stable p=0.610 p=0.144 
 
Table 5.4.4.5 highlighted that all intervals are not significantly different for the control 
group (p>0.05). Equally, when the stable group is considered separately the results 
showed p>0.05, therefore, no statistical significance was recorded. The only p<0.05* 
was found from not-stable group of the F-scan-Barefoot & With Insole for baseline-
3
rd
month interval; and for the stable group of HR Walkway baseline-3
rd
month only 
(p<0.05*). This suggests that there were no statistical difference in the t-PP for the 
control group (Table 5.4.4.5). 
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Table 5.4.4.5: details of the Wilcoxon’s test on Total-PP data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Total  - Peak Pressure Values (t-PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan - Shod 
Baseline – 3rd month  p=0.009** p=0.345 
3
rd
 month – 6th month  p=0.448 p=0.406 
Baseline – 6th month  p=0.091 p=0.127 
 
 
Stable  
Baseline – 3rd month  p=0.249 p=0.942 
3
rd
 month – 6th month  p=0.863 p=0.064 
Baseline – 6th month  p=0.145 p=0.157 
 
 
Not Stable  
Baseline – 3rd month  p=0.337 p=0.056 
3
rd
 month – 6th month  p=0.337 p=0.109 
Baseline – 6th month  p=0.337 p=0.679 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.172 p=0.126 
3
rd
 month – 6th month  p=0.552 p=0.986 
Baseline – 6th month  p=0.100 p=0.249 
 
 
Stable  
Baseline – 3rd month  p=0.271 p=0.596 
3
rd
 month – 6th month  p=0.802 p=0.806 
Baseline – 6th month  p=0.432 p=0.569 
 
 
Not Stable  
Baseline – 3rd month  p=0.391 p=0.011* 
3
rd
 month – 6th month  p=0.502 p=0.712 
Baseline – 6th month  p=0.100 p=0.121 
 
HR Walkway 
Baseline – 3rd month  p=0.748 p=0.236 
3
rd
 month – 6th month  p=0.407 p=0.459 
Baseline – 6th month  p=0.259 p=0.713 
 
 
Stable  
Baseline – 3rd month  p=0.307 p=0.952 
3
rd
 month – 6th month  p=0.777 p=0.650 
Baseline – 6th month  p=0.535 p=0.926 
 
 
Not Stable  
Baseline – 3rd month  p=0.263 p=0.035* 
3
rd
 month – 6th month  p=0.171 p=0.535 
Baseline – 6th month  p=0.279 p=0.352 
 
Trial Group (t-PP) 
 
As shown on Table 5.4.4.1, the descriptive statistics within the trial group of the F-scan 
(shod), the median values at baseline were 498.33, at 3
rd
 month 514.50, and at 6
th
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month 569.67 (Table 5.4.4.1).  With regards to F-scan with insole, descriptive statistics 
showed: median values at baseline were 341.33, at 3
rd
 month 335.83, and at 6
th
 month 
337.67 (Table 5.4.4.2). With regards to HR Walkway, descriptive statistics showed: 
median values at baseline were 452.83, at 3
rd
 month 448.83, and at 6
th
 month 436.83 
(Table 5.4.4.3).  
 
As shown on Table 5.4.4.4 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. A statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05).   
 
As shown on Table 5.4.4.5 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals, as well as with all interval considered with the stable-groups 
(p>0.05). It is possible to notice a stable trend for the t-PP for the within the trial group 
data over the 6 months. 
 
Comparison between the Control and the Trial Group (t-PP) 
 
 
As shown in Table 5.4.4.6 results highlighted that p<0.05* between control and trial 
patient when investigation were carried out with the F-scan while wearing the insole. In 
addition, no statistical difference was noted (p>0.05) with the F-Scan at barefoot and 
with HR Walkway (p>0.05). This suggests that there is a clear trend towards changes 
that happens between the control and the trial group only when t-PP data are compared 
with the F-Scan with insole, indicating the positive effect that FOs may have on JIA 
total plantar pressure. 
 
 
 
 
 
 
 
201 
 
Table 5.4.4.6: details of the Mann Whitney Test carried out on Total-PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Total  - Peak Pressure Values (t-PP) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.183 p=0.927 p=0.411 
Stable p=0.253 p=0.515 p=0.313 
Not stable p=0.203 p=0.311 p=0.093 
 
F-Scan – With Insoles p=0.090 p=0.000** p=0.001** 
Stable p=0.222 p=0.011* p=0.026* 
Not stable p=0.223 p=0.01** p=0.004** 
 
HR Walkway p=0.958 p=0.610 p=0.622 
Stable p=0.836 p=0.811 p=0.598 
Not stable p=0.610 p=0.104 p=0.08 
 
 
Figure 5.4.4.1: boxplot carried out on F-Scan Shod - Total PP data between control and trial patients 
at baseline (blue), 3
rd
 month (green) and 6
th
 month (yellow). 
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Figure 5.4.4.2: boxplot carried out on F-Scan with insole  - Total PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval  
 
 
Figure 5.4.4.3: boxplot carried out on HR Walkway - Total PP data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval 
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Total - Pressure Time Integral (t-PTI) 
 
Control Group (t-PTI) 
 
With regards to F-scan shod: median value at baseline was 80.72, 98.72 at 3
rd
 month 
and 89.80 at 6
th
 month (Table 5.4.4.7). 
 
Table 5.4.4.7: descriptive statistics on Total – PTI (F-Scan-shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Total - Pressure Time Integral - (t-PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 80.72(59.07) 98.72(47.91) 89.80(44.17) 87(64.33) 81.59(68.88) 89.54(55.42) 
 
With regards to F-scan With Insole: median value at baseline was 73.88(166.10), 
90.94(134.74) at 3
rd
 month, and 85.50(139.03) at 6
th
 month (Table 5.4.4.8).  
  
Table 5.4.4.8: descriptive statistics on Total – PTI (F-Scan-with insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Total - Pressure Time Integral - (t-PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 73.38(58.5) 90.94(48.03) 85.50(55.95) 67.66(50.46) 61.91(44.23) 71.75(53.22) 
 
With regards to HR Walkway the median value at baseline was 58.78, 54.82 at 3
rd
 
month, and 87.28 at 6
th
 month (Table 5.4.4.9). It is possible to notice a stable trend over 
the period of 6 months for the control group. 
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Table 5.4.4.9: descriptive statistics on Total – PTI (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Total - Pressure Time Integral - (t-PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 58.78(18.01) 54.82(17.11) 57.28(19.12) 55.06(24.88) 56.78(26.83) 53.66(24.41) 
 
 
As shown on (Table 5.4.4.10) the Friedman test shows p>0.05 in all cases, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained. The only p<0.05* was 
found from the HR Walkway, also when stable group was considered separately.  
Hence, a stable trend over the period of 6 months was noted particularly with the F-
Scan equipment.  
 
Table 5.4.4.10: details of the Friedman test on Total –PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
month and 6
th
month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Total - Pressure Time Integral - (t-PTI) - Friedman Test  (baseline, 3rd month & 6th 
month) 
 
 Control Trial 
F-Scan - Shod p=0.067 p=0.824 
Stable p=0.358 p=0.859 
Not stable p=0.116 p=0.210 
 
F-Scan – With Insoles p=0.143 p=0.926 
Stable p=0.205 p=0.844 
Not stable p=0.449 p=0.269 
 
HR Walkway p=0.048* p=0.668 
Stable p=0.920 p=0.859 
Not stable p=0.000** p=0.646 
 
Table 5.4.4.11 highlighted that all intervals are not significantly different (p>0.05). 
Equally, when the stable group is considered separately the results showed p>0.05, 
therefore, no statistical significance was recorded with F-scan shod, F-scan with insole 
and HR Walkway system for the control group. 
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Table 5.4.4.11: details of the Wilcoxon’s test on Total-PTI data with F-Scan shod, F-Scan with insole 
and HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01.  
 
Total - Pressure Time Integral - (t-PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan - Shod 
Baseline – 3rd month  p=0.086 p=0.364 
3
rd
 month – 6th month  p=0.993 p=0.535 
Baseline – 6th month  p=0.131 p=0.158 
 
Stable  
Baseline – 3rd month  p=0.215 p=0.797 
3
rd
 month – 6th month  p=0.850 p=0.441 
Baseline – 6th month  p=0.371 p=0.474 
 
 
Not Stable  
Baseline – 3rd month  p=0.263 p=0.163 
3
rd
 month – 6th month  p=0.737 p=0.642 
Baseline – 6th month  p=0.167 p=0.148 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.160 p=0.930 
3
rd
 month – 6th month  p=0.935 p=0.311 
Baseline – 6th month  p=0.234 p=0.229 
 
 
Stable  
Baseline – 3rd month  p=0.162 p=0.756 
3
rd
 month – 6th month  p=0.470 p=0.650 
Baseline – 6th month  p=0.388 p=0.312 
 
 
Not Stable  
Baseline – 3rd month  p=0.737 p=0.717 
3
rd
 month – 6th month  p=0.204 p=0.088 
Baseline – 6th month  p=0.411 p=0.569 
 
 
HR Walkway 
Baseline – 3rd month  p=0.055 p=0.682 
3
rd
 month – 6th month  p=0.052 p=0.572 
Baseline – 6th month  p=0.250 p=0.952 
 
 
Stable  
Baseline – 3rd month  p=0.528 p=0.866 
3
rd
 month – 6th month  p=0.975 p=0.797 
Baseline – 6th month  p=0.950 p=0.488 
 
 
Not Stable  
Baseline – 3rd month  p=0.028 p=0.278 
3
rd
 month – 6th month  p=0.000** p=0.121 
Baseline – 6th month  p=0.017* p=0.215 
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Trial Group (t-PTI) 
 
As shown on Table 5.4.4.7 within the trial group of the F-scan shod median value at 
baseline was 87, 81.59 at 3
rd
 month, and 89.54 at 6
th
 month (Table 5.4.4.7). The F-scan 
with insole, median value at baseline was 67.66, 61.91 at 3
rd
 month, and 71.75 at 6
th
 
month (Table 5.4.4.8). With regards to HR Walkway, descriptive statistics showed: 
median value at baseline was 55.06, 56.78 at 3
rd
 month and 53.66 at 6
th
 month (Table 
5.4.4.9).  
 
As shown on Table 5.4.4.10 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05).   
 
As shown on Table 5.4.4.11 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals, as well as with all interval considered with the stable-groups 
(p>0.05). 
 
 
Comparison between the Control and the Trial Group (t-
PTI) 
 
As shown in Table 5.4.4.12 results highlighted that there is statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole at 3
rd
 month (p<0.01**) and 6
th
 month (p<0.05*). In addition, 
no statistical difference was noted (p>0.05) with the F-Scan at barefoot and with HR 
Walkway (p>0.05). This suggests that there is a clear trend toward changes that happen 
between the control and the trial group with regards to t-PTI when the FOs are used 
particularly at 3
rd
 month and 6
th
 month intervals. 
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Table 5.4.4.12: details of the Mann Whitney Test carried out on Total-PTI with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Total - Pressure Time Integral - (t-PTI) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.532 p=0.306 p=0.923 
Stable p=0.332 p=0.590 p=0.637 
Not stable p=0.545 p=0.324 p=0.373 
 
F-Scan – With Insoles p=0.098 p=0.000** p=0.028** 
Stable p=0.178 p=0.003** p=0.137 
Not stable p=0.0220 p=0.018* p=0.03* 
 
HR Walkway p=0.416 p=0.838 p=0.354 
Stable p=0.355 p=0.879 p=0.674 
Not stable p=0.799 p=0.924 p=0.181 
 
 
Figure 5.4.4.4: boxplot carried out on F-Scan Shod - Total PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month. 
 
 
 
Figure 5.4.4.5: boxplot carried out on F-Scan with insole  - Total PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval 
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Figure 5.4.4.6: boxplot carried out on HR Walkway – Total PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval. 
5.4.5. Heel Contact 
Control Group (h-PP) 
 
With regards to F-scan shod: median value at baseline was 386.83, 386.33 at 3
rd
 month 
and 353.50 at 6
th
 month. It is possible to notice a stable trend over the period of 6 
months for the control group (Table 5.4.5.1). 
 
Table 5.4.5.1:descriptive statistics on Heel – PP (F-Scan Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
Heel – Peak Pressure Values - (hPP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 386.83(191.17) 386.33(219.58) 353.50(237.91) 333.83(290.67) 373.83(300.42) 371.33(291.84) 
 
With regards to F-scan with Insole: median value at baseline was 355.17, 375.67 at 3
rd
 
month, and 350.17 at 6
th
 month (Table 5.4.5.2).  
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Table 5.4.5.2: descriptive statistics on Heel– PP (F-Scan with insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Heel – Peak Pressure Values - (hPP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 355.17(220) 375.67(202.17) 350.17(221.08) 202.50(204.41) 252.33(142.33) 229.67(151.25) 
 
With regards to HR Walkway the median value at baseline was 349, 367.73 at 3
rd
 
month and 366.50 at 6
th
 month (Table 5.4.5.3). It is possible to notice a stable trend 
over the period of 6 months for the h-PP using the in-shoe and barefoot equipment for 
the control group. 
 
Table 5.4.5.3:descriptive statistics on Heel– PP (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients) 
Heel – Peak Pressure Values - (hPP)– HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 349(143.91) 367.73(137.67) 366.50(150.41) 378.83(180.92) 345.67(154) 359(147.58) 
 
On Table 5.4.5.4 Friedman test shows p>0.05 in all cases, therefore, no significance 
difference is obtained within the control group. Also when only the stable group is 
considered separately the same results are obtained. It is possible to notice a stable 
trend over the period of 6 months. 
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Table 5.4.5.4: details of the Friedman test on Heel – PP data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Heel – Peak Pressure Values - (hPP)–- Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.592 p=0.972 
Stable p=0.863 p=0.761 
Not stable p=0.549 p=0.646 
 
F-Scan – With Insoles p=0.482 p=0.972 
Stable p=0.313 p=0.165 
Not stable p=0.100 p=0.717 
 
HR Walkway p=0.107 p=0.781 
Stable p=0.068 p=0.510 
Not stable p=0.110 p=0.740 
 
Table 5.4.5.5 highlighted that all intervals are not significantly different for the control 
group (p>0.05). Equally, when the stable group is considered separately the results 
showed p>0.05, therefore, no statistical significance was recorded with F-scan shod, F-
scan with insole and HR Walkway system for the control group. 
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Table 5.4.5.5: details of the Wilcoxon’s test on Heel-PP data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Heel – Peak Pressure Values - (hPP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.294 p=0.797 
3
rd
 month – 6th month  p=0.616 p=0.360 
Baseline – 6th month  p=0.308 p=0.766 
 
Stable  
Baseline – 3rd month  p=0.690 p=0.935 
3
rd
 month – 6th month  p=0.962 p=0.261 
Baseline – 6th month  p=0.783 p=0.416 
 
 
Not Stable  
Baseline – 3rd month  p=0.247 p=0.438 
3
rd
 month – 6th month  p=0.478 p=0.959 
Baseline – 6th month  p=0.167 p=0.379 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.583 p=0.625 
3
rd
 month – 6th month  p=0.585 p=0.933 
Baseline – 6th month  p=0.636 p=0.733 
 
 
Stable  
Baseline – 3rd month  p=0.583 p=0.810 
3
rd
 month – 6th month  p=0.397 p=0.883 
Baseline – 6th month  p=0.467 p=0.731 
 
 
Not Stable  
Baseline – 3rd month  p=0.940 p=0.532 
3
rd
 month – 6th month  p=0.852 p=0.918 
Baseline – 6th month  p=0.926 p=0.918 
 
HR Walkway 
Baseline – 3rd month  p=0.693 p=0.343 
3
rd
 month – 6th month  p=0.233 p=0.182 
Baseline – 6th month  p=0.278 p=0.743 
 
 
Stable  
Baseline – 3rd month  p=0.133 p=0.258 
3
rd
 month – 6th month  p=0.789 p=0.159 
Baseline – 6th month  p=0.278 p=0.743 
 
 
Not Stable  
Baseline – 3rd month  p=0.126 p=0.865 
3
rd
 month – 6th month  p=0.053 p=0.836 
Baseline – 6th month  p=0.575 p=0.642 
 
Trial Group (h-PP) 
 
As shown on Table 5.4.5.1 within the trial group of the F-scan shod median value at 
baseline was 333.83, 373.83 at 3
rd
 month, and 371.33 at 6
th
 month (Table 5.4.5.1).  
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With regards to F-scan with insole, the median value at baseline was 202.50, 252.33 at 
3
rd
 month, and 229.67 at 6
th
 month (Table 5.4.5.2). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 378.83, 345.67 at 3
rd
 month 
and 359 at 6
th
 month (Table 5.4.5.3). It is possible to notice a stable trend over the 
period of 6 months for the trial group with all equipment used. 
 
As shown on (Table 5.4.5.4) the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05).   
 
As shown on (Table 5.4.5.5) Wilcoxon’s test shows that there is no statistical 
difference during all three intervals, as well as with all intervals considered with the 
stable-groups (p>0.05). Hence a stable trend over the period of 6 months for the trial 
group was attained. 
 
Comparison between the Control and the Trial Group (h-
PP) 
 
As shown in Table 5.4.5.6 results highlighted that there is statistical difference between 
control and trial patients when investigation were carried out with the F-scan while 
wearing the insole at baseline (p<0.01**), 3
rd
 month (p<0.01**), and 6
th
 month 
(p<0.01**). In addition, statistical difference was noted also when the stable group was 
considered separately. Interestinlgy no statistical difference was discovered while using 
F-scan shod and HR walkway (p>0.05). This suggests that there is a clear trend toward 
changes that happen between the control and the trial group with regards to h-PP at 
baseline, 3
rd
 month and 6
th
 month only when FOs were introduced in the JIA shoes. 
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Table 5.4.5.6: details of the Mann Whitney Test carried out on Heel-PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Heel – Peak Pressure Values - (hPP) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.848 p=0.638 p=0.728 
Stable p=0.857 p=0.911 p=0.823 
Not stable p=0.504 p=0.373 p=0.408 
 
F-Scan – With Insoles p=0.000** p=0.000** p=0.000** 
Stable p=0.001** p=0.001** p=0.002** 
Not stable p=0.005** p=0.001** p=0.002** 
 
HR Walkway p=0.898 p=0.272 p=0.676 
Stable p=0.098 p=0.914 p=0.258 
Not stable p=0.036 p=0.075 p=0.022* 
 
 
Figure 5.4.5.1: boxplot carried out on F-Scan Shod – Heel - PP data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month. 
 
Figure 5.4.5.2: boxplot carried out on F-Scan with insole - Heel PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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Figure 5.4.5.3: boxplot carried out on HR Walkway - Heel PP data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval. 
 
 
 
 
 
 
 
 
Heel - Pressure Time Integral - (h-PTI) 
Control Group (h-PTI)  
 
With regards to F-scan shod: median value at baseline was 51.18, 63.86 at 3
rd
 month 
and 49.70 at 6
th
 month (Table 5.4.5.7). 
 
Table 5.4.5.7: descriptive statistics on Heel – PTI (F-Scan shod) data at baseline, 3rd month and 6th month 
(control and trial patients) 
Heel – Pressure Time Integral (h-PTI) - F-Scan Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 51.18(42.43) 63.86(38.53) 49.70(32.87) 59.8(39.87) 58.33(38.99) 51.09(36.07) 
 
With regards to F-scan With Insole: median value at baseline was 53.76, 63.30 at 3
rd
 
month, and 54.16 at 6
th
 month (Table 5.4.5.8).  
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Table 5.4.5.8: descriptive statistics on Heel – PTI (With Insole) data at baseline, 3rd month and 6th month 
(control and trial patients) 
Heel – Pressure Time Integral - (h-PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 53.76(41.51) 63.30(39.59) 54.16(33.52) 38.67(43.16) 40.14(30.86) 36.51(32.16) 
 
With regards to HR Walkway the median value at baseline was 34.42, 35.10 at 3
rd
 
month and 34.60 at 6
th
 month (Table 5.4.5.9). It is possible to notice a stable trend over 
the period of 6 months for the control group with all the equipment used.   
 
Table 5.4.5.9: descriptive statistics on Heel – PTI (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients).  
Heel – Pressure Time Integral (h-PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 34.42 35.10 34.60 34.49(19.04) 35.31(20.17) 33.14(15.58) 
 
As shown on Table 5.4.5.10 the Friedman test shows p>0.05 in all cases, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained. Hence, a stable trend 
appeared to be recorded over the 6 months period of time for the control group. 
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Table 5.4.5.10: details of the Friedman test on Heel – PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Heel – Pressure Time Integral (h PTI) – Friedman Test  (baseline, 3rd month & 6th 
month) 
 
 Control Trial 
F-Scan - Shod p=0.325 p=0.454 
Stable p=0.256 p=0.290 
Not stable p=0.247 p=0.939 
 
F-Scan – With Insoles p=0.049* p=0.461 
Stable p=0.058 p=0.196 
Not stable p=0.165 p=0.829 
 
HR Walkway p=0.313 p=0.607 
Stable p=0.973 p=0.457 
Not stable p=0.079 p=0.068 
 
Table 5.4.5.11 highlighted that all intervals are not significantly different (p>0.05). 
Equally, when the stable group is considered separately the results showed p>0.05, 
therefore, no statistical significance was recorded with F-scan shod, F-scan with insole 
and HR Walkway system. In all intervals, a stable trend for the h-PTI seemed to be 
found using the Tekscan equipment.  
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Table 5.4.5.11: details of the Wilcoxon’s test on Heel-PTI data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Heel – Pressure Time Integral (h-PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.270 p=0.549 
3
rd
 month – 6th month  p=0.054 p=0.358 
Baseline – 6th month  p=0.304 p=0.154 
 
Stable  
Baseline – 3rd month  p=0.902 p=0.604 
3
rd
 month – 6th month  p=0.192 p=0.232 
Baseline – 6th month  p=0.099 p=0.188 
 
 
Not Stable  
Baseline – 3rd month  p=0.062 p=0.836 
3
rd
 month – 6th month  p=0.167 p=0.796 
Baseline – 6th month  p=0.654 p=0.605 
 
F-Scan – With Insoles 
Baseline – 3rd month  p=0.151 p=0.563 
3
rd
 month – 6th month  p=0.032* p=0.451 
Baseline – 6th month  p=0.590 p=0.542 
 
 
Stable  
Baseline – 3rd month  p=0.470 p=0.679 
3
rd
 month – 6th month  p=0.029* p=0.391 
Baseline – 6th month  p=0.369 p=0.397 
 
 
Not Stable  
Baseline – 3rd month  p=0.100 p=0.679 
3
rd
 month – 6th month  p=0.478 p=0.1 
Baseline – 6th month  p=0.709 p=0.756 
 
HR Walkway 
Baseline – 3rd month  p=0.464 p=0.744 
3
rd
 month – 6th month  p=0.384 p=0.434 
Baseline – 6th month  p=0.3 p=0.554 
 
 
Stable  
Baseline – 3rd month  p=0.971 p=0.181 
3
rd
 month – 6th month  p=0.850 p=0.857 
Baseline – 6th month  p=0.937 p=0.236 
 
 
Not Stable  
Baseline – 3rd month  p=0.135 p=0.049* 
3
rd
 month – 6th month  p=0.077 p=0.234 
Baseline – 6th month  p=0.048* p=0.379 
 
 
Trial Group (h-PTI) 
 
As shown on Table 5.4.5.7 within the trial group of the F-scan shod median value at 
baseline was 59.80, 58.33 at 3
rd
 month, and 51.09 at 6
th
 month (Table 5.4.5.7). With 
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regards to F-scan with insole, the median value at baseline was 38.67, 40.14 at 3
rd
 
month, and 36.51 at 6
th
 month (Table 5.4.5.8). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 34.49, 35.31 at 3
rd
 month 
and 33.14 at 6
th
 month (Table 5.4.5.9). It is possible to notice a quite stable trend over 
the period of 6 months for the trial group h-PTI. 
 
As shown on Table 5.4.5.10 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05). As shown on 
Table 5.4.5.11 Wilcoxon’s test shows that there is no statistical difference during all 
three intervals, as well as with all interval considered with the stable-groups (p>0.05). 
It is possible to notice a stable trend over the period of 6 months for the trial group. 
 
Comparison between the Control and the Trial Group (h-
PTI) 
 
As shown in Table 5.4.5.12 results highlighted that there is statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole at baseline (p<0.05*), 3
rd
 month (p<0.01**), and 6
th
 month 
(p<0.05*). In addition, statistical difference was noted also when the stable group was 
considered separately on the 3
rd
 month-6
th
month interval. No statistical difference was 
discovered while using F-scan shod and HR walkway (p>0.05). These data suggest that 
there is a clear trend toward changes that happen between the control and the trial 
group with regards to h-PTI at baseline, 3
rd
 month and 6
th
 month only when FOs were 
worn. 
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Table 5.4.5.12: details of the Mann Whitney Test carried out on Heel-PTI with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Heel – Presurre Integral (h-PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.103 p=0.103 p=0.103 
Stable p=0.103 p=0.103 p=0.103 
Not stable p=0.103 p=0.103 p=0.103 
 
F-Scan – With Insoles p=0.026* p=0.006** p=0.028* 
Stable p=0.123 p=0.021* p=0.438 
Not stable p=0.567 p=0.171 p=0.464 
 
HR Walkway p=0.646 p=0.649 p=0.276 
Stable p=0.939 p=0.541 p=0.823 
Not stable p=0.265 p=0.1 p=0.024 
 
 
Figure 5.4.5.4: boxplot carried out on F-Scan Shod - Heel PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month. 
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Figure 5.4.5.5: boxplot carried out on F-Scan with insole - Heel PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.5.6: boxplot carried out on HR Walkway – Heel PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval. 
 
 
 
 
 
 
 
 
221 
 
5.4.6. Midfoot – contact   
Midfoot - Peak Pressure Values- (m-PP) 
Control Group (m-PP) 
 
With regards to F-scan shod: median value at baseline was 108.33, 99.33 at 3
rd
 month 
and 90.83 at 6
th
 month. 
 
Table 5.4.6.1: descriptive statistics on Midfoot – PP (F-Scan shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
Midfoot – Peak Pressure Values - (m-PP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 108.33(85.75) 99.33(89.83) 90.83(122.75) 93.67(85.09) 106.67(108.33) 112(114.17) 
 
With regards to F-scan With Insole: median value at baseline was 98.5, 99.83 at 3
rd
 
month, and 111.50 at 6
th
 month (Table 5.4.6.2). 
 
Table 5.4.6.2: descriptive statistics on Midfoot – PP (F-Scan-With Insole) data at baseline, 3rd month and 
6
th
 month  (control and trial patients). 
Midfoot – Peak Pressure Values - (m-PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 98.5(106.33) 99.83(130.75) 111.5(123.17) 126.5(100.42) 139.83(130.33) 142(96.75) 
 
With regards to HR Walkway the median value at baseline was 88.50, 84.50 at 3
rd
 
month and 86.67 at 6
th
 month (Table 5.4.6.3). It is possible to notice a stable trend over 
the period of 6 months with some reduction of m-PP values particularly for the F-Scan 
(shod) for the control group (Table 5.4.6.1). 
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Table 5.4.6.3: descriptive statistics on Midfoot – PP (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients) 
Midfoot – Peak Pressure Values - (m-PP)– HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 88.5(52.05) 84.5(55.41) 86.67(52.59) 77(59.83) 81.5(62.58) 73.5(59.17) 
 
As shown on Table 5.4.6.4 the Friedman test shows p>0.05 in all cases; therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained.  
 
Table 5.4.6.4: details of the Friedman test on Midfoot – PP data with F-Scan shod, F-Scan with Insole 
and HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** 
means p<0.01. 
 
Midfoot – Peak Pressure Values - (m-PP) Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.376 p=0.266 
Stable p=0.067 p=0.147 
Not stable p=0.731 p=0.087 
 
F-Scan – With Insoles p=0.343 p=0.972 
Stable p=0.010* p=0.751 
Not stable p=0.204 p=0.229 
 
HR Walkway p=0.188 p=0.072 
Stable p=0.368 p=0.114 
Not stable p=0.462 p=0.444 
 
Table 5.4.6.5 highlighted that all intervals are not significantly different (p>0.05). 
Equally, when the stable group is considered separately the results showed p>0.05, 
therefore, no statistical significance was recorded with F-scan shod, F-scan with insole 
and HR Walkway system. This suggests that there is no statistical difference in m-PP 
for the control group. 
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Table 5.4.6.5: details of the Wilcoxon’s test on Midfoot- PP data with F-Scan shod , F-Scan with insole 
and HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Midfoot – Peak Pressure Values - (mPP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month p=0.978 p=0.633 
3
rd
 month – 6th month p=0.341 p=0.361 
Baseline – 6th month p=0.446 p=0.056 
 
Stable 
Baseline – 3rd month p=0.453 p=0.116 
3
rd
 month – 6th month p=0.027 p=0.707 
Baseline – 6th month p=0.199 p=0.022 
 
 
Not Stable 
Baseline – 3rd month p=0.255 p=0.205 
3
rd
 month – 6th month p=0.124 p=0.408 
Baseline – 6th month p=0.629 p=0.958 
 
F-Scan – With Insoles 
Baseline – 3rd month p=0.698 p=0.464 
3
rd
 month – 6th month p=0.478 p=0.980 
Baseline – 6th month p=0.682 p=0.624 
 
 
Stable 
Baseline – 3rd month p=0.074 p=0.140 
3
rd
 month – 6th month p=0.131 p=0.604 
Baseline – 6th month p=0.581 p=0.477 
 
 
Not Stable 
Baseline – 3rd month p=0.088 p=0.473 
3
rd
 month – 6th month p=0.210 p=0.438 
Baseline – 6th month p=0.981 p=0.717 
 
HR Walkway 
Baseline – 3rd month p=0.123 p=0.443 
3
rd
 month – 6th month p=0.288 p=0.017* 
Baseline – 6th month p=0.851 p=0.355 
 
 
Stable 
Baseline – 3rd month p=0.232 p=0.419 
3
rd
 month – 6th month p=0.724 p=0.027* 
Baseline – 6th month p=0.950 p=0.391 
 
 
Not Stable 
Baseline – 3rd month p=0.322 p=0.796 
3
rd
 month – 6th month p=0.212 p=0.352 
Baseline – 6th month p=0.985 p=0.756 
 
Trial Group (m-PP) 
 
Table 5.4.6.1 within the trial group of the F-scan shod median value at baseline was 
93.67, 106.67 at 3
rd
 month, and 112 at 6
th
 month (Table 5.4.6.1). With regards to F-scan 
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with insole median value at baseline was 126.50, 139.83 at 3
rd
 month, and 142 at 6
th
 
month (Table 5.4.6.2). With regards to HR Walkway, descriptive statistics showed: 
median value at baseline was 77, 81.50 at 3
rd
 month and 73.50 at 6
th
 month (Table 
5.4.6.3). Hence, it is possible to notice a quite stable trend over the period of 6 months 
for the F-scan (shod) and HR Walkway, however, descriptive statistics indicated an 
increase of m-PP with the F-Scan (with insole) data were collected (Table 5.4.6.1).  
 
As shown on Table 5.4.6.4, the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05).  
 
As shown on Table 5.4.6.5 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals, as well as with all intervals considered with the stable-groups 
(p>0.05). It is possible to observe a stable trend within the trial group when the 
equipment was adopted for investigation over the period of 6 months (Table 5.4.6.1).  
 
Comparison between the Control and the Trial Group (m-
PP) 
 
As shown in Table 5.4.6.6 results highlighted that there is statistical difference between 
control and trial patients when investigation were carried out with the F-scan while 
wearing the insole at baseline (p<0.01**), 3
rd
 month (p<0.01**), and 6
th
 month 
(p<0.01**). In addition, statistical difference was noted also when the stable group was 
considered separately. Interestinlgy, no statistical difference was discovered while 
using F-scan shod and HR walkway (p>0.05). These data are indicative of the 
significant peak pressure changes that occur at the midfoot only when the FOs are 
introduced in the JIA shoes (Table 5.4.6.6).  
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Table 5.4.6.6: details of the Mann Whitney Test carried out on Midfoot-PP with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
Midfoot – Peak Pressure Values - (mPP) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.803 p=0.438 p=0.267 
Stable p=0.818 p=0.502 p=0.184 
Not stable p=0.726 p=0.702 p=0.861 
 
F-Scan – With Insoles p=0.013* p=0.017* p=0.044* 
Stable p=0.004** p=0.009** p=0.006** 
Not stable p=0.962 p=0.949 p=0.524 
 
HR Walkway p=0.316 p=0.614 p=0.292 
Stable p=0.624 p=0.362 p=0.466 
Not stable p=0.390 p=0.667 p=0.545 
 
Figure 5.4.6.1: boxplot carried out on F-Scan Shod - Midfoot PP data between control and trial patients 
at baseline, 3
rd
 month and 6
th
 month. 
                  
Figure 5.4.6.2: boxplot carried out on F-Scan with Insole - Midfoot PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
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Figure 5.4.6.3: boxplot carried out on HR Walkway – Midfoot PP data between control and trial patients 
at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
 
 
 
Midfoot - Pressure Time Integral (m-PTI) 
 
Control Group (m-PTI) 
 
With regards to F-scan shod: median value at baseline was 24.44, 23.41 at 3
rd
 month 
and 23.54 at 6
th
 month (Table 5.4.6.7).  
 
Table 5.4.6.7: descriptive statistics on Midfoot – PTI (F-Scan Shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Midfoot – Pressure Time Integral (m-PTI) - F-Scan – Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 24.44(22.18) 23.41(26.39) 23.54(34.56) 26.80(22.36) 22.72(24.61) 30.39(27.61) 
 
With regards to F-scan with Insole: median value at baseline was 22.98, 25.65 at 3
rd
 
month, and 25.83 at 6
th
 month (Table 5.4.6.8).  
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Table 5.4.6.8: descriptive statistics on Midfoot–PTI (with insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Midfoot – Pressure Time Integral (m-PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 22.98(29.55) 25.65(34.92) 25.83(24.76) 32.23(26.66) 34.43(31.03) 33.61(27.41) 
 
With regards to HR Walkway the median value at baseline was 15.33, 13.41 at 3
rd
 
month and 16.34 at 6
th
 month (Table 5.4.6.9). It is possible to notice a stable trend over 
the period of 6 months for the control group. 
 
Table 5.4.6.9: descriptive statistics on Midfoot – PTI (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients).  
 
Midfoot – Pressure Time Integral (m-PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 15.33(9.18) 13.41(6.44) 16.34(9.54) 14.78(10.61) 14.14(13.2) 13.72(10.33) 
 
As shown on (Table 5.4.6.10) Friedman test shows p>0.05 in all cases, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained. The only interval where 
significance difference was met was for the control group of the F-scan with insole, 
similarly from the correspondent stable group p<0.05*. 
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Table 5.4.6.10: details of the Friedman test on Midfoot– PTI data with F-Scan shod, F-Scan with Insole 
and HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** 
means p<0.01. 
 
Midfoot – Pressure Time Integral (m-PTI); Friedman Test  (baseline, 3rd month & 6th 
month) 
 
 Control Trial 
F-Scan - Shod p=0.203 p=0.130 
Stable p=0.007** p=0.225 
Not stable p=0.390 p=0.174 
 
F-Scan – With Insoles p=0.043* p=0.582 
Stable p=0.020* p=0.931 
Not stable p=0.327 p=0.304 
 
HR Walkway p=0.072 p=0.064 
Stable p=0.358 p=0.109 
Not stable p=0.074 p=0.269 
 
Table 5.4.6.11 highlighted that all intervals are not significantly different (p>0.05). 
Interestingly, in the stable control group of the F-scan (shoes and with insole) and the 
HR Walkway, significant changes were found (p>0.05). It is possible to notice a stable 
trend over the period of 6 months for the control group particularly for the F-Scan shod 
and the HR Walkway. Also in this case, it is possible to notice a stable trend over the 
period of 6 months for the control group, with the exception of 3
rd
 month-6
th
month 
interval with the F-Scan (shod & with insole) and HR Walkway. 
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Table 5.4.6.11: : details of the Wilcoxon’s test on Total-PT data with F-Scan shod, F-Scan with insole 
and HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Midfoot – Pressure Time Integral - (m-PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.539 p=0.488 
3
rd
 month – 6th month  p=0.159 p=0.083 
Baseline – 6th month  p=0.672 p=0.261 
 
Stable  
Baseline – 3rd month  p=0.959 p=0.819 
3
rd
 month – 6th month  p=0.012* p=0.073 
Baseline – 6th month  p=0.054 p=0.118 
 
 
Not Stable  
Baseline – 3rd month  p=0.407 p=0.352 
3
rd
 month – 6th month  p=0.407 p=0.796 
Baseline – 6th month  p=0.177 p=0.717 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.727 p=0.860 
3
rd
 month – 6th month  p=0.179 p=0.464 
Baseline – 6th month  p=0.150 p=0.493 
 
 
Stable  
Baseline – 3rd month  p=0.453 p=0.448 
3
rd
 month – 6th month  p=0.004** p=0.474 
Baseline – 6th month  p=0.054 p=0.835 
 
 
Not Stable  
Baseline – 3rd month  p=0.062 p=0.334 
3
rd
 month – 6th month  p=0.149 p=0.326 
Baseline – 6th month  p=0.868 p=0.352 
 
HR Walkway 
Baseline – 3rd month  p=0.082 p=0.804 
3
rd
 month – 6th month  p=0.011* p=0.056 
Baseline – 6th month  p=0.585 p=0.097 
 
 
Stable  
Baseline – 3rd month  p=0.057 p=0.546 
3
rd
 month – 6th month  p=0.140 p=0.254 
Baseline – 6th month  p=0.765 p=0.223 
 
 
Not Stable  
Baseline – 3rd month  p=0.881 p=0.605 
3
rd
 month – 6th month  p=0.028 p=0.07 
Baseline – 6th month  p=0.179 p=0.196 
 
Trial Group (m-PTI) 
 
As shown on Table 5.4.6.7 within the trial group of the F-scan shod the median value at 
baseline was 26.80, 22.72 at 3
rd
 month, and 30.39 at 6
th
 month (Table 5.4.6.7). With 
230 
 
regards to F-scan with insole, median value at baseline was 32.23, 34.43 at 3
rd
 month, 
and 33.61 at 6
th
 month (Table 5.4.6.8). With regards to HR Walkway, descriptive 
statistics showed: median value at baseline was 14.78, 14.14 at 3
rd
 month and 13.72 at 
6
th
 month (Table 5.4.6.9). Therefore, it is possible to notice how the m-PTI was higher 
only when the F-Scan system was used with the FOs inside the shoes, suggesting that 
PTI increased only for the trial groups.  
 
As shown on Table 5.4.6.10 Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group. Statistical difference was not obtained 
(p>0.05) when stable group is considered separately. The non-stable group was found 
to be not significance difference (p>0.05).   
 
As shown on Table 5.4.6.11 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals, as well as with all intervals considered with the stable-groups 
(p>0.05). This suggests that there were no statistical differences in m-PTI over a period 
of the 6 month for the trial group, possibly indicating that FOs did not modify and 
retained its original prescription for the whole duration of the study. 
 
Comparison between the Control and the Trial Group (m-
PTI) 
 
 
As shown in Table 5.4.6.12 results highlighted that there is statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole at baseline (p<0.05*), 3
rd
 month (p<0.05*), and 6
th
 month 
(p<0.05*). In addition, statistical difference was noted also when the stable group was 
considered separately. No statistical difference was discovered while using F-scan shod 
and HR walkway (p>0.05).  Therefore, a clear trend was found between the control and 
the trial FOs only when orthotics were worn, which lasted for all the intervals 
investigated. 
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Table 5.4.6.12: details of the Mann Whitney Test carried out on -PTI with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
Midfoot – Pressure Time Integral - (m-PTI) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.925 p=0.744 p=0.245 
Stable p=0.935 p=0.935 p=0.096 
Not stable p=0.824 p=0.873 p=0.787 
 
F-Scan – With Insoles p=0.015* p=0.028* p=0.012* 
Stable p=0.012* p=0.012* p=0.002** 
Not stable p=0.726 p=0.774 p=0.702 
 
HR Walkway p=0.542 p=0.644 p=0.308 
Stable p=0.523 p=0.634 p=0.525 
Not stable p=0.545 p=0.975 p=0.588 
 
 
Figure 5.4.6.4: boxplot carried out on F-Scan Shod – Midfoot PTI data between control and trial patients 
at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.6.5: boxplot carried out on F-Scan with insole  - Midfoot PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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Figure 5.4.6.6: boxplot carried out on HR Walkway – Midfoot PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval 
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5.4.7. Forefoot – Contact 
Forefoot - Peak Pressure Values- (f-PP) 
 
Control Group (f-PP) 
 
With regards to F-scan shod: median value at baseline was 372, 411.50 at 3
rd
 month 
and 402 at 6
th
 month (Table 5.4.7.1).  
 
Table 5.4.7.1: descriptive statistics on Forefoot – PP (F-Scan-Shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Forefoot – Peak Pressure Values - (f-PP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 372(270.42) 421.5(340.5) 402(345.42) 381.33(338.5) 385.67(373.33) 380(319.17) 
 
With regards to F-scan With Insole: median value at baseline was 333.83, 369.83 at 3
rd
 
month, and 389.17 at 6
th
 month (Table 5.4.7.2).   
 
Table 5.4.7.2: descriptive statistics on Forefoot – PP (With Insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Forefoot – Peak Pressure Values - (f-PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 333.83(301.16) 369.83(277.42) 389.17(278.59) 258.17(267.66) 284(290.5) 340.83(253.25) 
 
With regards to HR Walkway median value at baseline was 305.17, 300.67 at 3
rd
 month 
and 307 at 6
th
 month (Table 5.4.7.3). It is possible to notice a stable trend over the 
period of 6 months for the control group. It is possible to notice a stable trend over the 
period of 6 months for the control group. 
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Table 5.4.7.3: descriptive statistics on Forefoot – PP (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Forefoot – Peak Pressure Values - (f-PP)– HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 305.17(197.91) 300.67(241.5) 307(220.59) 349.10(191.67) 354.13(195.84) 367.93(213.42) 
 
As shown as Table 5.4.7.4 the Friedman test shows p>0.05 in all cases; therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained. It is possible to notice a 
stable trend over the period of 6 months for the control group. 
 
Table 5.4.7.4: details of the Friedman test on Midfoot– PTI data with F-Scan shod, F-Scan with Insole 
and HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** 
means p<0.01. 
 
Forefoot – Peak Pressure Values (f-PP) Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.059 p=0.412 
Stable p=0.163 p=0.393 
Not stable p=0.026 p=0.829 
 
F-Scan – With Insoles p=0.225 p=0.903 
Stable p=0.249 p=0.570 
Not stable p=0.157 p=0.229 
 
HR Walkway p=0.066 p=0.736 
Stable p=0.121 p=0.633 
Not stable p=0.024 p=0.646 
 
Table 5.4.7.5 highlighted that with HR Walkway and the F-scan (shod and with insole) 
were not significantly different (p>0.05) for the control group. Same results were 
obtained with the control-stable group. No statistical significance was recorded with 
any other interval with the F-scan with insole and HR Walkway system. This suggests 
that there were no statistical difference in m-PP for the control group.  
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Table 5.4.7.5: details of the Wilcoxon’s test on  Forefoot-PP data with F-Scan shod, F-Scan with insole 
and HR Walkway (control and trial patients).  * means p<0.05, ** means p<0.01. 
 
Forefoot – Peak Pressure Values - (m-PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.011 p=0.091 
3
rd
 month – 6th month  p=0.775 p=0.671 
Baseline – 6th month  p=0.02 p=0.146 
 
Stable  
Baseline – 3rd month  p=0.031 p=0.174 
3
rd
 month – 6th month  p=0.30 p=0.756 
Baseline – 6th month  p=0.265 p=0.145 
 
 
Not Stable  
Baseline – 3rd month  p=0.218 p=0.234 
3
rd
 month – 6th month  p=0.126 p=0.569 
Baseline – 6th month  p=0.019 p=0.717 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.226 p=0.832 
3
rd
 month – 6th month  p=0.616 p=0.221 
Baseline – 6th month  p=0.125 p=0.603 
 
 
Stable  
Baseline – 3rd month  p=0.065 p=0.604 
3
rd
 month – 6th month  p=0.561 p=0.258 
Baseline – 6th month  p=0.282 p=0.135 
 
 
Not Stable  
Baseline – 3rd month  p=0.681 p=0.069 
3
rd
 month – 6th month  p=0.057 p=0.569 
Baseline – 6th month  p=0.322 p=0.109 
 
HR Walkway 
Baseline – 3rd month  p=0.430 p=0.723 
3
rd
 month – 6th month  p=0.355 p=0.430 
Baseline – 6th month  p=0.103 p=0.197 
 
 
Stable  
Baseline – 3rd month  p=0.048 p=0.223 
3
rd
 month – 6th month  p=0.888 p=0.275 
Baseline – 6th month  p=0.245 p=0.105 
 
 
Not Stable  
Baseline – 3rd month  p=0.156 p=0.255 
3
rd
 month – 6th month  p=0.078 p=0.816 
Baseline – 6th month  p=0.211 p=0.918 
 
Trial Group (f-PP) 
 
As shown on Table 5.4.7.1 within the trial group of the F-scan shod the median value at 
baseline was 381.33, 385.67 at 3
rd
 month, and 380 at 6
th
 month (Table 5.4.7.1). With 
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regards to F-scan with insole, median value at baseline was 258.17, 284 at 3
rd
 month, 
and 340.83 at 6
th
 month (Table 5.4.7.2). With regards to HR Walkway, descriptive 
statistics showed: median value at baseline was 349.10, 354.13 at 3
rd
 month and 367.93 
at 6
th
 month (Table 5.4.7.3). These data suggests that the median m-PP values appeared 
to be lower than without the FOs and HR Walkway. 
  
As shown on Table 5.4.7.4 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05). As shown on 
Table 5.4.7.5 Wilcoxon’s test shows that there is no statistical difference during all 
three intervals, as well as with all interval considered with the stable-groups (p>0.05). 
It is possible to notice a stable trend over the period of 6 months within the trial group. 
 
Comparison between the Control and the Trial Group (f-PP) 
 
As shown in Table 5.4.7.6 results highlighted that there is no statistical difference 
between control and trial patients when investigation were carried out with the F-scan  
(shod and with insole) and HR walkway (p>0.05) over 6 months period of time. This 
suggests that there is not a clear trend toward changes that happen between the control 
and the trial group with regards to m-PP. 
 
Table 5.4.7.6: details of the Mann Whitney Test carried out on Forefoot-PP with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Forefoot – Peak Pressure Values - (mPP) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.211 p=0.590 p=0.755 
Stable p=0.124 p=0.386 p=0.427 
Not stable p=0.975 p=0.849 p=0.567 
 
F-Scan – With Insoles p=0.241 p=0.054 p=0.063 
Stable p=0.458 p=0.153 p=0.329 
Not stable p=0.464 p=0.181 p=0.052 
 
HR Walkway p=0.688 p=0.869 p=0.831 
Stable p=0.829 p=0.808 p=0.772 
Not stable p=0.937 p=0.975 p=0.279 
 
237 
 
 
Figure 5.4.7.1: boxplot carried out on F-Scan Shod – Forefoot PP data between control and trial patients 
at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.7.2: boxplot carried out on F-Scan with insole - Forefoot PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.7.3: boxplot carried out on HR Walkway - Forefoot PP data between control and trial patients 
at baseline, 3
rd
 month and 6
th
 month interval.  
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Forefoot - Pressure Time Integral (f-PTI) 
 
Control Group (f-PTI) 
 
With regards to F-scan shod: median value at baseline was 54.19, 64.51 at 3
rd
 month 
and 58.45 at 6
th
 month for the control group (Table 5.4.7.7). 
 
Table 5.4.7.7: descriptive statistics on Forefoot – PTI (F-Scan Shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Forefoot – Pressure Time Integral (f-PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 54.19(33.06) 64.51(41.26) 58.45(45.23) 50.86(37.56) 60.76(44.26) 61.73(36.47) 
 
With regards to F-scan With Insole: median value at baseline was 55.10, 69.31 at 3
rd
 
month, and 62.39 at 6
th
 month (Table 5.4.7.8). 
 
Table 5.4.7.8: descriptive statistics on Forefoot – PTI (With Insole) data at baseline, 3rd month and 6th 
month (control and trial patients).  
 
Forefoot – Pressure Time Integral (f-PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 55.10(34.29) 69.31(41.11) 62.39(31.55) 47.54(35.26) 49.43(35.66) 53.26(40.04) 
 
With regards to HR Walkway the median value at baseline was 42.06, 40 at 3
rd
 month 
and 40.08 at 6
th
 month (Table 5.4.7.9). It is possible to notice a stable trend over the 
period within the 6 months period of time for the control group. 
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Table 5.4.7.9: descriptive statistics on Forefoot – PTI (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Forefoot – Pressure Time Integral (f-PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 42.06(20.51) 40(22.87) 40.08(21.16) 34.7(28.45) 38.35(28.66) 35.99(24.55) 
 
 
As shown on Table 5.4.7.10 the Friedman test shows p>0.05 in all cases, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained. The only interval where 
significance difference was met was for the control-stable group of the F-scan with 
insole. 
 
Table 5.4.7.10: details of the Friedman test on Forefoot – PTI data with F-Scan shod, F-Scan with Insole 
and HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** 
means p<0.01. 
 
Forefoot – Pressure Time Integral (f-PTI) –- Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.516 p=0.308 
Stable p=0.558 p=0.323 
Not stable p=0.074 p=0.829 
 
F-Scan – With Insoles p=0.235 p=0.819 
Stable p=0.008** p=0.984 
Not stable p=0.212 p=0.556 
 
HR Walkway p=0.143 p=0.865 
Stable p=0.459 p=0.662 
Not stable p=0.004 p=0.779 
 
Table 5.4.7.11 highlighted that all intervals are not significantly different (p>0.05) for 
the control group. Interestingly, in the stable control group of the f-scan (with insole) at 
baseline-3
rd
month interval, significant changes was found (p<0.05). Overall, it is 
possible to notice a stable trend over the period of 6 months for the control group. 
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Table 5.4.7.11: details of the Wilcoxon’s test on Forefoot- PTI data with F-Scan shod, F-Scan with insole 
and HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Forefoot – Pressure Time Integral - (f-PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.105 p=0.127 
3
rd
 month – 6th month  p=0.630 p=0.422 
Baseline – 6th month  p=0.088 p=0.422 
 
Stable  
Baseline – 3rd month  p=0.106 p=0.157 
3
rd
 month – 6th month  p=0.087 p=0.642 
Baseline – 6th month  p=0.509 p=0.403 
 
 
Not Stable  
Baseline – 3rd month  p=0.627 p=0.679 
3
rd
 month – 6th month  p=0.073 p=0.501 
Baseline – 6th month  p=0.030* p=0.959 
 
F-Scan – With Insoles 
Baseline – 3rd month  p=0.200 p=0.90 
3
rd
 month – 6th month  p=0.636 p=0.508 
Baseline – 6th month  p=0.436 p=0.900 
 
 
Stable  
Baseline – 3rd month  p=0.042* p=0.823 
3
rd
 month – 6th month  p=0.053 p=0.866 
Baseline – 6th month  p=0.981 p=0.439 
 
 
Not Stable  
Baseline – 3rd month  p=0.478 p=0.955 
3
rd
 month – 6th month  p=0.04* p=0.379 
Baseline – 6th month  p=0.263 p=0.088 
 
HR Walkway 
Baseline – 3rd month  p=0.359 p=0.880 
3
rd
 month – 6th month  p=0.052 p=0.577 
Baseline – 6th month  p=0.405 p=0.530 
 
 
Stable  
Baseline – 3rd month  p=0.617 p=0.409 
3
rd
 month – 6th month  p=0.981 p=0.523 
Baseline – 6th month  p=0.900 p=0.589 
 
 
Not Stable  
Baseline – 3rd month  p=0.067 p=0.379 
3
rd
 month – 6th month  p=0.001** p=0.796 
Baseline – 6th month  p=0.086 p=0.642 
 
 
Trial Group (f-PTI) 
 
As shown on Table 5.4.7.7 within the trial group of the F-scan shod the median value at 
baseline was 50.86, 60.76 at 3
rd
 month, and 61.73 at 6
th
 month (Table 5.4.7.7). With 
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regards to F-scan with insole, median value at baseline was 47.54, 49.43 at 3
rd
 month, 
and 53.26 at 6
th
 month (Table 5.4.7.8). With regards to HR Walkway, descriptive 
statistics showed: median value at baseline was 34.70, 38.35 at 3
rd
 month and 35.99 at 
6
th
 month (Table 5.4.7.9). It is possible to notice a stable trend over the period of 6 
months for the trial group.  
 
Friedman’s test was carried out; as shown on Table 5.4.7.10 the Friedman test 
displayed a p>0.05; hence, there is no statistical difference within the trial group. 
Statistical difference was not obtained (p>0.05) when stable group is considered 
separately. The non-stable group was found to be not significance difference (p>0.05). 
As shown on Table 5.4.7.11 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals, as well as with all intervals considered with the stable-groups 
(p>0.05).  It is possible to notice a stable-trend over the period of 6 months for the trial 
group with regards to f-PTI. 
 
Comparison between the Control and the Trial Group (f-
PTI) 
 
Results highlighted that there is no statistical difference between control and trial 
patients when investigation were carried out with the F-scan (shod – p>0.05; and with 
insole – p>0.05) and with the HR Walkway (p>0.05). In addition, no statistical 
difference was noted also when the stable group was considered separately. This 
suggests that there is a stable trend toward no changes that happen between the control 
and the trial group with regards to f-PTI. 
 
Table 5.4.7.12: details of the Mann Whitney Test carried out on Forefoot -PT with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Forefoot – Peak Pressure Values- (f-PTI) -Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.446 p=0.813 p=0.914 
Stable p=0.529 p=0.850 p=0.501 
Not stable p=0.774 p=0.633 p=0.524 
 
F-Scan – With Insoles p=0.289 p=0.087 p=0.141 
Stable p=0.189 p=0.051 p=0.416 
Not stable p=0.924 p=0.899 p=0.111 
 
HR Walkway p=0.753 p=0.725 p=0.521 
Stable p=0.374 p=0.822 p=0.524 
Not stable p=0.464 p=0.408 p=0.975 
242 
 
 
Figure 5.4.7.4: boxplot carried out on F-Scan Shod – Forefoot PTI data between control and trial patients 
at baseline, 3
rd
 month and 6
th
 month. 
 
Figure 5.4.7.5: boxplot carried out on F-Scan with insole  - Forefoot PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval 
 
 
Figure 5.4.7.6: boxplot carried out on HR Walkway – Forefoot PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval 
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5.4.8. 5th Metatarsal Head Contact 
5
th
 - Peak Pressure Values- (5
th
 -PP) 
 
Control Group (5
th
- PP) 
 
With regards to F-scan shod: median value at baseline was 158.5, 163 at 3
rd
 month and 
170 at 6
th
 month (Table 5.4.8.1).   
 
Table 5.4.8.1: descriptive statistics on 5
th
 – PP (F-Scan-Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
5
th
 Met. Head – Peak Pressure Values (5th-PP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 158.5(182.92) 163(172.42) 170(129.25) 162.33(142.58) 138.83(111.83) 173.05(166.74) 
 
With regards to F-scan with insole: median value at baseline was 172.33, 187.17at 3
rd
 
month, and 198.83 at 6
th
 month (Table 5.4.8.2). 
 
Table 5.4.8.2: descriptive statistics on 5
th
 – PP (With Insole) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
5
th
 Met. Head – Peak Pressure Values - (5th PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 172.33(171.67) 187.17(182) 198.83(150.67) 115.67(72.33) 149.83(82) 139(121.25) 
 
With regards to HR Walkway the median value at baseline was 130, 115.5 at 3
rd
 month 
and 121.33 at 6
th
 month (Table 5.4.8.3). It is possible to notice a stable trend over the 
period of 6 months for the control group. 
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Table 5.4.8.3: descriptive statistics on 5
th– PP (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
5
th
 Met. Head – Peak Pressure Values (5th-PP) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 130(62.91) 115.5(84.5) 121.33(92) 123.5(101.58) 121.17(102.91) 122.17(107.58) 
 
As shown on Table 5.4.8.4 the Friedman test shows p>0.05 in all intervals; therefore, 
no significance difference is obtained within the control group. Also when only the 
stable group is considered separately the same results are obtained.  
 
Table 5.4.8.4: details of the Friedman test on 5
th
 PP data with F-Scan shod, F-Scan with Insole and HR 
Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
5
th
 Met Head – Peak Pressure Values (5th PP) Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.607 p=0.117 
Stable p=0.303 p=0.024* 
Not stable p=0.287 p=0.144 
 
F-Scan – With Insoles p=0.754 p=0.092 
Stable p=0.378 p=0.138 
Not stable p=0.819 p=0.538 
 
HR Walkway p=0.336 p=0.988 
Stable p=0.353 p=0.671 
Not stable p=0.610 p=0.210 
 
Table 5.4.8.5 highlighted there is no statistical difference within the control groups.  
The only significant results was recorded within the stable group was found for the 
3
rd
month-6
th
 month interval (p<0.05*). No statistical significance was recorded with 
any other interval with the F-scan with insole and HR Walkway system. Therefore, it is 
possible to notice a stable trend over the period of 6 months. 
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Table 5.4.8.5: details of the Wilcoxon’s test on 5th-PP data with F-Scan shod, F-Scan with insole and HR 
Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
5
th
 Met. Head – Peak Pressure Values (5th PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.569 p=0.702 
3
rd
 month – 6th month  p=0.645 p=0.074 
Baseline – 6th month  p=0.613 p=0.061 
 
Stable  
Baseline – 3rd month  p=0.151 p=0.067 
3
rd
 month – 6th month  p=0.036* p=0.190 
Baseline – 6th month  p=0.962 p=0.025* 
 
 
Not Stable  
Baseline – 3rd month  p=0.255 p=0.034* 
3
rd
 month – 6th month  p=0.044* p=0.234 
Baseline – 6th month  p=0.360 p=0.877 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.874 p=0.123 
3
rd
 month – 6th month  p=0.766 p=0.325 
Baseline – 6th month  p=0.910 p=0.068 
 
 
Stable  
Baseline – 3rd month  p=0.722 p=0.097 
3
rd
 month – 6th month  p=0.122 p=0.422 
Baseline – 6th month  p=0.664 p=0.100 
 
 
Not Stable  
Baseline – 3rd month  p=0.502 p=0.865 
3
rd
 month – 6th month  p=0.156 p=0.717 
Baseline – 6th month  p=0.765 p=0.501 
 
HR Walkway 
Baseline – 3rd month  p=0.277 p=0.599 
3
rd
 month – 6th month  p=0.179 p=0.989 
Baseline – 6th month  p=0.633 p=0.757 
 
 
Stable  
Baseline – 3rd month  p=0.237 p=0.516 
3
rd
 month – 6th month  p=0.519 p=0.768 
Baseline – 6th month  p=0.347 p=0.498 
 
 
Not Stable  
Baseline – 3rd month  p=0.779 p=0.056 
3
rd
 month – 6th month  p=0.184 p=0.717 
Baseline – 6th month  p=0.709 p=0.079 
 
Trial Group (5
th
 – PP) 
 
As shown on Table 5.4.8.1 within the trial group of the F-scan shod the median value at 
baseline was 162.33, 138.83 at 3
rd
 month, and 173 at 6
th
 month (Table 5.4.8.1). With 
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regards to F-scan with insole, the median value at baseline was 115.67, 149.83 at 3
rd
 
month, and 139 at 6
th
 month (Table 5.4.8.2). With regards to HR Walkway, descriptive 
statistics showed: median value at baseline was 123.5, 121.17 at 3
rd
 month and 122.17 
at 6
th
 month (Table 5.4.8.3). It is possible to notice a stable trend over the period of 6 
months within the trial group; however, the F-scan with insole clearly recorded a lower 
5
th
-PP compared to the F-scan (shod) measurements. As shown on Table 5.4.8.4 the 
Friedman test displayed a p>0.05 for all intervals; hence, with the only exception for 
the F-Scan (shod) for the stable-trial group (p<0.05*). As shown on Table 5.4.8.5 
Wilcoxon’s test shows that there is no statistical difference during all three intervals, as 
well as with all interval considered with the stable-groups (p>0.05). This suggests that 
overall there were no statistical difference in 5
th
PP for the trial group 
 
Comparison between the Control and the Trial Group (5
th
- 
PP) 
 
As shown in Table 5.4.8.6 results highlighted that there is statistical difference between 
control and trial patients when investigation were carried out with the F-scan while 
wearing the insole at baseline (p<0.01**), 3
rd
 month (p<0.05*), and 6
th
 month 
(p<0.05*). In addition, statistical difference was noted also when the stable group was 
considered,particularly at baseline (p<0.05*) and 3
rd
 month (p<0.05*). On the other 
hand, no statistical difference was discovered while using F-scan shod and HR 
walkway (p>0.05). This suggests that there is a clear trend toward changes that happen 
between the control and the trial group with regards to 5
th
PP, indicating the positive 
effect applied by the FOs in JIA.  
 
Table 5.4.8.6: details of the Mann Whitney Test carried out on 5
th
- PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
5
th
 Met. Head – Peak Pressure Values - (5th-PP) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.799 p=0.35 p=0.981 
Stable p=0.975 p=0.587 p=0.181 
Not stable p=0.886 p=0.111 p=0.086 
 
F-Scan – With Insoles p=0.002** p=0.021* p=0.030* 
Stable p=0.009** p=0.039* p=0.249 
Not stable p=0.07 p=0.181 p=0.048* 
 
HR Walkway p=0.609 p=0.850 p=0.712 
Stable p=0.550 p=0.699 p=0.970 
Not stable p=0.937 p=0.750 p=0.599 
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Figure 5.4.8.1: boxplot carried out on F-Scan Shod – 5th met .head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.8.2: boxplot carried out on F-Scan with insole  - 5
th
 met. head PP data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval 
 
Figure 5.4.8.3: boxplot carried out on HR Walkway – 5th met. head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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5
th
 - Pressure Time Integral (5
th
 -PTI) 
Control Group (5
th
 –PTI) 
 
With regards to F-scan shod: median value at baseline was 42.90, 45.06 at 3
rd
 month 
and 38.14 at 6
th
 month (Table 5.4.8.7).   
 
Table 5.4.8.7: descriptive statistics on 5
th –PTI (F-Scan Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
5
th
 Met. Head – Pressure Time Integral (5th- PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 42.90(40.83) 45.06(44.77) 38.14(43.98) 36.79(35.45) 40.35(31.98) 42.61(59.08) 
 
With regards to F-scan With Insole: median value at baseline was 52.91, 42.70 at 3
rd
 
month, and 46.78 at 6
th
 month (Table 5.4.8.8).  
 
Table 5.4.8.8: descriptive statistics on 5
th
 – PTI (F-Scan- with insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
5
th
 Met. Head – Pressure Time Integral (5th - PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 52.91(53.31) 42.70(49.65) 46.78(50.42) 35.23(26) 38.09(23.85) 38.78(30.43) 
 
With regards to HR Walkway the median value at baseline was 33.82, 32.88 at 3
rd
 
month and 35.14 at 6
th
 month (Table 5.4.8.9). It is possible to notice a stable trend over 
the period of 6 months. 
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Table 5.4.8.9: descriptive statistics on 5
th
 – PTI (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
5
th
 Met. Head – Pressure Time Integral (5th-PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 33.82(20.93) 32.88(17.97) 35.14(25.24) 33.57(29.58) 34.83(32.9) 32.17(31.9) 
 
As shown on Table 5.4.8.10 the Friedman test shows p>0.05 in all cases for the control 
group. Therefore, no significance difference is obtained within the control group. Also 
when only the stable group is considered separately the same results are obtained 
(p>0.05) with the only exception for the non-stable group (p<0.05*). 
 
Table 5.4.8.10: details of the Friedman test on 5
th 
-PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
5
th
 Met. Head – Pressure Time Integral (5th-PTI) - Friedman Test  (baseline, 3rd month & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.882 p=0.637 
Stable p=0.303 p=0.094 
Not stable p=0.026* p=0.028* 
 
F-Scan – With Insoles p=0.793 p=0.949 
Stable p=0.558 p=0.770 
Not stable p=0.819 p=0.314 
 
HR Walkway p=0.115 p=0.351 
Stable p=0.184 p=0.142 
Not stable p=0.706 p=0.444 
 
Table 5.4.8.11 highlighted that most intervals are not significantly different (p>0.05). 
During the interval within 3
rd
month-6
th
month for the stable control group of the F-Scan 
(shod) and the HR Walkway, significant changes were found (p<0.05*). This suggests 
that there were no statistical difference in 5
th
 PTI. 
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Table 5.4.8.11: details of the Wilcoxon’s test on 5th- PTI data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
5
th
 Met. Head – Pressure Time Integral (5th-PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.935 p=0.936 
3
rd
 month – 6th month  p=0.707 p=0.083 
Baseline – 6th month  p=0.858 p=0.206 
 
Stable  
Baseline – 3rd month  p=0.404 p=0.102 
3
rd
 month – 6th month  p=0.04* p=0.249 
Baseline – 6th month  p=0.162 p=0.061 
 
 
Not Stable  
Baseline – 3rd month  p=0.332 p=0.004** 
3
rd
 month – 6th month  p=0.021 p=0.163 
Baseline – 6th month  p=0.100 p=0.379 
 
F-Scan – With Insoles 
Baseline – 3rd month  p=0.277 p=0.877 
3
rd
 month – 6th month  p=0.607 p=0.919 
Baseline – 6th month  p=0.374 p=0.455 
 
 
Stable  
Baseline – 3rd month  p=0.658 p=0.502 
3
rd
 month – 6th month  p=0.093 p=0.611 
Baseline – 6th month  p=0.285 p=0.428 
 
 
Not Stable  
Baseline – 3rd month  p=0.279 p=0.112 
3
rd
 month – 6th month  p=0.191 p=0.179 
Baseline – 6th month  p=0.940 p=0.796 
 
HR Walkway 
Baseline – 3rd month  p=0.607 p=0.952 
3
rd
 month – 6th month  p=0.038* p=0.276 
Baseline – 6th month  p=0.378 p=0.208 
 
 
Stable  
Baseline – 3rd month  p=0.286 p=0.650 
3
rd
 month – 6th month  p=0.198 p=0.581 
Baseline – 6th month  p=0.900 p=0.978 
 
 
Not Stable  
Baseline – 3rd month  p=0.627 p=0.379 
3
rd
 month – 6th month  p=0.100 p=0.234 
Baseline – 6th month  p=0.100 p=0.015 
 
Trial Group (5
th
 – PTI) 
 
As shown on Table 5.4.8.7 within the trial group of the F-scan shod the median value at 
baseline was 36.79, 40.35 at 3
rd
 month, and 42.61 at 6
th
 month (Table 5.4.8.7). With 
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regards to F-scan with insole, the median value at baseline was 35.23, 38.09 at 3
rd
 
month, and 38.78 at 6
th
 month (Table 5.4.8.8). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 33.57, 34.83 at 3
rd
 month 
and 32.17 at 6
th
 month (Table 5.4.8.9). It is possible to notice a stable trend over the 
period of 6 months but lower compared to the control group. 
 
As shown on Table 5.4.8.10 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05). As shown on 
Table 5.4.8.11 Wilcoxon’s test shows that there is no statistical difference during all 
three intervals, as well as with all intervals considered with the stable-groups (p>0.05).  
 
Comparison between the Control and the Trial Group (5
th
 –
PTI) 
 
As shown in Table 5.4.8.12 highlighted that there is statistical difference between 
control and trial patients when investigation were carried out only with the F-scan (with 
insole) particularly at baseline recordings (p<0.05*). In addition, statistical difference 
was noted as well when the stable group was analysed separately at baseline. This 
suggests that there is a clear trend toward changes that happen between the control and 
the trial group with regards to 5
th
-PTI particularly at baseline, however, these changed 
were not attained at 3
rd
month and 6
th
month. 
 
Table 5.4.8.12: details of the Mann Whitney Test carried out on 5
th
-PTI with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
5
th
 Met. Head – Pressure Time Integral (5th-PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.581 p=0.386 p=0.996 
Stable p=0.679 p=0.693 p=0.167 
Not stable p=0.975 p=0.104 p=0.065 
 
F-Scan – With Insoles p=0.016* p=0.093 p=0.071 
Stable p=0.015* p=0.138 p=0.232 
Not stable p=0.390 p=0.426 p=0.203 
 
HR Walkway p=0.671 p=0.549 p=0.397 
Stable p=0.350 p=0.693 p=0.581 
Not stable p=0.633 p=0.545 p=0.610 
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Figure 5.4.8.4: boxplot carried out on F-Scan Shod - PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.8.5: boxplot carried out on F-Scan with insole  - 5
th
 met. head PTI data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.8.6: boxplot carried out on HR Walkway – 5th met. head PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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5.4.9. 3rd / 4th – Metatarsal Head – Contact  
3
rd
 / 4
th
 - Peak Pressure Values- (3
rd
/4
th
 -PP) 
 
Control Group (3
rd
/4
th
 – PP) 
 
With regards to F-scan shod: the median value at baseline was 249.83, 299.50 at 3
rd
 
month and 263.17 at 6
th
 month (Table 5.4.9.1). 
 
Table 5.4.9.1: descriptive statistics on 3
rd
/4
th
 – PP (F-Scan-shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
3
rd
/4
th
 Met. Head – Peak Pressure Values (3rd/4th -PP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 249.83(220.17) 299.5(326.34) 263.17(265.75) 268.67(248.17) 285.33(311.75) 280.87(162.58) 
 
With regards to F-scan With Insole: the median value at baseline was 249.50, 289.83 at 
3
rd
 month, and 295.50 at 6
th
 month (Table 5.4.9.2). 
 
Table 5.4.9.2: descriptive statistics on 3
rd
/4
th
 – PP (F-Scan-With Insole) data at baseline, 3rd month and 
6
th
 month (control and trial patients). 
 
3
rd
/4
th
 Met. Head – Peak Pressure Values - (3rd/4th PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 249.5(272.92) 289.83(225.92) 295.50(251.33) 197(221.16) 197.67(171.59) 232.5(171.91) 
 
With regards to HR Walkway the median value at baseline was 199.83, 196.33 at 3
rd
 
month and 187 at 6
th
 month (Table 5.4.9.3). It is possible to notice a stable trend over 
the period of 6 months for the control group. 
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Table 5.4.9.3: descriptive statistics on 3
rd
/4
th
 – PP (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
3
rd
/4
th
 Met. Head – Peak Pressure Values (3rd/4th- PP) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 199.83(134.67) 196.33(136.83) 187(147.91) 183.5(133.66) 201.67(111.33) 199.67(98.42) 
 
As shown on Table 5.4.9.4 the Friedman test shows p<0.05* for the F-scan (shod) also 
for the stable group (p<0.05*). Instead, in all other cases, no significance difference is 
obtained within the control group for the F-scan (with insole) and HR Walkway 
(p>0.05).  
Table 5.4.9.4: details of the Friedman test on 3rd/4th - PP data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
3
rd
/4
th
 Met Head – Peak Pressure Values (3rd/4th PP) Friedman Test  (baseline, 3rd & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.005** p=0.500 
Stable p=0.008** p=0.544 
Not stable p=0.247 p=0.829 
 
F-Scan – With Insoles p=0.272 p=0.819 
Stable p=0.184 p=0.570 
Not stable p=0.449 p=0.403 
 
HR Walkway p=0.659 p=0.551 
Stable p=0.499 p=0.551 
Not stable p=0.009** p=0.939 
 
Table 5.4.9.5 highlighted there is no statistical difference within the control groups. 
The only significant results was recorded within the baseline-3
rd
month interval 
(p<0.05*) also for the stable group. No statistical significance was recorded with any 
other interval with the F-scan with insole and HR Walkway system (p>0.05). It is 
possible to notice a stable trend over the period of 6 months for the control group, 
excluding the F-scan (shod) at baseline. 
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Table 5.4.9.5: details of the Wilcoxon’s test on 3rd/4th- PP data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
3
rd
/4
th
 Met. Head – Peak Pressure Values (3rd/4th PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.002** p=0.239 
3
rd
 month – 6th month  p=0.302 p=0.776 
Baseline – 6th month  p=0.066 p=0.472 
 
Stable  
Baseline – 3rd month  p=0.009** p=0.186 
3
rd
 month – 6th month  p=0.056 p=0.917 
Baseline – 6th month  p=0.326 p=0.170 
 
 
Not Stable  
Baseline – 3rd month  p=0.108 p=0.796 
3
rd
 month – 6th month  p=0.550 p=0.438 
Baseline – 6th month  p=0.086 p=0.326 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.580 p=0.796 
3
rd
 month – 6th month  p=0.732 p=0.232 
Baseline – 6th month  p=0.136 p=0.689 
 
 
Stable  
Baseline – 3rd month  p=0.567 p=0.801 
3
rd
 month – 6th month  p=0.802 p=0.095 
Baseline – 6th month  p=0.093 p=0.265 
 
 
Not Stable  
Baseline – 3rd month  p=0.852 p=0.910 
3
rd
 month – 6th month  p=0.332 p=0.605 
Baseline – 6th month  p=0.601 p=0.196 
 
HR Walkway 
Baseline – 3rd month  p=0.807 p=0.710 
3
rd
 month – 6th month  p=0.463 p=0.997 
Baseline – 6th month  p=0.899 p=0.258 
 
 
Stable  
Baseline – 3rd month  p=0.303 p=0.299 
3
rd
 month – 6th month  p=0.338 p=0.697 
Baseline – 6th month  p=0.649 p=0.109 
 
 
Not Stable  
Baseline – 3rd month  p=0.067 p=0.352 
3
rd
 month – 6th month  p=0.027* p=0.642 
Baseline – 6th month  p=0.723 p=0.717 
 
Trial Group (3
rd
/4
th – PP) 
 
As shown on Table 5.4.9.1 within the trial group of the F-scan shod the median value at 
baseline was 268.67, 285.33 at 3
rd
 month, and 280.87 at 6
th
 month (Table 5.4.9.1). With 
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regards to F-scan with insole, the median value at baseline was 197, 197.67 at 3
rd
 
month, and 232.5 at 6
th
 month (Table 5.4.9.2). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 183.5, 201.67 at 3
rd
 month 
and 199.67 at 6
th
 month (Table 5.4.9.3).  It is possible to notice a stable trend over the 
period of 6 months for the trial group. As shown on Table 5.4.9.4 the Friedman test 
displayed a p>0.05 hence there is no statistical difference within the trial group 
compared to the control group. As shown on Table 5.4.9.5 Wilcoxon’s test shows that 
there is no statistical difference during all three intervals, as well as with all interval 
considered with the stable-groups (p>0.05).  
 
Comparison between the Control and the Trial Group 
(3
rd
/4
th
 – PP) 
 
 
As shown in Table 5.4.9.6 results highlighted that there is statistical difference between 
control and trial patients when investigation were carried out with the F-scan while 
wearing the insole at 3
rd
 month (p<0.05*), and 6
th
 month (p<0.05*). No statistical 
difference was discovered while using F-scan shod and HR walkway (p>0.05) in any of 
the intervals investigated. This suggests that there is a clear trend toward changes that 
happen between the control and the trial group with regards to 3
rd
/4
th
-PP that become 
particularly evident after 3 and 6 months after initial supply of the FOs. 
 
 
Table 5.4.9.6: details of the Mann Whitney Test carried out on 3
rd
/4
th
-PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
3
rd
/4
th
 Met. Head – Peak Pressure Values - (3rd/4th -PP) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.157 p=0.931 p=0.983 
Stable p=0.095 p=0.719 p=0.340 
Not stable p=0.702 p=0.836 p=0.340 
 
F-Scan – With Insoles p=0.355 p=0.031* p=0.046* 
Stable p=0.683 p=0.067 p=0.144 
Not stable p=0.524 p=0.279 p=0.086 
 
HR Walkway p=0.478 p=0.952 p=0.867 
Stable p=0.448 p=0.875 p=0.914 
Not stable p=0.911 p=0.924 p=0.750 
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Figure 5.4.9.1: boxplot carried out on F-Scan Shod – 3rd-4th met. head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.9.2: boxplot carried out on F-Scan with insole - 3
rd
-4
th
 met. head PP data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
 
Figure 5.4.9.3: boxplot carried out on HR Walkway - 3
rd
-4
th
 met. head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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3
rd
 / 4
th
 - Pressure Time Integral (3
rd
/4
th
 -PTI) 
Control Group (3
rd
/4
th
 – PTI) 
 
With regards to F-scan shod: the median value at baseline was 53.30, 71.81 at 3
rd
 
month and 59.98 at 6
th
 month (Table 5.4.9.7). 
 
Table 5.4.9.7: descriptive statistics on 3
rd
/4
th
 – PTI (F-Scan-Shod) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
3
rd
/4
th
 Met. Head – Pressure Time Integral (3rd/4th - PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 53.30(55.48) 71.81(63.78) 59.98(55.91) 56.69(42.84) 55.97(66.96) 62.79(50.5) 
 
With regards to F-scan With Insole: the median value at baseline was 60.42, 66.25 at 
3
rd
 month, and 68.86 at 6
th
 month (Table 5.4.9.8).  
Table 5.4.9.8: descriptive statistics on 3
rd
/4
th
 – PTI (F-Scan-With Insole) data at baseline, 3rd month and 
6
th
 month (control and trial patients). 
 
3
rd
/4
th
 Met. Head – Pressure Time Integral (3rd/4th- PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 60.42(54.81) 66.25(55.44) 68.86(50.31) 49.94(39.19) 50.29(43.66) 54.79(44.2) 
 
With regards to HR Walkway the median value at baseline was 46.93(83.55), 
44.74(173.91) at 3
rd
 month and 47.88(80.25) at 6
th
 month (Table 5.4.9.9). It is possible 
to notice a stable trend over the period of 6 month for the control group. 
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Table 5.4.9.9: descriptive statistics on 3
rd
/4
th
 – PTI (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
3
rd
/4
th
 Met. Head – Pressure Time Integral (3rd/4th -PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 46.93(30.96) 44.74(37.49) 47.88(32.21) 41.14(45.04) 43.77(39.07) 42.21(37.73) 
 
As shown on Table 5.4.9.10 the Friedman test shows p>0.05 in all cases, therefore, no 
significance difference is obtained within the control group. Also when only the stable 
group is considered separately the same results are obtained (p>0.05). The only 
exception occurred with the F-Scan (shod) (p<0.05*). 
 
Table 5.4.9.10: details of the Friedman test on 3
rd
/4
th– PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
3
rd
/4
th
 Met. Head – Pressure Time Integral (3rd/4th -PTI) - Friedman  
 Control Trial 
F-Scan - Shod p=0.032* p=0.551 
Stable p=0.057 p=0.323 
Not stable p=0.142 p=0.829 
 
F-Scan – With Insoles p=0.687 p=0.533 
Stable p=0.358 p=0.822 
Not stable p=0.705 p=0.269 
 
HR Walkway p=0.109 p=0.598 
Stable p=0.717 p=0.494 
Not stable p=0.022 p=0.939 
 
Table 5.4.9.11 highlighted that most intervals are not significantly different (p>0.05). 
Significant changes were only found with F-Scan (Shod) at baseline-3
rd
month 
(p<0.05*) also for its correspondent stable group only (p<0.05*). During the interval 
within 3
rd
month-6
th
month for the stable control group of the F-Scan (shod) and the HR 
Walkway, significant changes were found (p<0.05*). It is possible to notice a quite 
unclear trend over the period of 6 months for the 3
rd
/4
th
 PTI. 
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Table 5.4.9.11: details of the Wilcoxon’s test on Total-PT data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
3
rd
/4
th
 Met. Head – Pressure Time Integral (3rd/4th -PTI) - Wilcoxon’s 
Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.018 p=0.858 
3
rd
 month – 6th month  p=0.296 p=0.597 
Baseline – 6th month  p=0.066 p=0.285 
 
Stable  
Baseline – 3rd month  p=0.020* p=0.806 
3
rd
 month – 6th month  p=0.021* p=0.650 
Baseline – 6th month  p=0.172 p=0.096 
 
 
Not Stable  
Baseline – 3rd month  p=0.601 p=0.438 
3
rd
 month – 6th month  p=0.247 p=0.796 
Baseline – 6th month  p=0.135 p=0.605 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.719 p=0.558 
3
rd
 month – 6th month  p=0.304 p=0.980 
Baseline – 6th month  p=0.660 p=0.592 
 
 
Stable  
Baseline – 3rd month  p=0.280 p=0.883 
3
rd
 month – 6th month  p=0.167 p=0.909 
Baseline – 6th month  p=0.10 p=0.978 
 
 
Not Stable  
Baseline – 3rd month  p=0.411 p=0.109 
3
rd
 month – 6th month  p=0.852 p=0.836 
Baseline – 6th month  p=0.526 p=0.352 
 
HR Walkway 
Baseline – 3rd month  p=0.580 p=0.809 
3
rd
 month – 6th month  p=0.190 p=0.638 
Baseline – 6th month  p=0.310 p=0.875 
 
 
Stable  
Baseline – 3rd month  p=0.500 p=0.650 
3
rd
 month – 6th month  p=1.00 p=0.578 
Baseline – 6th month  p=0.881 p=0.674 
 
 
Not Stable  
Baseline – 3rd month  p=0.940 p=0.877 
3
rd
 month – 6th month  p=0.023* p=0.959 
Baseline – 6th month  p=0.117 p=0.278 
 
Trial Group (3
rd
/4
th – PTI) 
 
As shown on Table 5.4.9.7 within the trial group of the F-scan shod all appointments 
were carried out over the whole duration of the trial, and no missing data was recorded: 
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the median value at baseline was 56.69, 55.97 at 3
rd
 month, and 62.79 at 6
th
 month 
(Table 5.4.9.7). With regards to F-scan with insole, the median value at baseline was 
49.94, 50.29 at 3
rd
 month, and 54.79 at 6
th
 month (Table 5.4.9.8). With regards to HR 
Walkway, the median value at baseline was 41.14, 43.77 at 3
rd
 month and 42.21 at 6
th
 
month (Table 5.4.9.9). It is possible to notice a stable trend over the period of 6 months 
for the trial group. 
 
As shown on Table 5.4.9.10 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group compared to the control group. Statistical 
difference was not obtained (p>0.05) when stable group is considered separately. The 
non-stable group was found to be not significance difference (p>0.05). As shown on 
Table 5.4.9.11  Wilcoxon’s test shows that there is no statistical difference during all 
three intervals, as well as with all intervals considered with the stable-groups (p>0.05). 
It is possible to notice a stable trend over the period of 6 months. 
 
Comparison between the Control and the Trial Group 
(3
rd
/4
th
 – PTI) 
 
Mann Whitney Test highlighted that there is no statistical difference between control 
and trial patients when investigation were carried out with the F-scan (shod & with 
insole). Statistical difference was noted at 3
rd
 month only with the stable F-scan (with 
insole) group. This suggests that there is a clear trend toward changes that happen 
between the control and the trial group with regards to 3
rd
/4
th
-PTI. 
 
Table 5.4.9.12: details of the Mann Whitney Test carried out on 3
rd
/4
th
 – PTI with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
3
rd
/4
th
 Met. Head – Pressure Time Integral (3rd/4th -PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.146 p=0.731 p=0.755 
Stable p=0.189 p=0.703 p=0.385 
Not stable p=0.390 p=0.975 p=0.504 
 
F-Scan – With Insoles p=0.248 p=0.052 p=0.174 
Stable p=0.336 p=0.033* p=0.161 
Not stable p=0.874 p=0.726 p=0.774 
 
HR Walkway p=0.672 p=0.996 p=0.592 
Stable p=0.259 p=0.450 p=0.372 
Not stable p=0.408 p=0.226 p=0.524 
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Figure 5.4.9.4: boxplot carried out on F-Scan Shod – 3rd-4th month PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.9.5: boxplot carried out on F-Scan with insole  - 3
rd
-4
th
 month PTI data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.9.6: boxplot carried out on HR Walkway – Total PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval. 
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5.4.10. 2nd Metatarsal Head – Contact  
2
nd
 - Peak Pressure Values- (2
nd
 -PP) 
Control Group (2
nd
 –PP) 
 
With regards to F-scan shod: the median (IQR) value at baseline was 223.17, 286 at 3
rd
 
month and 302 at 6
th
 month (Table 5.4.10.1). 
Table 5.4.10.1: descriptive statistics on 2
nd
 – PP (F-Scan Shod) data at baseline, 3rd month and 6th month 
(control and trial patients) 
 
2
nd 
Met. Head – Peak Pressure Values (2nd -PP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 223.17(264.09) 286(315.16) 302(384.33) 302.17(278.83) 314.5(372.58) 320.5(335.92) 
 
With regards to F-scan With Insole: median value at baseline was 237, 288.67 at 3
rd
 
month, and 332.17 at 6
th
 month (Table 5.4.10.2). 
 
Table 5.4.10.2: descriptive statistics on 2
nd
 – PP(F-Scan With Insole) data at baseline, 3rd month and 6th 
month (control and trial patients) 
 
2
nd
 Met. Head – Peak Pressure Values- (2nd PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 237(269.5) 288.67(249.5) 332.17(286.59) 221.17(228.75) 246.83(189.67) 230.83(229.92) 
 
With regards to HR Walkway the median value at baseline was 226.5, 208 at 3
rd
 month 
and 218 at 6
th
 month (Table 5.4.10.3). It is possible to notice a stable trend over the 
period of 6 months for the control group for the HR Walkway measurements only. 
Instead, the F-scan (insole and shod) measurements did not seem to have a stable trend. 
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Table 5.4.10.3: descriptive statistics on 2
nd
 – PP(HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients) 
 
2
nd
 Met. Head – Peak Pressure Values(2nd- PP) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 226.5(166.75) 208(182.59) 218(179.16) 221.83(151.17) 221.67(170.58) 222.17(193) 
 
As shown on Table 5.4.10.4 the Friedman test shows p<0.05* for the F-scan Shod 
(p<0.05*). Instead, in all other cases, no significance difference is obtained within the 
control group for the F-scan with insole (p>0.05), and HR Walkway (p>0.05).  
 
Table 5.4.10.4: details of the Friedman test on 2
nd
 – PP data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
2
nd
 Met Head – Peak Pressure Values (2nd PP) Friedman Test  (baseline, 3rd & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.013* p=0.675 
Stable p=0.307 p=0.457 
Not stable p=0.004** p=0.814 
 
F-Scan – With Insoles p=0.019* p=0.904 
Stable p=0.205 p=0.266 
Not stable p=0.019* p=0.110 
 
HR Walkway p=0.241 p=0.432 
Stable p=0.823 p=0.544 
Not stable p=0.004** p=0.779 
 
Table 5.4.10.5 highlighted there is statistical difference within the control groups with 
F-scan (shod) at baseline-3
rd
month (p<0.05*) and baseline-6
th
 month; with F-Scan 
(with insole) at baseline-6
th 
month (p<0.05*); and HR Walkway at 3
rd
month-6
th
month. 
It is possible to notice a not stable trend over the period of 6 months for the control 
group. 
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Table 5.4.10.5: details of the Wilcoxon’s test on 2nd-PP data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
  
2
nd
 Met. Head – Peak Pressure Values(2nd PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.039* p=0.191 
3
rd
 month – 6th month  p=0.340 p=0.860 
Baseline – 6th month  p=0.008** p=0.430 
 
Stable  
Baseline – 3rd month  p=0.107 p=0.08 
3
rd
 month – 6th month  p=0.414 p=0.996 
Baseline – 6th month  p=0.213 p=0.345 
 
 
Not Stable  
Baseline – 3rd month  p=0.232 p=0.335 
3
rd
 month – 6th month  p=0.017* p=0.865 
Baseline – 6th month  p=0.009** p=0.959 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.267 p=0.318 
3
rd
 month – 6th month  p=0.091 p=0.705 
Baseline – 6th month  p=0.021* p=0.274 
 
 
Stable  
Baseline – 3rd month  p=0.049 p=0.160 
3
rd
 month – 6th month  p=0.962 p=0.474 
Baseline – 6th month  p=0.153 p=0.042 
 
 
Not Stable  
Baseline – 3rd month  p=0.313 p=0244 
3
rd
 month – 6th month  p=0.02* p=0.605 
Baseline – 6th month  p=0.048* p=0.098 
 
HR Walkway 
Baseline – 3rd month  p=0.159 p=0.195 
3
rd
 month – 6th month  p=0.025* p=0.983 
Baseline – 6th month  p=0.899 p=0.121 
 
 
Stable  
Baseline – 3rd month  p=0.425 p=0.353 
3
rd
 month – 6th month  p=0.771 p=0.694 
Baseline – 6th month  p=0.753 p=0.221 
 
 
Not Stable  
Baseline – 3rd month  p=0.002** p=0.379 
3
rd
 month – 6th month  p=0.002** p=0.501 
Baseline – 6th month  p=0.478 p=0.326 
 
Trial Group (2
nd – PP) 
 
As shown on Table 5.4.10.1 within the trial group of the F-scan shod the median value 
at baseline was 302.27, 314.5 at 3
rd
 month, and 320.5 at 6
th
 month (Table 5.4.10.1). 
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With regards to F-scan with insole, the median value at baseline was 221.17, 246.83 at 
3
rd
 month, and 230.83 at 6
th
 month (Table 5.4.10.2). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 221.83, 221.67 at 3
rd
 month 
and 222.17 at 6
th
 month (Table 5.4.10.3).  It is possible to notice a stable trend over the 
period of 6 months for the trial group. Also the values of the F-Scan (with insole) 
clearly appeared lower than those with F-Scan (shod). 
 
As shown on Table 5.4.10.4 the Friedman test displayed a p>0.05, hence there is no 
statistical difference within the trial group compared to the control group. As shown on 
Table 5.4.10.5 Wilcoxon’s test shows that there is no statistical difference during all 
three intervals, as well as with all interval considered with the stable-groups (p>0.05). 
It is possible to notice a stable trend over the period of 6 months for the trial group. 
 
Comparison between the Control and the Trial Group (2
nd
 –
PP) 
 
As shown in Table 5.4.10.6 results highlighted that there is statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole at 6
th
 month (p<0.05*). No statistical difference was 
discovered while using F-scan shod and HR walkway (p>0.05) in any of the intervals 
investigated. This suggests that only at 6
th
 month with the F-Scan (with insole) there is 
a clear trend towards changes that happen between the control and the trial group with 
regards to 2
nd
-PP. 
 
Table 5.4.10.6: details of the Mann Whitney Test carried out on 2
nd
-PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
2
nd
 Met. Head – Peak Pressure Values - (2nd -PP) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.062 p=0.289 p=0.620 
Stable p=0.078 p=0.199 p=0.313 
Not stable p=0.514 p=0.975 p=0.975 
 
F-Scan – With Insoles p=0.401 p=0.291 p=0.017* 
Stable p=0.673 p=0.429 p=0.154 
Not stable p=0.514 p=0.426 p=0.042 
 
HR Walkway p=0.891 p=0.306 p=0.465 
Stable p=0.826 p=0.500 p=0.357 
Not stable p=0.667 p=0.265 p=0.899 
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Figure 5.4.10.1: boxplot carried out on F-Scan Shod – 2nd met. head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.10.2: boxplot carried out on F-Scan with insole – 2nd met. head PP data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval 
 
 
Figure 5.4.10.3: boxplot carried out on HR Walkway – 2nd met. head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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2
nd 
- Pressure Time Integral (2
nd
 -PTI) 
Control Group (2
nd
 – PTI) 
 
With regards to F-scan shod: the median value at baseline was 49.77, 70.59 at 3
rd
 
month and 63.69 at 6
th
 month (Table 5.4.10.7).  
 
Table 5.4.10.7: descriptive statistics on 2
nd
 – PTI (F-Scan-Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
2
nd
 Met. Head – Pressure Time Integral (2nd - PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 49.77(64.18) 70.59(63.2) 63.69(68.45) 63.03(49.71) 56.34(75.09) 65.13(59.47) 
 
With regards to F-scan With Insole: the median value at baseline was 58.03, 60.61 at 
3
rd
 month, and 72.07 at 6
th
 month (Table 5.4.10.8).  
 
Table 5.4.10.8: descriptive statistics on  2
nd– PTI (F-Scan-with insole) data at baseline, 3rd month and 6th 
month (control and trial patients) 
 
2
nd
 Met. Head – Pressure Time Integral (2nd- PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 58.03(57.11) 60.61(59.68) 72.07(62.59) 48.93(50.8) 53.96(56.29) 49.37(56.29) 
 
With regards to HR Walkway the median value at baseline was 55.85, 49.75 at 3
rd
 
month and 52.91 at 6
th
 month (Table 5.4.10.9). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
 
 
 
 
 
 
269 
 
Table 5.4.10.9: descriptive statistics on 2
nd
 – PTI (HR Walkway) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
2
nd
 Met. Head – Pressure Time Integral (2nd -PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 55.85(38.63) 49.75(38.17) 52.91(30.01) 49.24(36.43) 53.63(42.14) 45.83(38.14) 
 
As shown on Table 5.4.10.10 the Friedman test shows p<0.05* only for the HR 
Walkway (also for the stable group). The rest of the tests showed p>0.05. It is possible 
to notice a stable trend over the period of 6 months for the control group with the 
exception of HR Walkaway data.  
 
Table 5.4.10.10: details of the Friedman test on 2
nd– PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01.  
 
2
nd
 Met. Head – Pressure Time Integral (2nd -PTI) - Friedman  
 Control Trial 
F-Scan - Shod p=0.793 p=0.686 
Stable p=0.823 p=0.344 
Not stable p=0.142 p=0.459 
 
F-Scan – With Insoles p=0.302 p=0.713 
Stable p=0.697 p=0.393 
Not stable p=0.605 p=0.039* 
 
HR Walkway p=0.047* p=0.736 
Stable p=0.697 p=0.706 
Not stable p=0.008** p=0.829 
 
Table 5.4.10.11 highlighted that most intervals are not significantly different (p>0.05). 
It is possible to notice a stable trend over the period of 6 months for the control group.  
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Table 5.4.10.11: details of the Wilcoxon’s test on 2nd-PTI data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
2
nd
 Met. Head – Pressure Time Integral (2nd -PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.898 p=0.499 
3
rd
 month – 6th month  p=0.732 p=0.432 
Baseline – 6th month  p=0.260 p=0.611 
 
Stable  
Baseline – 3rd month  p=0.833 p=0.223 
3
rd
 month – 6th month  p=0.346 p=0.461 
Baseline – 6th month  p=0.789 p=0.317 
 
 
Not Stable  
Baseline – 3rd month  p=0.881 p=0.326 
3
rd
 month – 6th month  p=0.044 p=0.776 
Baseline – 6th month  p=0.100 p=0.501 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.985 p=0.919 
3
rd
 month – 6th month  p=0.253 p=0.975 
Baseline – 6th month  p=0.195 p=0.646 
 
 
Stable  
Baseline – 3rd month  p=0.380 p=0.192 
3
rd
 month – 6th month  p=0.530 p=0.823 
Baseline – 6th month  p=0.802 p=0.552 
 
 
Not Stable  
Baseline – 3rd month  p=0.296 p=0.010* 
3
rd
 month – 6th month  p=0.003** p=0.717 
Baseline – 6th month  p=0.037* p=0.056 
 
HR Walkway 
Baseline – 3rd month  p=0.089 p=0.558 
3
rd
 month – 6th month  p=0.06 p=0.558 
Baseline – 6th month  p=0.100 p=0.558 
 
 
Stable  
Baseline – 3rd month  p=0.788 p=0.756 
3
rd
 month – 6th month  p=0.499 p=0.523 
Baseline – 6th month  p=0.671 p=0.596 
 
 
Not Stable  
Baseline – 3rd month  p=0.008** p=0.756 
3
rd
 month – 6th month  p=0.028* p=0.877 
Baseline – 6th month  p=0.411 p=0.836 
 
Trial Group (2
nd
 – PTI) 
 
As shown on Table 5.4.10.7 within the trial group of the F-scan shod the median value 
at baseline was 63.03, 66.34 at 3
rd
 month, and 66.34 at 6
th
 month (Table 5.4.10.7). With 
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regards to F-scan with insole, the median value at baseline was 48.93, 53.96 at 3
rd
 
month, and 49.37 at 6
th
 month (Table 5.4.10.8). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 49.24, 53.63 at 3
rd
 month 
and 45.83 at 6
th
 month (Table 5.4.10.9). It is possible to notice a stable trend over the 
period of 6 months for the trial group which is lower than the control groups.  
 
The Friedman test displayed a p>0.05 hence there is no statistical difference within the 
trial group. Wilcoxon’s test highlighted no statistical difference during all three 
intervals, as well as with all interval considered with the stable-groups (p>0.05).  
 
Comparison between the Control and the Trial Group (2
nd
 – 
PTI) 
 
As shown in Table 5.4.10.12 results showed that there is statistical difference between 
control and trial patients when investigation were carried out with the F-scan while 
wearing the insole at 6
th
 month (p<0.05*). No statistical difference was discovered 
while using F-scan shod and HR walkway (p>0.05) in any of the intervals investigated. 
This suggests that only at 6
th
 month with F-Scan (with insole) there is a clear trend 
toward changes that happen between the control and the trial group with regards to 2
nd
-
PTI. 
 
Table 5.4.10.12: details of the Mann Whitney Test carried out on 2
nd
 -PTI with F-Scan Shod, F-Scan 
with insole and HR Walkway data between control and trial patients.  * means p<0.05, ** means p<0.01. 
 
2
nd
 Met. Head – Pressure Time Integral (2nd-PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.673 p=0.221 p=0.586 
Stable p=0.120 p=0.327 p=0.274 
Not stable p=0.340 p=0.408 p=0.633 
 
F-Scan – With Insoles p=0.495 p=0.380 p=0.035* 
Stable p=0.369 p=0.424 p=0.167 
Not stable p=0.874 p=0.588 p=0.111 
 
HR Walkway p=0.807 p=0.219 p=0.836 
Stable p=0.925 p=0.514 p=0.572 
Not stable p=0.484 p=0.152 p=0.656 
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Figure 5.4.10.4: boxplot carried out on F-Scan Shod – 2nd met. head PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.10.5: boxplot carried out on F-Scan with insole – 2nd met. head PTI data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.10.6: boxplot carried out on HR Walkway – 2nd met. head PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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5.4.11. 1st metatarsal head - Contact 
1
st
 - Peak Pressure Values- (1
st
 -PP) 
 
Control Group (1
st
 – PP)  
 
With regards to F-scan shod: the median value at baseline was 166, 188 at 3
rd
 month 
and 172.83 at 6
th
 month (Table 5.4.11.1).  
 
Table 5.4.11.1: descriptive statistics on 1
st
 – PP (F-Scan -Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
1
st 
Met. Head – Peak Pressure Values (1st -PP) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 166(151.42) 188(152.66) 172.83(135.42) 176.33(184.67) 202.17(198.83) 186.67(174.41) 
 
With regards to F-scan With Insole: the median value at baseline was 178.5, 163 at 3
rd
 
month, and 198 at 6
th
 month (Table 5.4.11.2). 
 
Table 5.4.11.2: descriptive statistics on 1
st
 – PP (F-Scan – with insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
1
st
 Met. Head – Peak Pressure Values (1st -PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 178.5(154.16) 163(155.79) 198(149.33) 143.5(107.25) 161.5(168.75) 155.67(146.66) 
 
With regards to HR Walkway the median value at baseline was 160.67, 158.83 at 3
rd
 
month and 161.33 at 6
th
 month (Table 5.4.11.3). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
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Table 5.4.11.3: descriptive statistics on 1
st
 – PP (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients) 
 
1
st
 Met. Head – Peak Pressure Values (1st- PP) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 160.67(121.08) 158.83(94.41) 161.33(107.92) 138.5(96.5) 152.17(96.92) 162.5(93.25) 
 
The Friedman test showed p>0.05 for the F-scan Shod. No significance difference is 
obtained within the control group for the F-scan with insole (p>0.05), and HR 
Walkway (p>0.05) (Table 5.4.11.4). Similarly, it is possible to notice a stable trend 
over the period of 6 months for the control group. 
 
Table 5.4.11.4: details of the Friedman test on 1
st – PP data with F-Scan shod, F-Scan with Insole and HR 
Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
1
st
 Met Head – Peak Pressure Values (1st-PP) Friedman Test  (baseline, 3rd & 6th month) 
 
 Control Trial 
F-Scan - Shod p=0.206 p=0.216 
Stable p=0.477 p=0.333 
Not stable p=0.387 p=0.646 
 
F-Scan – With Insoles p=0.427 p=0.308 
Stable p=0.856 p=0.931 
Not stable p=0.350 p=0.047* 
 
HR Walkway p=0.982 p=0.543 
Stable p=0.459 p=0.142 
Not stable p=0.754 p=0.505 
 
Table 5.4.11.5 highlighted that there is no statistical difference within the control 
groups with F-scan (shod & with insole) and HR Walkway in all intervals.   
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Table 5.4.11.5: details of the Wilcoxon’s test on 1st-PP data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
1
st
 Met. Head – Peak Pressure Values (1st- PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.441 p=0.141 
3
rd
 month – 6th month  p=0.509 p=0.608 
Baseline – 6th month  p=0.087 p=0.288 
 
Stable  
Baseline – 3rd month  p=0.432 p=0.382 
3
rd
 month – 6th month  p=0.588 p=0.631 
Baseline – 6th month  p=0.189 p=0.307 
 
 
Not Stable  
Baseline – 3rd month  p=0.970 p=0.148 
3
rd
 month – 6th month  p=0.737 p=0.877 
Baseline – 6th month  p=0.232 p=0.679 
 
F-Scan – With Insoles 
Baseline – 3rd month  p=0.293 p=0.318 
3
rd
 month – 6th month  p=0.135 p=0.902 
Baseline – 6th month  p=0.479 p=0.546 
 
 
Stable  
Baseline – 3rd month  p=0.863 p=0.917 
3
rd
 month – 6th month  p=0.638 p=0.991 
Baseline – 6th month  p=0.707 p=0.795 
 
 
Not Stable  
Baseline – 3rd month  p=0.126 p=0.030* 
3
rd
 month – 6th month  p=0.052 p=0.836 
Baseline – 6th month  p=0.455 p=0.134 
 
HR Walkway 
Baseline – 3rd month  p=0.777 p=0.530 
3
rd
 month – 6th month  p=0.769 p=0.405 
Baseline – 6th month  p=0.760 p=0.102 
 
 
Stable  
Baseline – 3rd month  p=0.557 p=0.302 
3
rd
 month – 6th month  p=0.777 p=0.764 
Baseline – 6th month  p=0.311 p=0.317 
 
 
Not Stable  
Baseline – 3rd month  p=0.126 p=0.569 
3
rd
 month – 6th month  p=0.911 p=0.334 
Baseline – 6th month  p=0.490 p=0.098 
 
Trial Group (1
st
 – PP) 
 
As shown on Table 5.4.11.1 within the trial group of the F-scan shod the median value 
at baseline was 176.33, 202.17 at 3
rd
 month, and 186.67 at 6
th
 month (Table 5.4.11.1). 
276 
 
With regards to F-scan with insole, the median value at baseline was 143.5, 161.5 at 3
rd 
month, and 155.67 at 6
th
 month (Table 5.4.11.2). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 138.5, 152.17 at 3
rd
 month 
and 162.5 at 6
th
 month (Table 5.4.11.3). It is possible to notice a stable trend over the 
period of 6 months and also F-Scan (with insole) data appeared to be lower than the F-
Scan (shod).  
 
Friedman’s test was carried out; as shown on Table 5.4.11.4 the Friedman test 
displayed a p>0.05, hence there is no statistical difference within the trial group. As 
shown on Table 5.4.11.5 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals, as well as with all interval considered with the stable-groups 
(p>0.05).  
 
 
Comparison between the Control and the Trial Group (1
st
 – 
PP) 
 
 
As shown in Table 5.4.11.6 results highlighted that there is no statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
shod (p>0.05) and with insole (p>0.05) and HR walkway (p>0.05). This suggests that 
there is a stable trend toward changes that happen between the control and the trial 
group with regards to 1
st
-PP. 
 
Table 5.4.11.6: details of the Mann Whitney Test carried out on Heel-PT with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
1
st
 Met. Head – Peak Pressure Values- (1st -PP) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.200 p=0.223 p=0.417 
Stable p=0.136 p=0.202 p=0.254 
Not stable p=0.886 p=0.899 p=0.726 
 
F-Scan – With Insoles p=0.578 p=0.881 p=0.298 
Stable p=0.341 p=0.787 p=0.562 
Not stable p=0.656 p=0.762 p=0.152 
 
HR Walkway p=0.329 p=0.830 p=0.872 
Stable p=0.489 p=0.875 p=0.877 
Not stable p=0.494 p=0.824 p=0.656 
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Figure 5.4.11.1: boxplot carried out on F-Scan Shod -1
st
 met. head  PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
Figure 5.4.11.2: boxplot carried out on F-Scan with insole - 1
st
 met. head PP data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.11.3: boxplot carried out on HR Walkway – 1st met. head PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval.  
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1
st
 - Pressure Time Integral (1
st
 -PTI) 
Control Group (1
st
 PTI) 
 
With regards to F-scan shod: the median value at baseline was 40.55, 33.53 at 3
rd
 
month and 34.53 at 6
th
 month (Table 5.4.11.7).  
 
Table 5.4.11.7: descriptive statistics on 1
st
 PTI (F-Scan Shod) data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
 
1
st
 Met. Head – Pressure Time Integral (1st - PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 40.55(37.98) 33.53(36.61) 34.53(28.68) 37.73(57.17) 39.76(126.07) 32.24(83.37) 
 
With regards to F-scan With Insole: the median value at baseline was 39.7, 36.92 at 3
rd
 
month, and 39.90 at 6
th
 month (Table 5.4.11.8).  
 
Table 5.4.11.8: descriptive statistics on 1
st
 PTI (F-Scan-With Insole) data at baseline, 3
rd
 month and 6
th
 
month (control and trial patients) 
1
st
 Met. Head – Pressure Time Integral (1st- PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 39.70(33.69) 36.92(36.22) 39.90(25.43) 33.67(34.2) 35.74(41.14) 28.92(30.37) 
 
With regards to HR Walkway the median value at baseline was 40.39, 35.89 at 3
rd
 
month and 38.88 at 6
th
 month (Table 5.4.11.9). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
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Table 5.4.11.9: descriptive statistics on 1
st
 PTI (HR Walkway) data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
1
st
 Met. Head – Pressure Time Integral (1st -PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 40.39(24..82) 35.89(22.47) 38.88(24.93) 30.41(22.94) 35.29(22.74) 36.79(20.73) 
 
As shown on Table 5.4.11.10 the Friedman test shows p>0.05 for the F-scan (shod and 
with insole) and HR Walkway (also for the stable group). It is possible to notice a 
stable trend over the period of 6 months. 
 
Table 5.4.11.10: details of the Friedman test on 1
st
 PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
1
st
 Met. Head –Pressure Time Integral (1st-PTI) - Friedman  
 Control Trial 
F-Scan - Shod p=0.945 p=0.500 
Stable p=0.913 p=0.266 
Not stable p=0.638 p=0.646 
 
F-Scan – With Insoles p=0.549 p=0.198 
Stable p=0.795 p=0.274 
Not stable p=0.086 p=0.276 
 
HR Walkway p=0.244 p=0.713 
Stable p=0.920 p=0.937 
Not stable p=0.011* p=0.472 
 
Wilcoxon’s test was carried out which highlighted no statistical difference within the 
intervals (p>0.05) (Table 5.4.11.11).  
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Table 5.4.11.11: details of the Wilcoxon’s test on 1st-PTI data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
1
st
 Met. Head – Pressure Time Integral (1st -PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.940 p=0.542 
3
rd
 month – 6th month  p=0.574 p=0.175 
Baseline – 6th month  p=0.418 p=0.925 
 
Stable  
Baseline – 3rd month  p=0.935 p=1.00 
3
rd
 month – 6th month  p=0.936 p=0.120 
Baseline – 6th month  p=0.837 p=0.857 
 
 
Not Stable  
Baseline – 3rd month  p=0.737 p=0.088 
3
rd
 month – 6th month  p=0.232 p=1.00 
Baseline – 6th month  p=0.218 p=0.877 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.206 p=0.623 
3
rd
 month – 6th month  p=0.990 p=0.508 
Baseline – 6th month  p=0.210 p=0.078 
 
 
Stable  
Baseline – 3rd month  p=0.765 p=0.987 
3
rd
 month – 6th month  p=0.256 p=0.277 
Baseline – 6th month  p=0.367 p=0.160 
 
 
Not Stable  
Baseline – 3rd month  p=0.014* p=0.256 
3
rd
 month – 6th month  p=0.145 p=0.501 
Baseline – 6th month  p=0.296 p=0.326 
 
HR Walkway 
Baseline – 3rd month  p=0.410 p=0.611 
3
rd
 month – 6th month  p=0.195 p=0.626 
Baseline – 6th month  p=0.546 p=0.266 
 
 
Stable  
Baseline – 3rd month  p=0.597 p=0.530 
3
rd
 month – 6th month  p=0.888 p=0.874 
Baseline – 6th month  p=0.530 p=0.658 
 
 
Not Stable  
Baseline – 3rd month  p=0.023* p=0.877 
3
rd
 month – 6th month  p=0.044* p=0.438 
Baseline – 6th month  p=0.852 p=0.134 
 
Trial Group (1
st
 PTI) 
 
As shown on Table 5.4.11.7 within the trial group of the F-scan the median value at 
baseline was 37.73, 39.76 at 3
rd
 month, and 32.24 at 6
th
 month (Table 5.4.11.7). With 
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regards to F-scan with insole, the median value at baseline was 33.67, 35.74 at 3
rd
 
month, and 28.92 at 6
th
 month (Table 5.4.11.8). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 30.41, 35.29 at 3
rd
 month 
and 36.79 at 6
th
 month (Table 5.4.11.9). It is possible to notice a stable trend over the 
period of 6 months for the trial group. 
 
As shown on Table 5.4.11.10 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group. As shown on Table 5.4.11.11 Wilcoxon’s 
test shows that there is no statistical difference during all three intervals, as well as with 
all interval considered with the stable-groups (p>0.05). 
 
Comparison between the Control and the Trial Group (1
st
 
PTI) 
 
As shown in Table 5.4.11.12 results showed that there is no statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole or shod or HR Walkway (p>0.05) in any of the intervals 
investigated. This suggests that there are no significant changes between the control 
and the trial group with regards to 1
st
-PTI. 
 
Table 5.4.11.12: details of the Mann Whitney Test carried out on 1
st
-PTI with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
1
st
 Met. Head – Pressure Time Integral (1st-PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.355 p=0.311 p=0.609 
Stable p=0.323 p=0.369 p=0.654 
Not stable p=1.0 p=0.750 p=0.874 
 
F-Scan – With Insoles p=0.208 p=0.610 p=0.119 
Stable p=0.153 p=0.243 p=0.114 
Not stable p=0.849 p=0.588 p=0.679 
 
HR Walkway p=0.242 p=0.753 p=0.312 
Stable p=0.199 p=0.355 p=0.131 
Not stable p=0.726 p=0.567 p=0.949 
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Figure 5.4.11.4: boxplot carried out on F-Scan Shod – 1st met. head PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.11.5: boxplot carried out on F-Scan with insole  - 1
st
 met. head PTI data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
boxplot carried out on HR Walkway – 1st met. head PTI data between control and trial patients at 
baseline, 3
rd
 month and 6
th
 month interval.  
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5.4.12. Lesser Toes contact 
Lesser Toes - Peak Pressure Values- (lt -PP) 
 
Control Group (lt-PP) 
 
With regards to F-scan shod: the median value at baseline was 170.67, 147.5 at 3
rd
 
month and 163.67 at 6
th
 month (Table 5.4.12.1).  
 
Table 5.4.12.1: descriptive statistics on lt – PP (F-Scan- Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
Lesser Toes – Peak Pressure (lt - PP) - F-Scan – Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 170.67(135.34) 147.5(147.75) 163.67(143.25) 149.17(140.09) 159.67(153.33) 179.83(151.5) 
 
With regards to F-scan With Insole: the median value at baseline was 170.67, 174.17 at 
3
rd
 month, and 167.33 at 6
th
 month (Table 5.4.12.2). 
 
Table 5.4.12.2: descriptive statistics on lt – PP (F-Scan with Insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Lesser Toes – Peak Pressure Values (lt- PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 170.67(136.58) 174.17(146) 167.33(161.58) 155.83(161.16) 140.5(206.17) 182.67(139.67) 
 
With regards to HR Walkway the median value at baseline was 120.67, 116.33 at 3
rd
 
month and 122.83 at 6
th
 month (Table 5.4.12.3). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
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Table 5.4.12.3: descriptive statistics on lt–PP (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
Lesser Toes – Peak Pressure Values (lt -PP) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 120.67(59.58) 116.33(46.17) 122.83(60.34) 120(73.5) 111.17(88.34) 114.83(87.59) 
 
As shown on Table 5.4.12.4 the Friedman test shows p>0.05 for the F-scan (shod and 
with insole) and HR Walkway (also for the stable group). It is possible to notice a 
stable trend over the period of 6 months for the control group. 
 
Table 5.4.12.4: details of the Friedman test on lt–PP data with F-Scan shod, F-Scan with Insole and HR 
Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Lesser Toes – Peak Pressure Values (lt-PP) - Friedman  
 Control Trial 
F-Scan - Shod p=0.221 p=0.258 
Stable p=0.239 p=0.146 
Not stable p=0.522 p=0.175 
 
F-Scan – With Insoles p=0.432 p=0.643 
Stable p=0.142 p=0.671 
Not stable p=0.538 p=0.646 
 
HR Walkway p=0.149 p=0.659 
Stable p=0.071 p=0.817 
Not stable p=0.513 p=0.444 
 
Table 5.4.12.5 highlighted that the within intervals are not significantly different 
(p>0.05) with the exception of F-Scan (with insole) and HR Walkway for the 3
rd
month-
6
th
month interval. 
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Table 5.4.12.5: details of the Wilcoxon’s test on lt-PP data with F-Scan shod, F-Scan with insole and HR 
Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Lesser Toes – Peak Pressure vs. Time (lt-PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.192 p=0.780 
3
rd
 month – 6th month  p=0.854 p=0.059 
Baseline – 6th month  p=0.436 p=0.076 
 
Stable  
Baseline – 3rd month  p=0.232 p=0.110 
3
rd
 month – 6th month  p=0.974 p=0.029 
Baseline – 6th month  p=0.502 p=0.434 
 
 
Not Stable  
Baseline – 3rd month  p=0.575 p=0.056 
3
rd
 month – 6th month  p=0.737 p=0.836 
Baseline – 6th month  p=0.852 p=0.039 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.361 p=0.930 
3
rd
 month – 6th month  p=0.301 p=0.906 
Baseline – 6th month  p=0.943 p=0.894 
 
 
Stable  
Baseline – 3rd month  p=0.261 p=0.930 
3
rd
 month – 6th month  p=0.031* p=0.608 
Baseline – 6th month  p=0.725 p=0.913 
 
 
Not Stable  
Baseline – 3rd month  p=0.968 p=0.679 
3
rd
 month – 6th month  p=0.411 p=0.535 
Baseline – 6th month  p=0.575 p=0.679 
 
HR Walkway 
Baseline – 3rd month  p=0.874 p=0.266 
3
rd
 month – 6th month  p=0.052 p=0.436 
Baseline – 6th month  p=0.114 p=0.217 
 
 
Stable  
Baseline – 3rd month  p=0.936 p=0.261 
3
rd
 month – 6th month  p=0.037* p=0.735 
Baseline – 6th month  p=0.161 p=0.619 
 
 
Not Stable  
Baseline – 3rd month  p=0.709 p=0.642 
3
rd
 month – 6th month  p=0.679 p=0.352 
Baseline – 6th month  p=0.502 p=0.121 
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Trial Group (lt-PP) 
 
As shown on Table 5.4.12.1 within the trial group of the F-scan shod the median value 
at baseline was 149.17, 159.67 at 3
rd
 month, and 179.83 at 6
th
 month (Table 5.4.12.1). 
With regards to the F-scan with insole, the median value at baseline was 155.83, 140.5 
at 3
rd
 month, and 182.67 at 6
th
 month (Table 5.4.12.2). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 120, 111.17 at 3
rd
 month 
and 114.83 at 6
th
 month (Table 5.4.12.3). It is possible to notice a stable trend over the 
period of 6 months for the trial group. 
 
As shown on Table 5.4.12.4 the Friedman test displayed a p>0.05 hence there is no 
statistical difference within the trial group. As shown on Table 5.4.12.5 Wilcoxon’s test 
shows that there is no statistical difference during all three intervals (p>0.05). The only 
interval that was p<0.05* was with stable-F-Scan (shod) during the 3
rd
month-6
th
month. 
 
Comparison between the Control and the Trial Group (lt-
PP) 
 
As shown in Table 5.4.12.6 results showed that there is no statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole or shod or HR walkway (p>0.05) in any of the intervals 
investigated. This suggests that there is a stable trend between the control and the trial 
group with regards to t-PTI. 
 
Table 5.4.12.6: details of the Mann Whitney Test carried out on lt-PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Lesser Toes – Peak Pressure Values(lt-PP) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.558 p=0.585 p=0.785 
Stable p=0.183 p=0.918 p=0.452 
Not stable p=0.192 p=0.226 p=0.504 
 
F-Scan – With Insoles p=0.969 p=0.316 p=0.927 
Stable p=0.364 p=0.939 p=0.156 
Not stable p=0.072 p=0.026* p=0.092 
 
HR Walkway p=0.875 p=0.891 p=0.555 
Stable p=0.406 p=0.421 p=0.769 
Not stable p=0.077 p=0.356 p=0.484 
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Figure 5.4.12.1: boxplot carried out on F-Scan shod – Lesser Toe PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.12.2: boxplot carried out on F-Scan with insole  - Lesser Toe PP data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.12.3: boxplot carried out on HR Walkway – Lesser Toe PP data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval. 
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Lesser Toes - Pressure Time Integral (lt-PTI) 
Control Group (lt-PTI) 
 
With regards to F-scan shod: the median value at baseline was 26.26, 26.16 at 3
rd
 
month and 28.22 at 6
th
 month (Table 5.4.12.7). 
 
Table 5.4.12.7: descriptive statistics on lt-PTI (F-Scan Shod) data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
 
Lesser Toes – Pressure Time Integral (lt - PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 26.26(27.42) 26.16(33.22) 28.22(26.01) 27.78(20.18) 25.89(25.89) 32.74(28.95) 
 
With regards to F-scan With Insole: the median value at baseline was 29.4, 30.65 at 3
rd
 
month, and 31.7 at 6
th
 month (Table 5.4.12.8).  
 
Table 5.4.12.8: descriptive statistics on lt-PTI (F-Scan With Insole) data at baseline, 3
rd
 month and 6
th
 
month (control and trial patients). 
Lesser Toes –Pressure Time Integral (lt-PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 29.4(27.97) 30.65(24.78) 31.7(21.88) 32.22(38.07) 30.39(37.94) 32.08(35.6) 
 
With regards to HR Walkway the median value at baseline was 14.34, 13.72 at 3
rd
 
month and 15.62 at 6
th
 month (Table 5.4.12.9). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
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Table 5.4.12.9: descriptive statistics on lt-PTI (HR Walkway) data at baseline, 3
rd
 month and 6
th
 month 
(control and trial patients). 
Lesser Toes – Pressure Time Integral (lt -PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 14.34(11.74) 13.72(11.94) 15.62(14.37) 16.48(14.23) 15.9(14.3) 15.68(13.4) 
 
As shown on Table 5.4.12.10 the Friedman test shows p>0.05 for the F-scan (shod and 
with insole) and HR Walkway (also for the stable group). It is possible to notice a 
stable trend over the period of 6 months within the control group. 
 
Table 5.4.12.10: details of the Friedman test on lt– PTI data with F-Scan shod, F-Scan with Insole and 
HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Lesser Toes – Pressure Time Integral (lt-PTI) - Friedman  
 Control Trial 
F-Scan - Shod p=0.683 p=0.285 
Stable p=0.972 p=0.642 
Not stable p=0.449 p=0.294 
 
F-Scan – With Insoles p=0.612 p=0.504 
Stable p=0.293 p=0.428 
Not stable p=0.705 p=0.895 
 
HR Walkway p=0.104 p=0.230 
Stable p=0.111 p=0.205 
Not stable p=0.522 p=0.939 
 
Table 5.4.12.11 highlighted that all results are not significantly different (p>0.05). The 
only significant interval was found with the HR Walkway at 3
rd
month-6
th
month 
interval, also for the stable-HR Walkway.  
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Table 5.4.12.11: details of the Wilcoxon’s test on lt-PTI data with F-Scan Shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
Lesser Toes – Pressure Time Integral (lt-PTI) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.528 p=0.487 
3
rd
 month – 6th month  p=0.535 p=0.088 
Baseline – 6th month  p=0.993 p=0.143 
 
Stable  
Baseline – 3rd month  p=0.934 p=0.340 
3
rd
 month – 6th month  p=0.844 p=0.234 
Baseline – 6th month  p=0.857 p=0.674 
 
 
Not Stable  
Baseline – 3rd month  p=0.332 p=0.826 
3
rd
 month – 6th month  p=0.126 p=0.255 
Baseline – 6th month  p=0.654 p=0.030* 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.772 p=0.906 
3
rd
 month – 6th month  p=0.675 p=0.549 
Baseline – 6th month  p=0.615 p=0.510 
 
 
Stable  
Baseline – 3rd month  p=0.874 p=0.635 
3
rd
 month – 6th month  p=0.232 p=0.379 
Baseline – 6th month  p=0.318 p=0.353 
 
 
Not Stable  
Baseline – 3rd month  p=0.852 p=0.427 
3
rd
 month – 6th month  p=0.433 p=0.796 
Baseline – 6th month  p=0.575 p=0.756 
 
HR Walkway 
Baseline – 3rd month  p=0.994 p=0.723 
3
rd
 month – 6th month  p=0.021* p=0.162 
Baseline – 6th month  p=0.112 p=0.246 
 
 
Stable  
Baseline – 3rd month  p=0.761 p=0.611 
3
rd
 month – 6th month  p=0.009** p=0.074 
Baseline – 6th month  p=0.102 p=0.117 
 
 
Not Stable  
Baseline – 3rd month  p=0.478 p=0.836 
3
rd
 month – 6th month  p=0.654 p=0.836 
Baseline – 6th month  p=0.654 p=0.796 
Trial Group (lt-PTI) 
 
As shown on Table 5.4.12.7 within the trial group of the F-scan shod the median value 
at baseline was 27.78, 25.89 at 3
rd
 month, and 32.74 at 6
th
 month (Table 5.4.12.7). With 
regards to F-scan with insole, the median value at baseline was 32.22, 30.39 at 3
rd
 
month, and 32.08 at 6
th
 month (Table 5.4.12.8). With regards to HR Walkway, 
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descriptive statistics showed: median value at baseline was 16.48, 15.9 at 3
rd
 month and 
15.68 at 6
th
 month (Table 5.4.12.9). As shown on Table 5.4.12.10 the Friedman test 
displayed a p>0.05 hence there is no statistical difference within the trial group. As 
shown on Table 5.4.12.11 Wilcoxon’s test shows that there is no statistical difference 
during all three intervals (p>0.05). The only interval that was p<0.05* was with stable-
F-Scan (shod) during the 3
rd
month-6
th
month. 
Comparison between the Control and the Trial Group (lt-
PTI) 
 
As shown in Table 5.4.12.12 results indicated that there is no statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole or shod or HR walkway (p>0.05) in any of the intervals 
investigated. This suggests that no significant changes between the control and the trial 
group with regards to lt-PTI. 
 
Table 5.4.12.12: details of the Mann Whitney Test carried out on lt-PTI with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients.  * means p<0.05, ** means p<0.01. 
 
Lesser Toes –Pressure  Integral (lt-PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.443 p=0.517 p=0.258 
Stable p=0.183 p=0.918 p=0.452 
Not stable p=0.192 p=0.226 p=0.504 
 
F-Scan – With Insoles p=0.544 p=0.618 p=0.635 
Stable p=0.336 p=0.218 p=0.270 
Not stable p=0.588 p=0.226 p=0.203 
 
HR Walkway p=0.815 p=0.663 p=0.225 
Stable p=0.723 p=0.653 p=0.098 
Not stable p=0.949 p=1.00 p=0.679 
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Figure 5.4.12.4: boxplot carried out on F-Scan Shod – Lesser Toes PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.12.5: boxplot carried out on F-Scan with insole – Lesser Toes PTI data between control and 
trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
 
Figure 5.4.12.6: boxplot carried out on HR Walkway – Lesser Toes PTI data between control and trial 
patients at baseline, 3
rd
 month and 6
th
 month interval.  
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5.4.13. Distal Phalanx of the 1st toe 
Distal Phalanx of the 1
st
 toe - Peak Pressure Values- (dp -PP) 
Control Group (dp-PP) 
 
With regards to F-scan shod: the median value at baseline was 280.33, 254.5 at 3
rd
 
month and 301.33 at 6
th
 month (Table 5.4.13.1). 
 
Table 5.4.13.1: descriptive statistics on dp– PP (F-Scan Shod) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
Distal Phalanx of the 1
st
 toe – Peak Pressure Values (dp-PP) F-Scan-Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 280.33(275.42) 254.50(326.83) 301.33(321.66) 204.83(275.83) 235.33(286) 220.67(330.75) 
 
With regards to F-scan With Insole: the median value at baseline was 308.17, 282 at 3
rd
 
month, and 340.33 at 6
th
 month (Table 5.4.13.2). 
 
Table 5.4.13.2: descriptive statistics on dp– PP (F-Scan With Insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Distal Phalanx of the 1
st
 toe – Peak Pressure Values(dp-PP) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median (IQR) 308.17(275.33) 282(223) 340.33(320.5) 244.50(184.08) 260.83(234.59) 261.33(213.09) 
 
With regards to HR Walkway the median value at baseline was 285.67, 296.17 at 3
rd
 
month and 300.67 at 6
th
 month (Table 5.4.13.3). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
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Table 5.4.13.3: descriptive statistics on dp– PP (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
Distal Phalanx of the 1
st
 toe – Peak Pressure (dp-PP) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 285.67(127.09) 296.17(166.08) 300.67(243.92) 241.17(221.75) 254.83(209.75) 251.33(250.33) 
 
As shown on Table 5.4.13.4 the Friedman test shows p>0.05 for the F-scan (shod and 
with insole) and HR Walkway (also for the stable group). The only case where p<0.05* 
was found with stable and not-stable F-Scan (shod). 
 
Table 5.4.13.4: details of the Friedman test on dp– PP data with F-Scan shod, F-Scan with Insole and HR 
Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * means p<0.05, ** means 
p<0.01. 
 
Distal Phalanx of the 1
st
 toe – Peak Pressure Values (dp-PP) - Friedman  
 Control Trial 
F-Scan - Shod p=0.615 p=0.401 
Stable p=0.021* p=0.346 
Not stable p=0.020 p=0.895 
 
F-Scan – With Insoles p=0.640 p=0.457 
Stable p=0.697 p=0.366 
Not stable p=0.861 p=0.538 
 
HR Walkway p=0.982 p=0.126 
Stable p=0.459 p=0.393 
Not stable p=0.341 p=0.055 
 
Wilcoxon’s test was carried out and Table 5.4.13.5 highlighted that the only significant 
difference was found at the stable-F-scan (shod) at 3
rd
month-6
th
month (p<0.05*).   
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Table 5.4.13.5: details of the Wilcoxon’s test on dp-PP data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Distal Phalanx of the 1
st
 toe – Peak Pressure Values (dp-PP) - Wilcoxon’s Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.858 p=0.240 
3
rd
 month – 6th month  p=0.493 p=0.325 
Baseline – 6th month  p=0.227 p=0.062 
 
Stable  
Baseline – 3rd month  p=0.055 p=0.561 
3
rd
 month – 6th month  p=0.017* p=0.565 
Baseline – 6th month  p=0.203 p=0.181 
 
 
Not Stable  
Baseline – 3rd month  p=0.006** p=0.179 
3
rd
 month – 6th month  p=0.028* p=0.352 
Baseline – 6th month  p=0.852 p=0.173 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.588 p=0.551 
3
rd
 month – 6th month  p=0.538 p=0.341 
Baseline – 6th month  p=0.348 p=0.680 
 
 
Stable  
Baseline – 3rd month  p=0.310 p=0.172 
3
rd
 month – 6th month  p=0.519 p=0.160 
Baseline – 6th month  p=0.561 p=0.804 
 
 
Not Stable  
Baseline – 3rd month  p=0.467 p=0.140 
3
rd
 month – 6th month  p=0.837 p=0.569 
Baseline – 6th month  p=0.502 p=0.717 
 
HR Walkway 
Baseline – 3rd month  p=0.859 p=0.262 
3
rd
 month – 6th month  p=0.673 p=0.615 
Baseline – 6th month  p=0.732 p=0.077 
 
 
Stable  
Baseline – 3rd month  p=0.839 p=0.581 
3
rd
 month – 6th month  p=0.217 p=0.500 
Baseline – 6th month  p=0.480 p=0.808 
 
 
Not Stable  
Baseline – 3rd month  p=0.323 p=0.605 
3
rd
 month – 6th month  p=0.488 p=0.027* 
Baseline – 6th month  p=0.523 p=0.026 
 
 
 
 
296 
 
Trial Group (dp-PP) 
 
As shown on Table 5.4.13.1 within the trial group of the F-scan shod the median value 
at baseline was 204.83, 235.33 at 3
rd
 month, and 220.67 at 6
th
 month (Table 5.4.13.1). 
With regards to F-scan with insole, the median value at baseline was 244.50, 260.83 at 
3
rd
 month, and 261.33 at 6
th
 month (Table 5.4.13.2). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 241.17, 254.83 at 3
rd
 month 
and 251.33 at 6
th
 month Table 5.4.13.3. It is possible to notice a stable trend over the 
period of 6 months for the trial group. As shown on Table 5.4.13.4 the Friedman test 
displayed a p>0.05 hence there is no statistical difference within the trial group 
compared to the control group. As shown on Table 5.4.13.5 Wilcoxon’s test shows that 
there is no statistical difference during all three intervals (p>0.05).  
 
Comparison between the Control and the Trial Group (dp-
PP) 
 
As shown in table 5.4.13.6 results showed that there is statistical difference between 
control and trial patients when investigation were carried out with the F-scan while 
wearing the insole at baseline (p<0.05*) and at 6
th
 month; which mirrowed the results 
when the stable group was considered separately. The 3
rd
 month value was p=0.059 
hence just not significant. In addition, HR Walkway appeared to have p<0.05* at 
baseline only. This suggests that there is a clear trend toward changes that happen 
between the control and the trial group with regards to dp-PP. 
 
Table 5.4.13.6: details of the Mann Whitney Test carried out on dp-PP with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Distal Phalanx of the 1
st
 toe – Peak Pressure Values (dp-PP) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.082 p=0.349 p=0.146 
Stable p=0.100 p=0.733 p=0.093 
Not stable p=0.588 p=0.308 p=0.799 
 
F-Scan – With Insoles p=0.009* p=0.059 p=0.021* 
Stable p=0.011* p=0.188 p=0.030* 
Not stable p=0.308 p=0.07 p=0.373 
 
HR Walkway p=0.019* p=0.107 p=0.247 
Stable p=0.199 p=0.608 p=0.390 
Not stable p=0.008** p=0.016* p=0.356 
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Figure 5.4.13.1: boxplot carried out on F-Scan Shod – Distal Phalanx of the 1st toe, PP data between 
control and trial patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.13.2: boxplot carried out on F-Scan with insole  – Distal Phalanx of the 1st toe, PP data 
between control and trial patients at baseline, 3
rd
 month and 6
th
 month interval 
 
 
Figure 5.4.13.3: boxplot carried out on HR Walkway - Distal Phalanx of the 1
st
 toe, PP data between 
control and trial patients at baseline, 3
rd
 month and 6
th
 month interval 
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Distal Phalanx of the 1
st
 toe - Pressure Time Integral (dp-
PTI) 
Control Group (dp-PTI) 
 
With regards to F-scan shod: the median value at baseline was 40.42, 35.73 at 3
rd
 
month and 38.83 at 6
th
 month (Table 5.4.13.7).  
 
Table 5.4.13.7: descriptive statistics on dp –PTI (F-Scan Shod) data at baseline, 3rd month and 6th month 
(control and trial patients) 
 
Distal Phalanx of the 1
st
 toe – Pressure Time Integral (dp - PTI) - F-Scan - Shod 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 40.42(47.59) 35.73(42.49) 38.83(52.4) 29.81(45.3) 34.58(46.19) 36.59(41.92) 
 
With regards to F-scan With Insole: the median value at baseline was 45.99, 49.05 at 
3
rd
 month, and 41.89 at 6
th
 month (Table 5.4.13.8). 
 
Table 5.4.13.8: descriptive statistics on dp –PTI (F-Scan-With Insole) data at baseline, 3rd month and 6th 
month (control and trial patients). 
 
Distal Phalanx of the 1
st
 toe – Pressure Time Integral (dp- PTI) - F-Scan – With Insole 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 45.99(32.2) 49.05(46.21) 41.89(33.51) 40.17(35.13) 40.18(45.47) 37.01(36.1) 
 
With regards to HR Walkway the median value at baseline was 29.72, 29.71 at 3
rd
 
month and 26.17 at 6
th
 month (Table 5.4.13.9). It is possible to notice a stable trend 
over the period of 6 months for the control group. 
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Table 5.4.13.9: descriptive statistics on dp –PTI (HR Walkway) data at baseline, 3rd month and 6th month 
(control and trial patients). 
 
Distal Phalanx of the 1
st
 toe – Pressure Time Integral (dp -PTI) – HR Walkway 
 CONTROL TRIAL 
 Baseline 3
rd
 month 6
th
 month Baseline 3
rd
 month 6
th
 month 
Valid  58 58 56 62 62 62 
Missing 0 0 2 0 0 0 
Median(IQR) 29.72(15.01) 29.71(19.52) 26.17(20.35) 24.01(21.38) 25.46(19.28) 26.81(19.54) 
 
As shown on Table 5.4.13.10 the Friedman test shows p>0.05 for the F-scan (shod and 
with insole) and HR Walkway (also for the stable group). It is possible to notice a 
stable trend over the period of 6 months for the control group. 
 
Table 5.4.13.10: details of the Friedman test on distal phalanx of the 1
st
 toe – PTI data with F-Scan shod, 
F-Scan with Insole and HR Walkway at baseline, 3
rd
 month and 6
th
 month (control and trial patients). * 
means p<0.05, ** means p<0.01. 
 
Distal Phalanx of the 1
st
 toe – Pressure Time Integral (dp - PTI) - Friedman  
 Control Trial 
F-Scan - Shod p=1.00 p=0.142 
Stable p=0.080 p=0.323 
Not stable p=0.011* p=0.305 
 
F-Scan – With Insoles p=0.417 p=0.119 
Stable p=0.338 p=0.119 
Not stable p=0.705 p=0.717 
 
HR Walkway p=0.417 p=0.454 
Stable p=0.358 p=0.180 
Not stable p=0.861 p=0.570 
 
Wilcoxon’s test was carried out and Table 5.4.13.11 highlighted that statistical 
difference was found for stable-F-Scan (shod) at baseline-3
rd
month (p<0.05*), 
3
rd
month-6
th
month (p<0.05*). 
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Table 5.4.13.11: details of the Wilcoxon’s test on dp-PTI data with F-Scan shod, F-Scan with insole and 
HR Walkway (control and trial patients). * means p<0.05, ** means p<0.01. 
 
Distal Phalanx of the 1
st
 toe – Pressure Time Integral (dp - PTI) - Wilcoxon’s 
Test   
 Control Trial  
F-Scan – Shod 
Baseline – 3rd month  p=0.528 p=0.364 
3
rd
 month – 6th month  p=0.714 p=0.435 
Baseline – 6th month  p=0.763 p=0.042* 
 
Stable  
Baseline – 3rd month  p=0.026* p=0.831 
3
rd
 month – 6th month  p=0.035* p=0.909 
Baseline – 6th month  p=0.900 p=0.258 
 
 
Not Stable  
Baseline – 3rd month  p=0.037 p=0.163 
3
rd
 month – 6th month  p=0.030* p=0.148 
Baseline – 6th month  p=0.627 p=0.039* 
   
F-Scan – With Insoles 
Baseline – 3rd month  p=0.702 p=0.258 
3
rd
 month – 6th month  p=0.443 p=0.069 
Baseline – 6th month  p=0.562 p=0.511 
 
 
Stable  
Baseline – 3rd month  p=0.800 p=0.112 
3
rd
 month – 6th month  p=0.379 p=0.019* 
Baseline – 6th month  p=0.480 p=0.656 
 
 
Not Stable  
Baseline – 3rd month  p=0.765 p=0.570 
3
rd
 month – 6th month  p=0.823 p=0.642 
Baseline – 6th month  p=0.737 p=0.535 
 
HR Walkway 
Baseline – 3rd month  p=0.523 p=0.891 
3
rd
 month – 6th month  p=0.415 p=0.872 
Baseline – 6th month  p=0.392 p=0.955 
 
 
Stable  
Baseline – 3rd month  p=0.567 p=0.698 
3
rd
 month – 6th month  p=0.838 p=0.444 
Baseline – 6th month  p=0.405 p=0.608 
 
 
Not Stable  
Baseline – 3rd month  p=0.881 p=0.535 
3
rd
 month – 6th month  p=0.263 p=0.379 
Baseline – 6th month  p=0.681 p=0.352 
Trial Group (dp-PTI) 
 
As shown on Table 5.4.13.7 within the trial group of the F-scan shod the median value 
at baseline was 29.81, 34.58 at 3
rd
 month, and 36.59 at 6
th
 month (Table 5.4.13.7). With 
regards to F-scan with insole, the median value at baseline was 40.17, 40.18 at 3
rd
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month, and 37.01 at 6
th
 month (Table 5.4.13.8). With regards to HR Walkway, 
descriptive statistics showed: median value at baseline was 24.01, 25.46 at 3
rd
 month 
and 26.81 at 6
th
 month (Table 5.4.13.9). It is possible to notice a stable trend over the 
period of 6 months for the trial group. 
 
As shown on Table 5.4.13.10 the Friedman test displayed a p>0.05 hence there is no 
statistical difference. As shown on Table 5.4.13.11, Wilcoxon’s test shows that there is 
statistical difference only during F-Scan (shod) during the baseline-6
th
month interval; 
and for F-Scan (with insole) at 3
rd
month-6
th
month (p<0.05*). 
 
Comparison between the Control and the Trial Group (dp-
PTI) 
 
As shown in Table 5.4.13.12 results showed that there is no statistical difference 
between control and trial patients when investigation were carried out with the F-scan 
while wearing the insole or shod or HR walkway (p>0.05) in any of the intervals 
investigated. The only scenario where p<0.05* was found with the stable-F-Scan (with 
insole). This suggests that there is not a clear trend toward changes that happen 
between the control and the trial group with regards to dp-PTI. 
 
Table 5.4.13.12: details of the Mann Whitney Test carried out on dp-PTI with F-Scan Shod, F-Scan with 
insole and HR Walkway data between control and trial patients. * means p<0.05, ** means p<0.01. 
 
Distal Phalanx of the 1
st
 toe – Pressure  Integral (dp-PTI) - Mann Whitney Test 
 Baseline 3
rd
 Month 6
th
 Month 
F-Scan - Shod p=0.057 p=0.434 p=0.597 
Stable p=0.088 p=0.596 p=0.239 
Not stable p=0.226 p=0.545 p=0.679 
 
F-Scan – With Insoles p=0.159 p=0.303 p=0.419 
Stable p=0.040* p=0.254 p=0.365 
Not stable p=0.849 p=0.588 p=0.656 
 
HR Walkway p=0.175 p=0.313 p=0.490 
Stable p=0.203 p=0.590 p=0.449 
Not stable p=0.445 p=0.380 p=0.924 
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Figure 5.4.13.4: boxplot carried out on F-Scan Shod – Distal Phalanx of the 1st toe PTI data between 
control and trial patients at baseline, 3
rd
 month and 6
th
 month. 
 
 
Figure 5.4.13.5: boxplot carried out on F-Scan with insole  - Distal Phalanx of the 1
st
 toe PTI data 
between control and trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
Figure 5.4.13.6: boxplot carried out on HR Walkway – Distal Phalanx of the 1st toe, data between control 
and trial patients at baseline, 3
rd
 month and 6
th
 month interval. 
 
5.4.14. Summary of Plantar Pressure Mapping Outcomes 
In order to allow the reader to have a clear understanding of the vast plantar pressure 
mapping outcome results, a summary of the major findings are displayed in table 
5.4.14.1. 
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Table 5.4.14.1: this concise table shows the plantar pressure mapping outcome (PP and PTI) results 
comparison between the trial and the control group (baseline, 3
rd
month, 6
th
 month). Green background 
indicates that statistical significant difference was obtained (* means p<0.05; ** means p<0.01; p<0.001 
means p=0.000). Red background shows that statistical significant difference was not obtained (p>0.05).  
 
Secondary Outcome Results 
comparison between groups (Mann Whitney U-Test) 
  Baseline 3rd
 
month 6
th 
month 
Total 
PP p=0.090 p<0.001 p<0.001 
PTI p=0.098 p<0.001 p=0.028** 
 
Heel  
PP p<0.001 p<0.001 p<0.001 
PTI p=0.026** p=0.006** p=0.028* 
 
Midfoot 
PP p=0.013** p=0.017* p=0.044* 
PTI p=0.015** p=0.028* p=0.012* 
 
Forefoot 
PP p=0.241 p=0.054 p=0.063 
PTI p=0.289 p=0.087 p=0.141 
 
5
th
 met. head 
PP p=0.002** p=0.021* p=0.030* 
PTI p=0.016* p=0.093 p=0.071 
 
3
rd
 – 4th  
met. head 
PP p=0.355 p=0.031 p=0.046 
PTI p=0.248 p=0.052 p=0.174 
 
2
nd
 met. head 
PP p=0.401 p=0.291 p=0.017* 
PTI p=0.495 p=0.380 p=0.035* 
 
1
st
 met. head 
PP p=0.578 p=0.881 p=0.298 
PTI p=0.208 p=0.610 p=0.119 
 
Lesser Toes 
PP p=0.969 p=0.316 p=0.927 
PTI p=0.544 p=0.618 p=0.635 
 
Hallux  
PP p=0.009** p=0.059 p=0.021* 
PTI p=0.159 p=0.303 p=0.419 
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Chapter 6: Discussion 
 Patient Demographics 6.1.
According to a Cochrane review reported by Takken et al. (2008), JIA can be 
diagnosed in children up to the age of 18; this evidence was used to set the maximum 
age limit for this RCT. During the recruitment process some parents with children 
younger than 5 years old, showed interest in this study. In these occasions, the parents 
were told that according to the inclusion criteria, 5 years old was the minimum age, 
however, as it occurred with patient E31 & E32 when the child was old enough, the 
parents were recalled and they agreed to participate in the study. It can be argued that 
some parents recognised the importance of early podiatric intervention and they were 
keen to take part to the study.  
 
As a result of using the block randomisation, the number of patients that received the 
control FOs was similar with respect to the trial patients. With regards to multicentre 
recruitment more patients were recruited in Edinburgh as the paediatric rheumatology 
department run clinics on a weekly basis, compared to the monthly clinics at Ninewells 
Hospital.  
 
Attrition was very low with all participants, except with only one patient that failed to 
complete the last appointment for unknown reasons. In this study the ratio of female 
and male was 3:1. This fact may reflect the ratio described by Yang (2008) where the 
overall number of female with JIA was proportionally higher compared to male.  
 
It was noted how the shoe size rarely changed over the 6 months period of time, which 
allowed to repeat the recordings by using the same shoe and FOs. In only one case 
within the control group where the FOs size became too small, the patient was 
informed to contact the data collector and a larger FOs size with the same prescription 
was supplied back to the patient. It was important to closely monitor shoe sizes as the 
fitting of the FOs may vary, possibly compromising comfort and effectiveness.  
 
Undergrowth (possibly induced by premature fusion of epiphyseal plates) and 
overgrowth (possibly linked to inflammation or indirect increased of vascularisation 
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and release of growth factor) are typical signs of JIA (Szer et al 2006). Similar height 
levels were recorded in both groups during the trial. Due to symptomatic joints in the 
lower limb, JIA children may have more difficulties to exercise on a regular basis; and 
the chances to increase weight might be higher compared to healthy children (Broström 
et al. 2002; Broström 2004; Lelieveld et al. 2008; Thomson and Volpe 2001). However, 
as mentioned by these authors the general approach to treat JIA symptoms is to 
encourage movement and activity level; therefore, constant monitoring from the multi-
disciplinary paediatric rheumatology team should be carried out (Kutcha and Davidson 
2006; Szer et al 2006).  
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 Pharmacological Intervention  6.2.
 
Since the beginning of the recruitment process it was noticed how most of the 
candidates for the study were taking different types of drugs. Some of the JIA children 
have been taking drugs such as Methotrexate or Etanercept for many years. The overall 
number of potential participants that were not taking medications appeared very small 
since the beginning of the data collection stage. Therefore, in order to fully attribute 
any possible changes in pain level and quality of life, one of the important aspects of 
this study was to keep an updated record of medication changes. The medications 
prescribed to JIA children aimed to reduce the progression of the joint damage since 
early stages of the disease, which reflected the philosophy of prescribing FOs during 
the initial biomechanical consultations. Podiatric management may be able to provide 
immediate relief, instead the DMARDs drugs may take up to 6 months before fully 
exhibit their full response (Pisetsky 1995).  
 
Additionally, despite the conclusion made by Pisetsky (1995), in the study carried out 
by Powel et al. (2005) the inclusion criteria section stated that JIA children must have 
stable medication for only one month prior to entry the study. This study was carried 
out without monitoring the progression of pharmacological changes over a period of 
time, nor accounting them within the data analysis. These limitations were highlighted 
by the author. According to the survey carried out by Hendry et. al (2008) their findings 
had to be taken with caution as it was difficult to closely monitor the intensive 
pharmacological intervention that their patients received.   
 
By subdividing the groups into ‘stable’ and ‘not stable’ group it was possible to 
monitor the drug therapy changes within the patients and to observe if the increase or 
decrease of pain and quality of life can be attribute solely to the FOs intervention over 
the trial period. The methodological approach adopted in this RCT allowed accounting 
for pharmaceutical issues that may have had an impact on the final results.  
 
Additionally, in this RCT steroid injection details were recorded. It appeared that 
steroid injection was frequently considered as part of the early intervention treatment 
when joints may flare up and start becoming symptomatic. If a patient would have 
received an injection in the lower limbs at any time during the 6 months period it would 
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have been recorded and during statistical analysis the participant would have been 
considered as ‘non stable’ participant. In this JIA study, more importance was given to 
the results attained by the ‘stable’ group results, compared to the ‘non-stable’; because 
it was possible to precisely attribute and isolate data achieved solely by the FOs 
intervention. 
 
Few patients were included into the ‘not stable’; overall, the number of ‘stable’ patients 
remained the vast majority of the cases. Statistical tests for quality of life and gait 
analysis were carried out using SPSS by splitting the data and accounting for all these 
variables which may have indirectly affected the results.   
 
This pragmatic study truly reflected real on-going JIA clinical care; therefore, it was 
extremely important during the data collection to carefully monitor the 
pharmacological interventional supplied by the consultant and by the other members of 
the multidisciplinary team. By adopting this thorough methodology the true effects of 
the FOs intervention was possible to be recorded.   
 
Finally, data analysis showed that by splitting the groups into ‘stable’ and ‘not stable’, 
statistical significance changed within few parameters that were investigated. This fact 
confirmed the importance of accounting for ‘stable’ and ‘not stable’ groups, which 
significantly helped obtaining results that were purely reflecting the podiatric 
intervention adopted during the RCT investigation.  
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 Symptomatic Joints 6.3.
 
In normal circumstances the JIA child should be able to adduct the hip across the 
midline of the body by 20° and abducted laterally from the midline by 45°. When 
supine on the plinth, the JIA child should be able to flex the hip to the chest, at least of 
135° and on prone position the extension of the hip should reach 30°. During extension 
test of the hip, the practitioner should ensure that the child does not compensate with 
the lower spine, as this may provide faulty results; therefore, it is advisable to apply a 
gentle pressure on the buttocks while lifting the leg. In addition, the internal and 
external rotation test of the hip should provide useful feedback on whether active 
disease is present or not at the femoral head (Szer et al 2006). 
 
All biomechanical tests mentioned above were carried out prior to data recording with 
JIA children at the Motion Analysis Laboratory at Queen Margaret University and 
Ninewells Hospital. Each child was examined at open (on a provided plinth) and at 
close kinetic chain. Any possible joint deformities, limitation of ROM were recorded in 
the patient data sheet. 
 
As it was noticed during the recruitment visits with the paediatric rheumatology 
consultants, examination on the knee usually commences with palpation of the bursae 
and out-pocketing of the knee joint. With the RCT patients recruited in both hospitals 
who complained of knee pain, it was challenging to distinguish simple fluid from 
synovial thickening, because both may be noticeable at the same time. In a more severe 
arthritic knee, the excessive fluids make the patella very movable and ‘bouncy’ after 
being pushed distally. Szer et al (2006) recommend that the patella ROM should be 
tested independently from the rest of the knee in order to distinguish different types of 
pathologies. In contrast, a study carried out by Forslind et al (1997) reported that 
physical examination may have low reliability in the assessment of disease activity 
because different examiners may report different subjective findings (Forslind et al. 
1997). Antalgic gait due to knee flexion issues, must be rapidly recognised and treated 
by the clinician (Cakmak and Bolukbas 2005).  
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Conventional radiographs is adopted as initial radiologic evaluation and assessment of 
disease progression in JIA, which may have a limited application in early arthritis 
because they are not able to highlight inflamed synovium, cartilage destruction, and 
early bone erosions, all of which are recognised with magnetic resonance (MR) 
imaging (Forslind et al. 1997). Similarly, a more recent study conducted on 30 JIA 
children who presented active arthritis at the knees, concluded that MR imaging may 
potentially aid therapeutic decisions, particularly at early stages of the disease process, 
by helping the clinician in the quantification of synovitis, and cartilage and bone 
destruction which are not evident on conventional radiographs (Gylys-Morin et al. 
2001). 
 
Another clinical feature diagnosed in many recruited children in the study was 
‘patellofemoral syndrome’, which can be defined as retropatellar or peripatellar pain 
resulting from physical and biochemical changes in the patellofemoral joint. This 
condition is different from chondromalacia, which is the fraying and damage to the 
underlying patellar cartilage. In order to fully test the ROM of the knee, children should 
be placed in a supine position. The paediatric clinician should bear in mind that ‘one of 
the most obvious facts about grownups, is that they have forgotten what it is like to be a 
child" (Randall 1965). Therefore, in order to gain trust it is important to make the child 
feel comfortable and to spend some time to get to know the patient during the 
consultation (Thomson and Volpe 2001). If arthritis is not present, the knee should be 
flexed till the heel touches the buttock and may be extended slightly beyond neutral. 
During the biomechanical consultations for this RCT, it was often noticed that JIA 
children had knee hypermobility. 
 
Physical therapists should prescribe strengthening exercise for medial quadriceps and 
straight leg rises with the foot abducted by 45°. These exercises should be repeated 25 
to 30 times. In addition, if leg length discrepancy (LLD) is diagnosed, correction is 
required. Night splints should be worn in case flexion contractures begin to develop. 
According to a recent study of medical treatment of JIA, intra-articular corticosteroid 
injections (especially triamcinolone hexace-tonide (Zulian et al. 2004)) is effective for 
most patients presenting with flexion contractures or leg length discrepancies (Hashkes 
and Laxer 2005)  Finally, the activities that should be recommended to improve knee 
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pain are swimming, ascending and descending stairs, and kicking a ball (Cakmak and 
Bolukbas 2005; Emery et al. 1995). 
 
During this RCT study, biomechanical assessment was carried out with each 
participant, and foot and ankle pain was often reported by the children. An important 
step that should be made in order to improve clinical outcomes is to recognise 
inflammatory joint at early stage of the disease (Haber et al. 2010; Tattersall and 
Rangaraj 2008). The optimal management is highly variable in each JIA patient; some 
of the articles available only offer recommendations because the actual treatment 
should be customised to meet the conditions of each patient (Haber et al. 2010). In 
order to maintain function and to minimize deformities, early recognition of the disease 
and application of effective JIA therapy are vital (Haber et al. 2010). The 
podopaediatric intervention should focus on the examination on the affected and the 
unaffected joints; tests should be carried out with particular care on: joints, bones, 
insertion of tendons, ligaments ROM and strength. 
 
If pathologies are diagnosed as a direct compensation for antalgic gait, is it is advised 
that treatment should be focused to address the pain, rather than the deviation itself 
(Fairburn et al. 2002). These authors clearly support the idea that pain relief is the 
primary JIA treatment outcome, which reflects the main aim of this doctoral thesis. 
 
During data collection it was not possible to statistically quantify how long the 
symptoms have been present in different joints or tendons. A quite significant 
proportion of patients, particularly for the youngest children, could not recall with 
precision when the pain started. In some occasions the parents mentioned the child 
complained of pain in a particular joint but on examination the child showed no clinical 
signs of pathology. In addition, depending on the different arthritic flare up episodes, 
certain children before starting the data collection reported that some joints may 
became suddenly painful and acute, and other joints instead remained more stabled. 
Another fact that did not allow an accurate account of symptomatic joints was related 
to poly-arthritic JIA children. Some of them could not always remember exactly the 
history of symptomatic joints within the lower limbs, particularly in the toes, making it 
difficult to provide exact number. It can be argued that these are typical autoimmune 
symptoms patterns in JIA children that cannot be controlled and most of all it is 
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difficult to report them with statistical precision. Finally, even if the precise number of 
symptomatic joint was not statistically reported, it was still possible to intervene and 
provide podiatric care to the trial group. 
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 Subtalar Joint (STJ) 6.4.
 
In order to test repeatability skills from the data collector, the STJ ROM for each child 
recruited in this doctorial project, have been recorded three times in each visit and in 
each of the two follow up appointments (3
rd
 month and 6
th
 months). The ankle joint 
allows dorsiflexion and plantar flexion of the foot, therefore, the loss of dorsiflexion 
ROM due to synovitis, can have a direct effect on the level of ambulation and 
eventually on the level of activity and resistance (Rothschild 1999). The loss of plantar 
flexion, although less common, can occur in children and can lead to abnormal gait. In 
the survey carried out by Hendry et al. (2008) gait abnormalities, foot pathologies 
and/or active foot disease were outlined to be the most common reasons for referral to 
the specialist podiatrist. 
 
During data collection it was noted that children diagnosed with extended oligo- or 
polyarticular-onset JIA underwent multiple intra-articular corticosteroid injections at 
six month intervals, with the ankles and STJ commonly injected (Hendry et al. 2008). 
For this particular reason accurate details of joint injections were recorded and 
subsequently labelled as not-stable. Hashkes and Ronald (2008) recently reported that 
potential non-medical treatment for JIA could involve the use of orthotics as they are 
often used for ankle or subtalar arthritis or for foot deformities in order to reduce pain 
during ambulation and to improve gait. The authors also mention that arch support 
could be used for flatfoot, and to minimize pressure on metatarsal heads, thus 
preventing the formation of callus or subluxations of the toes (Hashkes and Ronald 
2008). This thesis may provide evidence to confirm the assumptions made by Hashkes 
and Ronald (2008).  
 
The ICC results confirmed the reliability of the STJ measurements taken in each of the 
data collection. These are important aspects as the prescription of the pre-formed semi-
rigid FOs highly depend on the correction added on the rearfoot to improve STJ 
alignments. According to Portney and Watkins (2000) the ICC results obtained in both 
groups STJ measurements can be considered as ‘excellent’. In addition, both groups 
presented with similar STJ features. None of the patients presented with less than 4° of 
eversion when measuring the difference between relax-calcaneal-stance-position 
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(RCSP) and the neutral-calcaneal-stance-position (NCSP). Additionally, none of the 
JIA children presented with STJ ROM of less than 12°, which may be considered to be 
an insufficient ROM required for functional FOs prescription. No changes of FOs rear-
foot prescription were made during the 6 month trial. In conclusion, the RCSP and the 
NCSP measurements proved to be highly repeatable (appendix II).  
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 Pain and Quality of Life Questionnaires 6.5.
 
In this chapter, primary and secondary outcomes results will be discussed in details. As 
mentioned in the chapter 4.4, within and between data analysis were carried out to 
provide extended details of the different parameters investigated.  
 
Because of the nature of this pragmatic research, many primary and secondary 
variables have not yet been explored before in JIA children; therefore the reader will be 
informed in details about the clinical implication and the links between the different 
outcomes variables.  
 
It is important to underline that Bonferroni adjustments were not utilised for the 
different reasons expressed in chapter 4.4.5. Within the statisticians community there is 
no clear consensus about the use of this type of adjustment which is proven to 
dramatically increase Type II errors (Perneger 1998). As new experimental studies are 
performed, the chances of finding significant results decline radically. Type I errors 
cannot decrease without inflating type II errors; and type II errors are deemed to be no 
less false than type I errors (Moran 2003). The use of Bonferroni procedures further 
reduces power, increasing a Type II error to unacceptable levels. Moran (2003) 
explained that if for example a researcher has 10 single tests in a table achieving with 
five of them statistical significance at p=0.049, with the use of Bonferroni correction, 
the maximum p-value to reject the first null-hypothesis is 0.005. Therefore, none would 
fall below that level; hence the researcher is forced to fail to reject all null hypotheses. 
Furthermore, Bonferroni adjustment possibly contributes to publication bias and 
obstructing the advance of the research field (Nakagawa 2004). P-values, although 
useful, are not more important than effect sizes and do not substitute the quality 
interpretation of recognised reviewers. Very few institutions would keep investing time 
and money in a research where significant finding are altered by the not correct use of a 
p-value adjustment test (Moran 2003).   
 
In the BMJ, Dr Perneger (1998) used the following example to explain why researchers 
should immediately discourage the use of Bonferroni adjustment: in a case of a doctor 
who orders 20 different laboratory tests for a patient, only to be told that some are 
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abnormal, without further details. Thus, Bonferroni adjustments provide an answer to a 
largely irrelevant question. Also, with the use of Bonferroni in experimental research, 
an effective treatment will highly risk to be no better than a simple placebo. Therefore, 
Bonferroni adjustment does not guarantee a prudent interpretation of clinical results 
(Perneger 1998).    
 
The same author also indicates that, if Bonferroni adjustment will routinely be used, 
cynical researchers would ‘slice their results like salami’, publishing one p-value at a 
time to escape the fret of the reviewers, which will end up in wasting time, energy and 
public money. Furthermore, meta-analysis would ‘go out of business’, since a pooled 
analysis would reject retrospectively all original discoveries by adding more tests to be 
adjusted for. According to Dr Perneger (1998) journals would have to create a new 
section names “p-value updates,” in which p-values of previously published papers 
would be corrected for newly published tests, based on the same study, and so on. This 
is clearly an unsustainable scenario in any research field. 
 
Finally, the best approach that should be adopted, it appears to be that researcher 
should simply report accurately the details of the methodology and the effect size, 
along with the exact p-values. Furthermore, the author/s should discuss in details the 
possible interpretations of each result, allowing the reader to independently reach a 
conclusion without the unclear support of Bonferroni test (Nakagawa 2004; Perneger 
1998).    
 
6.5.1. VAS 
In the field of pain research, the method often adopted for the quantification of pain 
severity and relief is VAS. The VAS is easy to use, the results are reproducible, and it 
can be applied in a variety of practice settings (Powell, Kelly and Williams 2001). Very 
little time is required to describe individual pain level and the subjects should feel 
better understood, less vulnerable and more cared for (Chapman and Kirby-Turner 
2002).  
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With regards to paediatric rheumatology, the VAS system has been successfully used to 
monitor and evaluate the pain level and improvements over a period of time whilst 
using prescribed FOs in JIA children (Marie 2005; Powell et al 2005). Recent studies 
conducted on acute pain with 96 patients provided 432 paired measures which 
highlighted the high repeatability level of the VAS (Bijur et al. 2001). As reported by 
the study presented by Dhanani et al. (2002) with 533 paediatric rheumatology patients, 
an 8mm difference in the VAS score is indicative of clinical difference (Dhanani et al. 
2002).  
 
During the RCT, an evaluation of pain level at baseline was conducted to identify if 
any discrepancies were present amongst the two groups. The same results at baseline 
were recorded when the medication status was considered separately in the statistical 
test.  
 
The improvement on pain level recorded by the parents suggested that FOs had a 
positive effect on JIA children. Pain improvement was statistically significant only for 
the trial group between baseline-3
rd
month, 3
rd
month-6
th
month and baseline-6
th
month 
intervals. These encouraging findings may indicate that FOs were able to reduce pain 
level in JIA children by the 3 months with further reduction in pain by 6 months. In 
addition, these results reflected the findings reported by Dhanani et al. (2002), because 
between the baseline and the 6
th
 month interval, 8mm difference was found for the trial 
group only. Another indication that FOs had a positive clinical effect upon improving 
the pain level in JIA children was that for the stable medication group, 8mm difference 
was found at baseline-6
th
month interval. These results appear to show the similar 
positive conclusions presented by Powell et al. (2005); however, this JIA study was 
able to involve a much greater number of participants and pain improvement was 
compared between a control and an active treatment group, providing a more robust 
evidence base. 
 
Finally, VAS appeared to be an easy, quick and effective tool for the investigation of 
pain in JIA children, and it will be useful to adopt this for future studies in paediatric 
rheumatology. The clinical implications of these findings, outline in the result section, 
are that children with JIA who are prescribed FOs with chair-side modifications should 
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experience a decrease in lower limb pain by three months. The trend showed that the 
trial group experienced reduction of symptoms for the whole duration of the study.   
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6.5.2. CHAQ   
 
All JIA children recruited at the ‘Royal Edinburgh Hospital for Sick Children’ and 
‘Ninewells Hospital, Dundee’ regularly received the CHAQ questionnaire before their 
paediatric rheumatology consultation. The 30 questions, grouped into 8 domains, are 
assessed in a scale range from 0 to 3 (Geerdink et al. 2009).  This questionnaire has 
been described as easy to administer and very well accepted by the patients and their 
parents. PRINTO cross-culturally adapted and evaluated the original English versions 
of the CHAQ in 32 different countries. The translated versions appear to be reliable and 
valid tools for the functional, physical and psycho-social assessment of children with 
JIA and can be easily used in routine clinical practice and in clinical trials (Ruperto et 
al. 2001). However, few issues have been reported about the CHAQ, particularly with 
regard to being able to distinguish accurately age with the variation of items in 
assessing chronic rheumatic diseases in children (Pouchot et al. 2004). Baring in mind 
these issues, CHAQ was handed out to the parents and all questions were always 
completed. It can be argued that compared to the PedsQL, the CHAQ does not account 
for the different age of the patients, which may have had an influence on the overall 
results obtained. 
 
Within the groups, CHAQ appeared to have recorded significant differences within 
both the control and the trial group, even when the stable group was analysed on its 
own. These results suggest that within the groups changes occurred during the whole 
duration of the trial. The median of the control group started at 0.13 (baseline), then 0 
(3
rd
 month) and 0.13 (6
th
 month); therefore, no major changes occurred for the control 
group during the study. On the other hand, the trial group showed a more positive trend 
towards quality of life improvement, 0.38 (baseline), 0.25 (3
rd
 month) 0.13 (6
th
 month). 
Additionally, clinical significance was found for the trial group at baseline-3
rd
month, 
3
rd
month-6
th
month, and baseline-6
th
month; indicating a positive trend of improvement 
of quality of life for the JIA children who worn the FOs during the whole period of the 
trial.  
 
With regards to the comparison between the groups, the CHAQ results showed 
significant difference only for the stable-trial group at baseline-6
th
month, which 
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reflected the data obtained for the VAS. Therefore, data indicated improvement for the 
stable-trial group only; however, changes were not significant between baseline-
3
rd
month and 3
rd
month-6
th
month.  
 
Although positive results emerged from the analysis of the CHAQ data, it is important 
to be mindful of the observations made by Pouchot et al. (2004) in which he expressed 
issues from the CHAQ system in detecting the age variation, particularly when 
investigating chronic rheumatic diseases in children. Furthermore, although the CHAQ 
is a widely used and well validated tool in paediatric rheumatology, it appears to be 
fairly insensitive to score changes. It is important not to over interpret the CHAQ score 
in isolation, but instead it is advisable to compare the trend of data in conjunction with 
other quality of life tools. 
 
Finally, the data gathered may indicate that parents observed an improvement in their 
children’s quality of life between the stable-trial groups. CHAQ data reflect the trend 
highlighted by the other tools adopted to investigate the pain and quality of life of JIA 
children. CHAQ is currently used on a regular basis during routine appointments within 
the paediatric rheumatology team at Edinburgh Royal Hospital for Sick Children and 
Ninewells Hospital (Dundee); it is important to notice that during the study nobody 
failed to complete the questionnaire or struggled to understand the questions. The 
clinical implications of the findings obtained with the CHAQ are that stable-children 
with JIA, who are prescribed FOs, should experience an improvement of quality of life 
within 6 months. 
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6.5.3. PedsQL Paediatric Generic module (version 4.0) 
 
This quality of life tool is completed directly by children and represents a valuable 
system to detect paediatric generic activities. PedsQL is designed to gather independent 
ratings from children and parents describing problems with children’s physical, 
emotional, social and school functioning (Sawyer et al. 2004). The generic core scale 
consists of 23 items, if more than 50% of the items in the scale are missing, the scale 
scores should not be computed (Varni et al. 2002); during this study all questionnaires 
were always fully completed and the questions were divided according to the age of the 
patient. Previous studies carried out on 5991 children ages 5–16 confirmed the 
reliability of this questionnaire’s feasibility, reliability, and validity of the PedsQL 4.0 
as a paediatric population health outcome (Varni et al. 2003). On the basis of these 
positive results, PedsQL 4.0 was provided to the JIA children during data collection. 
 
The results gathered in this RCT were very encouraging; PedsQL (paediatric generic) 
showed similar score level between the control and trial group at baseline indicating 
that both groups started with similar score levels. Statistical difference was observed 
for the trial group and stable-trial only; and it manifested in each of the intervals 
investigated during the study. The PedsQL (paediatric generic) was able to be answered 
by all the recruited children without issues. The younger age group was helped by the 
data collector who read out the questions.  
 
Analysis between the groups showed that statistical and clinical significance was 
attained for the trial group and stable-trial group only. The minimum 5 points 
difference between intervals determined if clinical significance was attained (Varni et 
al. 2002). Therefore, it appeared that the introduction of FOs as the only additional 
treatment intervention seemed to have an immediate positive effect on the quality of 
life of the children already within 3 months. Additionally, it appeared that the sharpest 
improvements occurred between baseline-6
th
month intervals; on the other hand, no 
particular changes were noted between the 3
rd
-month-6
th
month intervals. These results 
reflected the positive trend showed by Powell et al. (2005). However, during that study 
the only PedsQL score which contributed to the final conclusion was the physical 
functioning subscale. Instead, in this RCT all subscales (physical, emotional, social and 
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school functioning) were analysed and counted together to provide better overall 
conclusions on the quality of life impact that FOs have on the JIA children. 
    
Finally, the PedsQL (paediatric generic) questions independently answered by the 
children, suggested that for those JIA patients who received the FOs there is a trend of 
immediate clinical improvement of their quality of life compared to the control group.   
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6.5.4. PedsQL Paediatric Rheumatology module (version 
3.0 
According to Varni et al. (2002) this particular module (version 3.0) was designed to 
measure paediatric rheumatology–specific issues, which have been increasingly 
adopted for clinical trials, clinical practice and health care research. Evidence-based 
confirmed the reliability, validity and responsiveness of the PedsQL 3.0 Rheumatology. 
The responsiveness of the PedsQL in paediatric rheumatology was proven through 
patient changing score over time as a result of a clinical intervention (Varni et al. 
2002). According to Powell et al (2005), while a PedsQL Rheumatology Module does 
exist, it was not used in their trial. Instead, only the Physical Functioning Subscale of 
the PedsQL 4.0 was used for their investigation of JIA quality of life using expensive 
custom made FOs (Powell et al 2005). It can be argued that the remaining subscales of 
the PedsQL (emotional, social, therapeutic and school functioning) would have 
provided additional evidence to monitor the impact of FOs specifically in JIA quality of 
life.   
 
In the RCT the results acquired directly by the patients themselves, showed a similar 
score level between the control and trial group at baseline, indicating that both groups 
commenced the trial from a similar score level.  
 
Median values indicated no change within the control group over 6
th
 months; in 
contrast, the median values of the trial group started at 72.60, and then a sharp increase 
followed till 81.72 at the 3
rd 
month and at 6
th
 month were 89.67. The positive results 
obtained by Varni et al (2002) reflected the findings within the trial group attained for 
the whole duration of the study even when the stable group was considered separately. 
Statistical significance was not found within the control group. 
 
During data comparison between the groups, statistical significance was obtained 
particularly at baseline-3
rd
month and baseline-6
th
month, indicating that the 
improvement of JIA quality of life was recorded for the trial group in only 3 months 
and it was maintained for the whole duration of the trial. These positive outcomes are 
particularly important for this multicenter study, as the questions which were asked 
evaluated typical daily issues expressed by JIA children. The trial and stable-trial group 
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also showed a significant clinical improvement over the baseline-3
rd
month and 
baseline-6
th
month. Also in this PedQL (paediatric rheumatology module), if five points 
difference were recorded between each data collection, clinical significance was 
attained (Varni et al. 2002). Results showed that the difference at baseline-6
th
month 
interval was 9.05 for the trial group, and 10.10 for the stable-group. Therefore, clinical 
significance was acquired with more than twice the minimum score required.  
 
These encouraging results may suggest that PedsQL 3.0 was able to be completed by 
all participants without problems and that only the trial group appeared to report an 
improvement with regard to common issues related to paediatric rheumatology. These 
results reflect the positive trend previously identified by the PedsQL 4.0, and may 
provide new clinical evidence suggesting an improvement in quality of life already by 3 
months when using the FOs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
324 
 
6.5.5. PedsQL Parent Generic module (version 4.0)  
This particular PedsQL module (version 4.0) allows investigation of quality of life of 
patients from the parent’s point of view. According to the author of PedsQL, during 
each data collection parents have to complete the questionnaires independently, without 
consulting the child. Additionally, as happens with all other tools to investigate quality 
of life, exactly the same parent was asked to fill in the questionnaire. Failing to do so 
could have introduced reporting errors within the study which might have influenced 
the final results. In order to monitor any communication between parents and child, the 
data collector was always present to guarantee the appropriate procedure for 
completion. 
 
In a recent study, when the PedsQL 4.0 Generic Core Scales were administered to 
1,629 parents, the results indicated that the questionnaires were reliable for group 
comparisons also from the parent’s point of view (Varni et al. 2002). It can be argued 
that to accurately evaluate the quality of life of JIA children, clinicians should consider 
as many sources of information as possible. Sawyer et al. (2004) reported some 
dissimilarity in the final PedsQL data obtained from parents and children. This fact 
underlines how important it is for practitioners to compare questionnaire results from 
both children and their parents. Additionally, it can be argued that clinicians should 
receive adequate training to develop the required skills to assess children (Sawyer et al. 
2004). On the other hand, a more extended study based of PedsQL (parent generic) 
involved 10241 families which demonstrated the feasibility and measurement 
properties of this quality of life tool for parents (Varni et al. 2003).  
 
The results obtained from this JIA study reflected the conclusion made by Varni et al. 
(2002 and 2003). Firstly, the PedsQL Parent Generic module score in both groups 
started at similar levels. Over the course of the study, it appeared that statistical 
difference between the groups was acquired only at baseline-6
th
month in favour of the 
trial group. However, the same trend was not noted when the stable-trial group was 
considered on its own, suggesting that for those children who had stable medications, 
parent did not appear to notice any significant changes in their children’s quality of life. 
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Clinical significance for the PedsQL Parent module was achieved if five points 
difference were recorded between each data collection (Varni et al. 2002); however, 
Varni et al. (2003) concluded that minimal clinical significance for the parent can also 
be achieved with 4.5 points difference. During the RCT study, 5 points was deemed to 
be the more appropriate difference to be considered between the intervals, also to 
maintain the same role applied to the children data analysis and to allow an easier data 
comparison. During baseline-6
th
month interval, clinical significance was found only for 
the trial group (10.94) and not for the control group (3.91). It can be argued that, no 
significant changes were recorded during the first 3 months of the trial, and only after 6 
months, that parents appeared to record improvement in the quality of life of the active-
treatment group. On the other hand, as the questions asked of the parent were not 
specific to the child pathology, this evidence provides further confirmation that the 
PedsQL (parent generic) is suitable to establish a generic parental impression of their 
child’s quality of life.  
 
Finally, all parents were able to successfully complete the questionnaire supplied. The 
results obtained in this RCT provide similar findings to the Paediatric Generic Module 
(version 4.0), reflecting the conclusion made by Varni et al. (2002), suggesting that the 
perception of the child’s improvement is perceived correctly by their parents but it took 
up to 6 months before it became significant.  
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6.5.6. PedsQL Parent Rheumatology module (version 3.0)  
The PedsQL Parent Rheumatology Module (version 3.0) was randomly handed to the 
parents; the feedback received was usually very positive as the questions were 
specifically related to the issues often experienced on a daily basis by their JIA 
children. All questionnaires were completed by the same parent over the 6 months 
period of time in order to limit the introduction of reporting errors that could have 
affected the final results. This methodological approach was not adopted in the study 
from Powell et al. (2005), or at least the author failed to specify this important detail.  
 
Varni et al. (2002) confirmed reliability, validity, and responsiveness of the PedsQL 3.0 
Rheumatology Module in paediatric rheumatology with a population of 231 children 
and their parents. Recent evidence underlined the importance for clinicians in obtaining 
specific information about children’s quality of life and pain from both parents and 
children (Sawyer et al. 2004).   
  
Initially, the PedsQL (Parent Rheumatology Module) initial score in both groups 
started at similar levels, confirming that the perception of the quality of life was not 
different between the groups. Within the control group, median values were mostly 
stable and parents did not seem to report any significance changes over the whole study 
period. On the other hand, the parents of the active treatment group showed a sharp 
increase in the median values, starting from 62.52, then 79.00 at 3
rd
 month and finally 
reaching 83.70 at 6
th
 month. Data highlighted significance improvement within all 
intervals considered, even when the stable-trial group was considered independently.  
 
According to the data gathered from the comparison of the two groups, it appeared that 
clinical significance was found in both trial and stable-trial group at baseline-6
th
month 
interval with more than twice the minimum score required. The clinical implications of 
these findings are very positive, as the paediatric rheumatology questions answered by 
the parents match with the perception expressed by the JIA children, providing further 
evidence that FOs may have contributed to this positive final outcome. Furthermore, 
the results reflect the reliability and responsiveness of the PedsQL 3.0 Rheumatology 
Module previously investigated by other researchers (Sawyer et al. 2004; Varni et al. 
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2003). This additional evidence may help in the future to extend the use of the PedsQL 
in paediatric rheumatology.  
 
On the other hand, it worth noticing that although there was a positive trend already 
between baseline-3
rd
month and 3
rd
month-6
th
month, it was not substantial enough to 
acquire statistical significance. These findings may suggest that it takes up to 6 months 
for parents to identify improvements in their JIA child’s conditions; whereas the 
PedsQL (paediatric rheumatology) showed significant improvement for the trial group 
already after 3 months. These results may reflect previous observations made by other 
studies where few dissimilar data were recorded between parent and child data (Sawyer 
et al. 2004). Possible reasons for these slower parental observations may be related to 
lack of communication between the child and the parent; or that the observed changes 
only become noticeable in the longer term, whilst children report improvements earlier 
since they are in less pain by already 3 month. 
 
In conclusion, the PedsQL (parent rheumatology) scores suggest the FOs intervention 
to have had a positive impact in improving the quality of life of JIA children; results 
match the overall trend expressed by the parents and their child. However, the parent 
seemed to require more time to recognise quality of life improvements when compared 
to their children. 
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 Gait Analysis 6.6.
 
Motion analysis laboratories measure aspects relating to human locomotion as part of 
clinical practice or research (Sutherland 2005). However, the applications of gait 
analysis to humans with different pathologies such as Cerebral Palsy, Parkinson's 
disease, and neuromuscular disorders only started in the 1970s. With the advances of 
technology, video gait camera systems allowed researchers to obtain and record gait on 
pathological and healthy patients with significant reduction in costs and time 
(Sutherland 2002). 
 
With the aid of barefoot and in-shoe measurements technology, it has also been 
possible to diagnose recurrent foot pathologies in JIA children such as planus-valgus, 
pes cavus, hallux valgus, forefoot adduction and claw or hammer toes (Truckenbrodt et 
al. 1994). Research has suggested that barefoot pressure data from at least 3 to 5 steps 
are required and multiple barefoot walking trials across the platforms is needed during 
research data collection (Hughes et al. 1991). For these reasons, all JIA children 
involved in the RCT study were recorded using a 1.956m length HR Walkway, as well 
for the F-Scan, allowing for multiple steps recordings.  
 
Recent publications suggest that on some occasions certain recordings were excluded 
and repeated if they appeared incorrect, or if the subject stopped on the mat during 
walking, or if the patient did not keep walking past the mat for more than two steps 
(Zammit, Menz and Munteanu 2010).  Additionally, 3 trials seemed to be commonly 
used during paediatric gait analysis, as this number of trials has previously been proven 
to be sufficient in an analysis of force and pressure data (Hughes et al. 1991; van der 
Leeden et al. 2004).  
 
Hadfield et al. (2003) reported that the Tekscan software was able to evaluate the 
plantar pressure changes which occurred in the Achilles tendon after the medialising-
calcaneal-osteotomy (MCO). The data also revealed that average pressure over the 1
st
 
and 2
nd
 metatarsal heads decreased significantly after MCO surgical intervention. At 
the same time there was a significant increase in average pressure over the medial and 
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lateral aspect of the heel post-operation. This publication also confirmed the ability of 
the Tekscan system to detect forefoot pressure changes.  
 
Randolph (2000) concluded that the use of F-scan could benefit podiatrists for orthotic 
prescription to assist in pain relief and to improve excessive pressure on the foot, which 
could lead to foot ulceration (Randolph et al. 2000). Unlike other previous authors 
mentioned in this chapter, Randolph (2000) stated what he believed to be the 
disadvantages related to the F-scan system. Firstly, he referred to its high cost, which at 
the time of that study was $25 per each individual digital insole. Secondly, according to 
the author the time needed to interpret and analyse the data was deemed to be too 
lengthy, and it initially required training in order to carry out appropriate gait analysis.  
 
Similarly, Li et al (2000) tested the F-Scan with his participants walking in their shoes 
at a comfortable speed. Measurements were recorded 3 times for at least 3 consecutive 
footsteps. The same methodology was adopted in this JIA study. Li et al. (2000) 
reported that brand new F-scan sensors were used for each new subject enrolled in the 
research. The peak pressure over the entire foot was investigated as well as the hind-
foot, the midfoot, the forefoot; comparisons between the 2 groups were evaluated. 
Results revealed that FOs prescribed to the RA patients proved to reduce peak pressure 
more when compared to those of the control group. The RA group particularly showed 
greater reduction of pressure during the stance phase of gait (p<0.01). The author 
concluded that thanks to the F-scan system it was possible to prove the efficacy of FOs 
with RA patients (Li et al. 2000). It can be argued that, although the F-scan sensors 
might be quite costly, they seemed to be very durable over a period of time, particularly 
when dealing with children, and also the continuous software updates over the years 
made data analysis process much easier and quicker. 
 
According to Joanne (2007) approximately 6 to 7 consecutive steps should be recorded 
per trial at a sampling frequency of 50 Hz. The podiatrist should normally disregard the 
first and last step in order to exclude the effects of gait acceleration and deceleration 
(Joanne et al. 2007). The indications highlighted by this author were taken into 
consideration during the data collection stage of this study.  
 
330 
 
In conclusion, the previous studies carried out in gait analysis using Tekscan 
equipment, proved to be valuable clinical evidence that allows the construction of a 
robust and repeatable methodology for this pragmatic paediatric study. These 
guidelines were adopted for each gait analysis recording carried out with JIA children 
at the motion analysis lab in Queen Margaret University and the TORT centre.  
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6.6.1. Gait Time (sec) 
 
Gait time represents an important parameter that was investigated during this RCT 
study using the HR Walkway. It indicates the time from the first contact of the first step 
to the time of first contact of the last step registered on the walkway (Tekscan 2010). 
Currently this outcome measure is not often used in literature to report Tekscan gait 
analysis findings, particularly in children. One of the possible reasons may be because 
it is only recently that this parameter can be easily obtained from the new Tekscan 
software (version 7.0). 
 
Previous veterinary research recorded gait time in dogs. It appeared that the walkway 
system can be effectively used for comparison of the walking gait time and that the 
pressure-sensing walkway is a simple method for the acquisition of a temporal-spatial 
parameter (Jongmin et al. 2011). It can be argued that, although veterinary research is 
an extremely important field, more evidence base is needed to support the role of 
investigating gait time, particularly in children.  
 
Firstly, gait time comparison in this RCT showed that both groups started with similar 
values, confirming that no statistical difference was present between the groups at 
baseline. As gait time is a parameter that few instruments of gait-software can 
automatically gather, it was important for this study to monitor the level of repeatability 
of the Tekscan between each data recording. As shown in Appendix XIX, the ICC 
results measured over the three recordings taken in each data collection confirmed a 
high degree of repeatability and reproducibility. Precisely, the ICC can be defined as 
‘good’ in both control and trial groups, even when the stable group was considered 
separately.  
 
Data analysis (Friedman test) highlighted that statistical difference was found within 
the trial and stable-trial group, which was not obtained for the control group. 
Wilcoxon’s test reflected the same results, with the only exception being that the initial 
interval (baseline-3
rd
month) did not show statistical difference. In contrast, results 
showed a sharp increase for the trial group within 3
rd
month-6
th
month and baseline-
6
th
month. The same trend was confirmed once again when the stable-trial group was 
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considered independently. Furthermore, median values allow the researcher to verify 
how the control group values were really stable (baseline 1.10, 3
rd
 month 1.13, 6
th
 
month 1.11); instead, in the trial group a reduction in gait time was recorded at 
6
th
month (baseline 1.17, 3
rd
 month 1.17, 6
th
 month 1.04).  
 
On the contrary, the between group comparison analysis did not appear to show any 
significant results. However, even if statistically it was not significant, the stable-trial 
group showed a positive trend towards improvement (p=0.060). It can be argued that if 
more patients were involved in the study or if there would have been the opportunity to 
monitor gait time changes for example at 9
th
 month, possibly more significant results 
might have been identified from the children that received FOs intervention. As the 
recordings were carried out at barefoot, the results may suggest that the benefit of the 
treatment is reported mostly when the FOs are worn. Therefore, clinician should 
underline to the JIA children, that gait time can improve, primarily is FOs are worn 
regularly. 
 
Finally, this new evidence suggests that gait time improvement was found within the 
group that received FOs; however, it takes up to 6 months before they become 
significant. In conclusion, even if a trend toward gait time reduction was noted, it was 
not sufficient to achieve statistical significance. The results suggest that the effect of 
the podiatric intervention is recorded mostly if the FOs are worn. Hopefully these data 
can contribute to strengthen and add new knowledge on paediatric gait time. 
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6.6.2. Gait Velocity (cm/sec) 
Gait velocity is a parameter that is commonly investigated in paediatric rheumatology 
patients (Broström et al. 2002; Hartmann et al. 2010; Powell et al 2005; Szer et al 
2006).  A study of  twenty-three pre-pubertal children, aged between 5 and 11 years old 
suggested that JIA had significantly less participation in organised sports (Henderson et 
al. 1995). JIA children were found to have a walking velocity significantly lower than 
healthy children: therefore clinicians should encourage JIA children to participate in 
regular physical activities in order to prevent reduced fitness level (Broström et al. 
2002; Broström 2004). The study investigated 14 juvenile chronic arthritis, and 15 
healthy children. With the aid of a light-beam which triggered the recording, a second 
light beam was placed 5 metres away which stopped the timer. The walking velocity of 
arthritic children appeared to be 1.06 m/s, whereas healthy children seemed to be 
1.28m/s (Broström 2004).   
 
During this RCT study velocity was investigated on the JIA children with the aid of HR 
Walkway software. Initial gait velocity data showed that both groups started with 
similar values, confirming that no statistical difference was present between the groups 
at baseline. As well as for the gait time recordings, a repeatability test was carried out 
within each data collection, and the ICC values confirmed that the HR Walkway was 
able to record ‘good’ values (appendix XIX).  
 
Powell et al. (2005) reported that speed of ambulation was recorded using a stopwatch, 
and that 3 attempts were timed and an average speed of ambulation was recorded. From 
that publication, the reader is not informed about the repeatability skills of the data 
collector; additionally, the reaction time from each child may vary considerably 
depending on the age and the extension of the pathology. Instead, in our RCT study, 
gait velocity measurements were initiated by the software as soon as the heel came into 
contact with the digital platform. With a known length of the HR walkway and the 
contact time, speed of ambulation was automatically calculated. On the basis of the 
repeatability data obtained (appendix XIX), it can be argued that this methodology may 
be better than that of a manual stopwatch. 
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During the RCT study, the results have shown that there is a significant improvement in 
walking speed within the trial group either at 3
rd
 month-6
th
month and baseline-6
th
month 
intervals, compared to the control group. In addition, the stable-trial group was 
analysed separately and significant difference was found only within the baseline-
6
th
month interval. Results indicated that FOs have significantly contributed to improve 
walking speed of JIA children who wore FOs. However, changes did not occur 
immediately and the sharpest improvements were noted at 6
th
 month interval. On the 
other hand, when both groups were compared with each other, no significant changes 
were attained.  
 
It can be argued that these results reflect partially the conclusion made by Powell et al. 
(2005), as FOs appear to have a positive impact on the walking velocity of JIA 
children, with the considerable difference that in our RCT children received the chair 
side FOs on the same day. Customisation of the FOs was much more cost-effective 
compared to the POP custom made supplied by Powell et al (2005).  
 
Finally, it can be argued that podopaediatrics could play an important role within the 
paediatric rheumatology team and contribute to children’s ability to become more 
active. Podiatrists could potentially help the multidisciplinary team by providing cost-
effective and non-invasive intervention to arthritic children. Although no significant 
results were noticed between the groups, the active treatment group appeared to 
increase their speed of ambulation and one of the reasons may be because the trial and 
the stable-trial reported a reduction of pain and better quality of life level by the end of 
the study.  
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6.6.3. Stance Time (sec) 
The stance phase of the normal gait cycle begins with the strike of the heel on the 
ground and ends with toe-off at the beginning of the swing phase of gait; therefore, it 
represents the interval in which the foot is on the ground (60% of the gait cycle). The 
stance phase is commonly subdivided through different actions that occurred during 
ambulation: heel strike to foot-flat, foot flat through mid-stance, midstance to heel off, 
and finally from heel off to toe off (Valmassi 1996).  
 
It can be argued that as JIA children appear to walk slower than healthy children 
(Broström et al. 2002), their percentage stance time will be higher compared to what is 
deemed to be ‘normal’. During rehabilitation, clinicians should encourage JIA children 
to maintain a good physical activity level (Szer et al 2006). One of the aims of FOs 
intervention is to reduce the stance time of JIA and to encourage a more propulsive 
gait. If the swing phase time increases, the JIA child will exhibits less double leg 
support (Valmassi 1996).  
 
Stance time was calculated automatically by the HR Walkway software (version 7.0) 
and it provided values for the left and the right foot, however, as previously shown 
(Table 5.4.3.1), results were expressed by evaluating both feet accounted together. 
Results showed that both groups started with similar values in between both groups. 
With regards to the repeatability and reproducibility data, all recordings acquired were 
‘good’ (appendix XIX).  
 
Data analysis demonstrated that there is a trend of reducing the stance time only within 
the trial and stable-trial group. Furthermore, there is evidence that particularly within 
the trial and stable-trial group at baseline-6
th
month interval, statistical significant 
changes were recorded; indicating that the trial JIA children spend less time during 
stance phase. These results confirm the conclusion made by Valmassi (1996), in which, 
along with the improvement of symptoms, patients may exhibit reduction of stance 
time and potentially become more propulsive. 
  
During data comparison between the control and the trial group, no significant 
difference was found. However, the stable-trial group presented a clear trend towards 
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improvement of the stance time values between the baseline-6
th
month interval 
(p=0.055).  The not-stable trial group presented with significant difference between the 
groups in all the intervals investigated, suggesting a reduction in stance time compared 
to the control group. 
 
In conclusion, these data suggest that FOs may have a direct effect in reducing the 
stance time in JIA children within the trial group. Potentially if the study were to be 
conducted for a longer period of time, results might have been even more significant 
when compared to the control group. 
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6.6.4. Total Contact 
The Total contact area was identified by using the PP box available from the Tekscan 
software. With the aid of the PP box, peak pressure values were recorded to quantify 
the area where there is the highest amount of pressure. Hadfield et al. (2004) 
investigated the plantar foot pressure subdividing the foot into seven different regions 
using the HR Walkway; however, they failed to provide an overall result considering 
the total-foot contact. In contrast, Ahrony et al. (1998) proved the importance of 
investigating the PP on the ‘whole’ foot contact parameter. Their study was conducted 
using the F-Scan insole and the whole foot contact provided ‘good’ reliability for 
measurements of PP with their patients. The t-PP represents a very important parameter 
investigated in this RCT, as it provides new evidence on plantar pressure measurement 
with JIA children.  
 
Statistical difference was obtained between the groups only when F-Scan t-PP and t-
PTI measurements were taken with the FOs inside the shoes. On the other hand, the t-
PP and t-PTI data analysed for the HR Walkway and F-Scan-shod showed no 
difference between the groups. These results suggested a positive trend that the 
functional FOs adopted for this study were compared against no-corrective device, and 
that the Tekscan software was able to record the changes between the control and the 
trial FOs. These secondary outcome measures matched with the primary outcomes as 
the reduction of t-PP and t-PTI reflects the improvement of quality of life and reduction 
of pain for the trial group only. It can be argued that possible errors could have 
occurred during the recording process. In order to monitor any mistakes during data 
collection, repeatability tests were conducted in each of the 3 appointments made with 
the participants. The data acquired was demonstrated to have a ‘moderate’ and mostly 
‘good’ ICC score. These results may help to underline the reliability of the data 
acquired in this study, and add strength to the methodology adopted. 
 
In conclusion, the FOs appeared to significantly reduced t-PP and t-PTI values within 
and between the trial groups only. This positive trend of reduction of t-PP and t-PTI 
match with the improvement of quality of life and reduction of pain level only to the 
trial group. 
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6.6.5. Heel Contact 
 
Previous studies focused on quantifying the differences in gait between JIA patients 
and healthy controls. JIA patients showed reduced plantar flexion in push off motion 
(Hartmann et al. 2010). The authors mentioned that the 3D-gait analysis showed that 
the patient group suffered from malposition that can be attributed to movement 
restrictions. The main differences compared to controls lay in reduced hip extension, 
reduced knee extension, and reduced plantar flexion with a passive and decelerated 
push off of the ankle. At present there are no guidelines on how to improve the 
misalignment on some of those joints that may create muscle restriction. Hartmann et 
al. (2010) cautiously recommended mild strengthening exercise to reduce 
inflammation. However, it can be argued that if inflammation is present on the 
calcaneum, heel strike phase may be affected and possible antalgic gait may be adopted 
by the patients. Additionally, the joint malposition may be improved by simple 
podiatric intervention that may aim to readdress STJ alignment.  
 
In fact the results acquired in our RCT while using the F-scan with insole, confirmed 
that FOs supplied to the JIA children played a central role in reducing h-PP compared 
to the control FOs (Table 5.4.5.2). From the data acquired it appeared that FOs with 
chair-side modifications may aid in improving shock absorption at heel strike. 
Additionally, as reported in Table 5.4.5.8 also h-PTI values for the trial FOs are much 
lower compared when compared to the control FOs. These data reflect the aim of the 
study carried out by Hartmann et al. (2010); however, in this RCT it was possible to 
provide positive conclusions by utilising other cost-effective treatment solutions which 
may have a direct link in improving primary outcomes.  
 
Another study investigated the reliability of measure applied in different areas of the 
foot; one of these was the heel (Randolph et al. 2000). The healthy subjects were 
recruited to check if the F-scan insole was able to provide reliable h-PP values that 
could have been used in podiatric management for patients with diabetes. Their study 
concluded that the F-scan insoles are sufficiently reliable to provide PP values. Few 
considerations can be highlighted from this study: firstly, the author provided further 
confirmations on the importance of investigating only the heel area separately from the 
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rest of the foot. Secondly, it gives updated evidence that h-PP data are valuable data 
that need to be acquired with at-risk patients. On the other hand, the number of patients 
recruited is limited and they failed to provide details on the h-PTI. However, Zammit et 
al. (2010), demonstrated ‘moderate’ to ‘good’ h-PP MatScan reliability, but no details 
are provided with regard to h-PTI. It can be argued that particularly when diabetes 
patients are investigated, the treatment goal is to reduce the h-PTI in order to minimise 
the effect of pressure and time of loading (Tekscan 2008). 
 
As shown in Appendix XIX, the ICC scores gathered with JIA children for the 
repeatability and reproducibility study of h-PP and h-PTI within each data recording 
showed that most data had ‘moderate’ and ‘good’ values. This data carried out 
alongside the RCT, may add new evidence on the reliability level of the Tekscan 
equipment and add strength to the methodology of the study. 
 
Statistical difference was obtained between the groups at baseline, 3
rd
month and 
6
th
month only when F-Scan with insole was used and when h-PP measurements were 
taken with the FOs inside the shoes. Also stable-trial group for the h-PP reflected the 
same trend. The values for the h-PTI show significant difference between the groups 
when FOs measurements were carried out. The h-PP and h-PTI data for the HR 
Walkway and F-Scan-shod, showed no difference between the groups. This positive 
trend suggests that h-PP and h-PTI values are lower compared to the control group. The 
results are indicative of the fact that FOs contribute in the redistribution of pressure 
also from the heel area. It appears that the positive effects of the FOs are noted 
immediately, also for the stable-group, since the first recording using the F-Scan 
system. These secondary outcome measures reflects with the primary outcomes as the 
reduction of heel plantar pressure values, shows an improvement of quality of life and 
reduction of pain for the trial group only. These results matched with the conclusion 
made by Li et al. (2000), where heel plantar pressure values were reduced after the FOs 
prescription on adults affected by RA.  
 
All patients’ shoes were checked for suitability to fit FOs at each appointment. The 
chief investigator provided indications to the parents and the patients in how to 
recognise suitable foot wear. 
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In conclusion, previous evidence base confirmed the importance in investigating h-PP 
and h-PTI which was used as guidance during this data analysis. The FOs prescribed to 
the JIA children appeared to significantly reduce h-PP compared to the control FOs; 
which may contribute to improve symptoms and the overall quality of life on the active 
treatment group only. These positive results on reduction of h-PP and h-PTI with the 
use FOs are recorded immediately and reflect the early intervention approach 
considered by other members of the paediatric rheumatology team; and most 
importantly it appears to benefit the JIA children. 
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6.6.6. Midfoot contact 
 
Previous research conducted on adults diagnosed with RA confirmed that when F-Scan 
in-shoe analysis is carried out using FOs, the m-PP appear to be higher (Li et al. 2000). 
Additionally, the authors indicated that the FOs can have a cushioning effect and may 
significantly help in redistributing the plantar pressures. The RA gait recordings 
displayed a significant reduction in heel and forefoot peak pressure, and it seemed that 
one of the main reasons was related to the fact that the PP underneath the midfoot 
became greater. The gait analysis data reflected that the FOs supplied were perceived to 
be comfortable and reduced foot pain during walking (Li et al. 2000). This evidence 
supports the need to map the midfoot section of the foot during gait analysis and 
additionally that m-PP is a common parameter that is investigated to relate secondary to 
primary outcome measures. It can be argued that only 12 symptomatic and 8 healthy 
patients were recruited for their study, and the population of subjects were not solely 
women of the same age. The reader is not informed if the participants were randomised 
and m-PTI was not investigated. The methodology might have been more robust if: 
more patients with different age group were involved in the trial; and finally if only 
symptomatic RA patients were randomly compared against a control or a trial FOs.  
 
Unlikely to the Li et al. (2000) our RCT provided both m-PP and m-PTI. The results 
suggested that when a comparison between the groups was carried out, statistical 
significance was acquired in all intervals for m-PP and m-PTI, also for the stable group. 
Therefore, with this parameter too, the FOs supplied to the trial JIA children, appeared 
to have immediate effects since the baseline recordings, and it lasted for up to 6 
months. Data reflected the findings made by Li et al. (2000) because higher m-PP 
values were shown only for the trial group (Table 5.4.6.2 and Table 5.4.6.8). In 
contrast, the recording made with HR Walkway and F-Scan Shod did not presented any 
significant changes. Only the data acquired with the F-Scan (with insole) for the trial 
group, clearly show a trend in which the midfoot values are much higher compared to 
the control group. These results may suggest that redistributing the plantar pressures 
only occur when FOs are worn for the trial group.  
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According to the repeatability and reproducibility study carried out prior to the RCT, 
the results reflected the conclusion previously made by Randolph et al. (2000) and 
Zammit et al. (2010) in which they reported that the F-Scan and MatScan systems 
generally demonstrated ‘moderate’ to ‘good’ ICC score level in reporting m-PP.  As 
shown in the appendix XIX, the ICC score appeared to be mostly ‘good’ either for the 
m-PP and for m-PTI. This additional evidence based on the repeatability and 
reproducibility of the Tekscan may be useful for future gait analysis studies in 
podopaediatric. 
 
In conclusion, results seemed to suggest that in the stable-trial and trial group the m-PP 
and the m-PTI were significantly higher than the control group. Therefore, indicating 
that the FOs aid in redistributing plantar foot pressure as the midfoot makes contact 
with the insole. In the foot without the insole, the medial arch usually does not make 
contact, hence the low pressure was found in the control subjects who wore the placebo 
insole. These data reflect previous findings made by other authors, previously 
described, who investigated the effect of FOs. It can be argued that these secondary 
outcomes mirror the improvement of symptoms exhibited only by the JIA children who 
were part of the trial group.  
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6.6.7. Forefoot contact 
Plantar pressure examination can be used by the clinicians in the evaluation and 
management of adult and paediatric patients’ gait (Cakmak and Bolukbas 2005; Orlin 
and McPoil 2000). Particularly with JIA gait, it appears that due to juvenile arthritic 
foot pain at push-off, the ground reaction forces may be lower compared to healthy 
chidren (Broström et al. 2002). The forefoot is a parameter commonly investigated 
while using the Tekscan equipment (Hadfield et al. 2003; Joanne et al. 2007; Luo, 
Berglund and An 1998; Randolph et al. 2000; Riad et al. 2007). On the basis of this 
extensive evidence base in adult and paediatric gait, during our RCT each recording 
carried out with the JIA children was analysed considering the PP and PTI at the 
forefoot.  
 
With regards to the clinical management of JIA forefoot pain, often cushioning 
material, such as poron, was utilised with the aim to reduce the f-PP . As shown on 
Table 5.4.7.2, the values obtained with the F-Scan (with insole) for the trial group only 
were found to be lower compared to the control insole; in contrary, no changes for the 
HR Walkway and F-Scan (shod) were noticed. Therefore, the FOs appear to be able to 
reduce forefoot PP and PTI by shifting some of the load to the midfoot and increasing 
the m-PP and m-PTI. However, the comparison between the groups did not show 
significant differences for f-PP and f-PTI. Particularly for the f-PP, a positive trend was 
found at 3
rd
 month (p=0.054) and at 6
th
month (p=0.063); but it was not enough to 
achieve a statistical significant difference between the groups. It can be argued that one 
possible reason to explain these results is that only a few children presented with 
forefoot pain and pathologies: hence less corrections were applied on the forefoot of the 
FOs. Therefore when the control and the trial FOs were statistically compared on the 
forefoot, no particular differences were attained. Furthermore, as most of the young 
female participants wore very narrow fitting shoes, it was important to customise the 
FOs and reduce as much as possible the thickness of the FOs in the forefoot. A very 
thick FOs may have constricted the forefoot and subsequently incease the forefoot 
pressure. 
 
According to Randolph et al. (2000), the forefoot pressure data obtained by the Tekscan 
system are reliable in use for clinical management. These results reflected our findings 
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gathered during the repeatability and reproducibility study carried out alongside the 
RCT (Appendix XIX). The ICC score revealed that most of the f-PP and f-PTI were 
‘good’ with the F-Scan (shod and with insole) and HR Walkway. These results may 
suggest the positive repeatability level of the Tekscan equipment utilised in the study 
and may provide new evidence in the field of paediatric rheumatology. 
 
In conclusion, the f-PP and f-PTI results suggested that no significant difference was 
recorded between the trial and the control group. Overall, with the aid of cushioning 
materials and chair-side modifications applied on the FOs, the f-PP and f-PTI appeared 
to be reduced for the trial group only. It is important to remember that the forefoot 
corrections were less frequently applied compared to rear-foot adjustments, as they 
might have constricted the forefoot inside narrow fitting children’s shoes. Finally, the 
forefoot results comprised the 5
th
, 4
th
-3
rd
, 2
nd
 and 1
st
 metatarsal heads. The results of 
each of these parameters will be further explained in this chapter. 
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6.6.8. 5th metatarsal head contact 
 
Skin callus and bursae are often observed at the metatarso-phalangeal joints as a natural 
protective mechanism, but over a period of time they may become symptomatic. These 
observations were highlighted by Woodburn and Helliwell already in 1996 by using in-
shoes analysis systems on RA patients. Most of the publications only focus on the peak 
pressure of the rearfoot, midfoot and forefoot, but exclude investigation of the 
metatarsals. Tsung et al. (2004) are among the few authors that investigated both 5
th
-PP 
and 5
th
-PTI. They managed to map the forefoot in different anatomical areas using the 
F-Scan insole (shod and with insole). They analysed the different effect that FOs have 
in redistributing the pressure in diabetes patients against the healthy population. 
Although a very small number of participants took part in the trial (6 diabetes and 8 
healthy), this study provided additional evidence on the importance of investigating the 
metatarsal heads, not only for extrapolating peak pressure data, but also for Pressure 
Time Integral values (Tsung et al. 2004). It can be argued that at present most of the 
literature available on investigation of 5
th
 metatarsal pressure, is focussed primarily on 
diabetic patients (Joanne et al. 2007), and the evidence as yet available on JIA children 
are limited. Our RCT will be able to provide new evidence on the importance of 
identifying the effect of FOs on 5
th
 metatarsal pressure.   
 
According to the results, statistical significance was attained when comparison between 
the groups was carried out for 5
th
-PP (at baseline, 3
rd
 month and 6
th
 month) and 5
th
-PTI 
(at baseline). These findings indicate that the FOs contributed in the reduction of 5
th
-PP 
and 5
th
-PTI compared to the control FOs. Furthermore, changes were recorded only 
when the FOs were used by the JIA children, immediately after the initial data 
collection and did not vary for at least 6 months. The clinical implication of these 
results suggest that FOs have an immediate effect for symptomatic JIA children in 
reducing peak pressure and Pressure Time Integral over the 5
th
 metatarsal (Table 
5.4.8.2, Table 5.4.8.8), therefore reflecting the trend of reduction of pain highlighted in 
the primary outcome measures. It can be argued that if less pain is experienced during 
walking or running, the JIA children might be more encouraged to be active and take 
part in sport activities.  
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The reliability of the 5
th
 metatarsal-head has been extensively tested, and most of the 
publications concluded that the Tekscan equipment is able to provide ‘moderate’ to 
‘good’ ICC scores (Ahroni, Boyko, and Forsberg 1998a; Hadfield et al. 2003; Zammit, 
Menz and Munteanu 2010). According to the appendix XIX, the repeatability study of 
the 5
th
-PP and 5
th
-PTI conducted in parallel with the RCT, reflected the same 
conclusions as the authors previously mentioned.  
 
Finally, the investigation on the 5
th
 metatarsal head revealed that FOs have a significant 
effect when compared between the control FOs. The reduction of the 5
th
-PP and 5
th
-PTI 
not only were repeatable and reproducible over the whole duration of the study, but 
they may have directly contributed in improving the quality of life and reducing the 
symptoms from the JIA children. These findings could potentially be considered by the 
paediatric rheumatology team and the cost-effective inputs that podopaediatrics could 
bring into the care of JIA children may be welcome.  
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6.6.9. 3rd / 4th metatarsal head contact 
The 3
rd
 and the 4
th
 metatarsal heads are gait parameters that have been analysed 
separately from each other or together with the other metatarsals. For example, Tsung 
et al. (2004), considered the 3
rd
 met-head together with the 2
nd
 met-head; Hadfield et al. 
(2003) and Zammit et al. (2010) instead looked at 3
rd
 to 5
th
 met-head; and finally Paton 
et al. (2007) managed to individually investigate each metatarsal head. Therefore, on 
the basis of the previous publications, during this RCT different tests were carried out 
to evaluate the most suitable methodology that should have been adopted during data 
analysis. The plantar recordings were carried out on children age ranged 5 to 18 years 
old, and the feet dimension varied significantly. During data analysis it appeared that 
with the smallest foot sizes it was more difficult to accurately position the PP-boxes on 
the correct anatomical position. It can be argued that the PP-boxes have a limit in sizes, 
and on some occasions it was not enough to accurately isolate very small 3
rd
 and 4
th
 
metatarsal heads. Therefore, in order to reduce measurement errors and wrongly 
distinguish small children metatarsals, the 3
rd
 and 4
th
 met-heads were accounted 
together.  
 
During data analysis, particular care was adopted in monitoring the ICC of the 
measurements made with these smaller anatomical areas; however, as shown in 
appendix XIX, the ICC scores for the 3
rd
-4
th 
PP and 3
rd
-4
th 
PTI were mostly ‘good’. 
These findings confirmed that the methodology adopted was reliable. It can be argued 
that these latest findings may be used as possible guidance for future paediatric gait 
analysis.  
 
Results indicated that the 3
rd
/4
th
PP and 3
rd
/4
th
PTI values of the F-Scan (shod) and HR 
Walkway did not vary between the control and the trial groups; however, from Table 
5.4.9.2 and Table 5.4.9.8 it appeared that FOs facilitated the reduction of 3
rd
/4
th
PP and 
3
rd
/4
th
PTI. During F-Scan (with insole) data analyses, statistical tests seemed to suggest 
that for 3
rd
/4
th
PP significant difference was recorded between the groups at 3
rd
 month 
and 6
th
 month. The clinical implications of these data indicate that changes in 3
rd
/4
th
PP 
does not occur immediately; however, it is sustained for at least 6 months. Compared to 
previous rearfoot and midfoot PP parameters, the forefoot changes seem to take longer 
before becoming significant. In addition, statistical significance between the groups for 
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the 3
rd
/4
th
PTI, was only recorded for the stable F-Scan (with insole) at 3
rd
 month. 
Therefore, no clear patterns of improvement were highlighted. 
 
It is important to remember that forefoot corrections were less frequently used in 
comparison to rearfoot adjustments, as fewer JIA children appeared with forefoot 
pathologies, but also, because if the FOs were too bulky, comfort and fitting could have 
been affected. As shown from the descriptive tables previously mentioned, it can be 
argued that rearfoot correction and the use of appropriate materials aided in improving 
redistribution of pressure and reduction of PP and PTI.  
 
Finally, due to the small shoe sizes of some participant and sizing limitation of the PP 
boxes, 3
rd
 and 4
th
 metatarsals were accounted together. The results confirmed the 
repeatability and reproducibility of the data carried out and highlighted the positive 
effect that FOs has in comparison to the control FOs; which may be linked to the 
improvement of quality of life and reduction of pain experienced only by the trial 
group. 
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6.6.10. 2nd metatarsal head  
As the 2
nd
 met-head appears to be the most weight bearing metatarsal in the foot 
(Clough 2005), the Tekscan equipment allowed the investigation of the effect of FOs in 
JIA children in this particular anatomical area. The colour grading option available 
from the Tekscan software allowed easy identification of 2
nd
 metatarsal head from the 
gait recording compared to the adjacent 1
st
 met-head. Previous authors recognised the 
importance in isolating the 2
nd
 met-head during plantar mapping of the foot in order to 
specifically analyse and compare the differences that occur when podiatric intervention 
is applied (Ahroni, Boyko and Forsberg 1998a; Hadfield et al. 2003; Zammit, Menz 
and Munteanu 2010). Riad et al. (2007) instead, mapped the forefoot into medial and 
lateral aspect, and did not extrapolate 2
nd
PP and 2
nd
PTI. Similarly, Randolph et al. 
(2000) examined the forefoot as a whole; and finally, Powell et al. (2005) failed to 
make any plantar pressure recording on the forefoot.  
 
The JIA results showed that only for the trial group, 2
nd
PP and 2
nd
PTI were much 
reduced since baseline, compared to the control group; indicating that the FOs aid in 
redistributing pressure and reducing the time spent over this particular anatomical area 
(Table 5.4.10.2 and Table 5.4.10.8). Furthermore, only with F-Scan (with insole) 
recordings, statistical difference was noticed for 2
nd
PP and 2
nd
PTI between the groups 
6
th
 month interval. The clinical implication of these results may reflect the trend 
previously described for the 3
rd
-4
th
PP and PTI, in which FOs seems to have a slower 
effect of forefoot parameters compared to the immediate changes that were recorded 
since baseline on the rear-foot. Another factor that might have influenced these final 
results is that few forefoot corrections were applied underneath the 2
nd
 met-head simply 
because it was not necessary and also the data collector had to be mindful of possible 
fitting issues, particularly with young female subjects. It can be argued that this 
pragmatic study also provided new evidence in how to approach podopaediatric clinical 
management, in which caring for fitting issues proved to increase compliancy.  
 
As previously mentioned, in order to monitor if the JIA children regularly wore the FOs 
prescribed, both control and trial FOs were covered with black 0.75cm EVA material; 
the signs of dynamic impression demonstrated compliance, and were typically shown 
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underneath the 2
nd
 met-head, which also helped to establish the degree of durability of 
the materials over the 6 months. 
 
With regards to the repeatability of the recording taken, our results reflected the 
conclusion made by Ahori et al. (1998) and Zammit et al. (2010). The ICC scores 
emerged during each data collection session using the Tekscan equipment appeared to 
be mostly ‘good’. 
 
Finally, it appears that the FOs provided significant reduction of 2
nd
PP and 2
nd
PTI; 
however, these changes may require a few months before showing any effect, and are 
not as immediate as those made by the rearfoot correction. However, the data collected 
suggested a very high level of reliability and may contribute to build a wider 
knowledge on gait analysis of the 2
nd
 metatarsal head.     
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6.6.11. 1st metatarsal head contact 
During data analysis using the Tekscan software, the 1
st
 met-head appeared to be the 
easiest metatarsal head to identify. Apart from Riad et al. (2007) who subdivided the 
plantar foot pressure into medial and lateral forefoot areas; most of the gait publications 
available at present investigated the 1
st
 met-head during mapping of the foot (Ahroni, 
Boyko and Forsberg 1998a; Hadfield et al. 2003; Paton et al. 2007; Redmond, Landorf 
and Keenan 2009; Tsung et al. 2004; Zammit, Menz and Munteanu 2010). The authors 
mostly reported details about the 1
st
PP; in contrary, information regarding the 1
st
PTI is 
less frequently available. Only Redmond, Landorf and Keenan (2009) presented their 
results including 1
st
PTI. This RCT focussed also on 1
st
PTI, and it may add new 
evidence for the importance of this parameter particularly in paediatric gait.  
 
As shown from Figure 5.4.11.2 and Figure 5.4.11.5, no major changes occurred 
between the groups in all the intervals investigated. The reduction of 1
st
PP and 1
st
PTI 
was noted particularly for the children who wore the customised FOs; however it was 
not sufficient to distinguish it from the control group. Therefore, it appeared that no 
statistical difference was recorded between the groups for both 1
st
PP and 1
st
PTI. It can 
be argued that as for previous parameters mentioned, the narrow fitting shoes led to 
minimise the type of forefoot corrections. Although, kinetics wedges were often 
prescribed in the trial group, which would have implied a reduction of thickness 
underneath the 1
st
 met-head, the masking of these areas using the PP box prove that no 
significant changes were attained.  
 
The statistical tests carried out within the groups suggest that no changes occurred over 
the 6 months of the study. These results indicate that the control and trial FOs used did 
not undergo significant modifications during the whole duration of the trial; therefore 
they might be suitable for future podiatric studies where comparison of different FOs is 
investigated. 
 
During the repeatability and reproducibility study carried out in parallel with the RCT, 
it emerged that 1
st
PP and 1
st
PTI mostly displayed ‘good’ ICC values. It can be argued 
that with this parameter also, the repeatability results for the 1
st
PP and 1
st
PTI reflected 
the positive conclusion made by Ahori et al. (1998) and Zammit et al. (2010). This 
352 
 
evidence hopes to add further strength to this study and provide new information for 
future studies in paediatric gait. 
 
In conclusion, the technique of mapping the 1
st
met-head has been extensively used in 
previous studies, but only few papers focussed on 1
st
PP and 1
st
PTI together. The results 
did not show any significant difference between the trial and the control groups. 
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6.6.12. Lesser Toes contact 
Investigation of the lesser toes is less frequently carried out in gait analysis compared 
to other forefoot parameters; some authors completely excluded this parameter from 
plantar mapping of the foot (Ahroni, Boyko and Forsberg 1998a; Chen and Bates 2000; 
Hadfield et al. 2003; Paton et al. 2007; Randolph et al. 2000; Tsung et al. 2004). In 
other studies the lesser toes data were defined but not included in the final analysis of 
the results (Redmond, Landorf and Keenan 2009). On the other hand, Zammit et al. 
(2010) described the ‘good’ ICC scores obtained from the lesser toes data obtained 
during the repeatability tests. Finally, Clough (2005) also utilised Tekscan equipment to 
investigate the implications of functional hallux limitus for lesser-metatarsal overload. 
It can be argued that particularly in the paediatric field, fewer publications are yet 
available which provide details on how the lesser toes parameter changes with podiatric 
intervention. The equipment available for this study allowed focusing also on this 
parameter contributing to the evidence base. 
 
During the repeatability and reproducibility study, the ICC scores for the lesser toes 
appeared to be mostly ‘good’ (Appendix XIX).  
 
Results seem to suggest that no statistical difference is recorded between the trial and 
the control group, indicating that the FOs did not appear to have clinically any 
significant effect on the lt-PP and lt-PTI. Additionally, no major changes occurred 
within each group over the 6 months of the study. From the descriptive statistics (Table 
5.4.12.3 and Table 5.4.12.9) it emerged that during barefoot analysis on the HR 
Walkway, the lt-PP and lt-PTI appeared to be lower than the F-Scan (shod and with 
insole) recordings. Finally, the results suggest that no statistical difference for the lesser 
toes is obtained when FOs are introduced on the JIA children.  
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6.6.13. Distal Phalanx of the 1st toe 
The distal phalanx is the last parameter that was investigated during plantar foot 
mapping in this RCT. This anatomical part was extensively studied by previous authors 
using in-shoes and barefoot Tekscan systems (Ahroni, Boyko and Forsberg 1998a; 
Clough 2005; Hadfield et al. 2003; Tsung et al. 2004; Zammit, Menz and Munteanu 
2010). These authors focussed mostly on detecting peak pressure changes at the distal 
phalanx of the 1
st
 toe, and rarely mentioned the Pressure Time Integral values. It can be 
argued that it is useful to gather information on for how long pressure is applied over a 
period of time, as it might convey useful details with regards to paediatric propulsion 
phase of gait. Generally, suitable children shoes are designed with an inbuilt rocker sole 
in the forefoot increasing contact with the toes; therefore it is important to compared 
plantar pressure changes with and without FOs. On the basis of these previous 
publications dp-PP and dp-PTI was investigated with JIA children during in-shoes and 
barefoot analysis. According to the results gathered using the Tekscan equipment, it 
appears that statistical difference was obtained for F-scan (with insole) between the 
groups for the dp-PP at baseline and at 6
th
 months, but not for 3
rd
 month interval 
p=0.059, although showing a positive trend towards significance as well. With regards 
to dp-PTI the stable-baseline was the only interval that appeared to achieve significant 
difference, hence the changes that the FOs had on pressure over a period of time were 
not too dissimilar compared to the control group.  
 
From the descriptive statistics (Table 5.4.13.2, Table 5.4.13.8) with F-Scan (with 
insole) it was possible to notice that the control group data are generally higher 
compared to the trial group for the dp-PP and dp-PTI, suggesting that FOs help in 
reducing and redistributing some of the plantar pressure also from the distal phalanx of 
the 1
st
 toe. However, within the trial group only, the dp-PP increased over the months 
and the dp-PTI decreased. This trend indicates that the trial patients became more 
propulsive than before, hence higher dp-PP; however, as they became faster, because 
less symptomatic, the time spent on distal phalanx of the 1
st
 toe (dp-PTI) is reduced. On 
the basis of these findings, if the propulsion stage of the active treatment group is 
significantly different from the control group, it could be associated with the reduction 
of symptoms and improvement of quality of life of the trial patients. If the propulsion 
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phase is improved, better ambulation may occur as a result and the JIA children may 
exhibit a faster walking speed.  
 
From a clinical perspective, if JIA children can be more propulsive and walk faster by 
simply wearing customised FOs, this increased level of activity may be reflected in an 
improved quality of life level. 
 
Distal phalanx of the 1
st
 toe, analysis has been often investigated in adult and diabetic 
patients and less frequently in paediatric. Therefore, these findings may prove helpful 
in adding new evidence within paediatric rheumatology. The repeatability test has been 
previously carried out for the distal phalanx of the 1
st
 toe. Ahroni et al. (1998) used ICC 
to demonstrate the level of reliability of dp-PP which appeared to be ‘good’. 
Furthermore, Zammit et al. (2010) concluded that the ICC score of the Tekscan-mat 
system was ‘moderate-good’ also for the distal phalanx. According to the results 
attained in this RCT both dp-PP and dp-PTI were mostly ‘good’. 
 
In conclusion, many authors proved the importance of investigating the distal phalanx 
of the 1
st
 toe, most of them only focused on adult and diabetics and little evidence is yet 
available on distal phalanx on paediatric plantar pressure. A significant difference was 
highlighted between the groups, indicating a more propulsive gait for the trial group 
only. The positive repeatability values obtained may add strength to the findings. 
Finally, from a clinical point of view, the JIA children appeared to have an improved 
function of the distal phalanx and match with a faster ambulation data recorded only for 
the trial participants; therefore, this reflects the improved quality of life results for the 
trial children living with rheumatoid arthritis. 
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 Strengths of the Study 6.7.
 
This study has several strength points that contributed to the overall quality of the 
research:  
 
 RCT - firstly, this research has been conducted as a randomised control trial, with 
single blinded patient intervention. This methodology allowed the investigation of 
the effect of the FOs supplied to the trial group against a control group. Therefore, 
the improvements in the trial group could be attributed solely to the treatment FOs 
and not a placebo effect.   
 
 Multicentre - the benefits of multicenter trials from different geographic regions, 
allowed accessing a larger participant pool and permitted to compare results among 
centers; all of which may add strength to the study. The possibility of recruiting 
patients who lived in different parts of the country allowed the obtaining of results 
that may have better reflected the overall paediatric rheumatology conditions in 
Scotland and how they responded with FOs intervention.  
 
 Attrition rate – In this study, overall 239/240 visits were successfully completed. 
Specifically for the JIA trial, only one visit was not completed (6
th
 month interval). 
However, the results gathered from that patient (at baseline and 3
rd
 month) still 
contributed towards the final data analysis. This very low attrition rate was one of 
the strengths of this study. 
 
 Repeatability and reproducibility of the equipment – according to the results 
attained, the tools used to investigate pain, quality of life and gait parameter showed 
‘good’ ICC scores. This fact could be considered as a significant strength of this 
research because it gives more credibility to the results obtained. In addition, this 
study not only produced new evidence base with regards to podiatric intervention 
with JIA patients, but also added new evidence of the level of repeatability and 
reproducibility of the Tekscan equipment for future podiatric/biomechanical studies 
in children.   
 
 Tekscan sensor type, resolution and sampling rate – the in-shoe and the barefoot 
Tekscan systems both used the same type of sensors of equal resolution, this 
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allowed for F-scan and HR-Walkway measurements to be compared together. In 
addition, the sampling rate used was the same for the HR Walkway and F-Scan 
used in this study. 
 
 Medications – during data analysis it was possible to distinguish between the stable 
and the non-stable medication group; this allowed for any positive effect to be 
solely attributed to the FOs intervention and not to the medication changes.  
 
 Standardised shoes – by making sure that standardised shoes were worn for each 
data collection, no shoe construction variability errors were introduced during the 
gait recordings. Therefore, no effect can be attributed to wearing different shoe 
types during data collection.   
 
 FOs – the FOs prescribed were customised according to the biomechanical needs of 
the patient and supplied immediately on the initial appointment. This reflected the 
needs of current clinical practice in JIA of early treatment with an immediate 
supply of customised FOs at the first biomechanical visit, rather than waiting many 
weeks for a fitting appointment.  
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 Potential Limitation 6.8.
 
 
 Blinding – a double or triple blind methodology would have been more robust, 
compared to a single-blinded randomised control trial. 
 
 FOs durability – the effect of FOs was studied for a period of 6 months with each 
patient. Should this time frame have been extended further, it would have been 
possible to monitor the effectiveness of the FOs over, for example, one or two 
years. In this way, tests on the durability of the material could have been recorded. 
As a result, it would have been possible to provide extended guidelines for 
podopaediatrics specialists with regards to FOs replacement. Additionally, long 
term pain and quality of life outcomes could have been measured beyond 6 months. 
 
 Instrumentation and pre-test - more detailed investigation could have been 
carried out to effectively validate the equipment used. This study conducted on 
healthy children was carried out with the intent to establish the level of repeatability 
and reproducibility of the equipment used; however, many researchers previously 
highlighted the level of validity of the Tekscan equipment. The extensive evidence 
already attained so far, were taken into account during this trial. 
 
 Children shoes – during the data collection, female patients were found to be 
wearing very narrow school shoes. As the FOs had to be worn on a daily basis for a 
period of six months, it was of paramount importance that the FOs were 
comfortable. In some occasions, the supplied forefoot corrections could have had a 
positive effect on JIA gait. However, additional forefoot wedges were not often 
prescribed due to fitting issues. If more forefoot corrections were added onto the 
FOs, more significant changes in the forefoot parameters could have been recorded 
between the control and the trial group. However, this was a pragmatic study, 
reflecting real life clinical management which on the other hand is strength.  
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 Future Research  6.9.
 
The findings obtained from the present study suggested the need for a robust 
methodology such as randomised controlled trial to investigate primary and secondary 
outcome in JIA children. 
Further research is needed into the effects of FOs for a longer period of time. In this 
study the FOs were tested for a period of 6 months; it would be interesting to monitor 
how long the materials used are able to last and to retain the correction applied. With 
these additional data, podiatrists would be able to have further indications on how 
frequently FOs must be reviewed. In addition, as the child foot-size keeps growing, 
adjustments and substitution with a bigger pairs of FOs maybe required, ensuring that 
the child remains asymptomatic.  
Future research is required to compare the clinical outcomes from different types of 
FOs to treat JIA children. With more research it would be possible to establish the 
clinical effect of: different materials, different orthotics brands, and to test new 
customised FOs modifications suitable in JIA patients.  
In order to gather more robust results, it would also be beneficial to recruit a bigger 
number of patients from more paediatric rheumatology hospitals in UK and abroad. 
With the involvements of multicentre clinical trials in different countries, further 
analysis and data comparison will be carried out to establish the clinical impact of the 
podiatry intervention with symptomatic JIA children.  
During the time considered for data collection, improved JIA health-status were 
recorded for the trial group only. Although statistical analysis was not carried out, the 
BMI data seemed to suggest that, as the trial JIA group was in less pain and with 
improved quality of life, more activity level could have had a direct impact in reducing 
weight in JIA children. This encouraging trend could generate collaboration with 
nutritional and physiotherapy departments to tackle the ever growing issues of obesity 
in children and JIA. Therefore, this multidisciplinary approach could really provide 
new cost-effective and not-invasive treatment options for obesity in children and 
adolescent; and attract more private and public funding to meet these targets.  
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Further investments to promote research in podopaediatric will contribute to the 
development of more robust evidence and international guidelines, which will 
strengthen the role of podiatrists and the profession within the multidisciplinary 
paediatric rheumatology team.  
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Chapter 7: Conclusion  
 
The primary findings from this research are that FOs significantly reduce pain and 
improve quality of life of JIA children already in the 3 months since FOs are supplied. 
This also suggests that patients provided with cost-effective customised FOs may 
experience some quick improvements in their lower limbs symptoms, compared to the 
children who received the control FOs, which had no correction. It can be argued that 
these results strongly suggest how podiatric intervention can be carried out directly on 
the same day of the initial assessment. Furthermore, more JIA children showed a high 
level of compliancy. Therefore, if the FOs are regularly worn, there is a higher chance 
that the corrections applied to improve lower limb biomechanics, will be of benefit.   
 
With regards to the secondary outcomes, this pragmatic study was able to provide 
extensive details in paediatric gait and plantar pressure analysis, using modern 
technology to investigate Peak Pressure and Pressure Time Integral changes at in-shoe 
(with-insole and shod) and barefoot analysis. Significant difference was attained 
between the groups for the gait time, gait velocity, stance time, total plantar surface, 
heel contact, midfoot, 5
th
 – 3rd/4th – 2nd metatarsal heads and the distal phalanx of the 1st 
toe. On the basis of the positive findings, all the control JIA patients were contacted 
again as soon as the final results were gathered, and they were offered the option to be 
supplied with the trial FOs. 
 
According to the results obtained in this RCT, the tools used to investigate primary 
outcomes and the Tekscan equipment adopted for the secondary outcomes, appeared to 
have scored mostly ‘good’ and ‘excellent’ ICC scores. Therefore, this study may be 
helpful for future research who intend adopting the similar methodology.     
 
The clinical implications of these results are that practitioners should encourage JIA 
children to wear the FOs regularly for at least 6 months. Practitioners should also 
emphasise to their patients that redistribution of pressure and shock absorption occurs 
only if the device are worn regularly. Therefore, in order to encourage compliancy the 
practitioners need to ensure that FOs are comfortable and that appropriate 
modifications are utilised to aid in the reduction of foot pain. 
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The significant results obtained from this pragmatic study, strongly support the use of 
FOs in the treatment of JIA children, which highlights the central role of the podiatrists 
within the multidisciplinary team in paediatric rheumatology; and hopes to raise the 
profile of podiatrists working within paediatric hospitals and private practices. 
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Appendices  
Appendix I:  Symptomatic Joints 
 
On examination the most commonly symptomatic joints in the lower limbs appeared to 
be: the hip, medial aspect of the knee, patella-tibia tendon, tibial tuberosity, tibialis-
posterior tendon, achilles tendon, ankle joint, STJ, dorsal aspect of the midtarsal joint 
(talo-navicular and calcaneo-cuboid joint) and metatarsal heads. It was not possible to 
statistically calculate the most commonly affected joints. 
 
Subtalar Joint (STJ) 
 
Intra-test repeatability for STJ measurements 
 
All STJ measurements taken during each appointment were analysed throughout the 6 
months trial period. The data obtained from every patient in each of the three 
appointments were compared in order to investigate the repeatability skills of the data 
collector. As only D9 (control group) missed the last of the 3 appointments, only 2 
measurements were missed (left & right of the 6
th
 month). Therefore, within the control 
group 96.6% (n=56/58) of the measurements were completed. Instead, within the trial 
group 100% (n=62) STJ measurements were successfully carried out. 
 
Table 6.6.13.1: percentages of STJ measurements obtained (control and trial patients) 
 
 
 
 
 
In order to measure the reliability of the data recorded, both groups were split and ICC 
statistical test was carried out. With regard to the control group the ICC values = 0.950, 
and for the trial group ICC = 0.947. As previously explained in both cases ‘excellent’ 
ICC score were obtained. 
 
 
 
STJ measurements  
 Control Trial 
Valid 96.6% (n=56) 100% (n=62) 
Excluded  3.4% (n=2) 0% (n=0) 
Total  100% (n=58) 100% (n=62) 
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Table 6.6.13.2: details of the ICC score obtained from the STJ measurements at baseline (control and 
trial patients) 
 
 
 
 
 
 
 
STJ measurements for JIA subjects  
 
According to descriptive statistics all STJ data were collected at baseline, 58 for the 
control and 62 for the trial group; no missing data were reported. The overall degrees of 
correction required to maintain the STJ into neutral position in the control group was 
8.14° (SD2.01), 0.73, minimum 5° and maximum was 14°. Similarly, within the trial 
group the mean value was 7.27° (SD1.63), minimum STJ was 5° and maximum 12°. 
 
Table 6.6.13.3: descriptive statistics of the STJ measurements at baseline (control and trial patients) 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
ICC - STJ measurements at baseline 
 Control Trial 
ICC score 0.950 0.947 
Interpretation  ‘excellent’ ‘excellent’ 
STJ at Baseline 
 Control Trial 
Valid  58 62 
Missing 0 0 
Mean (SD) 8.14°(2.01) 7.27°(1.63) 
Minimum 5° 5° 
Maximum 14°  12°  
365 
 
Appendix II: Juvenile Idiopathic Arthritic FOs Survey 
 
 
 
 
 
Juvenile Idiopathic Arthritic FOs Survey 
 
                                                                                                       Yes            No 
 
Do you treat Juvenile Idiopathic Arthritis (JIA) patients? 
 
⁮ 
 
⁮ 
 
What FOs do you normally prescribe to JIA: 
 
  
 
Palliative Custom made 
 
 
⁮ 
 
 
⁮ 
 
Function custom made 
 
 
⁮ 
 
 
⁮ 
 
Palliative  Off-the-shelf 
 
 
⁮ 
 
 
⁮ 
 
Functional Off-the-shelf 
 
 
⁮ 
 
 
⁮ 
Other: 
 
If you prescribe Off-the-Shelf FOs, which type and brand of FOs do you normally 
prescribe for JIA patients? 
 
 
 
 
 
Andrea Coda 
Chief investigator 
PhD researcher in Paediatric Rheumatology 
BSc (Hons) MChS HPC Registered Podiatrist 
 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, 
Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
acoda@qmu.ac.uk 
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Appendix III: Liability insurance scheme 
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Appendix IV: ILAR Classification  
 
 
 
 
 
 
 
Study No:                                                                            (to be completed by chief investigator only) 
                    
 
 
 
CLASSIFICATION FOR POTENTIAL CANDIDATES 
 
                                                                                                              Yes            No 
ILAR CLASSIFICATION 
If one of the following applied, tick yes: 
  
 Systemic Arthritis 
 Oligoarthritis 
 Rheumatoid- Factor-Positive Polyarthritis   
 Rheumatoid- Factor-Negative Polyarthritis 
 Enthesitis-Related Arthritis  
 Psoriatic Arthritis  
 Undifferentiated Arthritis 
 
 
 
 
⁮ 
 
 
 
 
⁮ 
 
INCLUSION CRITERIA 
  
  
Diagnosed with JIA according to ILAR criteria  ⁮ ⁮ 
All subjects with lower extremity joint involvement with disease 
onset ranging from 5 to 18 years old. 
 
⁮ 
 
⁮ 
Ability to walk a minimum 15 meters without assistive devices 
 
⁮ ⁮ 
Ability to walk barefoot or shod ⁮ ⁮ 
No concomitant musculoskeletal disease, central or peripheral nerve 
disease and endocrine disorders, especially Diabetes Mellitus   
⁮ ⁮ 
No previous foot surgery  ⁮ ⁮ 
No foot osseous anomaly noted during the physical evaluation  ⁮ ⁮ 
      Six months since DMARD therapy ⁮ ⁮ 
No contraindications in prescription of insole ⁮ ⁮ 
 
 
If all the above boxes are ticked “Yes”, then patient is suitable to be invited to 
participate in the study. 
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Appendix V: Information sheet for participants up to 5 year old 
 
 
 
Andrea Coda :   (PhD Researcher ~ BSc MChS HPC Registered Podiatrist) 
Dr. J. Davidson - Consultant Paediatric Rheumatologist, Royal Hospital for Sick Children, Edinburgh. 
Dr. P. Fowlie - Consultant Paediatrician & Clinical Director, Ninewells Hospital.  
Dr. J. Walsh - Consultant Paediatric Rheumatology, Royal Hospital for Sick Children, Edinburgh. 
Dr. Tom Carline - Second Supervisor, Queen Margaret University. 
Dr. Derek Santos - Director of Study, Queen Margaret University. 
 
The following information sheet it is intended to be shown and explained to the child 
by their parent/ guardian. 
 
Contact details of the Chief Researcher 
Mr Andrea Coda 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
acoda@qmu.ac.uk 
 
Contact details of the independent adviser Mrs 
Lynne Flynn 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
lflynn@qmu.ac.uk 
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Appendix VI: Information sheets for potential participants from 6 to 
10 years old 
 
 
 
Andrea Coda:   (PhD Researcher ~ BSc MChS HPC Registered Podiatrist) 
 
Dr. J. Davidson - Consultant Paediatric Rheumatologist, Royal Hospital for Sick Children, Edinburgh. 
Dr. P. Fowlie - Consultant Paediatrician & Clinical Director, Ninewells Hospital.  
Dr. J. Walsh - Consultant Paediatric Rheumatology, Royal Hospital for Sick Children, Edinburgh. 
Dr. Tom Carline - Second Supervisor, Queen Margaret University. 
Dr. Derek Santos - Director of Study, Queen Margaret University. 
 
The following information sheet it is intended to be shown and explained to the child 
by their parent/ guardian. 
 
Study Title 
“The effect of FOs in children with joint pain” 
 
The purpose of the study 
 
FOs are worn in shoes to reduce foot, knee and leg pain. Not many people have studied 
the effect of FOs in children with painful joints. We want to find out if our FOs can 
help you walk better. 
 
Why have you been chosen? 
 
You have been chosen because you have painful joints. 
 
Do I have to take part? 
 
It is up to you. Please take part if you want to. If at any point you are not happy, then 
tell us and you can stop without any problems. 
 
What will happen if I decide to take part? 
 
If you are happy to take part we will give you FOs. You will have 50% chance 
of receiving a basic FOs or a corrective FOs. 
We will put the FOs in your shoes that you wear every day. You will have to do 2 
things: 
 
1st thing: you will have to answer few questions about joint pain (about 15 min). 
 
2nd thing: you will have to walk up and down in a room (barefoot, with shoes and with 
FOs in the shoes). 
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You will have to come to see us 3 times (at the start of the study, in 3 months’ time and 
in 6 months’ time). 
In total you will have to stay no longer than 1 hour.  You will be free to stop at any 
time and you will not have to say why. 
 
What do I have to do? 
 
The only thing that you have to do is to use the FOs when you wear your shoes and 
come back to university to tell me how you are getting on. 
 
 
 
 
 
 
 
 
 
 
 
What are the possible disadvantages and risks of taking part? 
We believe that this is a safe clinical assessment.  The researcher is not aware of any 
risks. 
What are the possible benefits of taking part? 
 
You will receive a pair of FOs which may help your joint pain. 
The information that we get from the study will help us to see if 
we can help children with the same joint pain that you have. 
 
What if something goes wrong? 
We do not expect anything to go wrong while wearing the FOs. 
 
Will my taking part in this study be kept confidential? 
Yes always. Please let me know if you want me to tell your doctor about you taking 
part to this research. 
 
Thank you for taking time to read this information sheet.  If you have any questions, 
please call Mr Andrea Coda. 
 
Contact details of the Chief Researcher 
Mr Andrea Coda 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, 
Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
acoda@qmu.ac.uk 
 
Contact details of the independent adviser Mrs 
Lynne Flynn 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
lflynn@qmu.ac.uk 
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Appendix VII: Information sheet for potential participants from 11 to 
15 years old 
 
 
 
 
Andrea Coda :   (PhD Researcher ~ BSc MChS HPC Registered Podiatrist) 
 
Dr. J. Davidson - Consultant Paediatric Rheumatologist, Royal Hospital for Sick Children, Edinburgh. 
Dr. P. Fowlie - Consultant Paediatrician & Clinical Director, Ninewells Hospital.  
Dr. J. Walsh - Consultant Paediatric Rheumatology, Royal Hospital for Sick Children, Edinburgh. 
Dr. Tom Carline - Second Supervisor, Queen Margaret University. 
Dr. Derek Santos - Director of Study, Queen Margaret University. 
 
 
 
Study Title 
“An investigation of clinical effectiveness of foot FOs on pain; quality of life and gait 
of young patients with arthritis”. 
 
You have been invited to take part in this research study. Before you decide it is 
important for you to understand what this research is all about.  Please read this 
information carefully.  If there is anything that is not clear or you would like more 
information please contact us at the telephone number below. 
 
The purpose of the study 
 
FOs which are worn in shoes can help to reduce foot, knee 
and leg pain and allow you to walk better. Unfortunately 
there is not a lot of research in children with joint pain. 
We want to study if FOs help reduce joint pain in 
children. 
 
Why have you been chosen? 
 
You have been chosen because you have painful joints. 
 
Do I have to take part? 
 
It is up to you to decide whether or not you would like to take part.  
You do not need to give a reason if you decide not to take part in the 
study. If you decide to take part you are free to stop at any time 
without giving a reason. 
What will happen if I decide to take part? 
If you agree to take part in the study you will be provided with a pair of new FOs which 
are to be worn inside your shoes all the time. You will have 50% chance of receiving a 
basic FOs or a corrective FOs If you agree to participate in the study, you will be asked 
to provide your height, weight and age. You will then be asked to do two things. 
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1st task: we will ask you a few questions about your joint pain (about 15 min). 
 
2nd task: you will have to walk up and down in a room (barefoot, with shoes and with 
insoles in the shoes) for about 30min. 
 
 
 
 
 
 
 
 
 
You will have to come to see us 3 times (at the start of the study, in 3 months time and 
in 6 months’ time). In total you will have to stay no longer than 1 hour.  You will be 
free to stop at any time and you will not have to say why. 
 
The researcher is not aware of any risks associated with these procedures. 
 
What do I have to do? 
 
 
 
 
 
 
 
 
 
The only thing that you have to do is to come to university and while wearing the FOs. 
 
What are the possible disadvantages and risks of taking part? 
 
We believe that this is safe clinical assessment.  The researcher is not aware of any 
risks. 
 
What are the possible benefits of taking part? 
 
We cannot promise that the FOs will help you but they may reduce your joint pain. The 
information that we will obtain from the study will help us to identify if we can help 
future children with the same joint pain that you have. It is intended that this 
information will be used by clinicians to help decide if prefabricated FOs are effective, 
and therefore used more frequently for helping patients with your condition. 
 
What if something goes wrong? 
 
You are being asked to take part in non-invasive clinical assessment and it is unlikely 
that anything will go wrong. 
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Will my taking part in this study be kept confidential? 
 
All information that is collected about you will be kept strictly confidential.  Any 
information about you which leaves the premises will have your name and address 
removed so that you cannot be recognised or identified. Please let me know if you want 
me to tell your doctor about you taking part in this research. 
 
 
What will happen to the results of the research study? 
 
The results of the research will be published some months after 
the study has been completed.  You will not be identified in any 
of the reports or medical publications and all data will only be 
kept until the study is completed. 
 
Thank you for taking time to read this information sheet.  If you 
have any questions, please call Mr Andrea Coda. 
 
 
 
Contact details of the Chief Researcher 
Mr Andrea Coda 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, 
Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
acoda@qmu.ac.uk 
 
Contact details of the independent adviser 
Mrs. Lynne Flynn 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, 
Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
lflynn@qmu.ac.uk 
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Appendix VIII: Information sheet for potential participants from 16 
to 18 years old and parents/ guardians 
 
 
 
 
Andrea Coda :   (PhD Researcher ~ BSc MChS HPC Registered Podiatrist) 
 
Dr. J. Davidson - Consultant Paediatric Rheumatologist, Royal Hospital for Sick Children, Edinburgh. 
Dr. P. Fowlie - Consultant Paediatrician & Clinical Director, Ninewells Hospital.  
Dr. J. Walsh - Consultant Paediatric Rheumatology, Royal Hospital for Sick Children, Edinburgh. 
Dr. Tom Carline - Second Supervisor, Queen Margaret University. 
Dr. Derek Santos - Director of Study, Queen Margaret University. 
 
 
Study Title 
“A randomised control trial to investigate the clinical effectiveness of pre-formed semi-
rigid foot orthoses, on pain, quality of life and the dynamics of gait of patients 
diagnosed with Juvenile Idiopathic Arthritis (JIA)” 
 
 
You have been invited to take part in this research study.  Before you decide if you 
would like to take part it is important for you to understand why the research is being 
conducted and what it will involve.  Please take the time to read the following 
information carefully and to discuss it with others if you wish.  If there is anything that 
is not clear or you would like more information please contact the chief investigator at 
the telephone number below. Take time to decide whether or not you would like to take 
part. 
 
The purpose of the study 
 
Orthoses are specialised FOs which are worn in shoes to reduce foot pain and allow a 
more comfortable walk. Unfortunately few studies have been conducted on children 
with Juvenile Idiopathic Arthritis. The purpose of this study is to investigate the 
effectiveness of prefabricated FOs in children with JIA. 
 
Why have you been chosen? 
 
You have been chosen because you have been diagnosed with Juvenile Idiopathic 
Arthritis by your doctor according to ILAR criteria (International League of 
Association for Rheumatology).  You have also been chosen because you do not suffer 
from any disease other than Juvenile Idiopathic Arthritis and because the disease is 
affecting joints in your lower limb. 
 
Do I have to take part? 
 
It is up to you to decide whether or not you would like to take part.  You do not need to 
give a reason if you decide not to take part in the study.  If you decide to take part you 
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will be given this information sheet to keep and will be asked to sign a consent form.  If 
you decide to take part you are free to withdraw from the study at any time without 
giving a reason. 
 
What will happen if I decide to take part? 
 
If you agree to take part in the study you will be provided with a pair of new FOs which 
are to be worn inside your shoes.  Following a “wearing in” period of approximately 
one week, the FOs should be worn in your shoes all of the time.  The purpose of these 
FOs is to reduce pain that you may be experiencing in your lower limbs due to your 
arthritis. You will have 50% chance of receiving a control FOs or a study FOs. If you 
agree to participate in the study, you will be asked to provide your height, weight and 
age.  You will then be asked to perform two different tasks. 
 
1st task: you will be asked to complete 3 questionnaires that should not take longer than 
15 minutes to complete. The questionnaire contains questions regarding your pain, foot 
function and your daily activities. 
 
2nd task: you will be asked to walk along a walkway at your chosen speed 
approximately 9 times. You will walk barefoot, with shoes (these will be provided) and 
with a pair of FOs in the shoes. 
 
If you decide to take part in the study, you will be asked to attend the gait laboratory for 
data collection on 3 separate occasions (at the start of the study, 3 months later, and 
then 3 months after that). 
 
The researcher is not aware of any risks associated with these procedures. The whole 
procedure should take no longer than 60 minutes.  You will be free to withdraw from 
the study at any stage and you will not have to give a reason. 
 
What do I have to do? 
 
The only things that you have to do are report to the gait laboratory and undertake the 
procedures outlined above.  There are no other requirements. 
 
What are the possible disadvantages and risks of taking part? 
The study involves a simple and safe clinical assessment.  The researcher is not aware 
of any risks. 
 
 
What are the possible benefits of taking part? 
 
The benefit of taking part is that you will receive a pair of FOs which may help reduce 
lower limb pain which you maybe experiencing due to your JIA.  The information that 
we will obtain from the study will help us to identify if we can help children with the 
same joint pain that you have. 
It is intended that this information will be used to provide clinicians with useful 
evidence about whether prefabricated FOs are effective, and whether they will be used 
more frequently to help patients with your condition. 
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What if something goes wrong? 
 
You are being asked to take part in a non-invasive clinical assessment and it is unlikely 
that anything will go wrong.  However, a risk assessment of the laboratory has been 
carried out and Queen Margaret University has a liability insurance scheme for 
compensation as a result of harm caused due to negligence on the part of the researcher 
in connection with the above mentioned study. 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you will be kept strictly confidential.  Any 
information about you which leaves the premises will have your name and address 
removed so that you cannot be recognised or identified. Please let me know if would 
like your General Practitioner (GP) to be informed about you taking part to this study. 
 
What will happen to the results of the research study? 
 
The results of the research will be published some months after the study has been 
completed.  The results will be published as research papers in scientific journals and 
will also be available as part of a research thesis at the Queen Margaret University 
Library.  You will not be identified in any of the reports or publications and all data 
will only be kept until the study and all associated works are completed. 
 
Who is organizing and funding the research? 
 
Mr Andrea Coda, a research student based at the Queen Margaret University 
Edinburgh, is conducting this study.  Queen Margaret University funds the study as a 
PhD research degree. Mr Andrea Coda is a BSc (Hons) MChS HPC Registered 
Podiatrist. 
 
Will my General Practitioner (GP) be informed if I decide to take part in the study? 
 
If you decide to take part in the study then your General Practitioner (GP) will only be 
informed of your participation if you want them to be informed.  On the consent form 
there is a box you can tick if you wish to give permission for you GP to be informed 
that you are taking part in the study. 
 
 
Thank you for taking time to read this information sheet.  If you have any questions 
please do not hesitate to contact Mr Andrea Coda during office hours. 
 
If you would like to contact an independent person, who knows about this project but is 
not involved in it, you are welcome to contact Mrs. Lynne Flynn.  Her contact details 
are given below. 
 
If you have read and understood this information sheet and you would like to be a 
participant in the study, please see the consent form. 
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Appendix IX: Consent form 
 
 
 
 
. 
 
 
 
 
 
CONSENT FORM 
 
 
Study No:                                                                               (to be completed by chief investigator only) 
 
“A randomised control trial to investigate the clinical effectiveness of pre-formed semi-
rigid foot orthoses, on pain, quality of life and the dynamics of gait of patients 
diagnosed with Juvenile Idiopathic Arthritis (JIA)” 
 
Name of PhD researcher: Andrea Coda   
                    Please initial box 
 
 I confirm that I have read and understood the information sheet  
      for the above study and have had the opportunity to ask questions    
 
 I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my legal rights being affected  
 
 I agree to participate in this study.      
 
 I give my permission for my General Practitioner (GP) to be informed of my participation in 
this study. 
 
 
Name of participant:           _________________________________ 
 
 
Name of parent/guardian:         __________________________________ 
 
 
Signature of parent/guardian:   __________________________________ 
 
 
Signature of researcher:            __________________________________ 
   
 
Date: ___________ 
Contact details: 
Andrea Coda 
PhD Research Student 
Email: acoda@qmu.ac.uk 
Phone: +44 (0)131 474 0000 
 
 1 copy for participant and 1 copy for chief investigator 
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Appendix X: Participant Medical History, Medication, CHA Scores 
 
 
 
Study No. 
 
MEDICAL HISTORY 
Age at onset  
Date of onset  
Sub-type of JIA  
 
Joint(s) Affected 
 
 
 
 
Symptoms 
 
 
 
MEDICATIONS 
Drug Name Dosage Frequency 
 
 
 
 
 
 
 
  
 
Joint Injection  (please 
circle) 
 
Yes / No 
 
If Yes, please specify: 
 
Date: 
 
Which Joint was injected: 
 
 
 
 
CHA SCORES: Date: Score: 
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Appendix XI: Participant details (Base Line, 3 month, 6 month) 
 
 
 
 
Study No. 
 
 
 
Baseline 
 
D.O.B.  
Date:  
Shoe Size  
Weight  
Height  
BMI  
 
3 Month 
 
Date:  
Shoe Size  
Weight  
Height  
BMI  
 
6 Month 
 
Date:  
Shoe Size  
Weight  
Height  
BMI  
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Appendix XII: Quality of Life Scores (Base Line, 3 month, 6 month) 
 
 
 
 
Study No. 
 
 
 
Baseline Scores                                                                          Date: 
 
Child PedQL Score (Generic)  
Child PedQL Score (Rheumatology)  
Parents PedQL Score (Generic)  
Parents PedQL Score (Rheumatology)  
CHAQ  
 
3 Months  Scores                                                                         Date: 
 
Child PedQL Score (Generic)  
Child PedQL Score (Rheumatology)  
Parents PedQL Score (Generic)  
Parents PedQL Score (Rheumatology)  
CHAQ  
   
6 Months Scores                                                                           Date: 
  
Child PedQL Score (Generic)  
Child PedQL Score (Rheumatology)  
Parents PedQL Score (Generic)  
Parents PedQL Score (Rheumatology)  
CHAQ  
 
 
 
 
Note: Higher Scores Indicate lower problems. 
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Appendix XIII: CHAQ Questionnaire 
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396 
 
Appendix XIV: CHAQ Scoring 
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Appendix XV: Information Sheet for Participants to the Repeatability 
and Reproducibility Study 
 
 
 
 
Andrea Coda - QMU Podiatry PhD Student QMU Edinburgh 
Dr. Tom Carline - Second Supervisor, Queen Margaret University. 
Dr. Derek Santos - Director of Study, Queen Margaret University. 
 
Information Sheet for Potential Participants to the Repeatability and Reproducibility 
Study. 
 
Study Title: 
 
“A study to test the Repeatability and Reproducibility of the F-Scan® and the HR 
WalkwayTM in the gait of healthy children”. 
 
You have been invited to take part in this research study. Before you decide if you 
would like to take part it is important for you to understand why the research is being 
conducted and what it will involve.  Please take the time to read the following 
information carefully and to discuss it with others if you wish.  If there is anything that 
is not clear or you would like more information please contact the chief investigator 
Mr. Andrea Coda at the number below.  Take time to decide whether or not you would 
like to take part. 
 
The purpose of the study 
Orthoses are specialised FOs which are worn in shoes to reduce foot pain and allow a 
more comfortable walk. Unfortunately few studies have been conducted on children. 
The purpose of this study is to investigate that modern in-shoes (F-Scan) and barefoot 
analysis system (HR Walkway) are able to provide repeatable and reproducible data, 
useful for clinical practice and research.  
 
Why have you been chosen? 
 
You have been chosen because you are a healthy subject, with no history of lower limb 
impairments and you are age ranging between 5 and 18 years old. 
 
Do I have to take part? 
It is up to you to decide whether or not you would like to take part.  You do not need to 
give a reason if you decide not to take part in the study.  If you decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form.  If 
you decide to take part you are free to withdraw from the study at any time without 
giving a reason. 
 
What will happen if I decide to take part? 
If you agree to take part in the study you will be asked to attend the Gait Laboratory at 
Queen Margaret University. If you agree to participate in the study, you will be asked 
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to provide your height, weight and age. You will be asked to walk along a walkway at 
your chosen speed approximately 9 times. You will be asked to walk barefoot and with 
shoes. 
. 
If you decide to take part to the study, you will be asked to attend the gait laboratory for 
data collection on 2 separate occasions (one week intervals between the 1st and the 2nd 
data collection). The researcher is not aware of any risks associated with these 
procedures. You will be asked to wear shorts and t-shirt.  The whole procedure should 
take no longer than one hour. You will be free to withdraw from the study at any stage 
and you would not have to give a reason. 
 
What do I have to do? 
 
The only things that you have to do are: report to the gait laboratory and undertake the 
procedures outlined above.  There is no other requirement. 
 
What are the possible disadvantages and risks of taking part? 
 
The study involves simple and safe clinical assessments.  The researcher is not aware of 
any risks. The Chief investigator, Mr Andrea Coda, has obtained enhanced disclosure 
of Scotland and he is a HPC registered Podiatrist. 
 
What are the possible benefits of taking part? 
 
The information that we will be able to collect will help us to identify if the equipment 
is repeatable and reproducible; and if the chief investigator (Mr Andrea Coda) will be 
able to record all the data required for a future bigger study on children affected by JIA 
(Juvenile Idiopathic Arthritis). It is intended that this information will be used to 
provide clinicians with useful evidence with regards to gait analysis and FOs 
prescription with symptomatic JIA children. 
 
What if something goes wrong? 
You are being asked to take part in non-invasive clinical assessments and it is unlikely 
that anything will go wrong.  However, a risk assessment of the laboratory has been 
carried out and Queen Margaret University has a liability insurance scheme for 
compensation as a result of harm caused due to negligence on the part of the researcher 
in connection with the above mentioned study. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you will be kept strictly confidential.  Any 
information about you which leaves the premises will have your name and address 
removed so that you cannot be recognised or identified. 
 
What will happen to the result of the research study? 
 
The results of this study will be collected, analysed and will allow to begin the bigger 
study on JIA children. The results will be published as research papers in scientific 
journals and will also be available as part of a research thesis at the Queen Margaret 
University Library. You will not be identified in any of the reports or medical 
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publications and all data will only be kept until the study and all associated works are 
completed. 
 
Who is organizing and funding the research? 
Mr Andrea Coda, a research student based at the Queen Margaret University 
Edinburgh, is conducting this study. Queen Margaret University funds the study as a 
PhD research degree. Mr Andrea Coda is a BSc (Hons) MChS HPC Registered 
Podiatrist. 
 
Will my General Practitioner (GP) be informed if I decide to take part in the study? 
If you decide to take part in the study then your General Practitioner (GP) will only be 
informed of your participation if you want them to be informed.  On the consent form 
there is a box you can tick if you wish to give permission for you GP to be informed 
that you are taking part in the study. 
 
Thank you for taking the time to read this information sheet.  If you have any questions 
please do not hesitate to contact Mr Andrea Coda during office hours. 
If you would like to contact an independent person, who knows about this project but is 
not involved in it, you are welcome to contact Mrs Lynne Flynn.  Her contact details 
are given below. If you have read and understood this information sheet and you would 
like to be a participant in the study, please see the consent form. 
 
Contact details of the Chief Researcher 
Mr. Andrea Coda 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, 
Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
acoda@qmu.ac.uk 
 
Contact details of the independent adviser 
Mrs. Lynne Flynn 
Podiatry 
School of Health Sciences 
Queen Margaret University Drive, 
Musselburgh 
EH21 6UU 
Tel: +44 (0)131 474 0000 
lflynn@qmu.ac.uk 
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Appendix XVI: Consent Form for Repeatability and Reproducibility 
Study 
 
 
 
Consent Form  
 
Study No:                                                                  (to be completed by chief 
investigator only) 
 
“A study to test the Repeatability and Reproducibility of the F-Scan® and the HR 
WalkwayTM in the gait of healthy children”. 
 
Name of PhD researcher: Andrea Coda 
Please initial box 
 
I confirm that I have read and understood the information sheet dated 
for the above study and have had the opportunity to ask questions 
 
I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my legal rights being affected 
 
I agree to participate in this study. 
 
 
Name of participant:              _________________________________ 
 
 
Name of parent/guardian:         __________________________________ 
 
 
Signature of parent/guardian:    __________________________________ 
 
 
Signature of researcher:            __________________________________ 
 
 
Date:  __________ 
Contact details: 
Andrea Coda 
PhD Research Student 
Email: acoda@qmu.ac.uk 
Phone: +44 (0)131 474 0000 
 
1 copy for participant and 1 copy for chief investigator 
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Appendix XVII: Contact details for Repeatability and Reproducibility 
Study Participants 
 
 
 
CONTACT DETAILS 
 
Study No.  
First Name  
Surname  
D.O.B.  
Address  
 
 
Postcode: 
 
Tel.  
Mobile  
Email  
 
 
Appendix XVIII: Repeatability and Reproducibility Study 
Participant’s details (Base Line, 1 week later) 
 
 
 
Study No. 
 
 
Baseline 
 
D.O.B.  
Date:  
Shoe Size  
Weight  
Height  
BMI  
 
1 Week Later 
 
Date:  
Shoe Size  
Weight  
Height  
BMI  
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Appendix XIX: ICC Scores  
 
ICC - Gait Time  
 
Details of ICC values on Gait Time obtained with the HR Walkway (control and trial patients) 
ICC – Gait Time (sec) - HR-Walkway 
 
ICC Control Trial 
Baseline (1st-2nd -3rd) 0.856 0.796 
3
rd
 month (1st-2nd -3rd) 0.793 0.658 
6
th
 month  (1st-2nd -3rd) 0.871 0.632 
 
 
Stable (1st-2nd -3rd) 
Baseline  0.934 0.773 
3
rd
 month 0.793 0.902 
6
th
 month 0.818 0.654 
 
 
Not Stable (1st-2nd -3rd) 
Baseline 0.486 0.878 
3
rd
 month 0.902 0.493 
6
th
 month 0.926 0.589 
 
 
Control Group  
 
The ICC values from the cadence for the control group appeared to be repeatable 
amongst the three recordings that regularly were taken in each data collection. With 
regards to the control group the ICC value was 0.856 at baseline, 0.793 at 3rd month, 
and 0.871 at 6th month. Results showed that with regards to the stable-control group, 
ICC score was 0.934 at baseline, 0.793 at 3
rd
 month and 0.818 at 6
th
 month. Instead, the 
not-stable control group appeared that the ICC score was 0.486 at baseline, 0.902 at 3
rd
 
month and 0.926 at 6
th
 month.  
 
Trial Group  
 
With regards to repeatability within the trial group the ICC value was 0.796 at baseline, 
0.658 at 3
rd
 month, and finally 0.632 at 6
th
 month. Similarly, stable-trial ICC score was 
0.773 at baseline, 0.902 at 3
rd
 month, and 0.654 at 6
th
 month. The not stable-trial group 
was 0.878 at baseline, 0.493 at 3
rd
 month and 0.589 at 6
th
 month. 
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ICC - Gait Velocity  
 
Details of ICC values on Velocity obtained with the HR Walkway (control and trial patients) 
ICC – Gait Velocity (cm/sec) - HR-Walkway 
 
ICC Control Trial 
Baseline (1st-2nd -3rd) 0.822 0.810 
3
rd
 month (1st-2nd -3rd) 0.838 0.724 
6
th
 month  (1st-2nd -3rd) 0.908 0.735 
 
 
Stable (1st-2nd -3rd) 
Baseline  0.834 0.795 
3
rd
 month 0.847 0.816 
6
th
 month 0.834 0.795 
 
 
Not Stable (1st-2nd -3rd) 
Baseline 0.748 0.870 
3
rd
 month 0.819 0.478 
6
th
 month 0.748 0.870 
 
 
Control Group 
 
The ICC values from the gait velocity for the control group appeared to be repeatable 
amongst the three recordings that regularly were taken in each data collection. With 
regards to the control group the ICC value was 0.822 at baseline, 0.838 at 3rd month, 
and 0.908 at 6th month. Results showed that with regards to the stable-control group, 
ICC score was 0.834 at baseline, 0.847 at 3
rd
 month and 0.834 at 6
th
 month. Instead, the 
not-stable control group appeared that the ICC score was 0.748 at baseline, 0.819 at 3
rd
 
month and 0.748 at 6
th
 month.  
 
Trial Group  
 
With regards to repeatability within the trial group the ICC value was 0.810 at baseline, 
0.724 at 3
rd
 month, and finally 0.735 at 6
th
 month. Similarly, stable-trial ICC score was 
0.795 at baseline, 0.816 at 3
rd
 month, and 0.795 at 6
th
 month. The not stable-trial group 
was 0.870 at baseline, 0.478 at 3
rd
 month and 0.870 at 6
th
 month. 
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ICC - Stance Time 
 
Details of ICC values  on Cadence obtained with the HR Walkway (control and trial patients). 
ICC – Stance Time (sec) - HR-Walkway 
 
ICC Control Trial 
Baseline (1st-2nd -3rd) 0.786 0.694 
3
rd
 month (1st-2nd -3rd) 0.733 0.692 
6
th
 month  (1st-2nd -3rd) 0.672 0.719 
 
 
Stable (1st-2nd -3rd) 
Baseline  0.736 0.676 
3
rd
 month 0.772 0.721 
6
th
 month 0.698 0.679 
 
 
Not Stable (1st-2nd -
3rd) 
Baseline 0.795 0.811 
3
rd
 month 0.497 0.624 
6
th
 month 0.592 0.829 
 
 
Control Group  
 
The ICC values from the stance time, for the control group appeared to be repeatable 
amongst the three recordings that regularly were taken in each data collection. With 
regards to the control group the ICC value was 0.786 at baseline, 0.733 at 3rd month, 
and 0.672 at 6th month. Results showed that with regards to the stable-control group, 
ICC score was 0.736 at baseline, 0.772 at 3
rd
 month and 0.698 at 6
th
 month. Instead, the 
not-stable control group appeared that the ICC score was 0.795 at baseline, 0.497 at 3
rd
 
month and 0.592 at 6
th
 month. 
 
Trial Group  
 
With regards to repeatability within the trial group the ICC value was 0.694 at baseline, 
0.692 at 3
rd
 month, and finally 0.719 at 6
th
 month. Similarly, stable-trial ICC score was 
0.676 at baseline, 0.721 at 3
rd
 month, and 0.679 at 6
th
 month. The not stable-trial group 
was 0.811 at baseline, 0.624 at 3
rd
 month and 0.829 at 6
th
 month. 
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ICC - Total - Peak Pressure Values - (t-PP) 
Details of ICC values on Total -PP obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Total  - Peak Pressure Values (t-PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.824 0.862 
3
rd
 month 0.832 0.774 
6
th
 month 0.776 0.536 
 
 
F-Scan – With Insoles 
Baseline 0.877 0.766 
3
rd
 month 0.493 0.891 
6
th
 month 0.871 0.799 
 
 
HR Walkway 
Baseline 0.765 0.750 
3
rd
 month 0.705 0.765 
6
th
 month 0.799 0.865 
 
 
Control Group - Peak Pressure Values (t-PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (barefoot and 
with insole) and with HR Walkway. With regards to the control group of F-scan 
barefoot, the ICC value was 0.824 at baseline, 0.832 at 3rd month, and 0.776 at 6th 
month. Results with F-scan insole showed that ICC score was 0.877 at baseline, 0.493 
at 3
rd
 month and 0.871 at 6
th
 month. Instead, the HR Walkway appeared that the ICC 
score was 0.765 at baseline, 0.705 at 3
rd
 month and 0.799 at 6
th
 month.  
 
Trial Group - Peak Pressure Values (t-PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan barefoot was 0.862 at baseline, 0.774 at 3
rd
 month, and finally 0.536 at 
6
th
 month. Similarly, F-scan with insole ICC score was 0.766 at baseline, 0.891 at 3
rd
 
month, and 0.799 at 6
th
 month. Finally the HR Walkway group was 0.750 at baseline, 
0.765 at 3
rd
 month and 0.865 at 6
th
 month. 
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ICC - Total - Pressure Time Integral - (PTI) 
Details of ICC values on Total -PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Total  - Pressure Time Integral - (PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.620 0.627 
3
rd
 month 0.785 0.805 
6
th
 month 0.738 0.793 
 
 
F-Scan – With Insoles 
Baseline 0.790 0.858 
3
rd
 month 0.760 0.783 
6
th
 month 0.803 0.322 
 
 
HR Walkway 
Baseline 0.585 0.880 
3
rd
 month 0.699 0.527 
6
th
 month 0.902 0.910 
 
 
Control Group - Pressure Time Integral - (PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.620 at baseline, 0.785 at 3rd month, and 0.738 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.790 at baseline, 0.760 at 3
rd
 
month and 0.803 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.585 at baseline, 0.699 at 3
rd
 month and 0.902 at 6
th
 month.  
 
Trial Group - Pressure Time Integral - (PTI) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.627 at baseline, 0.805 at 3
rd
 month, and finally 0.793 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.858 at baseline, 0.783 at 3
rd
 
month, and 0.322 at 6
th
 month. Finally the HR Walkway group was 0.880 at baseline, 
0.527 at 3
rd
 month and 0.910 at 6
th
 month.  
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ICC - Heel – Peak Pressure Values - (hPP) 
Details of ICC values on Heel -PP obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Heel – Peak Pressure Values - (hPP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.782 0.819 
3
rd
 month 0.658 0.806 
6
th
 month 0.756 0.867 
 
 
F-Scan – With Insoles 
Baseline 0.885 0.880 
3
rd
 month 0.841 0.772 
6
th
 month 0.807 0.786 
 
 
HR Walkway 
Baseline 0.684 0.687 
3
rd
 month 0.711 0.736 
6
th
 month 0.721 0.723 
 
Control Group Peak Pressure Values - (hPP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.782 at baseline, 0.658 at 3rd month, and 0.756 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.885 at baseline, 0.841 at 3
rd
 
month and 0.807 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.684 at baseline, 0.711 at 3
rd
 month and 0.721 at 6
th
 month.  
 
Trial Group Peak Pressure Values - (hPP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.819 at baseline, 0.806 at 3
rd
 month, and finally 0.867 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.880 at baseline, 0.772 at 3
rd
 
month, and 0.786 at 6
th
 month. Finally, the HR Walkway group was 0.687 at baseline, 
0.736 at 3
rd
 month and 0.723 at 6
th
 month. 
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ICC - Heel –Pressure Time Integral (h-PTI) 
Details of ICC values on Heel -PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Heel –Pressure Time Integral (h-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.862 0.634 
3
rd
 month 0.518 0.713 
6
th
 month 0.533 0.612 
 
 
F-Scan – With Insoles 
Baseline 0.703 0.763 
3
rd
 month 0.690 0.769 
6
th
 month 0.594 0.636 
 
 
HR Walkway 
Baseline 0.533 0.612 
3
rd
 month 0.703 0.763 
6
th
 month 0.690 0.769 
 
 
Control Group - Pressure Time Integral (h-PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.862 at baseline, 0.518 at 3rd month, and 0.533 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.703 at baseline, 0.690 at 3
rd
 
month and 0.594 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.533 at baseline, 0.703 at 3
rd
 month and 0.690 at 6
th
 month.  
 
Trial Group - Pressure Time Integral (h-PTI) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.634 at baseline, 0.713 at 3
rd
 month, and finally 0.612 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.763 at baseline, 0.769 at 3
rd
 
month, and 0.636 at 6
th
 month. Finally, the HR Walkway group was 0.612 at baseline, 
0.763 at 3
rd
 month and 0.769 at 6
th
 month. 
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ICC - Midfoot – Peak Pressure Values - (m-PP) 
Details of ICC values on Midfoot -PP obtained with F-Scan shod; F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Midfoot – Peak Pressure Values - (m-PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.800 0.760 
3
rd
 month 0.813 0.745 
6
th
 month 0.668 0.776 
 
 
F-Scan – With Insoles 
Baseline 0.885 0.607 
3
rd
 month 0.720 0.639 
6
th
 month 0.864 0.451 
 
 
HR Walkway 
Baseline 0.702 0.704 
3
rd
 month 0.684 0.661 
6
th
 month 0.673 0.739 
 
 
Control Group -Peak Pressure Values - (m-PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.800 at baseline, 0.813 at 3rd month, and 0.668 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.885 at baseline, 0.720 at 3
rd
 
month and 0.864 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.702 at baseline, 0.684 at 3
rd
 month and 0.675 at 6
th
 month.  
 
 
Trial Group -Peak Pressure Values - (m-PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.760 at baseline, 0.745 at 3
rd
 month, and finally 0.776 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.687 at baseline, 0.639 at 3
rd
 
month, and 0.451 at 6
th
 month. Finally, the HR Walkway group was 0.704 at baseline, 
0.661 at 3
rd
 month and 0.739 at 6
th
 month.  
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ICC - Midfoot – Pressure Time Integral (m-PTI) 
 
Details of ICC values on Midfoot -PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Midfoot – Pressure Time Integral (m-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.743 0.749 
3
rd
 month 0.664 0.742 
6
th
 month 0.708 0.951 
 
 
F-Scan – With Insoles 
Baseline 0.877 0.778 
3
rd
 month 0.849 0.724 
6
th
 month 0.913 0.654 
 
 
HR Walkway 
Baseline 0.727 0.797 
3
rd
 month 0.412 0.842 
6
th
 month 0.568 0.880 
 
Control Group - Pressure Time Integral (m-PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.743 at baseline, 0.664 at 3rd month, and 0.708 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.877 at baseline, 0.849 at 3
rd
 
month and 0.913 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.727 at baseline, 0.412 at 3
rd
 month and 0.568 at 6
th
 month. 
 
 
Trial Group - Pressure Time Integral (m-PTI) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.749 at baseline, 0.742 at 3
rd
 month, and finally 0.951 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.778 at baseline, 0.724 at 3
rd
 
month, and 0.654 at 6
th
 month. Finally, the HR Walkway group was 0.797 at baseline, 
0.842 at 3
rd
 month and 0.880 at 6
th
 month. 
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ICC - Forefoot – Peak Pressure Values - (f-PP) 
Details of ICC values on Forefoot – PP obtained with F-Scan shod F-Scan with insole and HR Walkway 
(control and trial patients). 
  
ICC - Forefoot – Peak Pressure Values - (f-PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.898 0.927 
3
rd
 month 0.832 0.860 
6
th
 month 0.893 0.881 
 
 
F-Scan – With Insoles 
Baseline 0.840 0.832 
3
rd
 month 0.839 0.856 
6
th
 month 0.847 0.862 
 
 
HR Walkway 
Baseline 0.840 0.855 
3
rd
 month 0.839 0.891 
6
th
 month 0.801 0.895 
 
Control Group - Peak Pressure Values - (f-PP) 
 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.898 at baseline, 0.832 at 3rd month, and 0.893 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.840 at baseline, 0.839 at 3
rd
 
month and 0.847 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.840 at baseline, 0.839 at 3
rd
 month and 0.801 at 6
th
 month.  
 
Trial Group - Peak Pressure Values - (f-PP) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.927 at baseline, 0.860 at 3
rd
 month, and finally 0.881 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.832 at baseline, 0.856 at 3
rd
 
month, and 0.862 at 6
th
 month. Finally, the HR Walkway group was 0.855 at baseline, 
0.891 at 3
rd
 month and 0.895 at 6
th
 month. 
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ICC - Forefoot – Pressure Time Integral (m-PTI) 
 
Details of ICC values on Total -PT obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC - Forefoot – Pressure Time Integral (m-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.858 0.845 
3
rd
 month 0.766 0.816 
6
th
 month 0.693 0.828 
 
 
F-Scan – With Insoles 
Baseline 0.895 0.836 
3
rd
 month 0.706 0.780 
6
th
 month 0.780 0.767 
 
 
HR Walkway 
Baseline 0.713 0.859 
3
rd
 month 0.866 0.905 
6
th
 month 0.823 0.883 
 
 
Control Group Pressure Time Integral (m-PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.858 at baseline, 0.766 at 3rd month, and 0.693 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.895 at baseline, 0.706 at 3
rd
 
month and 0.780 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.713 at baseline, 0.866 at 3
rd
 month and 0.823 at 6
th
 month.  
 
Trial Group Pressure Time Integral (m-PTI) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.845 at baseline, 0.816 at 3
rd
 month, and finally 0.828 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.836 at baseline, 0.780 at 3
rd
 
month, and 0.767 at 6
th
 month. Finally, the HR Walkway group was 0.859 at baseline, 
0.905 at 3
rd
 month and 0.883 at 6
th
 month. 
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ICC – 5th Met Head – Peak Pressure Values (5
th
 PP) 
Details of ICC values on 5
th
 -PT obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – 5th Met Head – Peak Pressure Values (5th PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.71 0.71 
3
rd
 month 0.679 0.591 
6
th
 month 0.659 0.725 
 
 
F-Scan – With Insoles 
Baseline 0.715 0.755 
3
rd
 month 0.735 0.577 
6
th
 month 0.73 0.805 
 
 
HR Walkway 
Baseline 0.638 0.7888 
3
rd
 month 0.769 0.691 
6
th
 month 0.848 0.817 
 
 
Control Group - Peak Pressure Values (5
th
 PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.71 at baseline, 0.679 at 3rd month, and 0.659 at 6
th
 month. Results 
with F-scan with insole showed that ICC score was 0.715 at baseline, 0.735 at 3
rd
 
month and 0.73 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.638 at baseline, 0.769 at 3
rd
 month and 0.848 at 6
th
 month.  
 
Trial Group - Peak Pressure Values (5
th
 PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.71 at baseline, 0.591 at 3
rd
 month, and finally 0.725 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.755 at baseline, 0.577 at 3
rd
 
month, and 0.805 at 6
th
 month. Finally, the HR Walkway group was 0.788 at baseline, 
0.691 at 3
rd
 month and 0.817 at 6
th
 month. 
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ICC – 5
th
 Met Head – Pressure Time Integral (5
th
-PTI) 
 
Details of ICC values on 5
th
 -PT obtained with F-Scan shod, F-Scan with insole and HR Walkway  
(control and trial patients). 
 
ICC – 5th Met Head – Pressure Time Integral (5th-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.711 0.691 
3
rd
 month 0.619 0.492 
6
th
 month 0.659 0.621 
 
 
F-Scan – With Insoles 
Baseline 0.712 0.786 
3
rd
 month 0.777 0.614 
6
th
 month 0.788 0.660 
 
 
HR Walkway 
Baseline 0.736 0.846 
3
rd
 month 0.773 0.767 
6
th
 month 0.801 0.879 
 
Control Group - Pressure Time Integral (5
th
 -PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.711 at baseline, 0.619 at 3rd month, and 0.659 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.712 at baseline, 0.777 at 3
rd
 
month and 0.788 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.736 at baseline, 0.773 at 3
rd
 month and 0.801 at 6
th
 month.  
 
Trial Group - Pressure Time Integral (5
th
 -PTI) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.691 at baseline, 0.492 at 3
rd
 month, and finally 0.621 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.786 at baseline, 0.614 at 3
rd
 
month, and 0.660 at 6
th
 month. Finally, the HR Walkway group was 0.846 at baseline, 
0.767 at 3
rd
 month and 0.879 at 6
th
 month. 
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ICC – 3
rd
/4
th
 Met Head – Peak Pressure Values (3
rd
/4
th
 PP) 
Details of ICC values on 3
rd
/4
th
 -PP obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients) 
 
ICC – 3rd/4th Met Head – Peak Pressure Values (3rd/4th PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.857 0.830 
3
rd
 month 0.882 0.801 
6
th
 month 0.832 0.862 
 
 
F-Scan – With Insoles 
Baseline 0.881 0.828 
3
rd
 month 0.806 0.877 
6
th
 month 0.816 0.802 
 
 
HR Walkway 
Baseline 0.808 0.821 
3
rd
 month 0.870 0.865 
6
th
 month 0.835 0.812 
  
Control Group - Peak Pressure Values (3rd/4th PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.857 at baseline, 0.882 at 3rd month, and 0.832 at 6
th
 month. Results 
with F-scan with insole showed that ICC score was 0.881 at baseline, 0.806 at 3
rd
 
month and 0.816 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.808 at baseline, 0.870 at 3
rd
 month and 0.835 at 6
th
 month.  
 
Trial Group - Peak Pressure Values (3rd/4th PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.830 at baseline, 0.801 at 3
rd
 month, and finally 0.862 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.828 at baseline, 0.877 at 3
rd
 
month, and 0.802 at 6
th
 month. Finally, the HR Walkway group was 0.821 at baseline, 
0.865 at 3
rd
 month and 0.812 at 6
th
 month. 
 
 
 
 
 
 
416 
 
ICC – 3
rd
/4
th
 Met Head – Pressure Time Integral (3
rd
/4
th
 -
PTI) 
 
Details of ICC values on  3
rd
/4
th
- PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients).  
 
ICC – 3rd/4th Met Head – Pressure Time Integral (3rd/4th -PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.888 0.823 
3
rd
 month 0.799 0.793 
6
th
 month 0.737 0.900 
 
 
F-Scan – With Insoles 
Baseline 0.887 0.959 
3
rd
 month 0.810 0.857 
6
th
 month 0.857 0.740 
 
 
HR Walkway 
Baseline 0.802 0.895 
3
rd
 month 0.805 0.842 
6
th
 month 0.812 0.848 
 
 
Control Group - Pressure Time Integral (3rd/4th -PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.888 at baseline, 0.799 at 3rd month, and 0.737 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.887 at baseline, 0.810 at 3
rd
 
month and 0.857 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.802 at baseline, 0.805 at 3
rd
 month and 0.812 at 6
th
 month.  
 
Trial Group - Pressure Time Integral (3rd/4th -PTI) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.823 at baseline, 0.793 at 3
rd
 month, and finally 0.9 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.959 at baseline, 0.887 at 3
rd
 
month, and 0.740 at 6
th
 month. Finally, the HR Walkway group was 0.895 at baseline, 
0.842 at 3
rd
 month and 0.848 at 6
th
 month. 
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ICC – 2
nd
 Met Head – Peak Pressure Values (2
nd
 PP) 
 
Details of ICC values on 2
nd
 -PP obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients).  
 
ICC – 2nd Met Head – Peak Pressure Values(2nd PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.923 0.908 
3
rd
 month 0.895 0.881 
6
th
 month 0.867 0.829 
 
 
F-Scan – With Insoles 
Baseline 0.915 0.758 
3
rd
 month 0.864 0.873 
6
th
 month 0.867 0.848 
 
 
HR Walkway 
Baseline 0.860 0.940 
3
rd
 month 0.825 0.453 
6
th
 month 0.878 0.851 
 
 
Control Group - Peak Pressure Values(2nd PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.923 at baseline, 0.895 at 3rd month, and 0.867 at 6
th
 month. Results 
with F-scan with insole showed that ICC score was 0.915 at baseline, 0.864 at 3
rd
 
month and 0.867 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.860 at baseline, 0.825 at 3
rd
 month and 0.878 at 6
th
 month.  
 
Trial Group - Peak Pressure Values(2nd PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.908 at baseline, 0.881 at 3
rd
 month, and finally 0.829 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.758 at baseline, 0.873 at 3
rd
 
month, and 0.848 at 6
th
 month. Finally, the HR Walkway group was 0.940 at baseline, 
0.453 at 3
rd
 month and 0.851 at 6
th
 month. 
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ICC – 2
nd
 Met Head – Pressure Time Integral (2
nd
 -PTI) 
 
Details of ICC values on 2
nd
 –PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – 2nd Met Head – Pressure Time Integral (2nd -PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.880 0.830 
3
rd
 month 0.846 0.816 
6
th
 month 0.791 0.794 
 
 
F-Scan – With Insoles 
Baseline 0.911 0.783 
3
rd
 month 0.946 0.853 
6
th
 month 0.791 0.794 
 
 
HR Walkway 
Baseline 0.799 0.872 
3
rd
 month 0.805 0.856 
6
th
 month 0.805 0.856 
 
 
Control Group - Pressure Time Integral (2nd -PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.880 at baseline, 0.846 at 3rd month, and 0.791 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.911 at baseline, 0.946 at 3
rd
 
month and 0.791 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.799 at baseline, 0.805 at 3
rd
 month and 0.805 at 6
th
 month.  
 
Trial Group - Pressure Time Integral (2nd -PTI) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.830 at baseline, 0.816 at 3
rd
 month, and finally 0.794 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.783 at baseline, 0.853 at 3
rd
 
month, and 0.794 at 6
th
 month. Finally, the HR Walkway group was 0.872 at baseline, 
0.856 at 3
rd
 month and 0.856 at 6
th
 month. 
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ICC – 1
st
 Met Head – Peak Pressure Values(1st- PP) 
 
Details of ICC values on 1
st
 - PP obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – 1st Met Head – Peak Pressure Values(1st- PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.794 0.719 
3
rd
 month 0.757 0.780 
6
th
 month 0.618 0.694 
 
 
F-Scan – With Insoles 
Baseline 0.725 0.760 
3
rd
 month 0.802 0.712 
6
th
 month 0.755 0.777 
 
 
HR Walkway 
Baseline 0.681 0.737 
3
rd
 month 0.708 0.734 
6
th
 month 0.630 0.654 
 
 
 
Control Group Peak Pressure Values (1st- PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.794 at baseline, 0.757 at 3rd month, and 0.618 at 6
th
 month. Results 
with F-scan with insole showed that ICC score was 0.725 at baseline, 0.802 at 3
rd
 
month and 0.755 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.681 at baseline, 0.708 at 3
rd
 month and 0.630 at 6
th
 month.  
 
Trial Group - Peak Pressure Values (1st- PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.719 at baseline, 0.780 at 3
rd
 month, and finally 0.694 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.760 at baseline, 0.712 at 3
rd
 
month, and 0.777 at 6
th
 month. Finally, the HR Walkway group was 0.737 at baseline, 
0.734 at 3
rd
 month and 0.654 at 6
th
 month. 
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ICC – 1
st
 Met Head – Pressure Time Integral (1st-PTI) 
 
Details of ICC values on 1
st
 PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – 1st Met Head – Pressure Time Integral (1st-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.714 0.645 
3
rd
 month 0.665 0.705 
6
th
 month 0.790 0.734 
 
 
F-Scan – With Insoles 
Baseline 0.695 0.713 
3
rd
 month 0.831 0.746 
6
th
 month 0.682 0.698 
 
 
HR Walkway 
Baseline 0.678 0.695 
3
rd
 month 0.684 0.647 
6
th
 month 0.540 0.683 
 
 
Control - Pressure Time Integral (1st-PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.714 at baseline, 0.665 at 3rd month, and 0.790 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.695 at baseline, 0.831 at 3
rd
 
month and 0.682 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.678 at baseline, 0.684 at 3
rd
 month and 0.540 at 6
th
 month. 
 
Trial Group - Pressure Time Integral (1st-PTI) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.645 at baseline, 0.705 at 3
rd
 month, and finally 0.734 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.713 at baseline, 0.46 at 3
rd
 
month, and 0.698 at 6
th
 month. Finally, the HR Walkway group was 0.695 at baseline, 
0.647 at 3
rd
 month and 0.683 at 6
th
 month. 
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ICC – Lesser Toes – Peak Pressure (lt-PP) 
 
Details of ICC values on lt -PP obtained with F-Scan shod, F-Scan with insole and HR Walkway (control 
and trial patients). 
 
ICC – Lesser Toes – Peak Pressure (lt-PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.747 0.839 
3
rd
 month 0.715 0.835 
6
th
 month 0.662 0.766 
 
 
F-Scan – With Insoles 
Baseline 0.733 0.810 
3
rd
 month 0.768 0.824 
6
th
 month 0.618 0.742 
 
 
HR Walkway 
Baseline 0.577 0.810 
3
rd
 month 0.602 0.737 
6
th
 month 0.379 0.701 
 
 
Control Group - Peak Pressure (lt-PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.747 at baseline, 0.715 at 3rd month, and 0.662 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.733 at baseline, 0.768 at 3
rd
 
month and 0.618 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.577 at baseline, 0.602 at 3
rd
 month and 0.379 at 6
th
 month.  
 
 
Trial Group - Peak Pressure (lt-PP) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.839 at baseline, 0.835 at 3
rd
 month, and finally 0.766 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.810 at baseline, 0.824 at 3
rd
 
month, and 0.742 at 6
th
 month. Finally, the HR Walkway group was 0.810 at baseline, 
0.737 at 3
rd
 month and 0.701 at 6
th
 month. 
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ICC – Lesser Toes – Pressure Time Integral (lt-PTI) 
 
Details of ICC values on lt –PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – Lesser Toes – Pressure Time Integral (lt-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.820 0.788 
3
rd
 month 0.757 0.800 
6
th
 month 0.503 0.865 
 
 
F-Scan – With Insoles 
Baseline 0.630 0.769 
3
rd
 month 0.308 0.829 
6
th
 month 0.644 0.868 
 
 
HR Walkway 
Baseline 0.155 0.635 
3
rd
 month 0.571 0.577 
6
th
 month 0.310 0.666 
 
 
Control Group - Pressure Time Integral (lt-PTI) 
 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.820 at baseline, 0.757 at 3rd month, and 0.503 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.630 at baseline, 0.308 at 3
rd
 
month and 0.644 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.155 at baseline, 0.571 at 3
rd
 month and 0.31 at 6
th
 month.  
 
Trial Group - Pressure Time Integral (lt-PTI) 
 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.788 at baseline, 0.800 at 3
rd
 month, and finally 0.865 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.769 at baseline, 0.829 at 3
rd
 
month, and 0.868 at 6
th
 month. Finally, the HR Walkway group was 0.635 at baseline, 
0.577 at 3
rd
 month and 0.666 at 6
th
 month. 
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ICC – Lesser Toes – Peak Pressure (dp-PP) 
 
Details of ICC values on dp-PP obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – Lesser Toes – Peak Pressure (dp-PP) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.786 0.779 
3
rd
 month 0.809 0.740 
6
th
 month 0.752 0.836 
 
 
F-Scan – With Insoles 
Baseline 0.796 0.638 
3
rd
 month 0.774 0.830 
6
th
 month 0.750 0.709 
 
 
HR Walkway 
Baseline 0.773 0.783 
3
rd
 month 0.777 0.781 
6
th
 month 0.829 0.805 
 
 
Control Group -Peak Pressure (dp-PP) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.786 at baseline, 0.809 at 3rd month, and 0.752 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.796 at baseline, 0.774 at 3
rd
 
month and 0.750 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.773 at baseline, 0.777 at 3
rd
 month and 0.829 at 6
th
 month.  
 
Trial Group - Peak Pressure (dp-PP) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.779 at baseline, 0.740 at 3
rd
 month, and finally 0.836 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.638 at baseline, 0.830 at 3
rd
 
month, and 0.709 at 6
th
 month. Finally, the HR Walkway group was 0.783 at baseline, 
0.781 at 3
rd
 month and 0.805 at 6
th
 month. 
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ICC – Distal Phalanx – Pressure Time Integral (lt-PTI) 
 
 
Details of ICC values on dp -PTI obtained with F-Scan shod, F-Scan with insole and HR Walkway 
(control and trial patients). 
 
ICC – Distal Phalanx – Pressure Time Integral (lt-PTI) 
 Control Trial 
 
F-Scan - Shod 
Baseline  0.744 0.731 
3
rd
 month 0.783 0.738 
6
th
 month 0.683 0.768 
 
 
F-Scan – With Insoles 
Baseline 0.701 0.576 
3
rd
 month 0.746 0.696 
6
th
 month 0.751 0.708 
 
 
HR Walkway 
Baseline 0.751 0.310 
3
rd
 month 0.698 0.688 
6
th
 month 0.789 0.558 
 
 
Control Group - Pressure Time Integral (lt-PTI) 
 
The ICC values for the control group appeared to be repeatable amongst the three 
recordings that regularly were taken in each data collection with F-scan (shod and with 
insole) and with HR Walkway. With regards to the control group of F-scan shod, the 
ICC value was 0.744 at baseline, 0.783 at 3rd month, and 0.683 at 6th month. Results 
with F-scan with insole showed that ICC score was 0.701 at baseline, 0.746 at 3
rd
 
month and 0.751 at 6
th
 month. Instead, the HR Walkway appeared that the ICC score 
was 0.751 at baseline, 0.698 at 3
rd
 month and 0.789 at 6
th
 month.  
 
Trial Group - Pressure Time Integral (lt-PTI) 
 
With regards to repeatability within the trial group the ICC value showed the following 
results: F-scan shod was 0.731 at baseline, 0.738 at 3
rd
 month, and finally 0.768 at 6
th
 
month. Similarly, F-scan with insole ICC score was 0.576 at baseline, 0.696 at 3
rd
 
month, and 0.708 at 6
th
 month. Finally, the HR Walkway group was 0.310 at baseline, 
0.688 at 3
rd
 month and 0.558 at 6
th
 month. 
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